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ABSTRACT 
 
This dissertation primarily focuses on how differences in molecular weight (MW) 
and structural composition affect the pharmacological activity of heparin and its 
derivatives. Heparins are a mixture of glycosaminoglycans chains which are used to 
prevent thrombosis in a number of clinical indications. Heparins promote the inhibition 
of blood coagulation via their plasmatic cofactors antithrombin (AT) and heparin cofactor 
II (HCII).  
In these studies, various heparins with molecular weights ranging from 2.6 to 16.5 
kDa were investigated. Not only the molecular weight but also the oligosaccharide 
composition greatly varied in these agents. One of the major objectives of this research 
was to investigate the pharmacological actions of a novel ultra low molecular weight 
heparin (ULMWH), namely semuloparin (AVE5026) and compare it with routinely used 
unfractionated heparin (UF) and the low molecular weight heparins (LMWH), 
enoxaparin and bemiparin. In addition, RO-14, another ULMWH, was studied for 
comparison. Semuloparin is currently in clinical development for the prevention of 
venous thromboembolism. Semuloparin is prepared by a highly selective 
depolymerization of the heparin backbone by a phosphazene base which preserves the 
antithrombin (AT) binding sequence. The unique structural features of semuloparin 
differentiate it from LMWHs. Unlike other depolymerized heparins where the 
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antithrombin (AT) affinity components and anti-Xa activity is decreased with the 
decrease in the molecular weight, semuloparin exhibits a relatively higher proportion of 
AT-binding components which translates into a higher anti-Xa activity.  
A comprehensive molecular and structural analysis provided crucial data on the 
physiochemical behavior of these agents. The molecular profiling of the various heparins 
was carried out utilizing two different methods including the NRC-I and EP method. 
Structural differences were assessed using scanning UV spectroscopy and circular 
dichroism. A comprehensive biochemical analysis included extensive testing of the in 
vitro anticoagulant and antiprotease actions. In addition, the neutralization profile of 
these agents using heparinase, protamine sulfate, platelet factor 4, polybrene, and a novel 
heparin antagonist, PMX60056 was determined.  
 To further characterize these agents, the in vivo pharmacologic actions of these 
heparins were studied in terms of their hemorrhagic and antithrombotic activities in a rat-
tail bleeding model and a rat jugular vein clamping model. In addition, the 
pharmacodynamic (PD) and pharmacokinetic (PK) profiles of these agents were 
investigated in a non-human primate colony solely dedicated for the investigation of the 
pharmacokinetic of heparins. Ex vivo analysis of plasma samples taken from monkeys 
treated with these heparins also examined their effects on tissue factor pathway inhibitor 
(TFPI) and thrombin activatable fibrinolytic inhibitor (TAFI). The non-anticoagulant 
effects of these heparins were also investigated in a murine Lewis lung carcinoma model, 
as previous studies have indicated that heparins may exhibit anti-tumor effects.  
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From these studies, it was shown that each of these agents exhibit distinct MW 
and compositional attributes. AT was determined to be the main cofactor required for the 
mediation of the anticoagulant and antithrombotic effects of these heparins, whereas an 
interaction with HCII was determined to play a relatively minor role. These studies also 
determined that the high-affinity AT binding of semuloparin promoted as effective, if not 
better, anticoagulant and antiprotease effects compared to UF and LMW heparins. 
Moreover, the anti-Xa effects of semuloparin were found to be superior to all other 
heparins at equal gravimetric concentrations.  
The neutralization profile of the anticoagulant and antiprotease effect of various 
agents was studied utilizing heparinase and four complexing agents namely, protamine 
sulfate, platelet factor 4, polybrene and PMX 60056.  The relative neutralization profile 
for each of these neutralizing agents was assay dependent and distinct from each other. 
The anti-IIa activities were relatively neutralized whereas the anti-Xa activity was only 
partially neutralized. 
In vivo, semuloparin had an equally as effective antithrombotic effect and a 
substantially lower bleeding profile in comparison to other heparins as measured in the 
various animal models. Overall, semuloparin showed favorable PD and PK 
characteristics, and was shown to be as effective as both heparin and the other LMW 
heparins at increasing both immunologic and functional TFPI levels and inhibiting TAFI 
activity in the plasma of non-human primates. 
 In addition to the anticoagulant effects of these heparins, these studies 
demonstrated that semuloparin as well as the other LMW heparins can strongly inhibited 
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tumor growth in vivo in a dose-dependent manner. They were shown to be as effective as 
a traditional chemotherapy in reducing tumor burden. Additionally, the lower MW 
heparins were determined to be more efficacious than unfractionated heparin. These 
studies showed that the effect of heparins on tumor growth may be mediated by their 
ability to induce tumor cell apoptosis and to inhibit angiogenesis.  
In conclusion, this dissertation clearly demonstrates that different MW and 
affinity profiles of UF, LMW, and ULMW heparins contribute to the unique 
pharmacological effects of these agents. In addition, these studies illustrate that heparins 
enrichment with the high-affinity AT binding sequences, which results in a higher anti-
FXa/FIIa ratio, promotes a better antithrombotic and safety profile compared to non-
enriched heparin derivatives. Overall, this dissertation provides a comprehensive 
biochemical and pharmacological investigation in which not only the molecular weight 
dependence, but also the differences in structural composition of heparin and its 
derivatives were determined. 
1 
 
CHAPTER ONE 
REVIEW OF LITERATURE 
 
A. Hemostasis 
Blood carries oxygen and nutrients to the various tissues of the body through a 
complex network of blood vessels. However, as with any system in the body, insults or 
injuries can cause disruption to the integrity of our vascular system. The ability of the 
body to respond to such an injury is known as hemostasis. Hemostasis is the process 
which causes the bleeding process to stop and keeps the blood within a damaged vessel. 
This process involves vascular constriction, platelet plug formation, and coagulation of 
the blood. 
The immediate response after a blood vessel becomes injured is constriction of 
the damaged blood vessel (vasoconstriction). Contributing factors to the vascular 
constriction include direct injury to the vascular smooth muscle, reflexes initiated by 
local pain receptors, and chemicals released by endothelial cells and platelets such as von 
Willibrand’s factor, ADP, and thromboxane. Vasoconstriction alone can significantly 
reduce blood loss for 20-30 minutes, providing time for the formation of a platelet plug 
and clotting of the blood. Normally, circulating platelets, which are positively charged, 
anuclear cells, are kept in the inactive state by the release of nitric oxide and prostacyclin, 
which are secreted by the endothelial cells that line the inside of the blood vessel. The
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release of prostacyclin keeps the endothelium of the blood vessel positively charged; 
therefore, platelets and the endothelium repel one another. At sites of blood vessel injury, 
the subendothelial layer becomes exposed and with it, various platelet adhesive proteins 
and activators. The most notable platelet adhesive protein is von Willebrand factor 
(vWF). vWF interacts with other adhesive proteins and activators like collagen, Factor 
VIII, and various other clotting factors. Circulating platelets bind to collagen via the 
glycoprotein Ia/IIa receptors located on their surface. Additional circulating vWF further 
strengthens this adhesion by forming additional links between the platelets and the 
collagen fibrils. This adhesion process causes the activation of the platelet. 
Platelets contain both α and β (dense) storage granules. The α storage granules 
contain platelet derived growth factor (PDGF), fibrinogen, fibronectin, platelet factor 4 
(PF4), β-thromboglobulin, thrombospondin-1, factor V, platelet activating factor (PAF), 
and von Willebrand factor (vWF) (Kaplan et al., 1981). The β granules contain ADP, 
ATP, histamine, calcium, and serotonin (5-HT2) (Holmsen et., 1987). Once platelets are 
activated, they can then release the contents of their storage granules. The release of these 
granules, in turn, activates additional circulating platelets, causes further aggregation, and 
activates coagulation. Aggregating agents found in the circulation as well as those 
released from the platelets themselves, cause further release of the platelet storage 
granule contents. Some of these agonists include ADP, collagen, thrombin, thromboxane 
(TXA2), PAF, serotonin, epinephrine, fibrinogen, and immune complexes (Packham, 
1994). 
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The membrane of the platelet expresses a variety of receptors for the various 
agonists including, the TXA2 receptor, 5-HT2 receptors, α2-adrenergic receptor, and 
thrombin receptor. Additionally, a diversity of glycoproteins also present on the 
membrane surface serve as receptors for vWF (GP Ib), collagen (GP Ia/IIa), fibronectin 
(GP IIb/IIIa), and fibrinogen (GP IIb/IIIa) (Hourani et al., 1991). 
Platelets, once activated, start to aggregate on the injury site through fibrinogen 
bridges, which link glycoprotein IIb/IIa receptors located on adjacent platelets. The 
aggregating platelets create what is commonly referred to as a platelet plug. Although the 
platelet plug initially arrests blood loss, a more stable fibrin based clot is needed in order 
to survive the shear force of the blood flow. This occurs with the help of the coagulation 
system. 
The activation of the coagulation cascade is an essential step in the formation of a 
fibrin based clot, which acts to stabilize the initial platelet plug. The coagulation system 
is comprised of a sophisticated network of zymogens that become activated to serine 
proteases. Additionally, non-enzymatic proteins, known as cofactors, also contribute to 
the coagulation process.  
Activation of the coagulation system has historically been known to occur by 
distinct intrinsic and extrinsic pathways (Davie et al., 1964; Macfarlane, 1964). These 
two pathways eventually converge onto a common pathway that causes the activation of 
factor X (FX) to factor Xa (FXa) (see figure 1). However, a few decades later, the notion 
that the two pathways are linked prior to activation of FX became widely accepted 
(Osterud et al., 1977). 
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When the coagulation cascade is initiated, either by tissue factor (TF) or by some 
other potent activator such as glass or kaolin, a waterfall cascade of activation takes 
place. Each activated serine protease goes on to activate the next zymogen in the series 
until eventually, thrombin is generated. Thrombin is the last key enzyme in the series and 
is responsible for cleaving fibrinogen to form fibrin, and thus forming a stable, fibrin-
based blood clot. 
One important player in the overall hemostatic process including coagulation, 
platelet, and fibrinolytic dependent processes that should not be overlooked is the 
endothelium. The endothelium is the thin layer of cells that line the interior surface of 
blood vessels. It serves as the barrier between the circulating blood in the lumen of the 
blood vessel and the rest of the vessel wall. The first role of the endothelium during the 
coagulation process is to help arrest the flow of blood after vascular injury by causing 
vasoconstriction (Tullis, 1976). Secondly, the vascular endothelial cells can release 
various mediators, which modulate plasmatic processes, during different physiological 
and pathological states. Some of the major roles of the endothelium in mediating the 
overall coagulation process are summarized by the following. 
1. Generation and release of nitric oxide, von Willebrand factor, 
prostaglandin derivatives, prostacyclin, and thromboxane A2 to modulate 
various platelet functions (Weksler et al., 1977). 
2. Regulation of thrombin and protein C activation by expression of 
thrombomodulin (Suzuki et al., 1987).  
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3. Release of tissue factor and TFPI to mediate opposing functions of the 
coagulation process (Osterud et al., 1995). 
4. Release of fibrinolytic mediators, including plasmin activators and 
inhibitors, in the regulation of the fibrinolytic system (Erickson et al., 
1985). 
 
B. Coagulation system 
The extrinsic pathway of the coagulation cascade is activated when the 
endothelial lining of the blood vessel becomes damaged, which can result from a cut, 
other abrasive injury, or even the rupture of atherosclerotic plaques. The opening in the 
vessel wall allows for TF, a cell surface glycoprotein, to become exposed to flowing 
blood. TF is expressed by subendothelial cells (e.g smooth muscle cells), cells 
surrounding blood vessels (e.g fibroblasts), which are not normally exposed to the 
circulating blood, and white blood cells (WBC). TF is the cell surface receptor for the 
serine protease factor VIIa (FVIIa). Exposure of TF allows for the formation of the 
activated TF/FVIIa complex. The TF/FVIIa complex then goes on to catalyze the 
conversion of the inactive protease FX into the active protease FXa. 
In contrast to the extrinsic pathway of activation, the intrinsic (contact) pathway 
activates its serine proteases by an amplification waterfall technique. Activation of the 
contact pathway is initiated with the formation of a complex of high-molecular-weight 
kininogen (HMWK), prekallikrein, and factor XII (FXII) on a collagen backbone. The 
formation of this complex converts both prekallikrein and FXII to their active forms.  
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Figure 1. The coagulation cascade consists of several different zymogens, cofactors, and 
inhibitors. There are two primary pathways, the intrinsic and extrinsic, which lead to the 
common pathway and, ultimately, the activation of thrombin. Thrombin converts 
fibrinogen to fibrin forming a clot. In addition, thrombin converts factor XIII to factor 
XIIIa which acts to stabilize the fibrin clot. 
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FXIIa goes on to convert FXI into FXIa. Factor XIa activates FIX. Factor IXa, along with 
its co-factor FVIIIa, form the tenase complex with the substrate, FX. The formation of 
this complex leads to the activation of FX to FXa. 
In contrast to the immense role TF and the extrinsic pathway play in blood 
clotting, the contact activation pathway seems only to have a minor role in initiating clot 
formation. This can be illustrated by the fact that patients with severe deficiencies of 
HMWK, prekallikrein, and FXII do not exhibit any bleeding disorders. Instead, the 
intrinsic pathway of activation seems to be more involved in inflammation due to the fact 
that patients without FXII (Hageman factor) suffer from chronic infections (Schousboe, 
2008; Woodruff et al., 2011). 
As previously mentioned both the extrinsic and intrinsic pathways of coagulation 
eventually converge at the common pathway and cause the activation of FX to FXa 
(Figure 1). Factor Xa is the final enzyme required for the conversion of prothrombin to its 
active form, thrombin. Optimization of this process occurs when FXa complexes with its 
co-factor, factor V, and Ca
2+
on a phospholipid surface. This is termed the prothrombinase 
complex. 
 The most important enzyme in the whole coagulation cascade is undoubtedly 
thrombin, otherwise known as FIIa. Thrombin’s most critical function, in the coagulation 
cascade, is as a serine protease that converts soluble fibrinogen into insoluble strands of 
fibrin—the building blocks for the hemostatic plug. However, thrombin has many other 
functions that are vital for maintaining hemostasis. In the coagulation pathway, thrombin 
acts to convert factor XI to XIa, VIII to VIIIa, and V to Va; these are considered positive 
8 
 
feedback mechanisms by which amplification can occur. Thrombin can also activate 
factor XIII to XIIIa (FXIIIa). Factor XIIIa is a transamidase that catalyzes the formation 
of covalent bonds between lysine and glutamine residues in fibrin. The covalent bonds 
increase the stability of the fibrin clot by crosslinking the fibrin polymers that form from 
activated monomers. In addition to its activity in the coagulation cascade, thrombin also 
promotes platelet activation and aggregation via activation of protease-activated receptors 
on the cell membrane of the platelet. 
 
1. Fibrinogen and fibrin 
Fibrinogen is a plasma glycoprotein that is converted by thrombin into fibrin 
during the coagulation process (Figure 2). Both fibrinogen and fibrin have various roles 
in coagulation, fibrinolysis, inflammatory responses, wound healing, and matrix 
interactions (Mosesson et al., 2005). These functions are regulated by interactive sites on 
fibrin/fibrinogen that are unmasked by the conversion of fibrinogen to fibrin (Mosesson 
et al., 2005). 
Fibrinogen is a 340 kDa glycoprotein that is synthesized in the liver by 
hepatocytes. It is normally presented in human blood plasma at a concentration range of 
1.5-4.0 g/L (Takeda, 1966). In its natural form, fibrinogen circulates in plasma as a 
soluble macromolecule which is capable of forming bridges between platelets; however, 
the major function of fibrinogen is as the precursor to fibrin. 
Fibrinogen is a hexamer containing two identical sets of three different 
polypeptide chains, namely, Aα (66.5 kDa), Bβ (45.5 kDa), and γ (46.5 kDa), which are 
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linked to one another by 29 disulfide bonds (Mosesson et al., 2005). The center part of 
the fibrinogen molecule is termed the E-region. This region contains the N-termini of all 
six (Aα, Bβ, and γ) polypeptide chains, three on each side. Two short peptides located on 
the ends of the N-terminal regions of the Aα and Bβ chains are known as fibrinopeptides 
A (FpA) and B (FpB), respectively (Standeven et al., 2005). These peptides shield 
polymerisation sites needed to form fibrin polymers. The three chains on each side of the 
E-region form α-helical coiled-coil structures which lead to two outer D domains. Here, 
the Bβ and γ-chains end, but the Aα chains continue on and extend back to the E-region. 
The Aα chains will remain associated with the E-region until fibrin monomers are formed 
(Weisel, 2001).  
The final events in the coagulation cascade result in the conversion of fibrinogen 
to fibrin and the consequent formation of a fibrin clot. The cleavage of fibrinogen by 
thrombin is the trigger for this event. Fibrin monomers are formed after thrombin-
catalysed cleavage of FpA from fibrinogen Aα-chains, thus initiating fibrin 
polymerization. Cleavage of the N-terminal sequences from first the Aα chain and then 
second the Bβ chain reveals new sequences in the Aα and Bβ chains located within the E 
domain. These new sequences within the E-domain, known as ‘knobs’, can interact with 
the D-domains of other fibrin monomers to form D-E-D-linked fibrin polymers 
(Standeven et al., 2005; Weisel, 2001). Initially, the fibrin monomers forms dimers; 
however, additional molecules are added forming a structure known as the two-stranded 
protofibril (Medved et al., 1990). Eventually, the protofibrils will aggregate laterally to 
form fibers (Weisel, 2005). The fibrils that make up the fibers will eventually branch and 
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create a three-dimensional network responsible for producing a space-filling gel that 
prevents excessive blood loss (Standeven et al., 2005; Weisel, 2005). In order to form a 
stable clot that is less susceptible to proteolytic or mechanical disruption, covalent cross-
linking of fibrin by activated coagulation Factor XIII (FXIIIa) must occur. Zymogen 
FXIII is a transglutaminase with a molecular weight of 320 kDa. FXIII has a 
heterodimeric structure consisting of two subunits (2 A and 2 B) and normally circulates 
in plasma as an inactive precurser bound to fibrinogen by its B-subunit (Standeven et al., 
2005; Weisel, 2001). Once FpA and FpB are released from fibrinogen, the inactive FXIII 
then becomes activated by thrombin. Thrombin cleaves an activation peptide from the N-
termini of the A-subunit of FXIII converting it to FXIIIa. FXIIIa then cross-links first, the 
γ-chain and then the α-chain of fibrin. Fibrin formation greatly accelerates the thrombin 
cleavage of the FXIII activation peptides, helping to achieve the co-ordination of events 
at this crucial moment in hemostasis. The continued formation of fibrin monomers, and 
subsequent creation of the protofibril structure, greatly accelerates the thrombin cleavage 
of additional FXIII activation peptides, which are needed for the continual growth of the 
stabilized clot (Curtis et al., 1983; Lewis et al., 1985). 
 
2. Fibrinolysis 
A part of the natural healing process includes removal of the fibrin-based clot—a 
process known as fibrinolysis (Figure 3). Fibrinolysis is important for the restoration of 
normal blood flow after the regeneration of the vessel wall. The fibrinolytic system is 
comprised of the proenzyme, plasminogen, enzymes that proteolytically activate 
plasminogen (tissue plasminogen activator), and several inhibitors that regulate activation 
11 
 
of plasminogen and activity of plasmin (plasminogen activator inhibitor type I and 
thrombin activatable fibrinolytic inhibitor). 
 
 
 
Figure 2. The formation of a fibrin based clot. Activation of fibrinogen by thrombin 
cleaves the two short peptides from the N-terminal regions of the Aα and Bβ chains, FpA 
and FpB, respectively. Removal of the N-terminal sequences from the Aα and Bβ chains 
reveals new N-terminal sequences in the Aα and Bβ chains located within the E domain. 
These sequences can interact spontaneously with the D-domains to form fibrin polymers. 
Under the influence of factor XIIIa, cross-linking of these fibrin polymers occurs to form 
cross-linked fibrin polymers. 
 
Plasminogen, which is produced in the liver, is the inactive precursor of the serine 
protease plasmin. During normal physiological conditions, plasminogen is found 
circulating in the blood stream. As a blood clot is formed, the circulating plasminogen, 
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which has a strong affinity for fibrin, becomes incorporated into the fibrin mesh where it 
stays until activated. Once fibrin is generated during the coagulation process, 
plasminogen binds to fibrin and is then converted to plasmin with the help of tissue 
plasminogen activator (tPA) (Standeven et al., 2005). Damage to the endothelium of a 
blood vessel causes the very slow release of t-PA into the blood. In the presence of fibrin, 
both t-PA and plasminogen bind to fibrin and form a ternary complex which increases the 
catalytic efficiency of t-PA by 1000-fold (Norrman et al., 1985). Generated plasmin that 
is not actively involved in the degradation of fibrin is rapidly inhibited by the plasmin 
inhibitor, α2-antiplasmin (Wiman et al., 1984). This confines the activity of plasmin to 
the vicinity of the clot. Interestingly, α2-antiplasmin and plasminogen activator inhibitor 
type I (PAI-1), another plasmin inhibitor, are cross-linked to fibrin in the clot. Fibrin, 
therefore, serves as a co-activator and substrate for plasmin and participates in the 
inhibition of plasmin (Standeven et al., 2005). Plasmin activity is also reduced by 
thrombin-activatable fibrinolysis inhibitor (TAFI), which is a powerful inhibitor of 
fibrinolysis. TAFI modifies fibrin in such a way that makes it more resistant to t-PA and 
plasminogen binding. Therefore, TAFI helps to prevent the degradation of fibrin (more 
detail on this subject will be given later in this review). 
 
 
 
 
13 
 
 
Figure 3. Fibrinolysis. Once fibrin is generated during the coagulation process, 
plasminogen binds to fibrin and is then converted to plasmin with the help of tissue 
plasminogen activator (tPA). In the presence of fibrin, both t-PA and plasminogen bind to 
fibrin and form a ternary complex which increases the catalytic efficiency of t-PA by 
1000-fold. Generated plasmin that is actively involved in the degradation of fibrin is 
rapidly inhibited by the plasmin inhibitor, α2-antiplasmin. Plasmin activity is also reduced 
by thrombin-activatable fibrinolysis inhibitor (TAFI). PAI-1 and PAI-2 inhibit both tPA 
and urokinase thereby contributing to the regulation of fibrinolysis. 
 
The conversion of plasminogen to activated plasmin unmasks a potent enzymatic 
domain responsible for the dissolution of the fibrin clot (Standeven et al., 2005). Since 
the generation of plasmin occurs when plasminogen is already complexed with fibrin, 
degradation of fibrin can occur immediately following its conversion from plasminogen. 
Plasmin cleaves fibrin in at least 50 specific sites, yielding very distinctive fibrin 
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degradation products (FDPs) that no longer retain their function (Weisel, 2005). FDPs are 
produced in a wide variety of molecular weights. Some of the most notable remaining 
FDPs are called fragment E complexes and D-dimers (DD(E)). D-dimers are so named 
because they contain two crosslinked D fragments of the fibrin protein that were used as 
clot stabalizers (Adam et al., 2009). D-dimers present in the circulation are an indicator 
of the formation and dissolution of a clot somewhere in the body. Determining D-dimer 
levels in the circulation is a commonly used method to (1) exclude VTE in certain patient 
population, (2) diagnosis and monitor coagulation activation in disseminated 
intravascular coagulation (DIC), (3) help to predict recurrent VTE and (4) risk 
stratification of patients for VTE recurrence (Adam et al., 2009). 
 
2.1 Thrombin activatable fibrinolytic inhibitor (TAFI) 
TAFI is a glycoprotein produced in the liver and secreted into the bloodstream as 
an inactive zymogen (60 kDa). As stated previously, TAFI is a powerful inhibitor of 
fibrinolysis. The active form, the enzyme TAFIa (35 kDa), attenuates premature 
breakdown of the fibrin clot. TAFI can be activated by several serine proteases such as 
thrombin, plasmin, or trypsin. The catalytic activation of TAFI by thrombin is increased 
1250-fold when thrombin is in a complex with thrombomodulin (Boffa et al., 1999; 
Bouma et al., 2001). The thrombin-thrombomodulin complex cleaves TAFI at Arg-92, 
which releases the activation peptide from the catalytic domain and exposes the complete 
active site of TAFI (Bouma et al., 2001).  
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When TAFI is activated, it functions by cleaving the arginine and lysine residues 
off the C-terminus of partially degraded fibrin, which are the binding sites for 
plasminogen and t-PA. Since plasminogen can no longer bind to fibrin, TAFI ultimately 
prevents the binding of plasmin and therefore the digestion of the modified fibrin (Bajzar 
et al., 1995; Bouma et al., 2001).  
 
3 Regulation of the coagulation cascade 
Any bodily system, if left unchecked, can cause detrimental damage to the host. 
The same can be said for the coagulation system; tight regulation is required in order to 
prevent pathologic states from occurring involving thrombosis or hemorrhage. There are 
many important proteins that are involved in the regulation of the coagulation system 
including antithrombin (AT), heparin cofactor II (HCII), tissue factor pathway inhibitor 
(TFPI) and protein C. AT, HCII, and TFPI will be discussed further in later sections. 
 
3.1 Protein C 
Just as the body has a procoagulant system, it also has a built-in anticoagulant 
pathway used for controlling thrombosis, known as the protein C anticoagulant pathway. 
The main components of the pathway involve protein C, protein S, thrombin, 
thrombomodulin (TM), and the endothelial cell protein C receptor (EPCR). 
The vitamin K-dependent zymogen, protein C, is activated (APC) by thrombin 
when it complexes with membrane bound TM on the surface of endothelial cells 
(Dahlback, 2005). Protein S, which is another vitamin K-dependent plasma protein, is a 
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required cofactor for activation of protein C (APC). The activation of protein C increases 
approximately 20-fold in vivo when it is bound to EPCR and is presented to the 
thrombin-thrombomodulin activation complex (Taylor et al., 2001). Once activated, PC 
dissociates from the EPCR and binds to protein S on the appropriate cell surface. Here, it 
inactivates factors Va and VIIIa, thereby inhibiting further thrombin generation (Esmon, 
2003).  
 
C. Thrombosis 
Blood clotting at a site of vascular injury is a vital and necessary function to 
prevent blood loss. However, when a thrombus is formed elsewhere within the vascular 
system, and it is not a part of a normal physiologic response to injury, it is termed 
thrombosis. Thrombosis is a pathological condition in which a thrombus forms within the 
vascular system and prevents oxygen and nutrients from reaching a particular organ or 
part of the body. Thrombosis is the most common single cause of death in the United 
States. Each year, more than 2 million people die from venous and arterial thrombosis or 
complications from such events (Bick and Haas, 2003). 
Initiation of a thrombotic episode may occur from events such as vessel damage, 
plaque rupture, or a dysfunctioning endothelium (Fuster et al., 1992). Additionally, 
aberrant activation or regulation of the hemostatic system or a combination of these 
mechanisms may result in thrombosis (Hathcock, 2006). Although some cases of 
thrombosis and hypercoagulability among patients will have a well defined etiology, 
most instances of initial venous or arterial thrombosis are unexplained. Meaning, 
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essentially, these cases are not associated with trauma, surgery, cardiac emboli or other 
problems (Bick and Haas, 2003). Bick and Haas (2003) described numerous clinical 
causes for both venous and arterial thrombosis such as general surgery, atherosclerosis, 
hypertension, diabetes mellitus, malignancy, and congestive heart failure, to name a few. 
However, in most cases, blood coagulation proteins or platelet defects already exist in the 
patient, and the clinical event merely reveals the existing condition (Bick and Haas, 
2003).  
A thrombus can form in either the venous or arterial vascular system. Venous 
thrombosis is a blood clot that forms within a vein and is usually caused by venous stasis 
or hypercoagulability (Martinelli et al., 2010). However, these contributing factors alone 
do not result in thrombosis automatically; activated coagulation factors are essential to 
the development of a thrombus (Pifarre, 1998). Venous thrombi are primarily comprised 
by red blood cells and fibrin and less by platelets (Martinelli et al., 2010). A large portion 
of venous thrombi occur in the deep veins of the lower leg or pelvis and results in deep 
vein thrombosis (DVT). Deep vein thrombi have a high propensity to break off and travel 
to the lungs where they cause pulmonary embolism. Together these two interrelated 
conditions are known as venous thromboembolism (VTE). VTE is the third most 
common vascular disease after stroke and acute myocardial infarction (Previtali et al., 
2011). Certain risk factors increase the likelihood of any one individual developing 
thrombosis. Some of these risk factors include age, pregnancy, estrogen use, surgery, 
cancer, chemotherapy, and obesity (Martinelli et al., 2010). All other risk factors aside, 
aging alone enhances activity of coagulation enzymes and causes an impairment of 
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fibrinolytic activity. There are corresponding age-dependent increases in PAI-I, the major 
inhibitor of fibrinolysis, and a corresponding age-dependent decrease in fibrinolytic 
activity (Wilkerson and Sane, 2002). 
The formation of a thrombus within an artery is known as arterial thrombosis. 
This type of thrombosis typically occurs following the rupture of a lipid plaque that is the 
hallmark of atherosclerosis (Mackman, 2008). The atherothrombi that develop at the 
ruptured plaques are rich in platelets that are activated after exposure to collagen or 
thrombin (Pifarre, 1998). Activation of these platelets causes receptor-mediated binding 
of additional platelets, which results in the rapid growth of the thrombus (Mackman, 
2008). An arterial thrombus which breaks off and causes an arterial embolism can 
potentially trigger an infarction at almost any organ in the body. 
The pathophysiology of venous thrombosis differs from that of arterial 
thrombosis, as reflected by the different ways in which they are treated. To put it simply, 
venous thrombosis is usually treated with drugs that target proteins of the coagulation 
cascade and arterial thrombosis is treated with drugs that target platelets. However, there 
are some degrees of overlap. For example, anticoagulants are used to treat a wide variety 
of conditions that involve venous or arterial thrombosis, including prophylaxis of VTE 
for medical and surgical patients and long-term prevention of ischemic stroke in patients 
with atrial fibrillation (Hart et al., 1999; Bick and Haas, 2003; Weitz, 2004). Heparins 
and vitamin K antagonists are the two main classes of anticoagulant drugs which target 
multiple proteases in the coagulation cascade. High and low-dose heparin is used to 
prevent DVT in patients with acute myocardial infarction (Pitt, 1980). Low molecular 
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weight heparins (LMWH) are used as alternatives to heparin and have been found to be 
as effective as heparin when treating patients with unstable angina (Bick and Haas, 
2003). Anticoagulants are also recommended as primary prophylaxis for VTE in all 
oncology patients admitted to the hospital for medical and surgical reasons (Lyman et al., 
2007). However, the main side effect of anticoagulant therapy, for all indications, is 
bleeding. A drug that will prevent coagulation without promoting bleeding has yet to be 
found. Nevertheless, smaller LMW heparins as well as drugs that target specific proteases 
of the coagulation cascade are in development, and they may provide safe and effective 
alternatives to the conventional therapies used for the prevention and treatment of various 
thrombotic disorders. 
 
D. History of heparins 
1. Heparins discovery 
In 1916, a serendipitous discovery was made by Jay McLean, a second year 
medical student in Dr. William Howell’s laboratory at Johns Hopkins University. 
McLean was researching the procoagulant activity of cephalin when he discovered that 
one of the isolated procoagulant fractions, from the liver, prevented blood from clotting 
(Couch, 1989; Marcum, 2000; McLean, 1959). In 1918, Dr. Howell termed this assumed 
phosphatide “heparin” to reflect its origin (Fye, 1984; Marcum, 2000).  However, by 
1922, Dr. Howell’s research determined that heparin was actually a carbohydrate and not 
a phosphatide as originally assumed (Howell, 1928). Additionally, that same year brought 
about the commercial availability of heparin by a company known as Hynson, Westcott 
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& Dunning (Fye, 1984), thus allowing invaluable access to the compound. By the early 
1930s, Howell began studying the effects of heparin in humans and those studies would 
continue throughout the ‘30s by other laboratories (Fye, 1984). From that point until 
today, heparin continues to be used for the treatment and prophylaxis of a variety of 
thrombotic related diseases. 
 Unfractionated heparin (UFH) belongs to a family of long unbranched 
polysaccharides known as glycosaminoglycans (GAGs). UFH is highly ionized (strongly 
acidic) and has the highest negative charge density of any known biological molecule. It 
is comprised of repeating units of sulfated glucosamine and uronic acid (either iduronic 
or glucuronic) connected by 1 – 4 linkages. The major sites of sulfation are the 2-N and 
6-O positions on glucosamine residues and the 2-O position on iduronate residues. The 
mean degree of sulfation is about 2.0-2.5 per disaccharide unit (Razi and Lindahl, 1995). 
UFH is found exclusively inside storage vesicles of mast cells in tissues such as 
lung and intestine. It is comprised of components that vary in molecular weight from 2 – 
40 kDa, thus being characterized by a high degree of heterogeneity. It is precisely this 
heterogeneity that bestows UFH with several different biological functions including 
inhibition of blood coagulation, inhibition of platelet aggregation, release of tissue factor 
pathway inhibitor, and plasma clearing effects.  
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Figure 4. Structure of heparin. The polymeric chain is composed of repeating 
disaccharide units of D-glycosamine and uronic acid linked by 1→4 interglycosidic 
bonds. The uronic acid residue could be either D-glucuronic acid or L-iduronic acid. The 
dotted brackets contain the pentasaccharide sequence required for AT binding. 
 
1.1 Heparin pharmacokinetics 
Heparin is usually administered by continuous IV infusion or SC injection. 
However, a higher initial dose of heparin is required after SC administration to overcome 
the low bioavailability associated with the SC route (Hull et al., 1986). After bolus IV 
injection, UFH has a half-life of approximately 1-2 hours (Eikelhoom and Hankey, 
2002), a volume of distribution of 40-70 ml/kg (Spruill et al., 2001), and it is eliminated 
from the blood exponentially (Olsson and Lagergren, 1963). Such first-order/linear 
kinetics would ordinarily suggest a constant half-life of the drug which is independent of 
the amount of drug injected. However, it is well known that the half-life of UFH 
increases with the dose administered (Boneu et al., 1987) and tend to have non-linear 
pharmacokinetics.  
Heparin clearance entails a combination of a much slower first-order mechanism 
and a rapid saturable mechanism (Olsson and Lagergren, 1963; Pipper, 1947). The slower 
unsaturable mechanism is renal, while the mechanism of the saturable phase of clearance 
is through binding to receptors on endothelial cells (Glimelius et al., 1978) and 
macrophages where it is depolymerized (McAllister and Demis, 1966). Boneu et al 
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(1987) demonstrated that when rabbits were injected with increasing doses of UFH, the 
disappearance of the anti-factor Xa activity was exponential when the dose was less than 
100 anti-FXa U/kg. Moreover, Boneu et al (1987) showed that when the doses were over 
100 anti-FXa U/kg, the disappearance of anti-FXa activity followed a concave-convex 
pattern. Essentially, the half-life of UFH continuously shortened as the heparin 
concentration in the plasma declined (Boneu et al., 1987). 
 
1.2 Structural analysis 
The chemical profile of these agents plays a pivotal role in determining the 
biologic activity of heparin (Casu 1989, Barrowcliffe 1995). Several methods have been 
developed for the structural analysis of heparins. Techniques such as gel permeation 
chromatography, scanning UV spectroscopy, circular dichroism, heparinase digestion, 
and nuclear magnetic resonance spectroscopy are useful tools to understand the 
underlying structure activity relationship of heparins. 
Since the molecular weight of heparins is one of the most important determinants 
for their biological activity and bioavailability (Emanuele and Fareed, 1987), a number of 
different physical methods have been used for the molecular weight determination. These 
consist of the number of average molecular weight (Mn), weight average molecular 
weight (Mw), and polydispersity, which are typically obtained using gel permeation 
chromatography high performance liquid chromatography (GPC-HPLC) (Ahsan et al, 
1994). The molecular weight profile of heparins has also been analyzed using additional 
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methods such as viscometry, ultracentrifugation and gradient polyacrylamide gel 
electrophoresis (PAGE) (Rice et al. 1987). 
In addition to molecular weight determination, oligosaccharide mapping of 
heparins can also provide structural information to establish a structure activity 
relationship (Linhardt et al., 1992). Heparin lyases I, II and III are used in this method to 
cleave specific linkages within the UFH and LMWH and provide a mixture of 
oligosaccharide products. These products can be further analyzed by strong anion 
exchange (SAX-HPLC, GPC-HPLC and PAGE. By using standard oligosaccharides and 
carbohydrate composition specific sequences can be further identified.  
High resolution analysis of heparin structure has relied on spectroscopic methods 
such as proton (
1
H) and carbon (
13
C) nuclear magnetic resonance (NMR) spectroscopy 
(Casu and Torri 1999.). Proton NMR spectroscopy is used to determine information such 
as the ratio of iduronic acid to glucuronic acid, the content of N-acetyl-glucosamine, and 
the patterns and degree of sulfation. These methods are quantitative and non-destructive 
and therefore can be used to analyze the highly depolymerized heparin-derived 
oligosaccharides. 
 
2. Heparin actions 
As early as the 1937, heparin was determined to be highly effective in preventing 
post operative thrombosis (Crafoord, 1937). Later, indications were extended to treatment 
of established venous thrombosis and pulmonary embolism (Barritt et al., 1960). 
Currently, the main clinical indications for heparin are in the prevention and treatment of 
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arterial and venous thromboembolism, thrombotic stroke, and in certain types of coronary 
artery syndrome, mainly unstable angina (Hirsh et al., 2001). Additionally, heparin is 
used for a number of other minor indications, such as hemodialysis and open heart 
surgery. Outside heparin’s inhibitory actions in the coagulation cascade, it is also had 
effects on inflammation and is able to inhibit myosin ATPase, hyaluronidase, RNA-
dependent DNA polymerase, renin and elastase (Fareed et al., 2003). The most common 
known side effects of heparin include excessive bleeding, heparin-induced 
thrombocytopenia (HIT), and to a lesser extent, skin necrosis, and osteoporosis (Gray et 
al., 2008).  
 
3. Mechanisms of action 
3.1 Antithrombin  
In 1939, heparin was shown to mediate its biological functions through a plasma 
protein, known at that time as heparin cofactor. The suggestion that heparin cofactor may 
actually be antithrombin (AT) was made in the 1950s with the work of Seegars, at Wayne 
State University and Fitzgerald, at MIT (Petitou, 2003). It was not until 1968 when 
Abildgaard (1968) isolated the plasma component, that it was renamed antithrombin 
(Verstraete, 1990). Rosenberg and his colleagues (Rosenberg et al., 1973; Rosenberg, 
1975) would confirm that AT was indeed, the true heparin cofactor. 
 AT is a globular glycoprotein produced by the liver and consists of 432 amino 
acids with a molecular weight of 58 kDa (Choay, 1989; Pike et al., 2005). It is known as 
a serine protease inhibitor (SERPIN) and is considered one of the most important 
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anticoagulant molecules in mammalian circulatory systems. AT is responsible for 
inhibiting active enzymes of the coagulation system and in doing so, precisely controls 
the coagulation process in order to localize clotting to the site of injury (Dahlback, 2005). 
It circulates in the plasma at levels of approximately 150 µg/ml and has a half-life of 3 
days (Quinsey et al., 2004).  
The main targets of AT are thrombin and factor Xa of the coagulation cascade; 
however, it can inhibit several other serine proteases including intrinsic pathway factors 
IXa, XIa, and XIIa as well as kallikrein and plasmin (Mourey et al., 1990; Pike et al., 
2005). AT binds thrombin in a 1:1 stoichiometric complex (Rosenberg et al, 1973). 
Rosenberg (1975) demonstrated that only AT bound to heparin or a heparin-like molecule 
(heparin sulfates or chondroitin sulfates) was capable of inhibiting thrombin. In the 
presence of heparin, the rate of thrombin inactivation by AT is dramatically increased 
~1000 fold (Li et al., 1976; Lane et al., 1989). 
 The interaction between AT and heparin (Figure 5) is dependent on a well-defined 
unique pentasaccharide sequence within heparin (Choay et al., 1983; Walenga et al., 
1988; ;Petitou et al., 2003). The AT/heparin interaction produces a conformational 
change in the structure of AT, which enables additional interactions between AT and 
heparin, resulting in stronger binding (Pike et al., 2005). The conformational change also 
exposes a protease reactive center loop (RCL) in AT. This conformational activation 
mechanism promotes binding of the RCL to the active site of factor Xa (Pike et al., 
2005). After the complex formation, the AT interaction reverts to low-affinity binding 
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followed by RCL cleavage, resulting in the release of heparin from the covalent AT–
factor Xa complex.  
The conformational change which occurs in AT after binding to the heparin 
pentasaccharide sequence does not substantially increase the rate of thrombin inhibition 
by itself. The strong inhibition of thrombin is due to a template mechanism of activation, 
whereby both AT and thrombin bind adjacently on the same heparin chain. Lane et al. 
(1984) demonstrated that a minimum heparin chain length of 18 saccharides (the 
pentasaccharide sequence and an additional adjacent 13 saccharides) is required for 
thrombin inhibition by AT. Negative charges available at the extended heparin 
polysaccharide units bind non-specifically to the exosite (positively charged region) of 
thrombin (Olson et al., 1992; Quinsey et al., 2004; Pike et al., 2005). Therefore, these 
interactions create a strong ternary complex between AT, thrombin, and heparin which 
produce a substantial increase in the role of inhibition of thrombin. Because the 
distribution of the pentasaccharide sequence in heparin is random, lower MW fragments 
of heparin will not be able to bind to or inhibit thrombin. Thus, heparin chains in the MW 
range of 5 – 10 kDa have an increase in thrombin inhibitory activity (Gray et al., 2008). 
 
3.2 Heparin cofactor II 
In addition to AT binding, heparin can also bind to another SERPIN known as 
heparin cofactor II (HCII). HCII shares considerable sequence homology to AT at the C-
terminal two-thirds of the protein but no homology exists near the N-terminal domain. 
HCII is a 66 kDa, single-chain glycoprotein which is 480 amino acids in length 
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(Tollefsen, 1995). It is synthesized in the liver, has a half-life of 2-3 days, and evidence 
suggests that HCII contributes 20-30% to the heparin-mediated inhibition of thrombin 
(Tollefsen, 1995). The plasma concentration of HCII is approximately 90 µg/ml 
(Tollefsen et al., 1982). The existence of this second heparin cofactor was first described 
in 1974 by Briginshaw (Briginshaw et al., 1974) and identified by Tollefsen in 1981 
(Tollefsen et al., 1981). It was later isolated by Tollefsen and named HCII (Tollefsen et 
al., 1982).  
 
Figure 5. Antithrombin/heparin binding. The main targets of AT are thrombin and factor 
Xa of the coagulation cascade. The interaction between AT and heparin is dependent on a 
well-defined unique pentasaccharide sequence within heparin. The AT/heparin 
interaction produces a conformational change in the structure of AT, which enables 
additional interactions between AT and heparin, resulting in stronger binding. The strong 
inhibition of thrombin is due to a template mechanism of activation, whereby both AT 
and thrombin bind adjacently on the same heparin chain. A minimum heparin chain 
length of 18 saccharides is required for thrombin inhibition by AT (A). The AT/heparin 
interaction produces a conformational change in the structure of AT which exposes a 
protease reactive center loop (RCL) in AT. This conformational activation mechanism 
promotes binding of the RCL to the active site of factor Xa (B).  
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Unlike AT, which is able to inhibit a variety of coagulation serine proteases, HCII 
is only able to inhibit thrombin, with which it forms a 1:1 stoichiometric complex 
(Tollefsen et al., 1982; Parker et al., 1985). Additionally, HCII can inhibit the proteolytic 
enzyme, chymotrypsin (Church et al., 1985). Heparin, dermatan sulfate, and heparin 
sulfate catalyze the formation of the HCII-thrombin complex, which increases the rate of 
thrombin inhibition ~1000-fold (Tollefsen et al., 1982; Tollefsen et al., 1983; Parker et 
al., 1985). However, much higher concentrations of heparin or heparan sulfate are 
necessary to activate HCII than AT (Tollefsen et al., 1982; Maimone et al., 1988). In 
contrast, dermatan sulfate has no significant effect on the activity of AT (Tollefsen et al., 
1983; Parker et al., 1985).  
There are three highly conserved sequences that are important for the binding and 
inhibition of thrombin by HCII: the reactive site, the glycosaminoglycan-binding site, and 
the N-terminal acidic domain. The reactive site Leu444 – Ser445 peptide bond where 
thrombin attacks and becomes trapped in a complex with HCII is located near the C-
terminus (Griffith et al., 1985; Van Deerlin et al., 1991). The presence of leucine in the 
P1 position of the reactive site is unusual for thrombin substrates, which usually contain 
an arginine; therefore, thrombin inhibition occurs at a very slow rate in the absence of 
glycosaminoglycans (Church et al., 1985; Derechin et al., 1990). In contrast, the 
replacement of arginine by leucine allows for the inhibition of chymotrypsin to occur 
more rapidly than the inhibition of thrombin when no glycosaminoglycans are present 
(Derechin et al., 1985; Tollefsen, 1994). Therefore, the rapid inhibition of thrombin by 
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HCII depends mostly on the presence of glycosaminoglycans and less on the amino acid 
sequence of the reactive site. 
The main body of HCII holds the glycosaminoglycan binding sites, which are 
located near the N-terminus. Two different studies that analyzed the natural variant HCII 
Oslo (Arg
189
 → His) demonstrated that dermatan sulfate and heparin interact with 
different amino acid residues located in the N-terminal acidic domain of HCII (Anderson 
et al., 1987; Blinder et al., 1989). These binding sites are not identical, but because of 
their location, do overlap one another. Unlike AT, which binds to a specific 
pentasaccharide sequence in heparin, HCII binds to most heparin oligosaccharides greater 
than 4 monosaccharide units in length. However, in order for HCII to maximally inhibit 
thrombin, at least 26 monosaccharide units are required (Sie et al, 1988). Additionally, 
Sie et al. (1988) showed that there are no functional groups in heparin that are critical for 
optimal thrombin inhibition by HCII. However, sulfate and carboxylate are important in 
as much as they contribute to an increase in global charge density of heparin and that the 
ability to activate HCII is directly correlated to the degree of charge density. In contrast 
to heparin binding, HCII preferentially binds to a minor hexasaccharide sequence located 
in dermatan sulfate (Maimone et al., 1990; Tollefsen, 1994). The high affinity binding 
site is a tandem repeat of three iduronic acid-2-sulfate→N-acetylgalactosamine 4-sulfate 
disaccharide subunits (Maimone et al., 1990; Tollefsen, 1994). 
The ability of heparin or DS to stimulate thrombin inhibition by HCII largely 
depends on the presence of an unusual N-terminal extension of 80 residues, which 
contains a tandem repeat of two highly acidic sequences located near the N-terminus of 
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HCII. (Ragg et al., 1990; Van Deerlin et al., 1991). This acidic domain resembles the C-
terminal portion of the thrombin inhibitor, hirudin, which binds with high affinity to 
anion-binding exosite I of thrombin. This N-terminal extension is sequestered in the 
native state through extended intramolecular contacts with the glycosaminoglycan 
binding sites of HCII and is released from these contacts only on binding to heparin-like 
glycosaminoglycans (Ragg et al., 1990; Van Deerlin et al., 1991; Tollefsen, 1994; 
Tollefsen, 1995). Therefore, the glycosaminoglycan chain functions as a catalytic 
template which allows for the simultaneous binding of HCII and thrombin. Once a 
glycosaminoglycan chain binds, the N-terminal acidic domain of HCII is displaced and 
free to interact with the anion-binding exosite I of thrombin. This interaction results in a 
5000-fold acceleration of thrombin inhibition (Tollefsen, 1994). 
 
3.3 Tissue factor pathway inhibitor (TFPI) 
The main route by which thrombin generation is initiated in response to vessel 
damage is the extrinsic, or tissue factor (TF)-initiated pathway of coagulation (Mackman, 
2006). TF is a 45 kDa transmembrane glycoprotein which is located at extravascular sites 
that are not normally exposed to the blood (Maroney et al., 2008). Coagulation is 
therefore initiated when the exposed tissue factor forms a 1:1 stoichiometric complex 
with small amounts of the normally circulating activated factor (F) VII (Broze et al., 
1988). FVII binds to the lipid portion of TF in the presence of calcium. As a result, FVII 
is auto-cleaved within the complex to FVIIa. The TF–FVII/FVIIa complex activates FX 
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and FIX and ultimately, through various feedback loops amplifying the production of 
FXa, produces the formation of thrombin (Broze et al., 1988). 
TF is known to play a significant role in the pathophysiology of many diseases 
such as inflammation and cancer. For instance, a variety of tumor cells types are known 
to constitutively and aberrantly express TF on their surfaces including, non-small cell 
lung, breast, pancreatic, and colon cancers (Sawada et al., 1999; Ueno et al., 2000; Ueda 
et al., 2001; Nakasaki et al., 2002). Moreover, the expression of TF in tumors is 
associated with increased angiogenesis, which may be due to the upregulation of vascular 
endothelial growth factor (VEGF) (Nakasaki et al., 2002; Zhang et al., 1994). A study by 
Yu and Rak (2004) showed that in vitro TF is secreted from cancer cells predominately in 
association with shed microparticles.  
Tissue factor pathway inhibitor (TFPI), originally referred to as extrinsic pathway 
inhibitor or lipoprotein-associated coagulation inhibitor, is a plasma Kunitz-type serine 
protease inhibitor, which modulates coagulation induced by TF. TFPI is the only known 
regulator of the TF-dependent pathway of coagulation. It is a 43 kDa protein with an 
acidic N-terminal region followed by three tandem Kunitz-type serine protease inhibitory 
domains and a basic C-terminal region (Lwaleed and Bass, 2006). The major site of TFPI 
production is in endothelial cells, which constitutively express the protein under normal 
conditions. TFPI is also normally expressed by vascular smooth muscle cells, mesangial 
cells fibroblasts, monocytes, cardiomyocytes, and megakaryocytes/platelets (Kereveur et 
al., 2001; Osterud et al., 1995). In addition, TFPI has been detected in macrophages and 
T cells in atherosclerotic lesions (Crawley et al., 2000). Once TFPI is produced, it is 
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stored in platelets (<2.5%), in plasma (10 – 50%), and bound to the endothelium (50-
80%) (Novotny et al., 1991; Lindahl et al., 1992; Werling et al., 1993). It normally 
circulates in plasma at a concentration of 1.0 - 2.5nM, and has a half-life of 60-120 
minutes (Broze, 1995; Lwaleed et al., 2006). 
TFPI abrogates blood coagulation by a two-step mechanism of action. First, TFPI, 
via its second Kunitz domain, directly binds to the active site of FXa and inhibits it. 
However, optimal inhibition of FXa also requires the carboxy terminus of TFPI (Wenzel 
et al., 1981). Second, TFPI, in an FXa-dependent way, inhibits the TF/FVIIa complex, 
presumably by forming a quaternary FXa/TF/FVIIa/TFPI complex (Broze et al., 1992). 
Girard and coworkers (1989) demonstrated that the first Kunitz domain of TFPI (K1) 
binds ionically to the active site of FVIIa in the TF/FVIIa complex. Despite its homology 
to K1 and K2, the third Kunitz domain (K3) has no described inhibitory function, but is 
required for optimal cell binding. 
Along with the other anticoagulant effects, heparin has been shown to release the 
pool of TFPI that is bound to glycoaminoglycans on the surface of the endothelium 
(Sandset et al., 1988; Holst et al., 1993). Additionally, heparin also upregulates TFPI 
gene expression which causes the elevation of both plasma and cellular TFPI pools 
(Crawley et al., 2008). The release of TFPI from the endothelium increases the plasma 
levels 1.5 to 3-fold. The amount of TFPI released into the plasma is determined by the 
dose of heparin administered. Interestingly, Hansen et al., 1996; Hansen et al., 1998; and 
Bendz et al., 1999 demonstrated that continuous and repeated intravenous and 
subcutaneous administration of heparin causes the partial depletion of TFPI antigen and 
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heparin releasable TFPI in man, but not during subcutaneous injections of LMWH. They 
theorized that the differential effects between heparin and LMWH on TFPI depletion 
could explain the apparent clinical superiority of LMWHs.  
Previous studies suggest that various low molecular weight heparins (LMWH) 
have differing abilities to release endogenous TFPI (Hoppensteadt et al., 1995; 
Hoppensteadt et al., 1996). In fact, it has been shown that pentasaccharide 
(fondaparinux), which is distinct from heparin and LMWH in that it solely targets only 
FXa, was unable to release TFPI (Hoppensteadt et al., 2003). In another study conducted 
by Bendz and coworker (2000), the dose-response relationship for escalating doses of 
two LMWHs, dalteparin and enoxaparin, on the release of endogenous TFPI was 
investigated. Participants were given 50, 100 and 200 U/kg dalteparin and 0.5, 1.0 and 
2.0 mg/kg enoxaparin as single subcutaneous injections. Peak free TFPI antigen and TFPI 
activity were detected after only 1 h, whereas anti-activated factor X (anti-FXa) and anti-
activated factor II (anti-FIIa) activities were detected after 2-6 h. Assumed therapeutic 
equivalent doses of dalteparin and enoxaparin gave similar release of endogenous TFPI, 
but dissimilar effects on anti-FXa and anti-FIIa activities. Another study demonstrated a 
molecular weight dependence of TFPI release by heparin and its low molecular weight 
fractions after intravenous and subcutaneous administration (Ma et al., 2007). Together, 
these data suggest that the amount of TFPI released during heparin and LMWH therapy is 
dependent on the dose of the anticoagulant given and the chemical nature of the agent. 
In addition to its anti-coagulant properties, TFPI has also been shown to regulate 
angiogenesis, tumor growth, and tumor metastasis (Mousa, 2005). Angiogenesis is 
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promoted directly through the interaction of the TF/VIIa protease complex and the 
protease-activated receptor 2 (PAR2) (Fernandez et al., 2004). Ahamed et al (2005) 
demonstrated that recombinant TFPI was able to attenuate PAR2 signaling in endothelial 
cells overexpressing TF and PAR2. Additionally, Holroyd et al (2012) demonstrated, in a 
murine model, a TF-independent inhibitory role of TFPI in angiogenesis, which was 
localized to the heparin-binding carboxyl terminus of TFPI and acted to inhibit VEGF (a 
potent angiogenic factor) signaling. Mousa et al. (2004) has demonstrated that a low-
molecular-weight heparin, tinzaparin, is capable of inhibiting angiogenesis by mediating 
the release of TFPI (Mousa et al., 2004). Therefore, heparin-mediated release of TFPI 
may be one of the many mechanisms by which heparins inhibit tumor growth. 
 
3.2 TAFI and heparins 
TAFI function may be affected by different drugs such as heparins and various 
low molecular weight heparins (LMWHs). The ability of heparins to inhibit TAFI may be 
linked to their anti-IIa activity, as thrombin plays a major role in the activation of TAFI. 
Different LMWHs have different degrees of anti-IIa and anti-Xa activity. Drugs with low 
anti-IIa activity may not inhibit TAFI enough to keep the patient from developing 
thrombi. Florian-Kujawski et al (2004) compared to the effects of heparin and various 
LMW heparins on TAFI activation in normal human plasma. They found that heparin 
produced the strongest inhibition of TAFI functionality compared to different LMW 
heparins at equigravimetric concentrations. However, the relative proportion of the anti-
IIa activity of the other LMWHs did not necessarily follow their inhibitory profiles of 
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TAFI. They suggest that other mechanisms may be at involved in the inhibition of TAFI 
(Florian-Kujawski et al, 2004). Overall, the ability of heparins to inhibit TAFI may be 
one of the many mechanisms by which they produce their therapeutic effects.  
 
4. Low molecular weight heparin (LMWH) 
Although UFH has a high degree of efficacy and safety, there are various diseases 
in which alternatives to UFH would be beneficial such as VTE, DVT, and cancer. 
Different pharmacological properties in which improvement is warranted include 
increased bioavailability, enhanced safety (less bleeding), greater convenience (fewer 
injections), and better efficacy (lower rate of thrombotic events). LMWHs represent an 
important alternative to UFH and have been touted to be more advantageous. Some of the 
most common commercially available LMWHs are enoxaparin sodium, dalteparin 
sodium, tinzaparin sodium, ardeparin sodium, and second-generation LMWH, bemiparin 
sodium (Iqbal and Cohen, 2011; Collignon et al., 1995; Hoy et al., 2010; Jeske et al., 
1999; Sanche-Ferrer, 2010). 
LMWHs are produced by controlled enzymatic or chemical depolymerization of 
UFH either by heparinase, benzylation followed by alkaline hydrolysis, nitrous acid 
degradation, or peroxidative cleavage (Hoppensteadt et al., 1993; Weitz, 1997). The 
different methods of production result in each LMWH having a distinct biochemical and 
pharmacological profile. Therefore, LMWHs are not interchangeable unless parallel 
clinical trials have been performed for each specific clinical indication (Bick et al., 2005).  
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LMWHs consist of only short chain polysaccharides which are approximately 
one-third the size of UFH (Fareed et al., 1998). LMWHs are defined as heparin salts 
having at least 60% of all chains with a molecular weight less than 8.0 kDa. On average, 
LMWHs have molecular weights ranging between 3.5 to 6.5 kDa (Gray et al., 2008).  
Having a lower molecular weight gives LMWHs several distinct characteristics 
from UFH. First, in contrast to UFH, which has an anti-FXa/FIIa ratio equal to 1, 
LMWHs have a ratio which is greater than 1, and this ratio generally increases as the 
molecular weight of the compound decreases (Gray et al., 2008). The benefit of having a 
greater anti-FXa/FIIa ratio is that it denotes a reduction in bleeding which is often a side 
effect of UFH. Second, having smaller molecular weight components means LMWHs are 
better absorbed following subcutaneous administration. Whereas, UFH has a 
bioavailability of approximately 20 to 30 percent (Fareed, 1985), LMWHs are virtually 
100 percent bioavailable after subcutaneous injection (Weitz, 1997). Additionally, the 
plasma half-life of LMWHs is two to four times as long as that of UFH; however, this is 
dependent on the dose, route of administration, and assay to detect the anticoagulant 
activity (Lockner et al., 1986; Fareed et al., 1986; Harenberg, 1990). LMWHs are mainly 
removed by non-saturable renal excretion; therefore, their pharmacokinetic parameters 
are dose independent (Boneu et al, 1987). These various attributes, in conjunction with 
the fact that LMWHs have a decreased propensity to bind to plasma proteins, 
macrophages, and endothelial cells in comparison to UFH (Young et al., 1994), means 
that they have a more predictable anticoagulant response than UFH. Consequently, 
LMWHs are less likely to cause heparin-induced thrombocytopenia (HIT) (Baroletti et 
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al., 2008), can be administered once daily, and do not require continuous monitoring 
(Handeland et al., 1990). 
LMWHs have been determined to be as safe and effective as UFH for various 
clinical indications including prevention and treatment of PE and deep vein thrombosis 
(DVT). Kakkar et al (1982 & 1985) demonstrated an increased efficacy for LMWHs as a 
prophylactic agent, with a DVT rate of 2.5% compared to 7.5% for UFH. Besides having 
FDA approval for postsurgical prophylaxis of DVT with or without pulmonary 
embolism, LMWHs are also approved for prophylaxis of ischemic complications of 
unstable angina and non-Q-wave myocardial infarction (Fareed et al., 2005; Aguilar and 
Goldhaber, 1999). 
LMWHs also have off-label indications for management of hypercoagulability 
associated with atrial fibrillation, treatment of thrombotic disorders during pregnancy, 
adjunctive therapy for complicated percutaneous coronary interventions, and prophylaxis 
of DVT during surgery, inflammatory bowel disease, cancer, sepsis, and other 
proliferative and ischemic disorders (Aguilar and Goldhaber, 1999). The potential uses of 
LMWHs are not limited to this list and continue to grow as further research is being 
performed. 
The most widely used LMWH is enoxaparin (Lovenox – Sanofi Aventis), which 
was FDA approved in 1993. Enoxaparin is derived from porcine heparin that undergoes 
benzylation followed by alkaline depolymerization. The average molecular weight of 
enoxaparin is approximately 4500 Da. It has 100U/mg of anti-Xa activity and 25 U/mg of 
anti-IIa activity, which corresponds to a 4:1 anti-Xa/IIa ratio. Enoxaparin is given as a 
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once (1.5 mg/kg) or twice daily (1 mg/kg every 12 hours) subcutaneous injection for the 
long-term treatment of acute DVT with or without PE. Enoxaparin is used mainly to 
prevent and treat deep vein thrombosis, pulmonary embolism, and acute coronary 
syndrome. Unfortunately, enoxaparin is associated with side effects such as bleeding and 
heparin-induced thrombocytopenia but at a lower incidence rate than UFH (Warkentin et 
al., 1995). 
Bemiparin (Hibor – Rovi Pharmaceutical Laboratories) sits in a unique position in 
terms of defining its categorical placement. In the literature, bemiparin is called both a 
second generation LMWH and also an ULMWH. This contradiction in terms exists 
primarily because bemiparin has the lowest mean molecular weight of any LMWH (3600 
Da) but interestingly, the longest half-life (5.3 h) and the highest anti-FXa/anti-FIIa 
activity ratio (8:1).  
Bemiparin is produced by chemical depolymerization, using β elimination 
methods, and fractionation of porcine UFH (Chapman et al., 2003). Like enoxaparin, 
bemiparin is given as a once daily subcutaneous injection. However, bemiparin is dosed 
at 3500 anti-Xa IU/day for the long-term treatment of DVT (Chapman et al., 2003). 
Several studies have demonstrated the safety and efficacy of bemiparin (Kakkar et 
al., 2000; Hidalgo et al., 2000; Kakkar et al., 2003). Currently, bemiparin is licensed in 
Europe for the prevention and treatment of VTE in patients undergoing surgery, 
treatment of establish DVT, as well as the prevention of clotting during hemodialysis 
(Chapman et al., 2003). As with other LMWHs, bleeding complications, wound 
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hematomas, and hematomas at the injection site were the most common adverse events in 
clinical trials (Kakkar et al., 2003; Navarro-Quilis et al., 2003). 
 
5. Ultra low molecular weight heparin (ULMWH) 
In trying to produce safer and more efficacious heparin and LWMH substitutes, 
ULMWHs have been developed. ULMWHs are obtained by selective and controlled 
depolymerization of heparin and have mean molecular weights ranging between 2-3 kDa. 
ULMWHs mainly produce their effects through inhibition of the coagulation enzyme 
factor Xa and to a lesser extent factor IIa (thrombin). The ULMWHs typically have an 
anti-FXa activity in the range of 60-160 U/mg and anti-FIIa activity less than 5 U/mg.  
Semuloparin (AVE5026) (Sanofi-Aventis) is a polydisperse mixture of oligomeric 
heparin fragments with a mean molecular weight between 2.0-3.0 kDa and a half-life of 
approximately 16-20 hours (Gomez-Outes et al., 2009; Lassen et al., 2009). It exhibits 
distinct structural features resulting from a highly controlled chemical depolymerization 
by a phosphazene base (Viskov et al., 2009). The depolymerization process protects the 
AT binding site from destruction, thus enriching semuloparin with high-affinity AT 
binding sequences. Viskov et al (2009) compared the percentage of AT-binding 
components between semuloparin and the frequently used LMWH, enoxaparin. As seen 
in Table 1, in fractions desalted and purified by chromatography, semuloparin exhibited a  
significant increase in the content of AT-binding material as compared with enoxaparin 
(Viskov et al, 2009). This enrichment confers semuloparin with higher than normal anti-
FXa activity (~160 U/mg) compared to that typically seen for heparins with such a low 
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molecular weight. However, the enrichment process does not affect the anti-FIIa activity 
(~2 U/mg) of semuloparin, which is markedly low due to its lower molecular weight. 
This high anti-FXa/IIa ratio may confer semuloparin with high antithrombotic efficacy  
Figure 6. The structure of semuloparin (AVE5026). Semuloparin is obtained by partial 
and controlled depolymerization of porcine heparin by a phosphazene base. The 
polysaccharide fragments have a heterogeneous MW distribution. The oligosaccharides 
are made of heparin disaccharidic sub-units, sizing from 1 to 11. The amino sugars can be 
N-sulfated or N-acetylated and both the hexuronic acid (mainly iduronic acid) and 
glucosamine moieties can bear O-sulfate groups at various positions (Modified from 
Viskov et al., 2009).  
 
and lesser bleeding propensity compared to LMWHs (Ansell, 2007). Accordingly, in a rat 
venous thrombosis model, Viskov et al. (2009) showed that semuloparin had a dose-
dependent antithrombotic activity equivalent to that of enoxaparin; similar results were 
obtained in dogs and rabbits. Additionally, they demonstrated that at equipotent doses, 
enoxaparin showed increased hemorrhage in rats, rabbits and dogs, whereas semuloparin 
did not affect bleeding parameters (Viskov et al., 2009). 
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% of 
AT-binding part 
Hexa Octa Deca Dodeca Tetradeca Hexadeca 
Enoxaparin 3-5 7-8 10-11 12-13 14-15 18-20 
Semuloparin 17-24 25-36 30-45 35-48 42-50 45-55 
 
Table 1: Comparison between enoxaparin and semuloparin of the AT-binding compounds 
in the fractions ranging from hexa to hexadecasaccharides (Modified and reprinted with 
permission from Viskov et al., Journal of Thrombosis and Haemostasis, 2009). 
 
Dubruc et al (2009) evaluated the pharmacokinetic data from the first three phase 
I studies for semuloparin which included single and repeated SC dosing in a total of 143 
healthy young and elderly subjects. In the 56 subject, single-dose escalation study (0.05 
to 1.4 mg/kg), they found that the anti-Xa and the anti-IIa activity increased 
proportionally to the dose. For doses of 0.3 mg/kg and up, the half-life was 
approximately 11 hours. The second study (72 subjects) was a repeat dose-escalation 
study included doses of 5 mg (only in elderly), 20, 60, and 100 mg given SC once daily 
for 14 days in healthy young male and elderly male and female subjects. (Dubruc et al., 
2009). After repeat dosing in elderly subjects, a 1.47-fold increase in accumulation of 
semuloparin from day 1 to day 14 was seen. Half-life ranged from 16.4 - 20.5 hours 
across the doses on day 14. The third study was a randomized open-label study carried 
out in 15 healthy male and female subjects to determine bioavailability of a single 60 mg 
SC dose compared to a 3-hour intravenous (IV) infusion. After a single SC 60 mg dose, 
the bioavailability was 98% compared with IV administration, the total clearance was 
0.60 ± 0.17 L/h, and the volume of distribution (VD) was 7.88 ± 1.45 L (Dubruc et al., 
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2009). Overall, Dubruc et al (2009) claimed that semuloparin was safe and well tolerated 
in these subjects. 
Semuloparin is currently in clinical development for the prevention of venous 
thromboembolism based on the expectation that it reduces bleeding risk, increases 
antithrombotic efficacy, and has once-daily administration. Lassen et al. (2009) 
investigated the use of semuloparin in 690 patients for the prevention of VTE after total 
knee replacement (TKR) surgery for a phase IIb clinical trial. They demonstrated that 
dosages between 20 and 40 mg provide a sufficient benefit-to-risk ratio for the prevention 
of VTE in TKR patients. Furthermore, the dosages of semuloparin were shown to be 
significantly more effective than enoxaparin (40 mg) at preventing VTE (Lassen et al., 
2009).  
Additional clinical trials to assess the efficacy and safety of semuloparin include 
extended prophylaxis in hip fracture surgery (HFS) (SAVE-HIP3, 454 patients) 
[www.clinical trials.gov; NCT00709904], short-term prophylaxis in HFS (SAVE-HIP2, 
1000 patients) [www.clinicaltrials.gov; NCT00721760], thromboprophylaxis in major 
abdominal surgery (SAVE-ABDO, 4400 patients) [www.clinical trials.gov; 
NCT00679588], short-term prophylaxis after total knee replacement (SAVE-KNEE, 
1060 patients) [www.clinicaltrials.gov; NCT00718224], the prophylaxis of VTE in total 
hip replacement (SAVE-HIP1, 2320 patients) [www.clinicaltrials.gov; NCT00697099], 
and thromboprophylaxis in cancer patients undergoing chemotherapy (SAVE-ONCO, 
3200 patients) [www.clinicaltrials.gov; NCT00694382]. Specifically, the SAVE-ONCO 
trial showed that semuloparin reduced the incidence of thromboembolic events in cancer 
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patients receiving chemotherapy, with no apparent increase in major bleeding (Agnelli et 
al., 2012)  
RO-14 (Rovi Pharmaceutical Laboratories) is another ULMWH currently being 
developed for deep DVT prophylaxis after hip surgery (White et al., 2002). It is 
manufactured from heparin by means of chemical degradation and has a mean molecular 
weight of 2.5 kDa. Unlike semuloparin, RO-14 is not enriched with high-affinity AT 
binding sequences; however, it will still have a greater anti-FXa/IIa ratio in comparison 
to LMWHs. Peak plasma concentrations of RO-14 are achieved 4 hours post-dose, and 
RO-14 has an elimination half-life of 5.6 hours after subcutaneous (SC) administration in 
non-human primates (Ma et al., 2003). RO-14 underwent a phase I clinical trial to 
evaluate the tolerability and pharmacokinetics after SC dosing (Rico et al., 2011). Results 
showed that RO-14 was well tolerated in adult males, with no bleeding events noted. 
Additionally, it had a longer elimination half-life than currently marketed LMWHs (Rico 
et al., 2011).  
 
6. Newer anticoagulants 
Over the past 60 years, heparins, LMW heparin, and vitamin K antagonists have 
been the cornerstone of antithrombotic treatment. They are widely used for the 
prophylaxis and treatment of VTE, DVT, and PE. However, during the last decades, there 
have been rather considerable advances in the development of new antithrombotic agents. 
A variety of synthetic, semi-synthetic, biotechnology, and naturally produced 
antithrombotic drugs that differ in their functional and structural heterogeneity represent 
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the spectrum of new agents (Fareed et al., 1999). Major efforts have also been made to 
produce orally administered anticoagulants with improved safety and efficacy profiles 
Weitz et al., 2008). The goal for these new anticoagulants is to be as effective as heparins 
and VKAs in preventing thrombus formation and at least as equally safe with regard to 
the bleeding risk (Weitz et al., 2008). Some of these new agents are capable of directly 
and indirectly inhibiting activated factor Xa and thrombin.  
The new oral direct factor Xa inhibitors include apixaban, rivaroxaban, 
betrixaban, edoxaban, and otamixaban (Tsiara et al., 2011; Huisman, 2011). These agents 
bind reversibly to the active site of factor Xa and inhibit it without using antithrombin as 
a mediator. Rivaroxaban, apixaban, and edoxaban are given as a fixed dose, and since 
their anticoagulant effects are predictable they do not require routine monitoring 
(Huisman, 2011). Rivaroxaban, an oxazolidone derivative, is licensed for the prophylaxis 
of VTE following orthopedic surgery; however, concerns have been raised over the 
potential for it to increase bleeding and cause wound complications (Gomez-Outes et al., 
2009). Rivaroxaban has an 80% oral bioavailability, a half-life of approximately 9 hours, 
and is cleared by the kidney and gut (Weitz et al., 2008). Rivaroxaban is approved in 
Canada and Europe for the prevention of VTE in patients who have undergone elective 
total hip or total knee replacement surgery. In the US, it is approved for the prophylaxis 
of DVT, with or without PE, in adult patients undergoing hip and knee replacement 
surgery and for stroke prevention in patients with non-valvular atrial fibrillation. 
Apixaban, on the other hand, is only approved in Europe for the prevention of VTE in 
adults undergoing elective hip or knee replacement surgery. However, apixaban is fast-
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tracked for approval in the US, as in the ARISTOTLE trial it outperformed warfarin in 
preventing stroke, increasing survival, and reducing bleeding (Weitz et al., 2008). 
Apixaban has been shown to have excellent bioavailability, a 12 hour half-life, and is 
known to be eliminated via both kidneys and bile (Raghavan et al., 2008). As for the 
remaining direct factor Xa inhibitors, betrixaban, edoxaban, and otamixaban, they are all 
in various stages of clinical trials and will not be discussed further. 
Some of the indirect factor Xa inhibitors include fondaparinux and idraparinux. 
Fondaparinux is a widely used indirect factor Xa inhibitor that is administered SC (Tsiara 
et al., 2011). Fondaparinux, which is a synthetic and biotechnology derived 
heparinomimetic, has been found to be effective for the prophylaxis and treatment of 
acute coronary syndromes and VTE (Weitz et al., 2008). It is a heparin-pentasaccharide, 
which represents the minimal binding portion of heparin (Weitz et al., 2008). Since 
fondaparinux has a plasma half-life of about 17 h, it can be administered subcutaneously 
once daily (Weitz et al., 2004). Fondaparinux has been approved in the US and Europe 
for the prevention of VTE or acute DVT/PE in patients undergoing hip fracture surgery, 
hip replacement surgery, or knee replacement surgery. 
Idraparinux, which is a highly sulfated derivative of fondaparinux, binds to 
antithrombin with such high affinity that its half-life is 130h (Weitz et al., 2004). The 
exceptionally long half-life allows idraparinux to be given subcutaneously once-weekly 
(Weitz et al., 2004). However, during clinical trials, idraparinux was found to cause 
major bleeding; thus, based on this information, it is unlikely it will be developed further 
(Weitz et al., 2008). 
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Direct thrombin inhibitors (DTI) are related in structure to the naturally occurring 
hirudin molecule. Hirudin is a polypeptide of 65 to 66 amino acids derived from the 
saliva of the medicinal leech Hirudo medicinalis and is the most potent naturally 
occurring specific inhibitor of thrombin (Fareed et al., 1999). Genetically engineered or 
recombinant analogs of hirudin are what are currently on the market. Compared to factor 
Xa inhibitors, direct thrombin inhibitors (DTI) have more diverse effects on coagulation. 
They prevent thrombin-mediated activation of different coagulation factors, thrombin-
induced platelet aggregation, and fibrin formation (Tsiara et al., 2011). Similarly to factor 
Xa inhibitors,
 
tissue factor-mediated thrombin generation is attenuated
 
by thrombin 
inhibitors (Tsiara et al., 2011). Also in contrast to heparins, direct
 
thrombin inhibitors 
have the capacity to act on fibrin-bound thrombin (Harenberg, 2008); however, this effect 
can also increase the
 
risk of bleeding. Among some of the direct thrombin inhibitors are 
lepirudin, bivalirudin, argatroban, all of which are administered parenterally, and 
dabigatran, which is given orally. 
Argatroban and lepirudin are approved in the US for treatment of patients with 
HIT and patients at risk of HIT who are undergoing percutaneous coronary intervention 
(PCI), along with their associated thromboembolic diseases (Fareed et al., 1999), whereas 
bivalirudin is licensed as an alternative to heparin only in PCI patients (Weitz et al., 
2008). Argatroban has a relatively short half-life (45 min) and undergoes hepatic 
metabolism (Koster et al., 2007). Because of its hepatic metabolism, it may be used in 
patients with renal dysfunction (Koster et al., 2007). Argatroban therapy is administered 
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IV, therefore, its effects must be monitored with the activated clotting time (ACT) or 
activated partial thromboplastin time (APTT) (Koster et al., 2007).  
Lepirudin is recombinant DNA form of the natural hirudin (r-hirudin) that is an 
irreversible inhibitor of thrombin (White et al., 2005). It is administered by IV infusion 
and monitored by the APTT (White et al., 2005). The half-life of lepirudin is between 0.8 
to 2 hours in normal healthy adults and mostly undergoes renal clearance and proteolytic 
cleavage (White et al., 2005).  
Bivalirudin, a 20 amino acid polypeptide synthetic hirudin analog, exhibits 
bivalent and reversible binding to the thrombin molecule (Parry et al., 1994). Similarly to 
lepirudin, bivalirudin is administered by IV infusion, although, unlike lepirudin it is 
monitored by the ACT (White et al., 2005). Bivalirudin has a small volume of 
distribution, a half life of 25 minutes, and is predominantly cleared by intracellular 
proteolysis (White et al., 2005). However, the remaining unchanged drug (approximately 
20%) is cleared renally (White et al., 2005). 
Dabigatran, a direct thrombin inhibitor, has been approved for stroke prevention 
in atrial-fibrillation patients in the US and Canada. Dabigatran is a LMW prodrug that 
exhibits no pharmacological activity. However, after oral administration, it is converted 
to its active form (Hankey and Eikelboom, 2011). The approximate half-life of dabigatran 
is about 8 hours after a single dose and ranges from 12 to 14 hours after multiple doses 
(Stangier et al., 2007). Dabigatran is mainly cleared by the kidneys; with up to 80% of it 
excreted unchanged (Stangier et al., 2007). Consequently, dabigatran is not 
recommended for use in elderly patients with reduced kidney function, as this may result 
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in elevated plasma concentrations and a prolonged half-life (Hankey and Eikelboom, 
2011). 
Although some of the recently developed anticoagulant and antithrombotic drugs 
may be equally as effective as the VKAs and LMWHs, there are concerns about their 
widespread use. Due to the fact that there is no simple and effective way to monitor these 
novel agents, treatment of hemorrhagic complications is more complicated.
 
Some of the 
newer agents require twice daily dosing, which potentially
 
lowers the effectiveness of the 
drug in patients with low compliance. There are no specific antidotes for these new drugs, 
and it is not clearly defined which agents can have their anticoagulant effects rapidly 
reversed in case of overdosing (Kessler, 2004). Furthermore, in some patients, especially 
those needing urgent interventional or surgical procedures, the lack of a specific antidote 
may be a disadvantage. 
 
7. Neutralization of heparins 
 
7.1 Platelet factor 4 
Platelet factor 4 (PF-4), first described by Niewiarowski and Thomas 
(Niewiarowski et al., 1969), is a natural antagonist of heparin. PF-4 has a mean molecular 
weight of 7.7 kDa and is 70 amino acids long. It is synthesized by megakarocytes and 
stored in the alpha granules of platelets (Barber et al., 1972). PF-4 is released from 
platelets by thrombin in the form of a high molecular weight PF-4 tetramer in a complex 
with two molecules of a chondroitin sulfate proteoglycan (Barber et al., 1972). Once 
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released, it is capable of neutralizing the anticoagulant effects of heparin in plasma 
(Kaser-Glanzmann et al., 1972). 
PF-4 has heparin binding sequences located on its C-terminal domains, which 
allows heparin to bind with high affinity (Zucker et al., 1991). Mayo et al (1989) 
demonstrated that PF-4 exists in solution in a concentration-dependent mixture of 
monomers, dimers, and tetramers which are comprised of two asymmetric PF-4 dimers. 
The tetrameric form of PF-4 is required for the high affinity heparin binding. This form 
allows heparin to wrap around PF-4 and bind to the two C-terminal domains where the 
heparin binding sequences are located (Mayo et al., 1989).  
Similarly to heparin’s inhibition of thrombin, a heparin chain length greater than 
18 saccharides is required for optimal PF-4 binding (Lane et al., 1984). Therefore, 
heparin molecules above 18 saccharides with both anti-thrombin and anti-factor Xa 
activities can be completely neutralized by PF-4, whereas molecules below 18 
saccharides, which retain anti-factor Xa activity, are more resistant to neutralization by 
PF-4. Indeed, a weaker neutralization by PF-4 has been seen for LMWHs in comparison 
to that of heparin (Lane et al., 1984).  
When exogenous heparin is administered, PF-4 is released from platelets to 
neutralize the anticoagulant activity of heparin. PF-4 inhibits heparin-dependent 
acceleration of thrombin inactivation by antithrombin and potentiates platelet aggregation 
in the presence of suboptimal concentrations of agonists, suggesting a procoagulant 
function (Zucker et al., 1991). However, PF-4 also inhibits Factor XII activation by 
negatively charged substances (Zucker et al, 1991). 
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The binding of PF-4 with heparins is associated with one of the adverse effects of 
heparin, namely heparin induced thrombocytopenia (HIT). HIT is characterized by a 
severe decline in platelet count (by >50%) in association with new thromboembolic 
complications (Reilly, 2003).  
When PF-4 is released, it binds to heparin, resulting in a conformational change in 
PF-4. This complex is considered a foreign antigen within the body and may be 
immunogenic. The immune response is characterized by initial IgM antibody formation, 
followed on the 5th day by the development of IgG antibodies (Warkentin, 1998; Reilly, 
2003). The IgG antibodies form a complex with heparin and PF-4 in the bloodstream. 
The tail of the IgG antibody binds to the Fc receptor on the surface of platelets, markedly 
enhancing activation. These activated platelets have a markedly shortened survival and 
are acutely consumed in prothrombotic processes, resulting in thrombocytopenia. HIT 
generally occurs 5 to 14 days after initiation of heparin therapy (Warkentin, 1998; Reilly, 
2003). However, only a subset (1-5% when UFH is used but <1% with LMWHs) of 
individuals who develop heparin antibodies actually develop HIT (Warkentin et al., 
1995; Smythe et al., 2007). 
 
7.2 Protamine sulfate 
In 1868, Friedrick Miescher identified a nitrogenous base bound to nuclear 
material of Rhine salmon sperm heads; which he name protamine (Horrow, 1985). In 
1937, Chargraff and Olsen demonstrated that protamine sulfate could neutralize the 
anticoagulant action of heparin (Chargaff et al., 1937). Today, the ability of protamine to 
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reverse the anticoagulant activity of heparin has contributed significantly to the field of 
cardiovascular surgery and the widespread therapeutic acceptance of heparin. Protamines 
are arginine-rich (nearly 67%) and strongly basic, small (45kDa) nuclear proteins that 
replace histones late in the haploid phase of spermatogenesis and are believed to be 
essential for sperm head condensation and DNA stabilization (Horrow, 1985; Balhorn, 
2007). Protamines are usually commercially prepared from salmon milt into a dried 
powder or solution.  
When administered alone, protamine has a mild anticoagulant effect. However, 
when it is given in the presence of heparin (which is strongly acidic), ionic forces form a 
stable precipitate, where intermolecular charge neutralization occurs, thereby causing the 
neutralization of heparin activity (Horrow, 1985; Schiele et al., 1986). Various factors 
influence the interaction of protamine and heparin including: individual molecular weight 
of a given protamine or heparin, charge type, and charge density (Schiele et al., 1986). 
The source of heparin has also been shown to affect the degree of neutralization by 
protamine (Lowary et al., 1971). Neutralization of porcine mucosal heparin requires less 
protamine sulfate neutralization of bovine mucosal heparin (Racanelli et al., 1989). A 
study by Dawes and Pepper (1982) demonstrated that molecular weight, degree of 
sulfation, and position of sulfate residues directly influence heparin’s affinity for 
protamine. However, out of all contributing factors, Dawes and Pepper (1982) 
determined that degree of sulfation is the most important determinant of heparin’s affinity 
to protamine. Binding of protamine to heparin most likely dissociates heparin from AT, 
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thereby breaking the heparin/AT complex and neutralizing heparin’s anticoagulant 
activity (Okajima et al., 1981). 
One of the major problems associated with protamine use in patients is the 
associated toxicity. Some of these adverse events include: complement activation, 
adverse hypotension, anaphylaxis, cellular derangements, mast and basophil 
degranulation with subsequent release of histamine, induction of platelet aggregation, and 
elevations of mean pulmonary arterial blood pressure (Frater et al., 1984; Horrow, 1986). 
 
7.3 Polybrene 
Polybrene, a quaternary ammonium polymeric salt, (hexadimethrine bromide) is a 
synthetic heparin antagonist used in clinical laboratories to neutralize the anticoagulant 
effects of heparin as well as to determine heparin activity in human plasma (Montalescot 
et al., 1990). Additionally, polybrene has been used as an alternative neutralizing agent 
for patients who are allergic to protamine after cardiopulmonary bypass surgery (Weiss et 
al., 1989). Essentially, heparin and polybrene form a polyanion-polycation interaction 
similar to that of protamine sulfate. Therefore, polybrene neutralizes the intermolecular 
charge of heparin and renders it inactive (Montalescot et al., 1990). Weiss et al (1958) 
demonstrated that a dose of 0.7 mg of polybrene to 1mg of heparin, completely and 
rapidly neutralizes the anticoagulant actions of heparin. Polybrene has also been shown to 
inhibit factor XII activation (Castenda et al., 1967).   
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7.4 PMX60056 
PMX 60056 (PolyMedix Inc., Radnor PA) is the clinical lead compound of a 
series of small molecule oligomers that interact strongly with heparin and LMWHs. PMX 
60056 consists of alternating lysine and 5-amino salicylic acid building units and has a 
molecular weight of 1.126 kDa. Previous work has demonstrated the effectiveness of 
PMX 60056 to neutralize the anti-IIa and anti-Xa activities of heparin, LMWH and 
fondaparinux following in vitro supplementation (Jeske et al., 2008). Using standardized 
animal models, it has been shown that PMX 60056 can neutralize the hemorrhagic and 
antithrombotic effects of heparin and a LMWH, enoxaparin (Kuziej et al., 2010). PMX-
60056 is designed to bind non-specifically in a charge based manner to both heparin and 
LMWH; therefore, preventing their binding to antithrombin, which thus inhibits the 
activity of these drugs and reverses their effects, restoring the ability of the blood to clot 
normally.  
 
8. Heparins and cancer 
The WHO ranks cancer as the second leading cause of death in the United States 
after heart disease, and the CDC puts the incidence of cancer at 16.5 per 100,000 persons. 
Patients with cancer are at high risk of venous thromboembolism (VTE), pulmonary 
embolism (PE), and bleeding (Sorensen et al., 2000; Khorana et al., 2007). VTE and PE 
are among the leading causes of morbidity and mortality in patients with cancer (Khorana 
et al., 2007) and are frequent complications of anticancer therapies such as active 
chemotherapy, thalidomide, erythropoietin agents, anti-angiogenic therapy, and high-
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dose steroids (Khorana et al., 2007; Wun et al., 2009). However, it is important to keep in 
mind that the risk of VTE or PE is not uniform for all cancers or for an individual cancer 
patient over time. Additionally, the comparative benefits and risks associated with 
treatment of thromboembolic episodes differs for patients with cancer compared to those 
without (Thodiyil et al, 2002).  
Cancer-derived tumor cells may activate coagulation events either directly, via 
contact with coagulation factors, or indirectly, through formation of cytokines capable of 
activating certain host cells such as endothelial cells (Rickles et al., 1992). However, 
current evidence indicates that the tissue factor (TF)/FVIIa pathway mediates the most 
copious procoagulant reactions in cancer by promoting thrombin generation (Kakkar et 
al., 1995; Kasthuri et al., 2009; Lindahl et al., 1991; Lindahl et al., 1992; Mackman, 
2009; Rak et al., 2009).  
Cancer-derived tumors cause the activation of the extrinsic pathway of the 
coagulation system by increasing the circulating levels of tissue factor (TF) (Kakkar et 
al., 1995; Iversen et al., 1998). Higher levels of TF are associated with higher levels of 
activated FVII. Additionally, the body’s immune response to a tumor, namely by 
activation of monocytes, may also be associated with TF-dependent activation of the 
coagulation system (Kakkar el al., 2009). Consequently, these conditions are connected 
with higher circulating levels of thrombin–antithrombin complexes and prothrombin 
fragments which indicate a systemic hypercoagulable state (Kakkar et al., 1995). The 
mechanism by which TF is increased in patients with cancer is not fully understood.  
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The interaction between cancer and blood coagulation is complex; it involves 
multiple interactions between endothelial cells, malignant cells, and the coagulation 
cascade. In cancer, coagulation and platelet activation may not only lead to 
thromboembolic complications, but may also promote the metastatic process and enhance 
tumor growth (Mousa, 2005). Therefore, inhibition of the coagulation system may play a 
role in altering the behavior of tumors as well as preventing complications such as VTE 
and PE.  
Heparin has been one of the most extensively used therapies for the prevention 
and treatment of thrombosis in cancer patients (Hirsh, 1991; Siragusa et al., 1996). 
Subcutaneous heparin treatment has been shown to increase the survival of patients with 
small cell lung cancer (Lebeau et al., 1994). Additionally, heparin is effective in 
preventing thrombosis after cancer surgery (Bergqvist et al., 1995), thrombotic 
complications of bone marrow transplantation (Monreal et al., 1996), and thrombosis 
associated with venous access catheters used to administer chemotherapy (Monreal et al., 
1996). Heparin’s effects on cancer are not limited to its anticoagulant properties; it has 
also been shown to inhibit tumor growth, metastases, and in certain model systems, 
angiogenesis (Fisher et al., 1961; Agostino et al., 1962; Owen, 1982; Drago et al., 1984; 
Folkman et al., 1983; Derbyshire et al., 1995). 
Recently, dalteparin was the first LMWH in the US to be approved for the 
treatment of thrombotic complications associated with cancer and cancer-therapy. Two 
major clinical trials, the CLOT study and Monreal cohort study, evaluated extended 
duration dalteparin for treatment of VTE in cancer patients (Lee et al., 2003; Monreal et 
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al., 2004). However, the approval by the US Food and Drug Administration (FDA) for 
the use of dalteparin in cancer patients was mainly based on clinical results from the 
CLOT study.  
The CLOT study was a 676 patient open-label trial which evaluated the safety and 
efficacy of dalteparin in reducing the recurrence of acute DVT, PE, or both compared to a 
coumarin or extended duration dalteparin in randomized patients with active cancer (Lee 
et al., 2003). Active cancer was defined as a diagnosis of cancer, other than squamous-
cell or basal-cell carcinoma of the skin. Patients were randomized into two groups of 338 
patients each. The first group received dalteparin at a dose of 200 IU/kg SC once daily 
for 5-7 days followed by a coumarin derivative for 6 months. The second group of 
patients received dalteparin alone at a dose of 200 IU/kg by once-daily SC injection for 
the first 4 weeks followed by dalteparin at a dose of 150 IU/kg for the remaining 5 
months (Lee et al., 2003). The primary outcome measured was symptomatic recurrent 
VTE at 6 months. 
During the study period, 27 of 336 patients (8%) in the dalteparin group had 
recurrent VTE, as compared with 53 of 336 patients (15.8%) in the coumarin derivative 
group (relative risk reduction 52%; p = 0.002). The overall mortality rate did not differ 
between the dalteparin group (39%) and the coumarin derivative group (41%). Lee et al 
(2003) concluded that in cancer patients with acute VTE, extended duration dalteparin 
was more effective than and as safe as a conventional oral anticoagulant in reducing the 
risk of recurrent thromboembolism. 
57 
 
In the Monreal cohort study (2004), the safety and effectiveness of long-term SC 
dalteparin was evaluated in 203 patients with symptomatic VTE and metastatic cancer of 
the lung, colon, prostate, breast, and stomach. Patients were initially given a 7-day course 
of SC dalteparin (10,000 IU) according to body weight followed by a once daily fixed 
dose (10,000 IU) for at least 3 months. The results showed that only 5.4% of patients 
developed major bleeding complication (6 fatal) and 8.9% developed VTE recurrences in 
the 3-month period. The authors concluded that a once daily fixed dose (10,000 IU) of 
SC dalteparin for 3 months was not associated with more complication in patients with 
liver or brain metastases (Monreal et al., 2004). 
Other studies have compared subcutaneously administered LMWH with 
intravenously administered unfractionated heparin (UFH) for the treatment of thrombosis 
in cancer. These studies have indicated increased survival in patients with venous 
thromboembolism and metastatic carcinoma who initially received treatment with 
LMWH compared with UFH (Hull et al., 1992; Prandoni et al., 1992; Leizorovicz et al., 
1994).  
Recently, the ULMWH, semuloparin, was evaluated for its safety and efficacy in 
preventing VTE in cancer patients receiving chemotherapy. The SAVE-ONCO study was 
a double-blind multicenter trial that randomly assigned patients (3212) with metastatic or 
locally advanced solid tumors, who were beginning to receive a course of chemotherapy, 
to receive 20mg/kg SC semuloparin once daily or placebo for approximately 3.5 months 
(Angelli et al., 2011). Patients with cancer of the pancreas, stomach, lung, colon or 
rectum, ovary, or bladder were included (Angelli et al., 2011). The main efficacy 
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endpoint was the combination of any symptomatic DVT, nonfatal PE, and death related 
to VTE. The main safety outcome was clinically relevant bleeding (Angelli et al., 2011). 
The results showed that VTE occurred in 3.4% of patients in the placebo group compared 
to 1.2% of patients in the treatment group (hazard ratio, 0.36; p<0.001) (Angelli et al., 
2011). No significant differences between the treatment and placebo group were noted in 
terms of clinically relevant and major bleeding. The authors concluded that 
thromboprophylaxis with semuloparin, compared to placebo, reduces the risk of VTE in 
cancer patients receiving chemotherapy. Furthermore, the beneficial effects seen with 
semuloparin were accompanied by no apparent increase in the incidence of major 
bleeding (Angelli et al., 2011). 
The use of LMW, ULMW, and UF heparins in patients with cancer may extend 
beyond their ability to provide preventative anticoagulant and antithrombotic effects. 
Various heparins have been shown to interfere with cancer cell growth and development 
(Falanga et al., 2003) as well as to inhibit cell metastasis (Hejna et al., 1999; Falanga et 
al., 2003). LMWHs have also been shown to inhibit angiogenesis to a greater extent than 
UFH (Norrby K, 1993).  
One study by Marchetti et al (2008) investigated whether enoxaparin, dalteparin, 
and UFH could inhibit the growth of microvascular endothelial cells (HMEC-1) 
promoted by tumor cells. They incubated HMEC-1 cells with tumor cell conditioned 
media (TCM) derived from human leukemic and breast cancer cells (MCF-7, 
MDA.MB.231, and NB4 cells lines) or recombinant cytokines, VEGF, TNF-α, or FGF-2, 
with or without heparins and measured capillary-like tube formation in Matrigel 
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(Marchetti et al., 2008). The authors reported that enoxaparin and dalteparin significantly 
inhibited all three TCM-induced increases in tubular formation in Matrigel, but were 
significantly less affected by UFH (Marchetti et al., 2008). Moreover, Marchetti et al 
(2008) showed that enoxaparin and dalteparin inhibited the recombinant cytokine-
induced tube formation 100% and 70-90%, respectively (Marchetti et al., 2008). 
Another study by Vignoli et al (2011) evaluated the LWMH, bemiparin, and the 
ULMWH, RO-14, in terms of their ability to inhibit the angiogenic response of TCM-
stimulated microvascular endothelium from human leukemia, breast cancer, and lung 
cancer cells in vitro. They demonstrated that both agents dose-dependently inhibited 
capillary-like tube formation in a Matrigel-based assay (Vignoli et al., 2011). Bemiparin 
and RO-14 were also shown to inhibit endothelial migration induced by TCM in a 
wound-healing assay (Vignoli et al., 2011). Additionally, the authors showed that both 
drugs inhibited a purified VEGF and FGF-2 elicited angiogenic response (Vignoli et al., 
2011). Results from both studies support a major role for LMW and ULMW heparins 
compared to UF heparins in inhibiting the proangiogenic effect exerted by tumor cells or 
purified angiogenic factors on microvascular endothelium. 
Various studies have shown that heparins can affect tumor cell apoptosis via an 
array of different mechanisms (Li et al., 2001; Chen et al., 2008; Ueda et al., 2009). One 
study looked at the mechanism of the effect of heparin on apoptosis in the 
nasopharyngeal carcinoma cell line CNE2 using a TUNEL assay, ladder detection assay, 
and flow cytometry. Li et al (2001) demonstrated that heparin dramatically increased the 
number of TUNEL-positive cells in a carcinoma cell line, indicating an increase in the 
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number of apoptotic cells from 2.8 ±0.3% to 33.6 ± 1.2%. Furthermore, the authors 
showed that the induction of apoptosis by heparin in CNE2 cells was probably regulated 
by increased expression of the proapoptotic proteins c-myc and bax.  
Another study by Ueda et al (2009) demonstrated that in oral squamous cell 
carcinoma cells, heparin treatment significantly reduced cell viability and increased 
apoptosis. The increases in apoptosis corresponded with a significant decrease in 
phosphorylated Akt, and consequently an activation of the mitochondrial pathway in 
heparin-sensitive cells (Ueda et al., 2009). Akt usually inhibits apoptosis by 
phosphorylating the antiapoptotic Bcl-2 family member Bad. Therefore, significantly 
decreasing phosphorylated Akt may be one way for heparin to induce apoptosis.  
The LMWH, dalteparin was shown to inhibit the viability of lung adenocarcinoma 
A549 cells, in vitro, in a dose- and time-dependent manner by arresting the cells in G(1) 
phase and inducing them to early apoptosis (Chen et al., 2008). Furthermore, the study 
showed that dalteparin exerted its effects through p21(WAF1) and p27(KIP1) proteins 
(Chen et al., 2008). Both p21 and p27 are potent cyclin-dependent kinase inhibitors 
(CKI) that inhibit the activity of cyclin-CDk2 or –CDK1 complexes, and thus function as 
regulators of cell cycle progression at G1. 
Together, these investigations suggest that heparins may function as inducers of 
apoptosis in a variety of different cancer cell lines. Additionally, these studies support the 
fact that a large spectrum of molecular mechanisms underlying the pro-apoptotic actions 
of heparins have exist.  
61 
 
In conclusion, LMW and ULMW heparins confer several important advantages 
over UFH for the treatment of thrombosis in cancer. First, LMWHs have a significantly 
longer half life than UFH; therefore, they can be administered subcutaneously once a day. 
Second, LMWH therapy does not normally require laboratory monitoring (Harrison et 
al., 1998). Finally, the use of LMWHs is associated with lower incidences of heparin-
induced thrombocytopenia (HIT) and heparin-induced osteoporosis (Warkentin et al., 
2008).  
Overall, in terms of their efficacy and safety profiles, cost-effectiveness, and 
practicality of use, the LMW and ULMW heparins offer several advantages over other 
available antithrombotics in cancer patients. In addition, emerging data supports that 
heparin and particularly low-molecular-weight heparins, may exert an antitumor effect 
which could contribute to improved survival in cancer patients when given for long-term 
prophylaxis. Such findings reinforce the importance of thromboprophylaxis with LMW 
and ULMW heparin in patients with cancer. 
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CHAPTER TWO 
STATEMENT OF PURPOSE 
Unfractionated heparin (UFH) is one of the oldest drugs still in clinical use. 
However, it is associated with several side effects such as bleeding, heparin-induced 
thrombocytopenia (HIT), and osteoporosis. The use of UFH also has disadvantages such 
as the need to be given intravenously and the need for continuous monitoring. More 
recently, the development of low molecular weight heparins (LMWHs) has provided an 
alternative to UFHs. Various clinical trials have demonstrated that LMWHs are as 
effective as UFH in the treatment of pulmonary embolism (Hull et al., 2000; Simonneau 
et al., 1997) and more effective for the treatment and prevention of deep vein thrombosis 
(Hull et al., 2000; Kakkar et al., 2003). Additionally, LMWHs can be administered as a 
once daily subcutaneous injection, which has eliminated the need for continuous 
monitoring, and are known to generate less bleeding in comparison to UFH. 
Both UFH and LMWHs produce their effects via interactions with various 
endogenous proteins such as antithrombin (AT) and heparin cofactor II (HCII). The 
degree to which these compounds exert their effects through AT and HCII, as well as 
other endogenous proteins, determines how well they inhibit various targets of the 
coagulation system and the severity of side effects. The continual search for 
antithrombotic drugs that have a better clinical profile has led to the development of more 
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extensively depolymerized versions of UFH known as ultra LMWHs (ULMWH). One 
promising ULMWH is semuloparin (AVE5026). To date, limited publications on 
ULMWHs are available. 
The primary purpose of this dissertation was to investigate whether ULMW 
heparins, such as semuloparin, provide a better pharmacologic profile compared to 
UFH and LMWHs in terms of safety and efficacy. For this investigation, five different 
heparins with varying molecular weight and composition were utilized. These include 
UFH, enoxaparin, bemiparin, semuloparin, and RO14. Their activities in biochemical and 
biological assays were compared in order to elucidate how their molecular composition 
affects their pharmacological actions. 
UFH was obtained from Sanofi, Choay Institute (Paris, France). It is the standard 
drug used clinically for anticoagulation. The average molecular weight is 14.0 kDa. It has 
a 1:1 anti- FXa/FIIa ratio, which means it is able to inhibit factor Xa to the same extent as 
factor IIa. UFH was selected for this study in order to examine how its higher molecular 
weight and structural differences compare to other lower molecular weight derivatives in 
terms of pharmacological actions such as its anticoagulant, antithrombotic, hemorrhagic, 
and non-anticoagulant effects.  
Enoxaparin was originally developed by former Pharmuka Laboratories 
(Gennevillers, France). Currently, this agent is marketed by Sanofi-Aventis (Paris, 
France), and its generic versions are marketed by Sandoz, Inc. USA (Princeton, NJ). It 
was selected for this study because it is the most commonly used and widely studied 
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LMWH (MW 4.5 kDa). Enoxaparin is the treatment of choice for the prevention and 
treatment of deep vein thrombosis or pulmonary embolism. Enoxaparin binds to and 
accelerates the activity of antithrombin, thus it preferentially potentiates the inhibition of 
coagulation factors Xa and IIa. However, it is known to have a 4:1 anti- FXa/FIIa ratio, 
which means it is able to inhibit factor Xa to a greater extent than factor IIa.  
Bemiparin has been developed by Laboratorios Farmaceuticos Rovi (Madrid, 
Spain). It is marketed as a second-generation LMWH because of its distinctive 
pharmacological properties. Bemiparin has an average molecular weight of 3.5 kDa. It 
was selected for this study because its anti-FXa/FIIa ratio (8:1) is markedly different than 
the other LMWH selected for this study and will allow for a valuable comparison. 
Semuloparin has been developed by Sanofi-Aventis (Paris, France). It is an 
ULMWH (MW <3.0 kDa). Its selection for this study is twofold. First, little is known of 
this compound and its mechanisms of action. Second, semuloparin is prepared by 
controlled chemical heparin depolymerization by a phosphazene base. This unique 
method of preparation preserves the high-affinity AT binding sequences and allows 
semuloparin to strongly bind to its cofactor, AT. This preservation, along with its low 
molecular weight, gives semuloparin a higher anti-FXa/FIIa ratio (>30:1) than 
enoxaparin and bemiparin and is expected to provide a better safety profile. 
RO14 has been developed by Laboratorios Farmaceuticos Rovi (Madrid, Spain) 
as an antithrombotic agent. It is manufactured from heparin by means of chemical 
degradation. Like semuloparin, it exhibits a very low mean molecular weight (<3.0 kDa); 
however, it does not have the enrichment of high-affinity AT binding sequences. It was 
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selected for this study for its distinctly different method of preparation in comparison to 
semuloparin. 
This dissertation is focused on delineating the pharmacological actions of various 
heparins by understanding how their molecular weight and composition play a role in 
these actions. Particular focus was paid to an ULMWH (semuloparin) and its distinct 
pharmacological profile. It is hypothesized that due to the preservation of the high-
affinity AT binding sequences, which results in a higher anti-FXa/FIIa ratio, 
semuloparin will exhibit a better antithrombotic and safety profile compared to 
other heparin derivatives. Additionally, due to their lower molecular weight and 
composition, ULMWHs will be able to exert effects on tumor growth. To investigate 
these claims, the following three specific aims were addressed: 
Specific Aim 1: 
To demonstrate the impact of molecular weight and AT affinity preservation on the 
biologic effects of heparin and its low and ultra low molecular weight derivatives. 
Specific Aim 2: 
A. To demonstrate to what extent SERPINS (AT and HCII) contribute to the 
anticoagulant, antiprotease, and protease generation effects of heparin and it’s low and 
ultra low molecular weight derivatives. 
B. To demonstrate the influence of the AT affinity preservation on the pharmacologic 
actions of an ultra low molecular weight heparin. 
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Specific Aim 3: 
A. To investigate the impact of molecular weight on various heparins’ activity in 
established models of tumor growth.  
B. To demonstrate the influence of AT affinity enrichment of an ultra low molecular 
weight heparin in established models of tumor growth.  
 
Significance 
Heparin, LMWHs, fondaparinux, and warfarin are the drugs of choice for the 
management of thromboembolism. However, treatment with these agents is not optimal. 
The efficacy-safety ratio of these agents can be improved. 
The coagulation inhibitor that mediates the actions of these heparins is a serine 
protease inhibitor known as antithrombin (AT). When these agents bind to AT via a 
specific pentasaccharide sequence, AT is modified, enabling it to inhibit factor Xa. In 
addition, heparin can bind AT and thrombin at the same time, resulting in a ternary 
complex which is necessary for thrombin inhibition. This reaction requires a 
polysaccharide chain that contains the pentasaccharide sequence and is at least 18 
residues in length. The inhibition of FXa by AT does not require ternary complex 
formation; however, the pentasaccharide sequence must be present in the heparin chain. 
Enoxaparin is a low molecular weight heparin made up primarily of 
oligosaccharide chains containing less than 18 saccharides units. Approximately 20 – 
30% of the oligosaccharide chains in enoxaparin have high affinity to AT. This results in 
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enoxaparin having a higher anti-Xa/IIa ration of 4:1. Advances in analytical and 
separation methods have allowed for the development of newer LMWHs and ULMWHs 
with more active components.  
Semuloparin is a hemisynthetic, ultra low molecular weight heparin with a unique 
AT binding oligosaccharide profile compared to LMWHs. Semuloparin is prepared by a 
highly selective depolymerization of the heparin backbone by phosphazene base which 
preserves the AT binding sequence. The unique structural features of semuloparin 
differentiate it from LMWHs. Unlike other depolymerized heparins where the 
antithrombin (AT) affinity components and anti-Xa activity is decreased with the 
decrease in the molecular weight, semuloparin exhibits a relatively higher proportion of 
AT-binding components which translates into a higher anti-Xa activity. A great majority 
of the oligosaccharide components in semuloparin are composed of tetra-, hexa-, octa- 
and deca- saccharides. Heparinase is capable of digesting semuloparin into mainly tetra-
saccharide components. These studies will help to determine the safety efficacy profile of 
semuloparin, an ULMWH with enhanced AT binding sequences, compared to UFH, 
enoxaparin, bemiparin, and RO14. Semuloparin may prove to be an alternative for the 
prevention of thrombosis with a better safety/efficacy profile in terms of a reduced 
bleeding risk, high antithrombotic activity, and a lower HIT potential. These studies will 
also determine the interactions of semuloparin with different SERPINS to identify its 
mechanism of action on blood coagulation. 
Tissue factor pathway inhibitor (TFPI) is known to be released after the 
administration of UFH and LMW heparins. This process is mainly responsible for the 
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control of tissue factor. In addition, TFPI has been shown to inhibit angiogenesis. This 
dissertation will explore the ability of the ULMWH, semuloparin to release TFPI after 
both IV and SC administration. 
Cancer patients are at a high risk for venous thromboembolism. The interaction 
between cancer and blood coagulation is complex and involves multiple interactions. 
Therefore, inhibiting the coagulation system may play a role in altering the behavior of 
tumors as well as preventing complications such as VTE and PE. UFH is used for the 
prevention and treatment of thrombosis in cancer patients, and has been shown to 
increase survival in patients with small cell lung cancer. Since semuloparin is an 
ULMWH with unique oligosaccharide sequences, it may be able to penetrate the tumor 
and prevent tumor growth. The effect of semuloparin in a mouse model of lung cancer 
was used to study the effect of this agent on tumor growth compared to UFH, LMWH 
and an ULMWH, with different properties than semuloparin. Additionally, the ability of 
these agents to inhibit growth factors like vascular endothelial growth factor (VEGF) and 
transforming growth factor beta (TGF-β) was examined to determine these agents effects 
on angiogenesis.  
Overall, these studies will help to identify the role of molecular weight and 
enhanced AT binding on the safety efficacy profile of heparin-like drugs. In addition, the 
role of molecular weight and enhanced AT binding on the ability of heparins to inhibit 
tumor growth will be elucidated, thus contributing to making an improved anticoagulant 
for the treatment of cancer associated thrombosis. Furthermore, these studies may help 
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clarify the extent to which the anti-cancer effects of heparins are related to their 
anticoagulant activity.  
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CHAPTER THREE 
 
MATERIALS AND METHODS 
 
 
A. Materials 
 
1. Anticoagulants  
1.1 Heparin (UFH) 
Porcine mucosal heparin sodium (lot HS0403), obtained in powder form from 
Gentium SpA (Villa Guardia (Como), Italy) was used throughout this dissertation. This 
agent was stored in a desiccator at room temperature (20 – 25 ºC). The average molecular 
weight of this batch was 16.5 kDa, as determined by high-performance liquid 
chromatography (HPLC). The specific activity of this preparation was 160 anti-factor Xa 
and IIa IU/mg as cross-referenced to an international heparin standard from the National 
Institute for Biological Standardization and Control, London, England (Mulloy et al., 
1997).  
 
1.2 Non- antithrombin affinity heparin (Non-AT AF UFH) 
Non-AT affinity heparin (lot P802HHB) was a generous gift from Sanofi-Aventis 
(Paris, France) and was obtained in powder form. This agent was stored in a desiccator at 
room temperature (20 – 25 ºC). The average molecular weight was 13.4 kDa, as 
determined by HPLC. 
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1.3 Enoxaparin 
 Enoxaparin (Lovenox) (lot 28666) syringes was obtained from Sanofi-Aventis 
(Paris, France) in sterile aqueous solution at a concentration of 100 mg/ml. This agent 
was stored at 5°C until use. The average molecular weight of this batch was 4.1 kDa, as 
determined by HPLC. Enoxaparin has anti-factor Xa and IIa activities of 100 IU/mg and 
36 IU/mg, respectively, as determined by using the anti-Xa and anti-IIa methods 
(described in Methods section) and the National Institute for Biological Standards and 
Control (NIBSC) standard for LMWH. 
 
1.4 Bemiparin 
 Bemiparin (Hibor
®
) (lot B-31) was obtained from Laboratorios Farmaceuticos 
ROVI, S.A. (Madrid, Spain) in sterile aqueous solution at a concentration of 2,500 IU/0.2 
ml anti-factor Xa activity. This agent was stored at 5°C until use. The average molecular 
weight of this batch was 3.8 kDa, as determined by HPLC. Bemiparin has anti-factor Xa 
and IIa activities of 108 IU/mg and 20 IU/mg, respectively, as determined by using the 
anti-Xa and anti-IIa methods (described Methods section) and the NIBSC standard for 
LMWH. 
 
1.5 Semuloparin (AVE5026) 
 Semuloparin (AVE5026) (lot 0500065365) was obtained from Sanofi-Aventis 
(Paris, France) in powder form. This agent was stored in a desiccator at room temperature 
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(20 – 25 ºC). The average molecular weight of this batch was 2.9 kDa, as determined by 
HPLC. The specific activity of this preparation was 156 anti-factor Xa IU/mg and < 5 
anti-factor IIa IU/mg, as determined by using the anti-Xa and anti-IIa methods (described 
Methods section) and the NIBSC standard for LMWH. 
 
1.6 High antithrombin affinity semuloparin (High-AT AF semuloparin) 
 High-AT affinity semuloparin (lot P32077-118.1) was a generous gift from Dr. 
Christian Viskov at Sanofi-Aventis (Paris, France) and was obtained in powder form. It 
was purified by an AT-affinity chromatography method. This agent was stored in a 
desiccator at room temperature (20 – 25 ºC). The average molecular weight was 3.3 kDa, 
as determined by HPLC. The specific activity of this preparation was 174 anti-factor Xa 
IU/mg and < 5 anti-factor IIa IU/mg, as determined by using the anti-Xa and anti-IIa 
methods (described Methods section) and the NIBSC standard for LMWH. 
 
1.7 Non-antithrombin affinity semuloparin (Non-AT AF semuloparin) 
 Non-AT AF semuloparin (lot VACMOP 3.133.1) was a generous gift from Dr. 
Christian Viskov at Sanofi-Aventis (Paris, France) and was obtained in powder form. It 
was purified by an AT-affinity chromatography method. This agent was stored in a 
desiccator at room temperature (20 – 25 ºC). The average molecular weight was 2.6 kDa, 
as determined by HPLC. The specific activity of this preparation was 82 anti-factor Xa 
IU/mg and < 5 anti-factor IIa IU/mg, as determined by using the anti-Xa and anti-IIa 
methods (described Methods section) and the NIBSC standard for LMWH. 
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1.8 RO-14 
 RO-14 was obtained from Laboratorios Farmaceuticos ROVI, S.A. (Madrid, 
Spain) in powder form. This agent was stored in a desiccator at room temperature (20 – 
25 ºC). The average molecular weight of this batch was 2.8 kDa, as determined by HPLC. 
The specific activity of this preparation was 80 anti-factor Xa IU/mg and < 10 anti-factor 
IIa IU/mg, as determined by using the anti-Xa and anti-IIa methods (described Methods 
section) and the NIBSC standard for LMWH. 
 
2. Protein/Enzymes 
2.1 Heparinase I 
Heparinase I (EC 4.2.2.7) was obtained from IBEX Pharmaceuticals, Montreal, 
Canada. This enzyme was extracted from Flavobacterium heparinum. Its molecular 
weight was reported to be 42.5 kDa. The potency was designated as >80 IU/mg, where 
one international unit (IU) is defined as the amount of enzyme that will liberate 1.0 
mole of unsaturated oligosaccharides from porcine mucosal heparin per minute at 30 ºC 
and pH 7.0 (Ernst et al., 1995). Purity of this enzyme was determined to be greater than 
90% by reverse-phase HPLC and SDS-PAGE analysis. The material was provided as a 
solution and was stored at –70 ºC until use. 
 
2.2 Protamine sulfate 
 Protamine sulfate was obtained from Choay Institute (Paris, France) in powder 
form and reconstituted in normal physiologic saline at a concentration of 25 µg/ml. It was 
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produced from salmon sperm and had a specific activity of 138 UAH (unit anti-
heparin)/mg. The mean molecular weight of this protamine as determined by HPLC is 4.0 
kDa. 
 
2.3 Polybrene
®
 
 Polybrene
®
 (1,5-dimethyl-1,5-diazaundecamethylene polymethobromide, 
hexadimethrine bromide), a cationic polymer (Lalezari, 1968), is a well-known anti-
heparin agent (Preston, 1953). It was obtained from Sigma-Aldrich
®
 (Milwaukee, WI) in 
powder form.  
 
2.4 Human platelet factor 4 
 Human platelet factor 4 (PF4) was obtained from Hyphen BioMed (Neuville-sur-
Oise, France). It was derived from human platelet concentrates and presented in the 
tetrameric form. The concentration was determined by an ELISA method using an 
internal reference from Hyphen BioMed calibrated against the 1
st
 International Standard 
for PF4 (NIBSC, 83/505, 400 IU per ampoule). Each vial was reconstituted with 1 ml of 
distilled water.  
 
2.5 PMX 60056 
 The synthetic salicylamide PMX 60056 (MW = 1.1 kDa) was obtained from 
PolyMedix
®
 (lot 53028-07-15; Radnor, PA) in powdered form and reconstituted in 
normal physiologic saline at a concentration of 25 µg/ml. Salicylamides are oligomers 
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that consist of alternating amino acids and 5-amino salicylic acid building units. PMX 
60056 consists of four such building units and is positively charged due to the 
incorporation of lysine side chains. PMX 60056 was designed to reverse the 
anticoagulant activity of both heparin and low molecular weight heparins (LMWHs) by 
preferentially binding to the oligosaccharide chains (preferentially the pentasaccharide 
sequence) in heparin and its derivatives, and thus preventing heparins from binding to 
their cofactor, antithrombin. 
 
2.6 Antithrombin 
Human antithrombin (AT) was obtained from American Diagnostica (Stamford, 
CT) in vials containing 2.5 IU. The antithrombin was immunoaffinity purified from 
pooled fresh frozen plasma by heparin-Sepharose chromatography and salt-gradient 
elution. The product was stored at 4 ºC until it was reconstituted with 1 ml of saline to 
obtain a final concentration of 2.5 IU. 
 
2.7 Heparin cofactor II 
 Heparin cofactor II (HCII) was obtained from Enzyme Research Laboratories 
(South Bend, IN). HCII was prepared from fresh frozen human plasma and was 
lyophilized. HCII was reconstituted to a concentration of 1 mg/ml using saline and stored 
at –70°C until use. 
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3. Molecular weight profiling 
 The mobile phase used in all of the HPLC studies was made using anhydrous 
sodium sulfate (0.3 M Na2SO4, pH = 5.0) (and HPLC-grade water from Sigma-Aldrich 
Inc. (St. Louis, MO). Thirteen standard heparin fractions (Sanofi, Paris, France) ranging 
in molecular weight from 51.0 kDa to 2.4 kDa were used to calibrate the GPC-HPLC 
instrument and to construct the standard curve. 
 
4. Blood products 
4.1 Blood bank plasma 
 Normal human CPDA-1 (anticoagulants: citrate, phosphate, dextrose, adenine) 
plasma was obtained from the Blood Bank, Department of Pathology, Loyola University 
Medical Center, Maywood, IL. This plasma was obtained from blood donated by normal 
healthy human volunteers who tested negative for acquired immunodeficiency syndrome 
(AIDS) and hepatitis B and C virus. The fresh frozen plasma packs (n = 5), not more than 
30 days old, were thawed at 37 ºC, and then the pooled plasma was aliquoted in volumes 
of 10 ml and frozen at –70oC for a period of not more than two months. 
 
4.2 Normal human citrated whole blood, platelet rich plasma, and platelet poor plasma 
The preparation of pooled plasma from human volunteers was in accordance with 
the guidelines of an approved IRB (#8013050296, Lu #200457) at Loyola University 
Medical Center. 
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 Under aseptic precautions, blood was obtained from the antecubital vein of the 
forearm of normal healthy volunteers (10 male and 10 female) using a double syringe 
technique using a BD Vacutainer
®
 push button blood collection needle (21g x ¾” x 12”) 
(Becton Dickinson and Company, Franklin Lakes, NJ) and immediately placed into a 4.5 
ml sodium citrate (3.2%) BD Vacutainer
®
 blood collection tube. The contents of the 
tubes were gently mixed. To make platelet rich plasma (PRP), the citrated blood samples 
were centrifuged at 4°C, 800 rpm (146 x g) for 20 minutes. The supernatant PRP was 
removed and then pooled. To make platelet poor plasma (PPP), the remaining citrated 
blood samples were centrifuged at 4°C, 3,000 rpm (2,053 x g) for 20 minutes. The 
supernatant platelet poor plasma was removed and then pooled. The pooled plasma was 
aliquoted (5 ml) and frozen at –70oC for a period of not more than two months. 
 
4.3 Normal rat plasma 
The preparation of pooled plasma from rats complied with the guidelines of the 
IACUC (#2010009, Lu #200457) at Loyola University Medical Center. 
Blood was collected from ketamine (90 mg/kg) and xylazine (10 mg/kg)-
anesthetized, groups of (n = 6) normal male Sprague-Dawley rats (Harlan Industries, 
Indianapolis, IN) by heart puncture. A total of 2.7 ml of blood was drawn from each rat 
using an 18 G (1.2 mm x 40 mm) BD Eclipse needle (Becton Dickinson and Company, 
Franklin Lakes, NJ) into polypropylene syringes containing 0.3 ml of 0.105 M sodium 
citrate solution. The blood was transferred into siliconized glass tubes (Vacutainer

, 
Becton Dickinson and Company, Franklin Lakes, NJ) and centrifuged (Beckman GPR 
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Centrifuge, Beckman Instruments Inc., Fullerton, CA) at 3,000 rpm (2,053 x g) at 4C for 
15 minutes. The supernatant plasma was separated using polypropylene transfer pipettes 
and pooled to obtain platelet poor normal rat plasma. The normal rat plasma was 
separated into 0.5 ml aliquots and stored frozen at –70 ºC.  
 
4.4 Normal monkey plasma 
Groups of primates (Macaca mulatta) (n = 12) were anesthetized with ketamine 
(20 mg/kg, I.M.) and blood samples were drawn from the saphenous vein using a 21 
gauge ¾ inch butterfly needle and a 5 ml syringe. The blood was transferred into a 4.5 ml 
sodium citrate (3.2%) BD Vacutainer
®
 blood collection tube (Becton Dickinson and 
Company, Franklin Lakes, NJ). Approximately 15 minutes later, the blood was 
centrifuged at 4°C, 3,000 rpm (2,053 x g) for 20 minutes. Plasma from a minimum of 14 
primates was pooled and aliquoted in 10 ml volumes. The pooled monkey plasma (NMP) 
was frozen in plastic tubes at -70°C for not more than 2 months. 
 
4.5 Normal mouse plasma 
Ten female C57B1/6 mice (JAX Mice, Bar Harbor, Maine) were sacrificed by 
CO2 asphyxiation and a cardiac puncture was performed using a 1 ml, 25 gauge, 5/8 inch 
injection needle. Blood was collected (450 µl) into a 1 ml eppendorf tube with 50 µl of 
3.2 % sodium citrate and then centrifuged at 3,000 rpm (2,053 x g) at 4C for 20 minutes 
to obtain normal pooled mouse plasma. The plasma was stored at -70 ºC for future use. 
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4.6 Antithrombin deficient plasma 
Antithrombin deficient plasma (AT-DP 220) from Enzyme Research Laboratories 
(South Bend, IN) was used to determine the anticoagulant and antiprotease effects of 
various anticoagulants independently of antithrombin. AT deficient plasma was prepared 
using anti-AT antibodies immobilized on agarose beads. The plasma contains < 0.01 
U/ml of AT as determined by ELISA methods and < 5% the amount in NHP as 
determined by functional methods. In addition, the plasma contained 20 mM HEPES. 
 
4.7 Heparin cofactor II depleted plasma 
Heparin cofactor II deficient plasma (HCII-DP 220) from Enzyme Research 
Laboratories (South Bend, IN) was used to determine the anticoagulant and antiprotease 
effects of various anticoagulants independently of heparin cofactor II. HCII depleted 
plasma was prepared using anti-HCII antibodies immobilized on agarose beads. The 
plasma contained < 0.01 U/ml of HCII as determined by ELISA methods and < 5% the 
amount in NHP as determined by functional methods. In addition, the plasma contained 
20 mM HEPES. 
 
5. Major instruments 
Major instruments used to perform various experiments reported in this 
dissertation include a Waters
TM
 high-performance liquid chromatography (HPLC) system 
(Milford, MA). This was used to determine the molecular profile of the various 
compounds. ProteinChip
®
 Surface Enhanced Laser Desorption/Ionization (SELDI) 
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System, Personal Edition (Bio-Rad Laboratories, Inc., Hercules, CA), in conjunction with 
Bio-Rad ProteinChip
® 
Data Mananger Client 4.1 software was used for analysis of 
protein to protein interactions. Scanning ultra-violet (UV) spectroscopy was performed 
on a Perkin-Elmer Lambda 25 UV/VIS spectrometer (Turku, Finland). Circular 
Dichroism (CD) spectra were recorded on a J-810 spectropolarimeter (JASCO, Easton, 
MD). A Fibrometer
TM
 (Becton Dickinson and Co., Rutherford, NJ) was used for clotting 
time determination. An ACL
TM
 300 Plus (Beckman-Coulter, Miami, FL) was used for 
antiprotease assays. A SpectraMax
®
 Plus
384
 Absorbance Microplate Reader (Molecular 
Devices, Sunnyvale, CA) was used to measure clot lysis, kinetics of various assays, and 
with the ELISA method. An FLx800
TM 
multi-detection microplate reader (BioTek

 
Instruments, Inc., Winooski, Vermont) was used to perform the thrombin generation 
assays. Dell™ OptiPlex™ GX620 personal computers linked to printers (HP LaserJet 
4200, San Diego, CA) were used for word processing, pharmacokinetic analysis, 
statistical analysis and graphics. All reagents and buffers were prepared using reagent 
grade chemicals. 
 
6. Animal experimentation 
 Both the primates and rats were anesthetized using ketamine HCl (100 mg/ml) 
obtained from Webster Veterinary (Devens, MA). Rats were also anesthetized using 
xylazine (100 mg/ml) from Phoenix Pharmaceutical Inc. (St. Joseph, MO). Beuthanasia

-
D from Schering-Plough (Union, NJ) was used to euthanize the rats after the 
experimental procedures. Mice were euthanized by CO2 asphyxiation. Hematologic 
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profiles was performed at the Clinical Laboratory, Department of Pathology at Loyola 
University Medical Center using a Beckman Coulter LH 750 Hematology Analyzer 
(Beckman Coulter Inc, Indianapolis, IN).  
 
7. Animals 
All animals were allowed an acclimation period of at least 4 days after arrival in 
the animal care facility. 
Male Sprague-Dawley rats (250 – 300 g, Harlan Industries, Indianapolis, IN) were 
used in the Rat-tail Bleeding Model and Rat Jugular Vein Clamping Model. The rats 
were pair-housed in the Comparative Medicine Facility of Loyola University Medical 
Center. These studies were performed under an IACUC (#2010009) approved protocol; 
LU #200457. 
Female C57BL/6 mice were obtained at 6-8 weeks of age (30 – 60 g, JAX Mice, 
Bar Harbor, Maine) and used for the Lewis Lung Carcinoma (LLC) Tumor Model. The 
mice were housed according to the institutional IACUC protocols of Loyola University 
Medical Center. These studies were performed under an IACUC (#2010023) approved 
protocol, LU #202385. 
Male and female non-human primates (Macaca mulatta) (4 - 16 kg) were used for 
the studies on the in vivo biologic actions of heparins. The primates were from the 
primate colony in the Comparative Medicine Facility of Loyola University Medical 
Center and housed according to the institutional IACUC protocols of Loyola University 
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Medical Center. These studies were performed under an IACUC (#08-063) approved 
protocol, LU # 200457. 
 All animal studies were carried out in compliance with the guidelines set forth by 
the Institutional Animal Care and Use Committee (IACUC), Loyola University Medical 
Center and the Principles of Laboratory Animal Care (National Institutes of Health, 
1985). 
 
B. Methods 
1. Physiochemical characterization of agents 
1.1 Gel permeation chromatography  
Molecular weight determinations were made using GPC in a high-performance 
liquid chromatography (HPLC) system (Waters 845, Millipore-Waters, Lexington, MA) 
equipped with Millennium

 2000 software designed for polymer analysis. The HPLC 
system consists of a computer, a LAC/E interface module, two 510 HPLC pumps, a 712 
WISP auto-injector, a 401 differential refraction index (RI) detector, and a 484 ultraviolet 
(UV) tunable absorbance detector. The UV and the RI detectors were linked in series, 
with the outlet of the joint columns (TSK G3000SW and TSK G2000SW, TosoHaas, 
Tokyo, Japan) attached to the UV detector. 
The molecular weight profile of each agent was determined using the method 
reported by Ahsan et al (1995). The system was equilibrated using freshly degassed 
mobile phase (0.3 M sodium sulfate) until a stable baseline was obtained. Analysis was 
carried out by injecting 20 μl of sample (10 mg/ml in 0.3 M sodium sulfate) into the 
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HPLC system. The flow rate for the mobile phase was 0.5 ml/min, and the run time for 
each sample was 65 minutes. The internal temperature for the RI detector was set at 35

C, 
and UV detection was made at 205 nm or 234 nm.  
Following each run, the elution profile of each sample was analyzed by the 
narrow range calibration (NRC) method and a modified European Pharmacopoeia (EP) 
method (Ahsan et al, 1995; Ahsan et al, 1993). The NRC method uses 13 calibrators 
ranging from 51.0 kDa to 2.4 kDa and requires the UV detector to be set at a wavelength 
of 205 nm. The modified European Pharmacopoeia (EP) method uses one digested 
heparin calibrator which has 8 distinct peaks ranging from 6.0 kDa to 1.8 kDa and 
requires the UV detector to be set at a wavelength of 234 nm. 
Calibration of the HPLC system was performed in a similar manner using the 
narrow range calibrators (10 mg/ml calibrators in 0.3 M sodium sulfate) with well-
defined molecular weights and the 1
st
 International Low Molecular Weight Heparin 
Reference Standard (# 90/686, National Institute for Biological Standardization and 
Control, London, UK) with a designated molecular weight for each peak. The log 
molecular weight of each calibrator or each component for the EP calibrators was plotted 
against its retention time. Using the Millennium

 2000 software, a third order polynomial 
regression equation (Log MW = D0 + D1 (RT) + D2 (RT)
 2
 + D3 (RT)
 3
) was fitted to the 
data points, where MW represents the calculated molecular weight, RT represents 
retention time and D0, D1, D2 and D3 represent coefficients calculated in the curve fitting 
process. The molecular weight profile of each agent was determined based on this 
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calibration curve. The molecular weight profile consists of such parameters as weight 
average molecular weight, number average molecular weight, and polydispersity. 
 
1.2 Scanning UV spectroscopy 
Scanning UV spectroscopy was performed on Perkin-Elmer Lambda 25 UV/VIS 
spectrometer (Turku, Finland). UFH, enoxaparin, bemiparin, semuloparin, and RO-14, at 
a concentration of 1 mg/ml in deionized water, were scanned from 190 to 320 nm with 1 
nm resolution at 120 nm/min. Scanning UV spectroscopy was used to help differentiate 
the various heparins obtained by different methods of production. 
 
1.3 Circular dichroism 
Circular dichroism (CD) refers to the differential absorption of left and right 
circularly polarized light. It is exhibited in the absorption bands of optically active chiral 
molecules. CD is most notably used to investigate secondary structure of proteins. CD 
was used to help differentiate the various heparins obtained by different methods of 
production. CD spectra were recorded between 260 nm and 190 nm on a J-810 
spectropolarimeter (JASCO, Easton, MD) using quartz sample cell, 0.02 cm path length, 
1 nm resolution, at a scanning rate of 50 nm/min at 37 ºC. The most commonly used units 
in current literature are mean residue ellipticity (degree cm2 dmol -1) and the difference 
in molar extinction coefficients called the molar circular dichroism (CD) or delta epsilon 
(liter mol-1 cm-1). Values are presented in molar CD. CD spectra of the heparin samples 
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were recorded at concentrations of 10 mg/ml in water and were relative to (+)-10-
camphorsulfonic acid (1.0 mg/ml). 
 
2. Global anticoagulant assays 
2.1 Activated clotting time 
 The activated clotting time (ACT) is a whole blood clotting assay commonly used 
clinically to monitor heparin and low molecular weight heparins in interventional 
cardiology (Moliterno et al., 1995). Celite coagulation tubes purchased from International 
Technidyne (Edison, NJ) were used for this assay. Each celite tube contains 12 mg of 
diatomaceous earth and is designated to activate 2 ml of whole blood. 
The assay was performed as follows. An aliquot of 1.8 ml of blood from a healthy 
volunteer was drawn via the anterior cubital vein of the forearm (IRB # 8013050296) into 
a syringe containing 200 l of the test drug or saline and then gently mixed. The blood 
was transferred to an ACT tube. The tube was agitated vigorously for approximately 10 
sec and immediately inserted into a Hemochron

 801 (International Technidyne 
Corporation, Edison, NJ) test well. The time for the blood to clot was recorded digitally 
on the face of the instrument. The agents were tested at final concentrations of 10 and 25 
µg/ml.  
 
2.2 Prothrombin time 
The prothrombin time (PT) is a global clotting assay, which measures the 
inhibition of factors involved in the extrinsic pathway of coagulation (FVIIa and FXa). 
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This assay is commonly used to monitor oral anticoagulant therapy. It is based on the 
measurement of time to clot after plasma has been activated by tissue factor and calcium 
chloride. The reagent used was Dade
® 
Thromboplastin C Plus, which was purchased from 
Siemens Healthcare Diagnostics Inc (Newark, DE, ISI = 1.55 on the ACL 300). This 
reagent contained lyophilized rabbit brain thromboplastin and calcium. Each bottle was 
reconstituted with 10 ml of distilled deionized water and was kept refrigerated (4C) until 
use.  
The assay was performed as follows. An aliquot of 250 l of test plasma was 
added to an individual test cup and then placed into the ACL carousel in a defined 
sequence. NHP and saline samples were included in every carousel as controls. The 
reagent was placed in the appropriate position (Dade
® 
Thromboplastin C Plus in position 
1). A clean ACL rotor was placed in the carousel. The appropriate parameters were set on 
the machine before running the test. An aliquot of 100 µl of each of the plasma samples 
and 100µl of pre-warmed Thrombplastin C Plus were incubated at 37°C for 5 minutes 
and then measured on an ACL 300 plus (Beckman-Coulter, Miami, FL). Measurement of 
clotting time was stopped at 300 seconds as clotting times beyond 300 seconds are 
outside of the linear range of the instrument.  
 
2.3 Activated partial thromboplastin time 
 The activated partial thromboplastin time is a screening test for the intrinsic 
pathway of coagulation (factors I, II, V, VIII, IX, X, XI and XII) and commonly used for 
monitoring heparin therapy. It is based on the measurement of time to clot after plasma 
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has been activated by a platelet substitute (purified phospholipids) plus added activator 
(micronized silica) and calcium chloride.  
 The TriniCLOT
TM
 APTT S kit (Trinity Biotech USA Inc, Jamestown, NY) was 
used to determine the APTT of the test samples. The following reagents were included in 
the TriniCLOT
TM
 APTT S kit: TriniCLOT APTT CaCl2 (0.02 M) and TriniClOT APTT 
S reagent. The reagent contains purified phospholipids (porcine and galline), micronized 
silica (activator), stabilizer, and 0.02% sodium azide as preservative. All reagents were 
kept refrigerated (4C) until use. Each vile of TriniCLOT APTT CaCl2 (0.02 M) and 
TriniClOT APTT S reagent came ready to use. 
When the assay was used to analyze whole blood from various species or rat 
plasma, the assay was performed as follows. A sufficient volume of TriniCLOT APTT S 
reagent and TriniCLOT APTT S CaCl2 were prewarmed to 37°C. An aliquot of 100 l of 
test plasma, whole blood, control or calibration curve and 100 l of APTT reagent were 
added to the test cup and incubated at 37C for 5 minutes. Following the incubation time, 
100 l of CaCl2 was added to the test cup and the clotting time was measured using a 
Fibrometer

 (BBL, Cockeysville, MD). 
When the assay was utilized for human or primate plasma, the assay was 
performed as follows. An aliquot of 250 µl of each of the plasma samples were placed 
into individual test cups, which are then placed in an ACL test cup carousel in a defined 
sequence. NHP or NMP and saline samples were included in every carousel as controls. 
The reagents were placed in their appropriate positions (TriniCLOT APTT S reagent in 
position 2 and CaCl2 in position 3). A clean ACL rotor was placed in the carousel. The 
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appropriate parameters were set on the machine before running the test. An aliquot of 100 
µl of each of the plasma samples and 100µl of APTT reagent were incubated at 37°C for 
5 minutes. After 5 minutes of incubation, prewarmed calcium chloride was added to 
trigger coagulation and the clotting times were then measured on an ACL 300 plus 
(Beckman-Coulter, Miami, FL). Measurement of clotting time was stopped at 300 
seconds as clotting times beyond 300 seconds are outside of the linear range of the 
instrument.  
 
2.4 Heptest
 
 The Heptest

 (Haemachem Laboratories, Inc, St. Louis, MO) is based on the 
measurement of time to clot after plasma has been activated by bovine factor Xa and 
RECALMIX

, an optimized mixture of CaCl2 and brain cephalin in a bovine plasma 
fraction . Bovine factor Xa and RECALMIX

 were obtained in lyophilized form and 
were reconstituted with 2 ml of filtered deionized water. RECALMIX

 was pre-warmed 
at 37C for at least 15 minutes prior to beginning the assay. The bovine factor Xa was 
used at room temperature. The assay was performed in the following manner. 100 l of 
test plasma, controls or calibration curve and 100 l of bovine factor Xa were added to 
the test cup and incubated at 37C for 2 minutes. Following the incubation period, 100 l 
of pre-warmed CaCl2 was added to the test cup and the clotting time was measured using 
a Fibrometer

 (BBL, Cockeysville, MD). Measurement of clotting time was stopped at 
300 seconds as clotting times beyond 300 seconds are outside of the linear range of the 
instrument. 
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2.5 Thrombin time 
Thrombin time (TT) is a clot-based assay, which measures the time it takes for 
thrombin to convert fibrinogen to fibrin after the addition of a known amount of thrombin 
to plasma. Thrombin was obtained from Enzyme Research Laboratories (South Bend, IN) 
and was reconstituted with 0.02 M CaCl2 to yield 10 U/ml or 5 U/ml solutions which 
gave a baseline clotting time of 6±1.4 seconds and 9±1.8 seconds, respectively. Thrombin 
was kept frozen at -70°C until use. The assay was performed as follows. 200 l of test 
plasma, calibration curve or control was added to a test cup and incubated at 37 ºC. After 
three minutes, 100 l of either 10 U/ml or 5 U/ml thrombin was added and the clotting 
time was measured using a Fibrometer

 (BBL, Cockeysville, MD). 
 
3. Chromogenic antiprotease assays 
3.1 Anti-factor Xa assay/spectrophotometer 
The anti-Xa assay is a chromogenic assay, which measures the inhibition of factor 
Xa by different anticoagulants. The inhibition of factor Xa in rat plasma samples was 
measured using a Spectramax Plus 384. Actichrome
®
 Heparin (anti-FXa) reagents 
(American Diagnostica Inc, Stamford, CT), which included a bovine Factor Xa reagent 
(20 nKat), human Antithrombin reagent (lyophilized in buffer of 0.05 M Tris-HCL, 0.175 
M NaCl, 7.5 mM EDTA, pH 8.4), and Spectrozyme
®
 FXa (4 µM), were used. All 
reagents were reconstituted with filtered deionized water prior to use. The assay was 
performed using a microtiter plate method as follows. First, a 1:2 dilution of the plasma 
sample was made using saline. An aliquot of 25 µl of the diluted sample was added to 
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each well of the plate. Then, 75 µl of AT was added to each test well and incubated for 2 
minutes at 37 ºC. Next, 75 µl of Spectrozyme
®
 FXa was added to each well and 
incubated at 37 ºC for 10 minutes. An aliquot of 75 µl of acetic acid (2%) was then added 
to stop the reaction and the optical density was read on the microplate spectrophotometer 
at 405 nm. Percent inhibition was calculated using the following formula: % Inhibition = 
[100 - (O.D. sample/O.D.baseline) x 100]. 
 
3.2 Anti-factor Xa assay/ACL 
The inhibition of factor Xa in human and primate samples was performed on the 
ACL 300 Plus fast kinetics coagulation analyzer (Beckman-Coulter, Hialeah, FL), in the 
following manner. Test samples were prepared by placing 250 l of test plasma into 
individual test cups, which were then placed in an ACL-test cup-carousel and their 
positions were recorded. Up to 17 plasma samples could be inserted into one carousel. 
Normal human pool plasma and saline samples were included in every carousel as 
controls. Bovine factor Xa (1.0 mg/ml) (Enzyme Research Laboratories, South Bend, IN) 
was reconstituted with 4 ml (final factor Xa concentration of 6µg/ml) of Xa/IIa buffer 
(50mM Tris, 175 mM NaCL, 7.5 mM Na2 EDTA, 800 mls distilled H2O, pH = 8.4, 25 
ºC) prior to use. The substrate, Spectrozyme FXa (5 µM) (American Diagnostica, 
Stamford, CT) was reconstituted by adding 2 ml of distilled water. The reagents were 
placed in their appropriate positions (bovine factor Xa in position 2 and Spectrozyme 
FXa in position 3). A clean ACL rotor was also placed in the instrument. Once the 
reagents and samples were in their proper places, the ACL keypad was used to set the 
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appropriate specifications for the anti-Xa assay. An aliquot of 10 l of plasma was 
incubated for 1 minute at 37 ºC, followed by the addition of 100 l of bovine factor Xa. 
After 5 minute incubation at 37 ºC, 75 l of Spectrozyme FXa was added and the optical 
density change at 405 nm was measured for 30 seconds. 
The results were processed on an IBM compatible PC. The results were given as 
optical density (O.D.) values and were then converted to % factor Xa inhibition using the 
following equation: % Inhibition = [100 - (O.D. sample/O.D.baseline) x 100]. 
 
3.3 Anti-factor IIa assay/spectrophotometer 
The anti-IIa assay is a chromogenic assay, which measures the relative inhibition 
of thrombin relative to control plasma. The inhibition of factor IIa in rat plasma samples 
was measured using a Spectramax Plus 384. Actichrome
®
 Heparin (anti-FIIa) reagents 
(American Diagnostica Inc, Stamford, CT), which included a bovine thrombin reagent, 
human antithrombin reagent, and Spectrozyme
®
 TH (1.8 µM), were used. Both the 
bovine thrombin reagent and Spectrozyme
®
 TH were reconstituted with 2 ml of filtered 
deionized water, while the antithrombin reagent was reconstituted with 5 ml. The assay 
was performed using a microtiter plate method as follows. A 1:16 dilution of each plasma 
sample was made using saline. Next, 100 l of the antithrombin reagent was added to the 
plate, followed by 12.5 l of the plasma sample, standard, or control. These were then 
mixed and allowed to incubate for 2 minutes at 37°C. Then, 100 l of the thrombin 
reagent was added to the well and mixed and incubated at 37°C for 2 minutes. An aliquot 
of 100 l of the thrombin substrate was then added and incubated for exactly 1 minute at 
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37°C. 100 l of acetic acid (2 %) was added to stop the reaction and then the optical 
density was read at 405 nm. Percent inhibition was calculated using the following 
formula: % Inhibition = [100 - (O.D. sample/O.D.baseline) x 100]. 
 
3.4 Anti-factor IIa assay/ACL 
The inhibition of factor IIa in human and primate plasma samples was measured 
on the ACL 300 Plus fast kinetics coagulation analyzer (Beckman-Coulter, Hialeah, FL), 
in the following manner. Test samples were prepared by placing 250 l of test plasma 
into individual test cups, which were then placed in an ACL test cup carousel and their 
positions were recorded. Up to 17 plasma samples could be loaded into one carousel. 
Normal human or primate pool plasma and saline samples were included in every 
carousel as controls. Human thrombin (Enzyme Research Laboratories, South Bend, IN) 
was diluted to 5 U/ml in Xa/IIa buffer. The substrate, Spectrozyme TH (American 
Diagnostica, Stamford, CT) was reconstituted by adding 5 ml of distilled water (5 µM). 
The reagents were plated in their appropriate positions (thrombin in position 2 and 
Spectrozyme TH in position 3). A clean ACL rotor was also placed in the instrument. 
Once the reagents and samples were in their proper places the ACL keypad was used to 
set up the appropriate specifications for the anti-II assay. A 10 l aliquot of plasma was 
incubated for 1 minute at 37 ºC, followed by the addition of 100 l of thrombin. 
Following 1 minute incubation at 37 ºC, 40 l of Spectrozyme TH was added and the 
optical density change at 405 nm was measured for 30 seconds. 
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The results were processed on an IBM compatible PC. The results were given as 
optical density (O.D.) values and were then converted to % factor IIa inhibition by using 
the following equation: % Inhibition = [100 - (O.D. sample/O.D.baseline) x 100] 
 
4. Antithrombin/heparin cofactor II mediated antiprotease assays 
4.1 Purified antithrombin system 
A modified version of the method described by Jeske was used (Jeske, 1996). The 
ability of an agent to mediate antiprotease activity via AT was measured using an 
amidolytic substrate assay performed on the the ACL 300 Plus fast kinetics coagulation 
analyzer (Beckman-Coulter, Hialeah, FL). Test agents were serially diluted in a 1.0 U/ml 
AT solution and were placed in sample cups such that the final assay concentrations of 
the test agents ranged from 0 to 10 g/ml. The samples were analyzed using amidolytic 
anti-IIa and anti-Xa assays as previously discussed. Percent inhibition and maximal 
reaction rates were determined. Potency evaluations were made by comparing IC50 values 
for each agent. IC50 values were calculated in the following manner: Data from each 
individual run was plotted as percent inhibition relative to saline versus concentration 
(µg/ml). The concentration verses percent inhibition was plotted and the linear portion of 
each curve was used to determine the IC50 value by extrapolating the concentration 
required to produce 50% inhibition.  
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4.2 Purified heparin cofactor II system 
 The ability of an agent to mediate antiprotease activity via HCII was measured 
using and amidolytic substrate assay run on the ACL-300+ fast kinetics analyzer. Agents 
were diluted in saline and placed in sample cups such that the final concentrations ranged 
from 0 to 100 µg/ml. An aliquot of 4.2 µl of a 500 µg/ml human HCII solution was added 
to the sample cups such that the final concentration of HCII in the assay was 8.0 µg/ml. 
The first reagent consisted of human thrombin diluted to 2.5 U/ml with Tris buffer (50 
mM Tris, 175 mM NaCl, 7.5 mM EDTA, pH 8.4 at 25°C). The second reagent consisted 
of 2.5 mM Spectrozyme TH. The instrument was programmed such that 100 µl of sample 
and 50 µl of reagent 1 were placed into individual compartments in a reaction rotor. The 
reagents were incubated at 37°C for 1 minute and were mixed together. An aliquot of 100 
µl of reagent 2 was added to the rotor and the reaction rotor was spun at 1200 r.p.m. 
Optical density readings at 405 nm were made continuously for all compartments for 60 
seconds. The data downloaded for analysis to an IBM PC containing the Instrument 
Laboratories research program. A printout of the change in optical density with time was 
obtained. Percent inhibition was determined. Potency evaluations were made by 
comparing IC50 values for each agent. IC50 values were calculated in the following 
manner: Data from each individual run was plotted as percent inhibition relative to saline 
versus concentration (µg/ml). The concentration verses percent inhibition was plotted and 
the linear portion of each curve was used to determine the IC50 value by extrapolating the 
concentration required to produce 50% inhibition.  
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4.3 Antithrombin depleted plasma system 
Test agents were serially diluted in AT depleted plasma (Enzyme Research; South 
Bend, IN) to obtain a final concentration range of 0 - 50 µg/ml. The samples were 
analyzed using the Heptest
®
, anti-Xa, and anti-IIa assays, as previously discussed.  
 
4.4 Heparin cofactor II depleted plasma system 
Test agents were serially diluted in HCII depleted plasma (Enzyme Research; 
South Bend, IN) to obtain a final concentration range of 0 – 50 µg/ml and analyzed using 
Heptest
®
, anti-Xa, and anti-IIa assays, as previously discussed.  
 
5. Neutralization profiles 
5.1 Heparinase digestion assay 
Heparin, enoxaparin, bemiparin, semuloparin, and RO14 were subjected to 
heparinase digestion in the following manner: An aliquot of 70 µl of each agent (10 
mg/ml) was added to an eppendorf tube along with 10 µl of CaCl2, 10 µl of either 
heparinase (10 U) or saline (vehicle control), and an additional 10 µl of saline for a total 
volume of 100 µl. The solutions were mixed, incubated for 30 minutes at 37°C, and then 
treated to a 100°C hot water bath for 3 minutes. The final heparinase concentration was 
1.0 U. After digestion the heparinase/agent or saline/agent solutions were supplemented 
in normal human plasma to obtain final concentrations ranging from 0 - 10 μg/ml. 
Anticoagulant activity was determined using the APTT, thrombin time, and Heptest
®
 
assays. Antiprotease activity was determined using anti-Xa and anti-IIa assays. The 
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experiment was performed in triplicate on three different days using the same protocol. 
For each assay, % neutralization was calculated by the following formula after baseline 
correction was performed:  
% Neutralization = [1- (post heparinase µg/ml/pre heparinase µg/ml) * 100] 
Since UFH was effectively neutralized by the various antagonists tested, it was used as 
the standard for which to select an appropriate concentration to calculate the % 
neutralization. As such, the 5.0 µg/ml concentration was selected because it was the 
lowest heparin concentration that still allowed for maximal neutralization but did not 
exceed the ability for the antagonist to exert an effect. 
 
5.2 Protamine sulfate neutralization assay 
Heparin, enoxaparin, bemiparin, semuloparin, and RO14 were supplemented in 
normal human plasma to obtain final concentrations ranging from 0 - 25 μg/ml. 
Protamine sulfate was added to the heparin supplemented plasma to obtain a final 
protamine concentration of 25 μg/ml. Anticoagulant activity was determined using the 
PT, APTT, the thrombin time and Heptest
®
 assays. Antiprotease activity was determined 
using anti-Xa and anti-IIa assays. The experiment was performed in triplicate on three 
different days using the same protocol. For each assay, % neutralization was calculated 
by the following formula after baseline correction was performed:  
% Neutralization = [1- (post protamine µg/ml /pre protamine µg/ml) * 100] 
Since UFH was effectively neutralized by the various antagonists tested, it was used as 
the standard for which to select an appropriate concentration to calculate the % 
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neutralization. As such, the 6.25 µg/ml concentration was selected because it was the 
lowest heparin concentration that still allowed for maximal neutralization but did not 
exceed the ability for the antagonist to exert an effect. 
 
5.3 PF4 neutralization assay 
 Heparin, enoxaparin, bemiparin, semuloparin, and RO14 were supplemented in 
normal human plasma to obtain final concentrations ranging from 0 - 25 μg/ml. PF4 was 
added to the heparin supplemented plasma to obtain a final PF4 concentration of 25 
μg/ml. Anticoagulant activity was determined using the PT, APTT, the thrombin time 
and Heptest
®
 assays. Antiprotease activity was determined using anti-Xa and anti-IIa 
assays. The experiment was performed in triplicate on three different days using the same 
protocol. For each assay, % neutralization was calculated by the following formula after 
baseline correction was performed:  
% Neutralization = [1- (post PF4 µg/ml /pre PF4 µg/ml) * 100] 
Since UFH was effectively neutralized by the various antagonists tested, it was used as 
the standard for which to select an appropriate concentration to calculate the % 
neutralization. As such, the 6.25 µg/ml concentration was selected because it was the 
lowest heparin concentration that still allowed for maximal neutralization but did not 
exceed the ability for the antagonist to exert an effect. 
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5.4 Polybrene neutralization assay 
Heparin, enoxaparin, bemiparin, semuloparin, and RO14 were supplemented to 
normal human plasma to obtain final concentrations ranging from 0 - 25 μg/ml. 
Polybrene was added to the heparin supplemented plasma to obtain a final polybrene 
concentration of 25 μg/ml. Anticoagulant activity was determined using the PT, APTT, 
the thrombin time and Heptest
®
 assays. Antiprotease activity was determined using anti-
Xa and anti-IIa assays. The experiment was performed in triplicate on three different days 
using the same protocol. For each assay, % neutralization was calculated by the following 
formula after baseline correction was performed:  
% Neutralization = [1- (post polybrene µg/ml /pre polybrene µg/ml) * 100] 
Since UFH was effectively neutralized by the various antagonists tested, it was used as 
the standard for which to select an appropriate concentration to calculate the % 
neutralization. As such, the 6.25 µg/ml concentration was selected because it was the 
lowest heparin concentration that still allowed for maximal neutralization but did not 
exceed the ability for the antagonist to exert an effect. 
 
5.5 PMX 60056 neutralization assay 
Heparin, enoxaparin, bemiparin, semuloparin, and RO14 were supplemented to 
normal human plasma to obtain final concentrations ranging from 0 - 25 μg/ml. PMX 
60056 was added to the heparin supplemented plasma to obtain a final PMX 60056 
concentration of 25 μg/ml. Anticoagulant activity was determined using the PT, APTT, 
the thrombin time and Heptest
®
 assays. Antiprotease activity was determined using anti-
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Xa and anti-IIa assays. The experiment was performed in triplicate on three different days 
using the same protocol. For each assay, % neutralization was calculated by the following 
formula after baseline correction was performed:  
% Neutralization = [1- (post PMX 60056 µg/ml /pre PMX 60056 µg/ml) * 100] 
Since UFH was effectively neutralized by the various antagonists tested, it was used as 
the standard for which to select an appropriate concentration to calculate the % 
neutralization. As such, the 6.25 µg/ml concentration was selected because it was the 
lowest heparin concentration that still allowed for maximal neutralization but did not 
exceed the ability for the antagonist to exert an effect. 
 
6. In vitro biochemical and pharmacological assays 
6.1 Technothrombin
®
 thrombin generation assay  
 Thrombin generation assay (TGA) is a means for determining thrombin 
generation over time in plasma. This assay is based on monitoring the formation of 
thrombin by means of a fluorogenic substrate upon activation of the coagulation cascade 
by tissue factor. From the change in fluorescence over time, the concentration of 
thrombin (nM) in the sample was calculated using a thrombin calibration curve. 
 These experiments utilized the Thrombin Generation Assay Instrument from 
BioTek, FLx800TM TBI-Gen5 Software (BioTek, Winooski, VT), and the 
TECHNOTHROMBIN
®
 TGA kit (Technoclone, Vienna, Austria). The TGA reagent, RC 
High (high concentration of phospholipid micelles containing 71.6 pM rhTF 
(recombinant human tissue factor) in Tris-Hepes-NaCl buffer), was used. The reagent 
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and substrate (Fluorogenic substrate 1 mM Z-G-G-R-AMC, 15mM CaCl2) were 
reconstituted and given a 20 minute reconstitution time per manufacture guidelines. In 
each of the wells tested, 40 µl of sample was mixed with 10 µl of reagent, followed by 50 
µl of substrate. Once the substrate was added to the plate, it is placed in the TGA 
machine and read at ~360nm/~460nm (excitation/emission). The samples were read at 37 
ºC. Analysis of results was done automatically with the TECHNOTHROMBIN
®
 TGA 
evaluation software. Results were given in nanomolar (nM) of thrombin generated and 
were then converted to % inhibition by using the following equation:  
% Inhibition = [100 - (nM Thrombin sample/nM Thrombin.baseline) x 100] 
 
6.2 Agonist induced platelet aggregation 
The effects of heparin and its derivatives on platelet function were assessed using 
an agonist-induced platelet aggregation assay. Aliquots of 9 ml of blood were drawn from 
healthy volunteers (n=10) using a double syringe technique to avoid contamination by 
tissue factors released upon venipuncture. Standard venipuncture was performed using 
Vacutainer brand Safety-LokTM blood collection sets (23 G ¾, 0.6  19mm, Becton 
Dickinson and Company, Franklin Lakes, NJ). The blood was transferred to plastic test 
tubes containing 1 ml of 3.2% sodium citrate. Platelet rich plasma (PRP) was prepared by 
spinning the citrated blood at 800 rpm (146 x g) for 15 minutes at room temperature. 
After removing PRP, the remaining blood was spun further at 3,000 rpm (2,053 x g) for 
15 minutes to obtain platelet poor plasma (PPP). PPP was used to blank the aggregometer 
(PAP-4) (BioData Corporation, Hatboro, PA). Aggregations were performed in the 
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following manner. Aliquots of 400 µl of PRP and 50 µl of drug (final concentration of 10 
µg/ml) were added into the aggregometer tubes and allowed to incubate at 37
o
C for 2 to 4 
minutes. Then, 50 µl of agonist was added into each tube. The agonists included: ADP 
(1.15 and 0.58 µg/ml, Sigma-Aldrich
®
, Milwaukee, WI), collagen (0.8 µg/ml, Helena 
Laboratories, Beaumont, TX), epinephrine (10 µg/ml, Bio/Data Corporation, Horsham, 
PA), arachidonic acid (500 µg/ml, Bio/Data Corporation, Horsham, PA), and human 
thrombin (1 U/ml, Enzyme Research Laboratories, South Bend, IN). All agonist 
concentrations are final assay concentrations. The aggregation profile was analyzed in 
terms of the maximum percent aggregation. Saline supplementation was used as a 
control. 
 
6.3 Heparin induced thrombocytopenia (HIT) screening 
The heparin derivatives were evaluated for their ability to promote platelet 
aggregation induced by HIT antibodies according to the method of Brace (Brace et al., 
1990). Aliquots of 290 µl of PRP and 160 µl of HIT serum were warmed in a cuvette for 
1 to 2 minutes at 37
o
C. 5, 10, and 20 µl of a 1 mg/ml solution of each agent being tested 
were then added. The platelet aggregation response was monitored for 30 minutes. The 
HIT serum was obtained from patients clinically diagnosed with heparin-induced 
thrombocytopenia and verified using GTI - PF4 ENHANCED® Solid Phase ELISA for the 
detection of PF4 heparin-dependent antibodyes (GTI Diagnostics, Waukesha, WI). 
 
 
102 
 
6.4 Fibrinokinetics 
Fibrinokinetic measurements, which represent a kinetic method for the monitoring 
of the rate of fibrin formation, was used to determine differences among LMW and 
ULMW heparins in their ability to inhibit clot formation. Measurements were made using 
the following method. UFH, enoxaparin, bemiparin, semuloparin, and RO-14 were 
supplemented in citrated NHP at a concentration range of 0 to 10 µg/ml. The 
supplemented NHP (200 µl) was added to a 96-well plate. Next, an aliquot of 25 µl of 
Thrombin (5U) and then 25 µl of calcium chloride (0.25 mM) were added to the 
supplemented NHP. Rate of fibrin formation was recorded at 405 nM on a SpectraMax
®
 
Plus
384
 Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA) every 
minute for 30 minutes.  
 
6.5 Modified Pefakit

 TAFI  
Pefakit

 TAFI (Pentapharm, Inc, Basel Switzerland) is a plasma based 
chromogenic assay, which utilizes a synthetic substrate specific for TAFIa. A modified 
version of this kit was used in which polybrene was removed from the activator. The 
amount of activated TAFI in plasma or other fluids containing TAFI can be measured 
using this method. Prior to determining the TAFI functional activity in normal human 
plasma (NHP), the Pefakit

 TAFI assay was validated for its use in such plasma. A 
calibration curve was constructed for NHP by diluting the NHP 50, 25, 12.5, 6.25, and 
3.12% with 5% albumin. TAFI activation was measured by the change in OD (A405) at 5 
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minutes for human plasma. Functional TAFI levels in NHP were detectable and the 
calibration curves were relatively linear with R
2
 values of at least 0.99.  
UFH, enoxaparin, bemiparin, semuloparin and RO-14 were supplemented in NHP 
at concentration ranges of 0 to 10 µg/ml for UFH and 0 to 100 µg/ml for the rest of the 
agents. The calibrators and controls were reconstituted with 1 ml of distilled deionized 
water. The calibrators were diluted as follows: four tubes were set up; one with 100 l of 
the calibrator (100%), tube two with 70 l of calibrator and 30 l of water (70%), tube 
three with 30 l of calibrator and 70 l of water (30%) and tube four with 100 l of water 
(0%). There were two controls, one with a high TAFI level and the second with a low 
TAFI level. Plasma samples were diluted 1:2 with saline. An aliquot of 10 l of the 
dilution, calibrators, and controls were added to a 96-well plate. An aliquot of 100 l of 
reagent 1, activator, (thrombin, thrombomodulin, Pefabloc
®
 FG, CaCl2, DTNB (Ellman’s 
reagent), Tris, Aprotinin and Prionex
®
) was added to the 96-well plate. The plate was 
then covered and incubated at 37 C for 3 minutes. After the incubation, 100 l of 
reagent 2, start, (substrate, Tris and Mannit) was added to the plate. The plate was read at 
405nm on a SpectraMax
®
 Plus
384
 Absorbance Microplate Reader (Molecular Devices, 
Sunnyvale, CA) every minute for 60 minutes. TAFI activation was measured by the 
change in OD (A405) at 5 minutes for human plasma. Inhibition of TAFI generation was 
presented as percent inhibition and IC50 values were determined. 
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7. Antithrombotic/hemorrhagic effects 
7.1 Rat-tail transection bleeding model 
The rat tail bleeding model was used to evaluate the hemorrhagic potential of the 
agents following subcutaneous (SC) and intravenous (IV) administration (Dejana et al., 
1982). All research was conducted in compliance with the guidelines set forth by the 
Institutional Animal Care and Use Committee (IACUC), Loyola University Medical 
Center and the Principles of Laboratory Animal Care. 
Five male, Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) per group 
were used (total rats = 90/route of administration). Following the induction of anesthesia 
by an intramuscular injection of ketamine (90 mg/kg) and xylazine (10 mg/kg), a baseline 
blood pressure reading was obtained using a Stoelting automatic non-invasive blood 
pressure system (Stoelting Company, Wood Dale, IL). Before drug administration, the 
abdominal area of the animals was shaved and the area of injection was sterilized with 
alcohol swabs. All drugs or saline were administered either SC or IV at the dosages 
presented in Table 1. Intravenous injections were administered through the tail vein or 
femoral vein. Injections administered subcutaneously were made posteriorly on the dorsal 
side of the animal by pinching the skin to create a fold and inserting the needle in 
between the fold and gently discharging the content from the syringe. A second blood 
pressure reading was taken after drug administration and 5 minutes prior to tail 
transaction. At 10 minutes after IV injection or 120 minutes after SC injection, bleeding 
was induced by transecting the distal 2 mm of the rat tail.  The tail tip was gently blotted 
with filter paper every 30 sec until thrombosis occurs and bleeding stops. Care was taken 
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that no pressure was exerted on the tail tips, which could have affected hemostasis. For 
each treatment group the mean bleeding time ± standard error of mean was determined. 
 
Table 2 – Rat-tail transection bleeding model/jugular vein clamping model 
protocol 
Drug Number of Animals Drug Concentration 
Saline SC and IV = 5/Group SC = 0.5, 1.0 and 2.5mg/kg 
IV = 0.25, 0.5 and 1.0mg/kg 
UFH SC and IV = 5/Group SC = 0.5, 1.0 and 2.5mg/kg 
IV = 0.25, 0.5 and 1.0mg/kg 
Enoxaparin SC and IV = 5/Group SC = 0.5, 1.0 and 2.5mg/kg 
IV = 0.25, 0.5 and 1.0mg/kg 
Bemiparin SC and IV = 5/Group SC = 0.5, 1.0 and 2.5mg/kg 
IV = 0.25, 0.5 and 1.0mg/kg 
Semuloparin SC and IV = 5/Group SC = 0.5, 1.0 and 2.5mg/kg 
IV = 0.25, 0.5 and 1.0mg/kg 
RO14 SC and IV = 5/Group SC = 0.5, 1.0 and 2.5mg/kg 
IV = 0.25, 0.5 and 1.0mg/kg 
 
7.2 Rat jugular vein clamping model 
 The rat jugular vein clamping model (Raake, W & Elling, H, 1988) was used to 
evaluate the anti-thrombotic effects of the agents administered subcutaneously (SC) and 
intravenously (IV). After the completion of the rat-tail transaction bleeding model, the rat 
jugular vein clamping model was performed. First, the skin on the neck was shaved and 
an incision was made centrally above the trachea. The right jugular vein was isolated and 
covered with ultrasound transmission gel. An initial reading of vessel blood flow by a bi-
directional Doppler probe was taken. Next, a manual clamping of the jugular vein for one 
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minute was performed using mosquito forceps. The first clamping was made 50 minutes 
after IV drug administration or 160 minutes after SC administration. Clamping of the 
blood vessel causes endothelial damage and initiates clot formation. Blood flow was 
measured 5 minutes after clamping. The procedure continued until the vessel had 
thrombosed and blood flow ceased, as measured by the probe five minutes post-
clamping. The effectiveness of the antithrombotic agent was determined by the number 
of clampings required to cause vascular occlusion. 
 After completion of the thrombosis model, a cardiac puncture was performed for 
blood collection approximately 110 minutes after IV administration and 210 minutes 
after SC administration. The rat was euthanized with an intra-cardiac injection of 
Beuthanasia D (0.3 ml) and a urine sample was collected by bladder puncture. Plasma 
samples were prepared as described previously. APTT (whole blood and plasma), anti-
FXa (plasma), and anti-FIIa (plasma) were performed (see methods above) to determine 
the circulating levels of the agents used. 
 
8. Pharmacodynamics and pharmacokinetics in primates 
8.1 Comparative investigation of heparin and its derivatives 
Fourteen male and female Rhesus monkeys (Macaca mulatta) weighing 4.0 – 
16.0 kg were used for pharmacodynamic, pharmacokinetic, and tissue factor pathway 
inhibitor release studies. The animals were housed in individual cages in accordance with 
the Guide for the Care and Use of Laboratory Animals and the National Research 
Council. All research was conducted in compliance with the guidelines set forth by the 
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Institutional Animal Care and Use Committee (IACUC), Loyola University Medical 
Center and the Principles of Laboratory Animal Care. 
The three drugs used in this study were semuloparin, enoxaparin and 
unfractionated heparin. Each agent was dissolved in 0.9% physiologic saline prior to 
administration to groups of primates. Six primates per group were anesthetized with 
ketamine (20 mg/kg, IM) before drug administration. All agents were administered at the 
dosages according to Table 2. 
Blood samples were drawn from the saphenous vein using a 21 gauge ¾ inch 
butterfly needle at baseline, 60, 240, 360 and 1680 minutes post-IV drug administration. 
Following subcutaneous administration, an additional blood sample was drawn at 1920 
minutes, since it was known that some of these agents have a long half-life. Throughout 
the study, animals were evaluated for signs of bleeding. 
Fifteen minutes after each blood draw, 500 µl of whole blood was removed from 
the citrated blood collection tube before plasma was separated and analyzed using the 
APTT and Heptest
® 
assays. Plasma samples were separated immediately by 
centrifugation of citrated blood at 3,000 rpm (2,053 x g) for 20 min, then aliquoted, and 
frozen at -70°C for future analysis of their coagulation profile using the APTT, Heptest
®
, 
thrombin time (5U), anti-Xa and anti-IIa assays (as discussed previously). In addition 
TFPI antigen levels were measured. A 3 week washout period was used between 
experiments. 
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TABLE 3 – Pharmacodynamics in non-human primates protocol  
Drug Dosage Route Number of 
Animals 
Blood Draw 
Timings 
Semuloparin 0.25 mg/kg 
and 0.5 mg/kg 
Intravenous N=6 0, 60, 240, 360, 
1680 minutes 
post drug 
administration 
Semuloparin 1.0 mg/kg and 
2.5 mg/kg 
Subcutaneous N=6 0, 60, 240, 360, 
1680, 1920 
minutes. post 
drug 
administration 
Enoxaparin 0.25 mg/kg 
and 0.5 mg/kg 
Intravenous N=6 0, 60, 240, 360, 
1680, 1920 
minutes post 
drug 
administration 
Enoxaparin 1.0 mg/kg and 
2.5 mg/kg 
Subcutaneous N=6 0, 60, 240, 360, 
1680 minutes. 
post drug 
administration 
Unfractionated 
Heparin 
0.25 mg/kg 
and 0.5 mg/kg 
Intravenous N=6 0, 60, 240, 360, 
1680 minutes 
post drug 
administration 
Unfractionated 
Heparin 
1.0 mg/kg  Subcutaneous N=6 0, 60, 240, 360, 
1680 minutes 
post drug 
administration 
 
Circulating concentrations of the drugs were calculated based on calibration 
curves constructed by supplementing normal pooled monkey plasma with semuloparin, 
enoxaparin, or UFH over a concentration range of 0 - 20 μg/ml.  
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8.2 Ex vivo ASSERACHROM
®
 total TFPI assay 
TFPI antigen levels were determined using ASSERACHROM
®
 Total TFPI 
ELISA kits (Stago, Parsippany, NJ). This was a sandwich, enzyme-linked immunoassay 
which utilized a murine anti-TFPI monoclonal as the capture antibody and a murine anti-
TFPI monoclonal antibody-peroxidase conjugate for detection of the captured TFPI. The 
bound peroxidase is revealed by its activity at a predetermined time using the substrate 
ortho-phenylenediamine in the presence of urea peroxide. Six TFPI standards ranging in 
concentration from 0 to 200 ng/ml were diluted in buffer and were used to construct a 
calibration curve. Freeze-dried human plasma containing a TFPI level of approximately 
120 ng/ml was used as the calibration standard. Optical density readings and standard 
curve calculations were made using a SpectraMax
®
 Plus
384
 Absorbance Microplate 
Reader (Molecular Devices, Sunnyvale, CA). 
 
8.3 Ex vivo ACTICHROME
®
 TFPI activity assay 
The ACTICHROME
® 
TFPI Activity Assay (American Diagnostica Inc., 
Stamford, CT) was a chromogenic assay intended for the measurement of active TFPI in 
plasma, where TFPI exhibits an inhibitory effect on the TF/FVIIa complex. All reagents 
were reconstituted per manufacturer’s guidelines. Each sample was diluted 1:20 in TFPI 
Reference Plasma prior to performing the assay. An aliquot of 20 µl of TFPI Standard, 
diluted Reference Plasma, or diluted test samples were added to each well. Next, 20 µl of 
TF/FVIIa complex were added to the wells. The micro-test plate was covered and 
incubated at 37°C for 30 minutes. After 30 minutes, 20 µl of human Factor X was added 
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to each well. The plate was covered and incubated at 37°C for 15 minutes. Twenty µl of 
EDTA was added to each well, and then 20 µl of SPECTROZYME FXa was added. The 
reaction began immediately upon addition of the SPECTROZYME FXa. The reaction 
was stopped at 5 minutes by adding 50 µl of glacial acetic acid to each well. The 
absorbance of the solution was read at a wavelength of 405 nm on a SpectraMax
®
 Plus
384
 
Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA). 
 
8.4 TAFI activation in non-human primates 
The modified Pefakit

 TAFI assay (Pentapharm, Inc, Basel Switzerland,) which 
was previously described, was used to evaluate plasma samples from non-human 
primates treated with UFH, enoxaparin, and semuloparin (see doses above).The plate was 
read at 405nm on a SpectraMax
®
 Plus
384
 Absorbance Microplate Reader (Molecular 
Devices, Sunnyvale, CA) every minute for 60 minutes. Prior to determining the TAFI 
generation activity in non-human primate plasma, the Pefakit

 TAFI assay was validated 
for its use in such plasma. A calibration curve was constructed for non-human primate 
plasma by diluting the normal monkey plasma (NMP) 50, 25, 12.5, 6.25, and 3.12% with 
5% albumin. Functional TAFI levels in NMP were detectable and the calibration curves 
were linear with R
2
 values of at least 0.99. The change in OD at 5, 30, and 60 minutes 
was evaluated for the ability to accurately calculate functional TAFI levels. In accordance 
with previous TAFI studies done in our lab, the change in OD at 5 minutes was not 
sufficient to calculate the functional TAFI levels in NMP. Additionally, when functional 
TAFI levels were calculated from the change in OD at 60 minutes, they were considered 
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to be too high. Therefore, all TAFI results were based on the change in OD at 30 minutes 
for the NMP samples.  
 
8.5 Pharmacokinetic analysis 
Plasma concentrations of various compounds were plotted against corresponding 
sample times using graphing software, GraphPad Prism
®
 Version 4.0 for Windows 
(GraphPad Software, San Diego, CA). Pharmacokinetic (PK) parameters were calculated 
using non-compartmental analysis based on statistical moment theory (Gibaldi and 
Perrier, 1982; Gibaldi, 1984; Rowland and Tozer, 1989; Cornelli and Fareed, 2001) as 
shown below.  
The maximum concentrations of each compound in plasma (Cmax) and the time 
to reach Cmax (tmax) were determined by visual examination of graphs.  
Because of the nature of the plasma data, the elimination rate constant (Ke) was 
only able to be estimated as the slope of the terminal portion of the ln plasma 
concentration versus time curve formed by the last three to four blood collection time 
points.  
The estimated terminal half-life (T1/2) of elimination was calculated using the 
equation, 
T1/2= 0.693/Ke. 
The area under the concentration-time curve up to the last blood sampling time 
(AUC0-t) was estimated using the trapezoid rule and extrapolated to infinity (AUC0-) 
using the equation, 
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AUC 0– = AUC 0-t + Ct /Ke 
where Ct was the concentration of each compound at the last sampling time (t). 
The estimated total body clearance (CL) was calculated as the dose/AUC ratio as 
follows: 
CLsys= Dose/ AUC 0–; 
The estimated volume of distribution (Vd) was calculated using the equation, 
Vd= CL / ke. 
 
9. Lewis lung carcinoma (LLC) tumor model 
9.1 In vivo assays 
9.1.1 Cell lysate preparation 
 Cell lysates were prepared from LLC cells as follows: supernatants (media) from 
each cell culture plate were collected. An aliquot of 500 µl of HyClone 1X phosphate 
buffered solution (PBS) (Thermo Fisher Scientific, Pittsburgh, PA) was added to each 
plate. Cells were scraped off the sides and center of each plate using a cell scraper. The 
cells and PBS from each plate were removed and placed into an eppendorf tube. An 
additional 500 µl of PBS was added to each plate, and the plate was scraped again. Once 
again, the cells and PBS were added to the eppendorf tube. The cells and buffer solution 
were spun at 13,000 rpm (38,544 x g) for 5 minutes to create a pellet of cells. Afterwards, 
the PBS solution was removed from each tube without disturbing the pellet of cells. An 
aliquot of 500 µl of homogenization buffer (10 mM Tris-HCL, pH 7.4; 2 mM EGTA; 150 
mM NaCl; 1% Triton X-100; pH 7.4) and 10 µl of protease inhibitor cocktail (Sigma-
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Aldrich
®
, Milwaukee, WI) was added to each eppendorf tube, and then the tube was put 
on ice until they were sonicated. Each eppendorf tube was sonicated twice for 
approximately 30 seconds using a QSonica sonicator 4000 homogenizer (Thermo Fisher 
Scientific, Pittsburg, PA). Cell lysates were then collected and frozen immediately at -
70°C until future use. 
 
9.1.2 VEGF and TGFβ assay 
 The effects of UFH, enoxaparin, bemiparin, semuloparin, and non-AT affinity 
semuloparin on VEGF and TGFβ levels in the supernatant and lysates of cultured LN7 
cells were measured. Briefly, UFH, enoxaparin, bemiparin, semuloparin, and non-AT 
affinity semuloparin were supplemented in cell media at concentrations ranging from 0 - 
1.0 mg/ml. Cells were plated in a 100 mm dish at a concentration of 200,000 cells/dish in 
a final volume of 9.0 ml of media. After 24 hours, the cells were treated with the various 
drugs. An aliquot of 1.0 ml of each drug was added to the wells to achieve final 
concentrations of 100 µg/ml, 10 µg/ml, and 1 µg/ml. Saline was used as control. The 
cells were incubated for 72 hours in a cell culture incubator (at 37°C in a humidified 
atmosphere with 5.0% CO2). After 72 hours, the cell supernatants and lysates were 
collected and frozen (as described above). The amount of VEGF and TGFβ were 
measured in the supernatants and cell lysates using commercially available Quantikine
®
 
ELISA kits for mouse VEGF and TGFβ (R&D Systems, Minneapolis, MN) according to 
the manufacturer’s protocol. A 1.5 dilution was carried out on the cell supernatants. For 
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the cell lysates, the protein concentration was measured using the Lowry Protein Assay. 
All lysates were diluted to a final protein concentration of 1 mg/ml prior to analysis.  
 The amount of VEGF was also measured in the plasma samples collected from 
the tumor bearing C57B1/6 mice using the commercially available Quantikine
®
 ELISA 
kits for mouse VEGF  (R&D Systems, Minneapolis, MN). 
 
9.1.3 Cell viability assay 
The effects of heparin and its derivatives on cell proliferation were measured 
using the CellTiter 96
®
 AQueous One Solution Cell Proliferation Assay (Promega 
Corporation, Madison, WI). UFH, enoxaparin, bemiparin, semuloparin, and non- AT 
affinity semuloparin were supplemented in complete media, which consisted of HyClone 
Classical Liquid Media Dulbeccos Modified Eagles Medium (DMEM), with high 
glucose, L-glutamate, and no sodium pyruvate, 10% HyClone standard fetal bovine 
serum (FBS), and 5% HyClone penicillin/streptomycin (10,000 U each in 0.85% NaCl) 
(all from Thermo Fisher Scientific, Pittsburgh, PA), over a concentration range of 0 to 1.0 
mg/ml. Cells were plated on a 96 well plate at a density of 300 and 150 cells/well in a 
final volume of 90µl. Aliquots of 10 µl of each drug were added to the wells to achieve 
final concentrations of 100 µg/ml, 10 µg/ml, 1 µg/ml, and 0.1 µg/ml. Each concentration 
of drug was run in triplicate. Cells without treatment were used as control. The cells were 
incubated for 72 hours in the dark in a cell culture incubator at 37°C in a humidified 
atmosphere with 5.0% CO2. After 72 hours, the media was aspirated off and the cells 
were washed with 120 µl of PBS. Next, a 100 µl media/20 µl Promega dye solution was 
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added to each well and left to incubate for the time necessary to see color development. 
After 1 hour, the plate was read at 490 nm on a Spectramax Plus 384 spectrophotometer. 
 
9.1.4 Matrigel tubular formation assay 
Matrigel purified from Engelbreth-Holm-Swarm (EHS) mouse sarcoma (EHS) 
(Kleinman, 2001) tumors was thawed at 4°C on ice and plated on the bottom of 24 well- 
plates (250 µl per well) and incubated at 37°C for 16 h. Endothelial cells (100,000 cells) 
were seeded on Matrigel in F12 medium containing 10% FBS and heparin, enoxaparin, 
bemiparin, semuloparin, non-AT affinity semuloparin, high-AT affinity semuloparin or 
saline (control) at final concentrations of 100, 50, and 1 g/ml. The cultures were 
maintained at 37°C in a 2.5% CO2 humidified atmosphere for 24 h (Staton, et al., 2006). 
Each treatment was performed in triplicate. Tube formation was examined under an 
inverted light microscope at 10x magnification. Three images were randomly taken in 
different areas and quantified by two different observers. The total number of tubular 
formations as well as the total length of connected cells forming tubular structures on the 
Matrigel was measured and determined using image analysis software (Image J; NIH, 
Bethesda, MD, USA), and expressed as mm tube length (Dreyfuss, et al., 2010). 
 
9.1.5 Endothelium binding assay 
Endothelial cells (1x10
4
/well) derived from rabbit thoracic aorta (Dr. Helena 
Nader’s Laboratory, São Paulo, Brazil) were cultured on 12-mm-diameter glass 
coverslips in 24-well plates (Corning Costar Corp., Cambridge, MA) using Ham’s 
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Nutrient Mixture F-12 cell culture media (Invitrogen, Carlsbad, CA) for 3 days prior to 
use. All solutions were prepared in PBS (0.1 M, pH 7.4 at 4 ºC). After washing, the cells 
were incubated with biotinylated heparin (1g/ml) in the presence or absence of 100 
times molar excess of different heparin preparations in PBS with 1% BSA. After washing 
several times, the cells were fixed (2% formaldehyde, 30 min, 22 °C) and washed with 
glycine (0.1 M) one time and several times with PBS. The presence of biotinylated 
heparin was detected after incubation with streptavidin conjugated to Texas Red (5 
g/ml). After washing, the cells were finally incubated with DAPI with 0.01% of saponin 
(3 M, 2 min), washed, mounted in Fluoromount-G and examined using a scanning 
confocal microscope (Zeiss LSM-510 NLO, Carl Zeiss, Jena, Germany). 
 
9.2 In vivo LLC tumor model 
Female C57B1/6 mice were obtained at 6-8 weeks of age (JAX Mice, Bar Harbor, 
Maine) and housed according to institutional IACUC protocols of Loyola University 
Stritch School of Medicine. A lung-metastasizing cell variant (LN7), cloned by limiting 
dilution from a metastatic LLC lung nodule was used for all studies. The LLC-LN7 cells 
were cultured in RPMI-1640 containing 10% heat inactivated fetal bovine serum (FBS), 
100 U/ml penicillin, 100 μg/ml streptomycin, 0.02 HEPES buffer, 5 x 10 -5 M β-
mercaptoethanol and 2 mM glutamine (Sigma, St. Louis, MO). 
An implantation method which was previously described was utilized for the in 
vivo mouse studies (Rashid, 2007). C57B1/6 mice were implanted with LN7 tumor cells 
by dorsal subcutaneous injection of 5 x 10 
5
 cells in the upper back. When tumors were 
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first palpable, after approximately 1 week of growth, mice were treated with daily 
subcutaneous injections for the next two weeks at approximately 1 cm away from the 
tumor growth in the lower back according to Table 3. At the end of the treatment period, 
mice were sacrificed by CO2 asphyxiation and the spleens and tumors isolated. 
Additionally, a cardiac puncture was performed in order to collect blood samples for 
further testing. 
Taxol:  from D7 to D22, 2 inj/week, IP. Heparins: from D7 to D22, 1 inj daily, SC. 
 
 
 
 
 
 
 
 
 
Tumor volume monitoring: 
V= [0.5(L×W×H)] 
 
Day 23 
sacrifice 
Day 1 
LN7 Cell injection 
 
Taxol/Heparin  
administration 
 
Day 7 
Tumor growth 
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Table 4. Mouse LLC Tumor Model Protocol 
Drug/ Dosage Number of animals  
vehicle /vehicle n=6 
Taxol (15 mg/kg) / vehicle 
Taxol (7.5 mg/kg) / vehicle     
n=6     
n=6  
Vehicle / Unfractionated 
Heparin (UFH) 
UFH 250 μg/kg  
UFH 500 μg /kg 
UFH 1.0 mg/kg 
 
 
n=6      
n=6   
n=6         
Vehicle / Semuloparin 
Semuloparin 250 μg/kg                                                        
Semuloparin 500 μg/kg 
Semuloparin 1.0 mg /kg 
 
n=6      
n=6   
n=6         
Vehicle / Non-AT Semuloparin 
Non-AT Semuloparin 250 μg/kg                                                         
Non-AT Semuloparin 500 μg/kg  
Non-AT Semuloparin 1.0 mg /kg 
 
n=6
n=6   
n=6         
Vehicle / Enoxaparin              
Enoxaparin 250 μg/kg                                                                    
Enoxaparin 500 μg/kg 
Enoxaparin 1.0 mg /kg 
 
n=6      
n=6   
n=6         
Vehicle / Bemiparin 
Bemiparin 250 μg/kg                                          
Bemiparin 500 μg/kg 
 Bemiparin 1.0 mg /kg 
 
n=6
n=6   
n=6         
Taxol/ UFH  
UFH 250 μg/kg                                          
UFH 500 μg/kg  
UFH 1.0 mg /kg 
 
n=6    
n=6   
n=6         
Taxol/ Semuloparin 
Semuloparin 250 μg/kg                                          
Semuloparin 500 μg/kg 
Semuloparin 1.0 mg /kg 
 
n=6      
n=6   
n=6         
Taxol/  Enoxaparin 
Enoxaparin 250 μg/kg                                           
Enoxaparin 500 μg/kg  
Enoxaparin 1.0 mg /kg 
 
n=6      
n=6   
n=6         
Taxol/  Bemiparin 
Bemiparin 250 μg/kg                                           
Bemiparin 500 μg/kg   
Bemiparin 1.0 mg /kg 
 
n=6
n=6   
n=6         
Total N = 192 
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9.2.1 Histology 
A common observation in the LLC mouse model is splenomegaly. Spleens were 
removed, grossly observed, and then weighed to determine any effect of heparin 
treatment on spleen size.  
The LLC mouse model is noted for rapid tumor growth and therefore central 
tumor necrosis. Tumors were removed after sacrifice, weighed and then measured by 
calipers to determine tumor volume. In order to determine tumor volume by external 
caliper, the greatest longitudinal diameter (length) and the greatest transverse diameter 
(width) were determined. Tumor volume based on caliper measurements were calculated 
by the modified ellipsoidal formula: Tumor volume = [0.5(length × width
 
× height)]. 
 
9.2.2 B-cell lymphoma 2 (BCL-2) staining and analysis 
Immunohistochemistry staining with BCL-2 antibodies was performed on a 
BenchMark XT automated slide preparation system (Ventana Medical Systems, Inc., 
Tucson, AZ) in the pathology laboratories at Loyola University Medical Center 
(Maywood, IL). Briefly, slices from the Lewis lung carcinoma tumors, which were 
removed from mice treated with heparins at a dose of 500 µg/ml, were taken and paraffin 
embedded. The slides with the paraffin embedded tissues were then deparaffinized in 
order to allow for future staining. Slides were rehydrated with a decreasing series of 
alcohol solutions (100 to 80%) until rinsed with deionized water. Slide were then 
incubated with cell conditioning solution (CC1) (Ventana Medical Systems, Inc., Tucson, 
AZ), first for 30 minutes and then again for 60 minutes. CC1 was used to hydrolyze the 
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covalent bonds formed by formalin in tissues, thus allowing the renaturation of protein 
molecules and increasing antibody accessibility. Next, the slides were incubated with a 
BCL-2 antibody (Cell Marque, Rocklin, CA) for 40 minutes. The slides were then 
counterstained using iVIEW™ DAB Detection Kit (Ventana Medical Systems, Inc., 
Tucson, AZ) in order to visualize the BCL-2 antibody using light microscopy. Finally, 
the slides were counterstained with hematoxylin for 8 minutes, post counterstained with 
bluing reagent for 4 minutes, and coverslipped.  
A single-blind quantitation of BCL-2 staining was performed by an independent 
observer (JML). JML is a medical pathologist at Loyola University Medical Center 
(Maywood, IL). Prior to quantitation, the observer used control slides to calibrate 
between high, moderate, and low amounts of BCL-2 staining. Based on the calibration 
procedure, a rating scale from 0 to 3 was decided upon, with 0 meaning no BCL-2 
staining present, and 3 meaning high levels of BCL-2 staining present. After all slides 
were scored, slides which were determined to have BCL-2 staining equal to 2 or above 
were considered to be positive and significant. 
 
9.2.3 Hematoxylin and eosin (H&E) staining and mitotic figures analysis 
 H&E staining was performed by the pathology laboratories at Loyola University 
Medical Center (Maywood, IL). Slices from the Lewis lung carcinoma tumors, which 
were removed from mice treated with heparins at a dose of 500 µg/ml, were mounted on 
glass slides prior to staining. Each slide was treated in succession with a variety of 
solutions as shown in Table. 
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 Light microscopic evaluation of mitotic activity has long served as a reasonable 
assessment of cell proliferation or rate of turnover of cells in that tissue. Therefore, H&E 
stained slices of Lewis lung tumors removed from mice, treated with various heparins at 
a concentration of 500 µg/ml, were evaluated for the number of mitotic figures present in 
3 high-powered microscopic fields. A single-blind quantitation of mitotic figures was 
performed by an independent observer (JML). JML is a medical pathologist at Loyola 
University Medical Center (Maywood, IL). Counts of mitotic spheres were used as a 
proliferation index.  
Table 5 . H&E Staining Procedure 
Step Solution Time (min/sec) 
1 Xylene 2:00 
2 Xylene 2:00 
3 Xylene 2:00 
4 100% Alcohol 1:00 
5 95% Alcohol 1:00 
6 80% Alcohol 1:00 
7 Wash :30 
8 Hematoxylin 8:00 
9 Wash 1:30 
10 HCL :01 
11 Wash :45 
12 Ammonia water :30 
13 Wash 1:30 
14 95% Alcohol 1:00 
15 Eosin 2:00 
16 95% Alcohol 1:00 
17 95% Alcohol 1:00 
18 100% Alcohol 1:00 
19 100% Alcohol 1:00 
20 100% Alcohol 1:00 
21 Xylene 1:00 
22 Xylene 1:00 
 Xylene 1:00 
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10. Data processing and statistical analysis 
 The experimental data obtained in this dissertation is presented as the mean ± 
standard deviation (SD) or mean ± standard error of the mean (SEM) and is indicated as 
such throughout this document. The results obtained from the biochemical experiments 
were analyzed using a two-way analysis of variance (ANOVA) followed by a Bonferroni 
multiple comparison test. This analysis was used to determine statistically significant 
differences between the effects of heparin and its derivatives. If a significant difference 
was notes using the two-way ANOVA in a given assay system, the concentration 
response data for each agent was analyzed by one-way ANOVA followed by a Dunnett’s 
post hoc analysis to determine the statistical significance of the effect of each 
concentration relative to a control. Potency comparisons (IC50) were compared using a 
one-way ANOVA followed by a Tukey multiple comparison test. Other data were 
analyzed using one of the following statistical tests and were labeled as such: 
Students t-test (unpaired), one-way ANOVA with a Tukey multiple comparison test, 
Pearson’s chi-square test and Fisher’s exact test. In all cases a p value < 0.05 was 
considered statistically significant. Computed p values were presented for each analysis. 
Graphs with data and error bars were drawn using Microsoft Excel 2003 (Microsoft
®
 
Corporation, Redmond, WA) or GraphPad Prism version 5.0 for Windows (GraphPad 
Software, San Diego, CA).  
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CHAPTER FOUR 
RESULTS 
 
A. Physicochemical characterization of various heparins 
 The compositional and molecular characteristics of heparin and its derivatives 
play a critical role in the determination of their biological properties. Therefore, 
molecular weight distribution profile, heparinase digestion profile, scanning ultraviolet 
(UV) spectroscopy, and circular dichroism (CD), analyses were performed on UFH, 
enoxaparin, bemiparin, semuloparin, high and non-AT AF semuloparin, and RO-14 to 
characterize their physicochemical properties. 
 
1. Gel-permeation chromatography 
1.1 Molecular weight profiles 
 The molecular weight profiles for UFH, non-AT AF UFH, enoxaparin, bemiparin, 
high-AT AF semuloparin, semuloparin, non-AT AF semuloparin and RO-14 were 
determined by size-exclusion chromatography (SEC) in a high-performance liquid 
chromatography (HPLC) system. The molecular weight of each sample was determined 
by a narrow range calibration (NRC) method or a modified European Pharmacopoeia 
(EP) method, as previously described in the ‘Materials and Methods’ section. 
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The elution profiles for UFH, enoxaparin, bemiparin, semuloparin, and RO-14, 
which were analyzed using the NRC method, are shown in Figure 7. Panel A shows the 
elution profiles using the UV detection method, while Panel B shows the elution profiles 
using the RI detection method. The calculated molecular weights were comparable 
between the UV and RI detectors, with the RI detector producing only slightly higher 
molecular weights compared to the molecular weights determined by the UV detector.  
UFH had the broadest peak, with an elution time of approximately 18 minutes, 
indicating a higher degree of heterogeneity compared to the other agents. The elution 
time for each sample is defined as the time between the start of separation (the time at 
which the solute enters the column or the beginning of the peak) and the time at which 
the sample fully elutes (end of the peak). Enoxaparin and bemiparin had similar elution 
times which spanned approximately 15 minutes. Semuloparin and RO-14 had relatively 
narrow peaks indicating that they have the greatest degree of homogeneity compared to 
the other agents. The trends were similar between the UV and RI detectors.  
The elution profiles for UFH, enoxaparin, bemiparin, semuloparin, and RO-14, 
which were analyzed using the EP method, are shown in Figure 8. Similar to the results 
obtained using the NRC method, UFH had the broadest peak with an elution time of 
approximately 17 minutes. Enoxaparin and bemiparin had similar elution times which 
spanned approximately 14 minutes. Semuloparin and RO-14 had relatively narrow peaks 
indicating that they have the greatest degree of homogeneity compared to the other 
agents.
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Figure 7. Elution profiles of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 as 
measured by size-exclusion chromatography (SEC) using the NRC method. Both the UV 
205 nm (A) and RI (B) detector methods were used. The arrows point to the peak with 
the indicated mean MW. 
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Figure 8. Elution profiles of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 as 
measured by SEC using the EP method (234 nm). The UV detector method was used. 
The arrows point to the peak with the indicated mean MW. 
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The molecular weight profiles for UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 obtained with the UV and RI detectors for both the NRC and EP methods are 
tabulated in Table 6. Since heparins are heterogeneous in nature, the molecular weights 
of the various heparins determined by GPC represent average molecular weights cross 
referenced to the NRC and EP curves. As seen in Table 6, heparin exhibited the highest 
mean molecular weight of 16.5 kDa as measured by UV detection when using both the 
NRC and EP methods. UFH’s average molecular weight was only slightly higher (17.0 
kDa) when measured by the RI detector using the NRC method. When measured by UV 
detection using the NRC method, enoxaparin had the next highest molecular weight (4.2 
kDa), followed by bemiparin (3.8 kDa), semuloparin (2.9 kDa), and RO-14 (2.6 kDa). 
The rank order was the same after UV detection using the EP method. For enoxaparin, 
bemiparin, semuloparin, and RO-14, the molecular weights were higher when determined 
by the EP method. 
As seen in Table 6, UFH had the greatest polydispersity and was the most 
heterogeneous compared to all other agents when determined by both the NRC and EP 
methods. Polydispersity is a measure of the homogeneity of the fractions making up the 
heparin sample. It is defined as the ratio between the number average molecular weight 
(Mn) and the weight average molecular weight (Mw). For each of the heparins, the 
polydispersity decreased as the molecular weight decreased.  
The elution profiles for high-AT AF semuloparin, semuloparin, and non-AT AF 
semuloparin, which were analyzed using the NRC method, are shown in Figure 9. Panel
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TABLE 6   
 
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR UFH, ENOXAPARIN, 
BEMIPARIN, SEMULOPARIN AND RO-14 AS MEASURED BY THE NRC AND EP 
METHODS 
 
Detector/Method: UV (205 nm)/NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
 
UFH 
 
12,534 
 
16,500 
 
1.31 
Enoxaparin 3,539 4,177 1.18 
Bemiparin 3,361 3,811 1.13 
Semuloparin 2,647 2,903 1.10 
RO-14 2,498 2,640 1.06 
    
 
Detector/Method: RI/NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
 
UFH 
 
13,173 
 
16,997 
 
1.29 
Enoxaparin 3,725 4,183 1.12 
Bemiparin 3,583 3,953 1.10 
Semuloparin 2,889 3,055 1.06 
RO-14 2,609 2,715 1.04 
    
 
Detector/Method: UV (234 nm)/EP 
 
Agent Mn (Da) Mw (Da) Polydispersity 
 
UFH 
 
13,314 
 
16,485 
 
1.23 
Enoxaparin 3,800 4,395 1.15 
Bemiparin 3,541 3,962 1.11 
Semuloparin 2,988 3,277 1.09 
RO-14 2,750 2,980 1.08 
    
 
The molecular weights of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 were 
determined by gel permeation chromatography.  Mw is the weight average molecular 
weight, and Mn is the number average molecular weight.  The calculated MWs were 
comparable between the two calibration methods. 
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Figure 9. Elution profiles of high-AT AF semuloparin, semuloparin, and non-AT AF 
semuloparin as measured by SEC using the NRC method. Both the UV 205 nm (A) and 
RI (B) detector methods were used. The arrows point to the peak with the indicated mean 
MW. 
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A shows the elution profiles using the UV detection method, while Panel B shows the 
elution profiles using the RI detection method. The elution times were comparable for all 
three compounds (approximately 10 minutes) after UV detection. However, after RI 
detection, non-AT AF semuloparin had a shorter elution time (6 minutes) compared to 
high-AT AF semuloparin and semuloparin (10 minutes).  
The molecular weight profiles for high-AT AF semuloparin, semuloparin, and 
non-AT AF semuloparin obtained with the UV and RI detectors using the NRC method 
are tabulated in Table 7. The calculated molecular weights were similar between the UV 
and RI detectors, with the RI detector producing only a slightly higher molecular weight 
for semuloparin (RI: 3.1 kDa) compared to the UV detector (UV: 2.9 kDa). As would be 
expected, the high-AT AF semuloparin had a higher molecular weight (3.3 kDa) 
compared to both semuloparin (2.9 kDa) and the non-AT AF semuloparin (2.6 kDa). The 
polydispersity was similar for semuloparin and its high- and non-AT affinity fractions 
after both UV and RI detection; although, semuloparin showed a slight increase (1.10 vs. 
1.06) when measured by the UV detection method. 
The elution profiles for UFH and non-AT AF UFH, which were analyzed using 
the NRC method, are shown in Figure 10. Panel A shows the elution profiles using the 
UV detection method, while Panel B shows the elution profiles using the RI detection 
method. As seen in Panel A, UFH started eluting sooner and had a longer elution time (20 
minutes) compared to the non-AT AF UFH (17 minutes). The retention time for both 
agents was approximately the same (32 minutes). The retention time of a solute is take 
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TABLE 7  
 
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR HIGH-AT AF 
SEMULOPARIN, SEMULOPARIN AND NON-AT AF SEMULOPARIN AS 
MEASURED BY THE NRC METHOD 
 
Detector/Method: UV (205 nm)/NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
 
High-AT AF Semuloparin 
 
3,080 
 
3,279 
 
1.06 
Semuloparin 2,647 2,903 1.10 
Non-AT AF Semuloparin 2,426 2,579 1.06 
    
 
 
Detector/Method: RI/NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
 
High-AT AF Semuloparin 
 
3,169 
 
3,342 
 
1.05 
Semuloparin 2,889 3,055 1.06 
Non-AT AF Semuloparin 2,532 2,600 1.03 
    
 
The molecular weights of High-AT AF semuloparin, semuloparin, and non-AT AF 
semuloparin were determined by gel permeation chromatography.  Mw is the weight 
average molecular weight, and Mn is the number average molecular weight.  The 
calculated MWs were comparable between the UV and RI detectors, with the RI detector 
producing only slightly higher MWs. 
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Figure 10. Elution profiles of UFH and non-AT AF UFH as measured by SEC using the 
NRC method. Both the UV 205 nm (A) and RI (B) detector methods were used. The 
arrows point to the peak with the indicated mean MW.  
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as the elapsed time between the time of injection of a sample and the time of elution of 
the maximum peak of that sample. With RI detection (B), both the elution times and 
retention times were similar for both agents (approximately 18 minutes and 32 minutes, 
respectively). 
The molecular weight profiles for UFH and non-AT AF UFH obtained with the 
UV and RI detectors using the NRC method are tabulated in Table 8. The calculated 
molecular weights were comparable using either the UV or RI detectors, with the RI 
detector producing only slightly higher molecular weights for both agents compared to 
the UV detector. UFH had a higher mean molecular weight (UV: 16.5 kDa; RI: 17.0 kDa) 
compared to non-AT AF UFH (UV: 13.5 kDa; RI: 14.3 kDa). The polydispersity was 
similar for both agents after both UV and RI detection. 
The overall results indicated that UFH had the highest mean molecular weight and 
was the most heterogeneous in nature. Overall, decreases in mean molecular weight were 
associated with decreases in polydispersity. Semuloparin and RO-14 were considered to 
be the most homogenous of all agents tested. While similar mean molecular weight 
determinations were made by UV and RI detectors, results were not identical. The RI 
detection method consistently produced higher mean molecular weight determinations 
compared to the UV detection method. The mean molecular weights calculated using the 
NRC and EP method were similar.  
Changes in the structural composition of UFH and semuloparin were also 
apparent after molecular weight determinations were made using the HPLC method. The
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TABLE 8 
 
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR UFH AND NON-AT AF 
UFH AS MEASURED BY THE NRC METHOD 
 
Detector/Method: UV (205 nm)/NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
 
UFH 
 
12,534 
 
16,500 
 
1.31 
Non-AT AF UFH 10,033 13,446 1.34 
    
 
 
Detector/Method: RI/NRC 
 
Agent Mn (Da) Mw (Da) Polydispersity 
 
UFH 
 
13,173 
 
16,997 
 
1.29 
Non-AT AF UFH 11,214 14,282 1.27 
    
 
The molecular weights of UFH and non-AT AF UFH were determined by gel permeation 
chromatography.  Mw is the weight average molecular weight, and Mn is the number 
average molecular weight.  The calculated MWs were comparable between the UV and 
RI detectors, with the RI detector producing only slightly higher MWs.
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presence or absence of AT binding sequences to both UFH and semuloparin resulted in 
increases or decreases in mean molecular weight, respectively, to these agents. However, 
corresponding changes between mean molecular weight and structural composition did 
not produce any meaningful differences in the polydispersity of these agents (Table 11). 
 
1.2 Heparinase Degradation 
To compare the effects of heparinase-I on the physicochemical properties of 
heparin and its derivatives, UFH, enoxaparin, bemiparin, semuloparin, and RO-14 were 
subjected to heparinase-I digestion. Previous studies have shown (Xiao et al., 2011), that 
heparinase 1 cleaves heparins at both the GlcNS6S (1 → 4) IdoA2S and GlcNS3S6S (1 
→ 4) IdoA2S linkages (see ‘List of Abbreviations’ for full description). Interestingly, 
Xiao et al (2011) demonstrated that heparinase I had selectivity for the GlcNS3S6S (1 → 
4) IdoA2S linkages, which were found primarily within the antithrombin binding sites, 
compared to the major disaccharide repeating unit GlcNS6S (1 → 4) IdoA2S. 
In this study, heparinase digestion resulted in the fragmentation of each agent into 
its oligosaccharide components; mainly, di, tetra, hexa, octa, and deca saccharides for all 
the heparin samples. The mean molecular weight for each digested sample was 
determined using GPC with the NRC method. The compiled chromatograms are shown 
in Figures 11 and 12.  
In Figure 11, Panel A shows the elution profiles for the non-digested samples, 
while Panel B shows the elution profiles for the heparinase digested samples. As seen in
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TABLE 11 
COMPARISON OF ANTI-FXA, ANTI-FIIA ACTIVITY, AND MEAN MOLECULAR 
WEIGHT 
 
PD, polydispersity; U, units; MW, molecular weight; Da, Daltons. 
 
 
 
 
 
Drug FXa (U mg
-1
) FIIa (U mg
-1
) FXa/FIIa 
ratio 
MW 
(Da) 
PD 
UFH  160-180 160-180 >1.5 15000 1.31 
Enoxaparin  100-110 20-35 3.3-5.3 4136 1.16 
Bemiparin  80-110 5-10 8 3811 1.13 
Semuloparin  ~160 ~2 >30 2903 1.10 
RO-14  75-110 10 >20 2699 1.06 
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Figure 11, heparinase was clearly capable of depolymerizing the various heparins as 
evident by the shift to the right of each peak and subsequent decrease in mean molecular 
weight for all agents (B). Additionally, the similar post-digested mean molecular weights 
(ranging from 2.13 to 2.26 kDa) for each heparin demonstrates a similar degree of 
heparinase digestion.  
The calculated molecular weights for pre- and post-heparinase digestion samples 
were comparable between the UV and RI detectors, with the RI detector producing only 
slightly higher molecular weights compared to the molecular weights determined by UV 
detection (Figure 12). The results for the pre and post heparinase digestion of UFH, 
enoxaparin, bemiparin, semuloparin, and RO-14, obtained with the UV and RI detectors 
for the NRC method, are tabulated in Table 9.  
 
2. Scanning UV spectroscopy 
Typical UV spectra of samples containing carboxylic acid groups were observed 
with the highest band around 190 nm, arising from carboxylate chromophores of 
iduronate and glucuronate as well as N-acetyl chromophores of the glucosamine residues 
(Figure 13). Also, all LMW and ULMW heparins presented an extra broad band from 
215 to 255 nm indicating that they are produced by -eliminative methods (Figure 13).  
The absorbance at 190 nm arises predominately from carboxylate chromophores, 
and the band at 230 nm indicates the double bond in the uronic acid residue generated 
from the depolymerization reaction; therefore, the ratio of the maximum absorbances at
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Figure 11. Heparinase digestion of various heparins as measured by SEC using the NRC 
method. Pre (A) and post (B) heparinase elution profiles were determined using the UV 
detection method. Heparinase (1 U/ml final concentration) was incubated with various 
heparins (10 mg/ml, pH = 5.0) at 37°C for 30 min. The arrows point to the peak with the 
indicated mean MW.  
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Figure 12. Heparinase digestion of various heparins as measured by SEC using the NRC 
method. Pre (A) and Post (B) heparinase elution profiles were determined using the RI 
detection method. Heparinase (1 U/ml final concentration) was incubated with various 
heparins (10 mg/ml, pH = 5.0) at 37°C for 30 min. The arrows point to the peak with the 
indicated mean MW. 
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TABLE 9 
 
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR UFH, ENOXAPARIN, 
BEMIPARIN, SEMULOPARIN AND RO-14 PRE AND POST HEPARINASE 
DIGESTION AS MEASURED BY THE NRC METHOD 
 
Detector/Method: UV (205 nm)/NRC 
 
Agent Pre Mw (Da) Post Mw (Da) 
 
UFH 
 
16,500 
 
2,256 
Enoxaparin 4,177 2,134 
Bemiparin 3,811 2,225 
Semuloparin 2,903 2182 
RO-14 2,640 2,220 
   
 
 
Detector/Method: RI/NRC 
 
Agent Pre Mw (Da) Post Mw (Da) 
 
UFH 
 
16,997 
 
2,074 
Enoxaparin 4,183 2,251 
Bemiparin 3,953 2,373 
Semuloparin 3,055 2,267 
RO-14 2,715 2,239 
   
 
The molecular weights UFH, enoxaparin, bemiparin, and semuloparin pre and post 
heparinase digestion were determined by gel permeation chromatography.  Mw is the 
weight average molecular weight, Mn is the number average molecular weight, and RNI 
is relative neutralization index.   
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Figure 13. Scanning UV spectra of UFH, enoxaparin, bemiparin, semuloparin, and RO-
14 (1 µg/ml). The vertical gray lines highlight the peak absorbance (ABS) at 190 nm and 
230 nm. 
Agents  Abs190 nm Abs230 nm Ratio Abs190 nm / Abs230 nm  
Enoxaparin 3.261 1.435 2.27 
Bemiparin 3.622 1.907 1.89 
Semuloparin 3.01 1.884 1.59 
RO-14 3.457 2.213 1.56 
Table 10. Comparison of the UV spectra features of enoxaparin, bemiparin, semuloparin, 
and RO-14. The ratio of the maximum absorbances at 190 and 230 nm were used as a 
molecular weight comparison parameter for compounds produced by -elimination 
reactions. 
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190 and 230 nm was used as a molecular weight comparison parameter for compounds 
produced by -elimination reactions (Table 10). RO-14, the agent with the lowest MW, 
presented the lowest 190/230 nm ratio. This ratio strongly correlated (r
2
 = 0.92) with the 
MW of the various heparins that were determined by HPLC. 
 
3. Circular Dichroism 
The CD spectra of ULMWHs are shown in Figure 14. The CD spectra features 
arose from the electronic transition occurring in the oxygen atoms (ring, glycosidic 
linkage, and hydroxyl group), with a maxima around 190 nm, as well as from electronic 
transition occurring on the carboxylate and N-acetyl chromophores, maxima around 210 
nm. The introduction of a 4,5 double bond (C=C) into the non-reducing end of the 
uronate residue, as a result of the β-elimination reaction used in the production of the 
various heparins, resulted in an additional negative band with its maxima at 230 nm.  
 
B. In Vitro Studies  
The therapeutic actions of heparin and its derivatives are predominately the result 
of their interactions with a diversity of plasma proteins including factor Xa and thrombin. 
The ability of heparins to bind to and inhibit various serine proteases is predominately 
mediated by the cofactors, AT and HCII. The binding of heparins with AT and HCII is 
strongly influenced by the molecular weight (MW) and structural composition of each
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Figure 14. CD spectra of UFH, enoxaparin, bemiparin, semuloparin, and RO-14. The 
spectral features arose from the electronic transition occurring in the oxygen atoms, with 
maxima around 190 nm, as well as from electronic transition occurring on the 
carboxylate and N-acetyl chromophores, maxima around 210 nm. The introduction of a 
double bond resulted in an extra negative band with its maxima at 230 nm. 
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heparin. In this section, the effect of MW on anticoagulation and antiprotease activity 
was determined using well-defined biochemical systems in which UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 were supplemented to whole blood (WB), normal 
human platelet poor plasma (PPP) and platelet rich plasma (PRP) at various 
concentrations. In order to determine to what extent AT and HCII binding affect the 
anticoagulant and antiprotease properties of the various heparins, UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 were supplemented in AT depleted and HCII 
depleted plasma systems, as well as, both AT and HCII purified systems. Additionally, 
the effect of these various heparins on the inhibition of thrombin generation was 
determined using a highly sensitive thrombin generation assay. Similarly, high and non-
antithrombin affinity fractions of semuloparin were also evaluated in NHP, HCII and AT 
purified systems, as well as in the thrombin generation assay. The following section aims 
to elucidate and characterize the anticoagulant and antiprotease effects of each heparin, 
and to know to what extent each of the cofactors contributes to these effects. 
 
1. Studies in whole blood and normal citrated plasma 
1.1 Activated clotting time 
 UFH, enoxaparin, bemiparin, semuloparin, and RO-14 were supplemented in 
whole blood at final concentrations of 10 or 25 µg/ml, and the activated clotting time 
(ACT) was determined using celite tubes as described in the ‘Material and Methods’ 
section. Figure 15 compares the effect of the five drugs on the ACT relative to a saline
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Figure 15. The effect of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 at a 
concentration of 10 µg/ ml on the activated clotting time. UFH, enoxaparin, bemiparin, 
and semuloparin exhibited strong anticoagulant effects by significantly prolonging the 
clotting time when compared to saline control (*p <0.05). UFH produced the most potent 
anticoagulant effects and was significantly (+p <0.001) stronger than all other agents. 
Enoxaparin and bemiparin were significantly (#p <0.05) stronger than RO-14. The data 
represent the mean ± standard deviation (n=5). Statistical analysis of the data was 
performed using a one-way ANOVA followed by Bonferroni’s multiple comparison test.  
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control. At the 10 µg/ml concentration, UFH (330.0 ± 8.1 sec), enoxaparin (177.0 ± 2.4 
sec), bemiparin (167.8 ± 4.4 sec), and semuloparin (153.6 ± 6.6 sec) exhibited strong 
anticoagulant effects, significantly (p <0.05) prolonging the clotting time compared to 
saline control (123.8 ± 1.6 sec). Similar results were observed at the 25 µg/ml 
concentration (p <0.001). RO-14 (165.7 ± 3.5 sec) was able to significantly (p < 0.05) 
increase the clotting time compared to baseline (126.0 ± 1.5 sec), but only at the highest 
concentration tested. The 2.5-fold increase in drug concentration produced an 
approximate 1.13 to 1.36-fold increase in the clotting times for all agents. UFH produced 
the most potent anticoagulant effect and was significantly (p <0.001) stronger than all 
other agents at both concentrations. Both enoxaparin and bemiparin prolonged the 
clotting time significantly (p <0.05) longer than RO-14 at both concentrations. At the 25 
µg/ml concentration, bemiparin and enoxaparin produced a significantly (p <0.05) 
stronger anticoagulant effect than semuloparin (Figure 16). The individual data from this 
assay is presented in Table 12. 
 These results indicate that the various heparins tested were able to produce a 
strong anticoagulant response in vitro at a concentration of 10 µg/ml and 25 µg/ml. 
However, a 2.5-fold increase in dose did not produce a proportional increase in the 
clotting time. Moreover, MW-dependent increases in clotting times were observed. One 
caveat, however, is that the MW difference between enoxaparin and bemiparin did not 
correlate to a differentiation in their clotting times. 
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Figure 16. The effect of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 at a 
concentration of 25 µg/ ml on the activated clotting time. All agents exhibited strong 
anticoagulant effects by significantly prolonging the clotting time when compared to 
saline control (*p <0.05). UFH produced the most potent anticoagulant effects and was 
significantly (+p <0.001) stronger than all other agents. Enoxaparin and bemiparin 
significantly (#p <0.01) prolonged the clotting time compared to semuloparin and RO-
14. The data represent the mean ± standard deviation (n=5). Statistical analysis of the 
data was performed using a one-way ANOVA followed by Bonferroni’s multiple 
comparison test.  
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1.2 Supplementation in whole blood and retrieved platelet poor plasma 
1.2.1 Global anticoagulant assays 
To determine the extent of which heparins bind to cellular components, the global 
anticoagulant effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 were 
determined following supplementation in whole blood (WB) and retrieved platelet poor 
plasma (PPP) using the activated partial thromboplastin time (APTT) and Heptest
®
 
assays. The anti-Xa and IIa assays were not used in these studies because change in 
optical density cannot be monitored in whole blood. The agents were supplemented at a 
concentration range of 0 to 2.5 µg/ml. If the clotting time of any test exceeded 300 sec, 
the test was stopped, as the values would be outside the linear sensitivity of the assay. 
Statistical significance (p <0.05) between treatment and control was determined by one-
way ANOVA followed by Tukey’s multiple comparison test. Statistical significance (p 
<0.05) between agents was determined using a two-way ANOVA followed by 
Bonferroni’s multiple comparison test. Compiled data for these studies can be found in 
Table 13 of Appendix 1. 
 
1.2.1.1 APTT 
The anticoagulant effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-
14 as measured by APTT are shown in Figure 17. In WB, UFH (91.1 ± 16.3 sec), 
enoxaparin (51.3 ± 7.1 sec), and bemiparin (53.0 ± 7.5 sec) significantly (p <0.05)
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Figure 17. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in whole blood as measured by the APTT assay. All agents were 
supplemented in the whole blood of 10 different donors (5 male and 5 female) over a 
concentration range of 0 to 2.5 µg/ml. UFH, enoxaparin, and bemiparin exhibited 
significant (*p <0.001; ^p <0.05) anticoagulant effects at the 2.5 µg/ml concentration 
compared to control. Additionally, at the same concentration, UFH had a significantly (p 
<0.001) longer clotting time compared to all other agents. The data represent the mean ± 
standard deviation (n=10). Statistically significant differences between treatment and 
control for each agent were determined by one-way ANOVA followed by Tukey’s 
multiple comparison test. Statistical differences between agents were determined using a 
two-way ANOVA followed by Bonferroni’s multiple comparison test. Results were 
considered to be statistically significant if p <0.05. 
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prolonged the clotting time at a concentration of 2.5 µg/ml (Figure 17), when compared 
to baseline values (41.4 ± 4.6 sec). At the same concentration, UFH produced a 
significantly (p <0.001) longer clotting time than all other agents. 
 When supplemented in retrieved PPP (Figure 18), UFH, bemiparin, semuloparin, 
and RO-14 exhibited significant (p <0.05) anticoagulant effects at concentrations above 
1.25 µg/ml when compared to control. Conversely, enoxaparin was only able to 
significantly prolong the clotting time at the 2.5 µg/ml concentration (p <0.05) when 
compared to baseline. At concentrations above 1.25 µg/ml, UFH had significantly (p 
<0.001) longer clotting times compared to all other agents. Compared to whole blood 
results, supplementation in retrieved PPP produced higher clotting times for all agents as 
determined by the APTT assay. 
 
1.2.1.2 Heptest
®
 
Figure 19 show the anticoagulant effects of the various heparins as measured by 
the Heptest
®
 assay. When supplemented in WB (Figure 19), semuloparin and bemiparin 
exhibited significant (p <0.001) anticoagulant effects at all concentrations compared to 
control. At concentrations above 0.62 µg/ml, enoxaparin and RO-14 produced 
significantly (p <0.01) longer clotting times compared to baseline. When compared to 
baseline values, UFH produced significantly (p <0.01) longer clotting times at 
concentrations above 1.25 µg/ml. At the 2.5 µg/ml dose, semuloparin (97.6 ± 19.4 sec)
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Figure 18. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in PPP as measured by the APTT assay. All agents were 
supplemented in the PPP of 10 different donors (5 male and 5 female) over a 
concentration range of 0 to 2.5 µg/ml. At concentrations above 1.25 µg/ml, UFH, 
bemiparin, semuloparin, and RO-14 exhibited significant (*p <0.05) anticoagulant effects 
compared to control. Compared to control, enoxaparin was only able to prolong the 
clotting time at the 2.5 µg/ml concentration (p <0.05). At the 2.5 and 1.25 µg/ml 
concentrations, UFH had significantly (p <0.001) longer clotting times compared to all 
other agents. The data represent the mean ± standard deviation (n=10). Statistically 
significant differences between treatment and control for each agent were determined by 
one-way ANOVA followed by Tukey’s multiple comparison test. Statistical differences 
between agents were determined using a two-way ANOVA followed by Bonferroni’s 
multiple comparison test. Results were considered to be statistically significant if p 
<0.05.
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Figure 19. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in whole blood as measured by the Heptest
®
 assay. All agents 
were supplemented in the whole blood of 10 different donors (5 male and 5 female) over 
a concentration range of 0 to 2.5 µg/ml. Semuloparin and bemiparin exhibited significant 
(*p <0.001) anticoagulant effects at all concentrations compared to control. At 
concentrations above 0.62 µg/ml, enoxaparin and RO-14 produced significantly (^p 
<0.01) longer clotting times compared to control. UFH produced significantly (#p <0.01) 
longer clotting times at concentrations above 1.25 µg/ml. At the 2.5 µg/ml concentration, 
semuloparin had a significantly (p <0.05) longer clotting time compared to UFH and 
enoxaparin. The data represent the mean ± standard deviation (n=10). Statistically 
significant differences between treatment and control for each agent were determined by 
one-way ANOVA followed by Tukey’s multiple comparison test. Statistical differences 
between agents were determined using a two-way ANOVA followed by Bonferroni’s 
multiple comparison test. Results were considered to be statistically significant if p 
<0.05.
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had a significantly (p <0.05) longer clotting time compared to UFH (71.2 ± 16.9 sec) and 
enoxaparin (70.0 ± 12.8 sec).  
In retrieved PPP (Figure 20), at concentrations above 0.31 µg/ml, all agents were 
capable of significantly (p <0.01) prolonging the clotting time when compared to 
baseline values. UFH (182.3 ± 27.5 sec) produced significantly (p <0.001) longer clotting 
times compared to all other agents at the 2.5 µg/ml concentration. Additionally, UFH was 
significantly (p <0.05) more potent than enoxaparin and RO-14 at the 1.25 µg/ml 
concentration and still more potent than RO-14 at the 0.62 µg/ml concentration (p 
<0.01). Enoxaparin, semuloparin, and bemiparin produced significantly (p <0.05) longer 
clotting times compared to RO-14 at the 2.5 µg/ml concentration, and semuloparin and 
bemiparin were still more potent than RO-14 at the 1.25 µg/ml concentration (p <0.05). 
The compiled data for these studies are found in Table 13. Compared to the whole blood 
results, supplementation in retrieved PPP produced higher clotting times for all agents as 
determined by the Heptest
®
 assay. 
Results from these studies suggest that when supplemented in whole blood, 
heparins bind to various cellular components which reduce their anticoagulant effects. 
This is evident by the fact that clotting times increased dramatically when each agent was 
supplemented in the retrieved PPP compared to when supplemented in whole blood. 
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Figure 20. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in PPP as measured by the Heptest
®
 assay. All agents were 
supplemented in the PPP of 10 different donors (5 male and 5 female) over a 
concentration range of 0 to 2.5 µg/ml. All agents exhibited significant (*p <0.01) 
anticoagulant effects at all concentrations compared to control. UFH produced 
significantly (p <0.001) longer clotting times compared to all other agents at the 2.5 
µg/ml concentration. Additionally, UFH was significantly (p <0.05) stronger than 
enoxaparin and RO-14 at the 1.25 µg/ml concentration and still stronger than RO-14 at 
the 0.62 µg/ml concentration (p <0.01). Enoxaparin, semuloparin, and bemiparin 
produced significantly (p <0.05) longer clotting times compared to RO-14 at the 2.5 
µg/ml concentration, and semuloparin and bemiparin were still stronger than RO-14 at 
the 1.25 µg/ml concentration (α p <0.05). The data represent the mean ± standard 
deviation (n=10). Statistically significant differences between treatment and control for 
each agent were determined by one-way ANOVA followed by Tukey’s multiple 
comparison test. Statistical differences between agents were determined using a two-way 
ANOVA followed by Bonferroni’s multiple comparison test. Results were considered to 
be statistically significant if p <0.05. 
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1.3 Supplementation in platelet poor plasma and platelet rich plasma 
In order to determine the role of platelet factor 4 (PF4) release from platelets in 
neutralizing the anticoagulant and antiprotease actions of heparins, UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 were supplemented in platelet poor plasma (PPP) 
and platelet rich plasma (PRP), and then the global anticoagulant and antiprotease effects 
of each agent were measured using the activated partial thromboplastin time (APTT),  
Heptest
®
, 5 U calcium chloride thrombin time (5U Ca2
+ 
TT), anti-Xa, and anti-IIa  
assays. The agents were supplemented in a concentration range of 0 to 25 µg/ml. If the 
clotting time of any test exceeded 300 sec, the test was stopped, as the values would be 
outside the linear sensitivity of the assay. Statistical significance (p <0.05) between 
treatment and control was determined by one-way ANOVA followed by Tukey’s 
multiple comparison test. Statistical significance (p <0.05) between agents was 
determined using a two-way ANOVA followed by Bonferroni’s multiple comparison 
test. All data for this section are compiled in Tables 13 through 18. 
 
1.3.1 Global anticoagulant assays 
1.3.1.1 APTT 
The anticoagulant effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-
14 as measured by APTT are shown in Figure 21. When supplemented in PPP (Figure 
21), UFH exhibited significant anticoagulant effects at concentrations above 3.1 µg/ml
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Figure 21. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in PPP as measured by the APTT assay. All agents were 
supplemented in the PPP of 3 different donors over a concentration range of 0 to 25.0 
µg/ml. UFH exhibited significant anticoagulant effects at concentrations above 3.1 µg/ml 
compared to all other agents  (p <0.001) and control (*p <0.001). At concentrations 
above 6.2 µg/ml, enoxaparin, bemiparin, semuloparin, and RO-14 produced significantly 
(#p <0.01) longer clotting times compared to control. Enoxaparin and bemiparin had a 
stronger anticoagulant effect compared to semuloparin and RO-14 at the 25.0 µg/ml 
concentration (p <0.05). The data represent the mean ± standard deviation (n=3). 
Statistically significant differences between treatment and control for each agent were 
determined by one-way ANOVA followed by Tukey’s multiple comparison test. 
Statistical differences between agents were determined using a two-way ANOVA 
followed by Bonferroni’s multiple comparison test. Results were considered to be 
statistically significant if p <0.05. 
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compared to all other agents (p <0.001) and control (p <0.001). At concentrations above 
6.2 µg/ml, enoxaparin, bemiparin, semuloparin, and RO-14 produced significantly (p 
<0.01) longer clotting times compared to baseline values. Enoxaparin (113.0 ± 8.0 sec) 
and bemiparin (100.8 ± 8.7 sec) had a more potent anticoagulant effect compared to 
semuloparin (62.3 ± 6.1 sec) and RO-14 (49.2 ± 1.3 sec) at the 25.0 µg/ml concentration 
(p <0.05). 
When supplemented in PRP (Figure 22), UFH exhibited a significant (p <0.01) 
anticoagulant effect at concentrations above 3.1 µg/ml compared to control. At 
concentrations above 6.25 µg/ml, UFH produced longer clotting times compared to all 
other agents (p <0.001). Enoxaparin (74.5 ± 8.7 sec) and bemiparin (80.6 ± 6.3 sec) were 
significantly (p <0.05) more potent compared to RO-14 (48.0 ± 5.7 sec) at the highest 
concentration. Additionally, bemiparin (80.6 ± 6.3 sec) was more potent than 
semuloparin (54.6 ± 5.2 sec) at the same concentration (p <0.05). Enoxaparin, bemiparin, 
semuloparin, and RO-14 produced significantly (p <0.01) longer clotting times compared 
to baseline values at concentrations above 12.5 µg/ml.  
In the APTT assay, variations in the anticoagulant activities of the different 
heparins after supplementation in PPP and PRP were evident (Tables 14 - 18). At 
concentration above 12.5 µg/ml, the anticoagulant effects of UFH were not affected by 
supplementation in PPP or PRP. However, for UFH, supplementation in PPP produced 
nearly 2-fold higher clotting times compared to supplementation in PRP for all 
concentration below 6.25 µg/ml. Similar trends were observed for all other heparins.
158 
 
0 5 10 15 20 25 30
0
50
100
150
200
250
300
350
UFH
Enoxaparin
Bemiparin
Semuloparin
RO-14
*
^
* ^
*
*
Concentration:g/ml
T
im
e
 (
S
e
c
o
n
d
s
)
 
 
Figure 22. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in PRP as measured by the APTT assay. All agents were 
supplemented in the PRP of 3 different donors over a concentration range of 0 to 25.0 
µg/ml. UFH exhibited significant (*p <0.01) anticoagulant effects at concentrations 
above 3.1 µg/ml compared to control. At concentrations above 6.25 µg/ml, UFH 
produced longer clotting times compared to all other agents (p <0.001). Enoxaparin and 
bemiparin were significantly (p <0.05) stronger compared to RO-14 at the highest 
concentration. Additionally, bemiparin was stronger than semuloparin at the same 
concentration (p <0.05). Enoxaparin, bemiparin, semuloparin, and RO-14 produced 
significantly (^p <0.01) longer clotting times compared to control at concentrations 
above 12.5 µg/ml. The data represent the mean ± standard deviation (n=3). Statistically 
significant differences between treatment and control for each agent were determined by 
one-way ANOVA followed by Tukey’s multiple comparison test. Statistical differences 
between agents were determined using a two-way ANOVA followed by Bonferroni’s 
multiple comparison test. Results were considered to be statistically significant if p 
<0.05. 
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However, even at the highest concentrations, supplementation of the LMW and ULMW 
heparins in PRP reduced the clotting times compared to supplementation in PPP. 
Notably, the fold changes between the clotting times after supplementation in PPP versus 
PRP were not as great for the LWM and ULMW heparins as those seen with UFH. In 
fact, a MW dependence was observed. As the molecular weight of the heparins 
decreased, so did the fold-changes between the clotting times after supplementation in 
PPP versus PRP when determined by the APTT assay. 
 
1.3.1.2 Heptest
®
 
All agents were supplemented in the PPP of 3 individual donors over a 
concentration range of 0 to 25.0 µg/ml (Figure 23). UFH, enoxaparin, bemiparin, and 
semuloparin exhibited significant (p <0.001) anticoagulant effect at all concentrations 
compared to control. At concentrations above 1.5 µg/ml, RO-14 produced significantly (p 
<0.01) longer clotting times compared to baseline values. At all concentrations, UFH and 
semuloparin produced longer clotting times compared to enoxaparin and RO-14 (p 
<0.05). At concentrations above 3.125 µg/ml, UFH was significantly stronger (p <0.01) 
than bemiparin. Semuloparin produced significantly (p <0.05) longer clotting times 
compared to bemiparin at concentrations above 6.25 µg/ml. Bemiparin produced longer 
clotting times compared to RO-14 at all concentrations (p <0.05); whereas, enoxaparin 
was only stronger at concentrations above 6.25 µg/ml (p <0.01). Only at concentrations
160 
 
 
Figure 23. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in PPP as measured by the Heptest
®
 assay. All agents were 
supplemented in the PPP of 3 different donors over a concentration range of 0 to 25.0 
µg/ml. UFH, enoxaparin, bemiparin, and semuloparin exhibited significant (*p <0.001) 
anticoagulant effect at all concentrations compared to control. At concentrations above 
1.5 µg/ml, RO-14 produced significantly (^p <0.01) longer clotting times compared to 
control. At all concentrations, UFH and semuloparin produced longer clotting times 
compared to enoxaparin and RO-14 (p <0.05). At concentrations above 3.125 µg/ml, 
UFH was stronger (p <0.01) than bemiparin. Semuloparin was stronger (p <0.05) than 
bemiparin at concentrations above 6.25 µg/ml. Bemiparin produced longer clotting times 
compared to RO-14 at all concentrations (p <0.05); whereas, enoxaparin was only 
stronger at concentrations above 6.25 µg/ml (p <0.01). Only at concentrations of 6.25 
and 12.5 µg/ml was UFH able to produce longer clotting times compared to semuloparin 
(p <0.001). The data represent the mean ± standard deviation (n=3). Statistically 
significant differences between treatment and control for each agent were determined by 
one-way ANOVA followed by Tukey’s multiple comparison test. Statistical differences 
between agents were determined using a two-way ANOVA followed by Bonferroni’s 
multiple comparison test. Results were considered to be statistically significant if p 
<0.05. 
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of 6.25 and 12.5 µg/ml was UFH able to produce longer clotting times compared to 
semuloparin (p <0.001).  
When supplemented in PRP (Figure 24), UFH, enoxaparin, semuloparin, 
bemiparin, and RO-14 exhibited a significant (p <0.05) anticoagulant effect at all 
concentrations compared to control. At concentrations above 6.25 µg/ml, UFH produced 
longer clotting times compared to enoxaparin, bemiparin, and RO-14 (p <0.05). Only at a 
concentration of 12.5 µg/ml was UFH (263.7 ± 3.7 sec) able to produce a significantly (p 
<0.01) longer clotting time compared to semuloparin (166.0 ± 49.2 sec). Semuloparin 
produced significantly (p <0.05) longer clotting times compared to enoxaparin, 
bemiparin, and RO-14 at concentrations above 12.5 µg/ml. Bemiparin (227.3 ± 5.7 sec) 
produced a significantly (p <0.05) stronger anticoagulant effect compared to RO-14 
(150.1 ± 6.4 sec) and enoxaparin (181.3 ± 31.5 sec) at the 25.0 µg/ml concentration. 
In the Heptest
®
 assay, variations in the anticoagulant activities of the different 
heparins after supplementation in PPP and PRP were evident (Tables 14 - 18). At the 
25.0 µg/ml concentration, the anticoagulant effects of all agents were not as affected by 
supplementation in PPP or PRP as they were at lower concentrations. At concentrations < 
12.5 µg/ml, supplementation of each heparin in PPP prolonged the clotting times to a 
greater extent compared to supplementation in PRP. Once again, molecular weight 
dependence was observed; although, when determined by the Heptest
®
 assay, the 
differences in fold-change between supplementation in PPP and PRP were not as great as 
those seen in the APTT assay. 
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Figure 24. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in PRP as measured by the Heptest
®
 assay. All agents were 
supplemented in the PRP of 3 different donors over a concentration range of 0 to 25.0 
µg/ml. UFH, enoxaparin, semuloparin, bemiparin, and RO-14 exhibited significant (*p 
<0.05) anticoagulant effect at all concentrations compared to control. At concentrations 
above 6.25 µg/ml, UFH produced longer clotting times compared to enoxaparin, 
bemiparin, and RO-14 (p <0.05). Only at the concentration of 12.5 µg/ml was UFH able 
to produce longer clotting times compared to semuloparin (p <0.01). Semuloparin was 
stronger than enoxaparin, bemiparin, and RO-14 at concentrations above 12.5 µg/ml (p 
<0.05). Bemiparin was stronger than RO-14 and enoxaparin at the 25.0 µg/ml 
concentration (p <0.05). The data represent the mean ± standard deviation (n=3). 
Statistically significant differences between treatment and control for each agent were 
determined by one-way ANOVA followed by Tukey’s multiple comparison test. 
Statistical differences between agents were determined using a two-way ANOVA 
followed by Bonferroni’s multiple comparison test. Results were considered to be 
statistically significant if p <0.05. 
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1.3.1.3 5U Ca
2+
 TT 
Figure 25 show the anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 as measured by the 5U Ca
2+
 TT assay after supplementation in 
PPP. When supplemented in PPP, UFH exhibited significant (p <0.001) anticoagulant 
effects at all concentrations compared to baseline values. At concentrations above 6.25 
µg/ml, enoxaparin produced significantly (p <0.01) longer clotting times compared to 
control. At concentrations above 12.5 µg/ml, bemiparin produced longer clotting times 
compared to control (p <0.05). Semuloparin (24.2 ± 1.6 sec) was only able, significantly, 
to (p <0.05) increase the clotting time at the 25.0 µg/ml concentration compared to 
control (16.2 ± 2.0 sec). At concentrations above 0.78 µg/ml, UFH produced an 
appreciably stronger (p <0.05) anticoagulant effect compared to bemiparin and RO-14. 
Compared to semuloparin, UFH only significantly prolonged the clotting times at 
concentrations above 1.25 µg/ml (p <0.01). UFH was only stronger than enoxaparin at 
the 1.56, 3.125, and 6.26 µg/ml concentrations (p <0.01). Enoxaparin significantly (p 
<0.01) prolonged the clotting times compared to bemiparin, semuloparin, and RO-14 at 
concentrations above 12.5 µg/ml. At a concentration of 25.0 µg/ml, bemiparin (53.9 ± 
18.7 sec) was significantly (p <0.05) stronger than RO-14 (13.8 ± 0.9 sec) at prolonging 
the clotting time. 
Figure 26 shows the anticoagulant effects of all agents, as measured by the 5U 
Ca
2+
 TT assay, after supplementation in PRP. UFH exhibited significant (p <0.001) 
anticoagulant effects at concentrations above 3.125 µg/ml, compared to baseline values. 
At concentrations above 3.125 µg/ml, UFH was significantly more potent (p <0.001)
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Figure 25. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in PPP as measured by the TT (5U Ca
2+
) assay. All agents were 
supplemented in the PPP of 3 different donors over a concentration range of 0 to 25.0 
µg/ml. UFH exhibited significant (*p <0.001) anticoagulant effect at all concentrations 
compared to control. At concentrations above 6.25 µg/ml, enoxaparin produced 
significantly (^p <0.01) longer clotting times compared to control. At concentrations 
above 12.5 µg/ml, bemiparin produced longer clotting times compared to control (+p 
<0.05). Semuloparin was only able to increase the clotting time at the 25.0 µg/ml 
concentration (#p <0.05) compared to control. At concentrations above 0.78 µg/ml, UFH 
was stronger (p <0.05) than bemiparin and RO-14. Compared to semuloparin, UFH was 
able to significantly prolong the clotting times at concentrations above 1.25 µg/ml (p 
<0.01). UFH was only stronger than enoxaparin at the 1.56, 3.125, and 6.26 µg/ml 
concentrations (p <0.01). Enoxaparin was able to significantly (p <0.01) prolong the 
clotting times compare to bemiparin, semuloparin, and RO-14 at concentrations above 
12.5 µg/ml. At a concentration of 25.0 µg/ml, bemiparin was stronger than RO-14 (p 
<0.05). The data represent the mean ± standard deviation (n=3). Statistically significant 
differences between treatment and control for each agent were determined by one-way 
ANOVA followed by Tukey’s multiple comparison test. Statistical differences between 
agents were determined using a two-way ANOVA followed by Bonferroni’s multiple 
comparison test. Results were considered to be statistically significant if p <0.05. 
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Figure 26. Comparative anticoagulant effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in PRP as measured by the TT (5U Ca
2+
) assay. All agents were 
supplemented in the PRP of  different donors over a concentration range of 0 to 25.0 
µg/ml. UFH exhibited significant (*p <0.001) anticoagulant effect at concentrations 
above 3.125 µg/ml, compared to control. At concentrations above 12.5 µg/ml, enoxaparin 
and bemiparin produced significantly (^p <0.01) longer clotting times compared to 
control. At concentrations above 3.125 µg/ml, UFH was stronger (p <0.001) than 
bemiparin, semuloparin, and RO-14. UFH was only stronger than enoxaparin at the 
3.125, 6.25, and 12.5 µg/ml concentrations (p <0.001). Enoxaparin was able to 
significantly (p <0.01) prolong the clotting times compared to bemiparin, semuloparin, 
and RO-14 at concentrations above 12.5 µg/ml. At concentrations above 12.5 µg/ml, 
bemiparin was stronger than semuloparin and RO-14 (p <0.05). The data represent the 
mean ± standard deviation (n=3). Statistically significant differences between treatment 
and control for each agent were determined by one-way ANOVA followed by Tukey’s 
multiple comparison test. Statistical differences between agents were determined using a 
two-way ANOVA followed by Bonferroni’s multiple comparison test. Results were 
considered to be statistically significant if p <0.05. 
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than bemiparin, semuloparin, and RO-14. UFH produced a more potent anticoagulant 
effects compared to enoxaparin at the 3.125, 6.25, and 12.5 µg/ml concentrations (p 
<0.001). At concentrations above 12.5 µg/ml, enoxaparin and bemiparin produced 
significantly (p <0.01) longer clotting times compared to control. Additionally, 
enoxaparin significantly (p <0.01) prolonged the clotting times compared to bemiparin, 
semuloparin, and RO-14 at concentrations above 12.5 µg/ml. At concentrations above 
12.5 µg/ml, bemiparin was stronger than semuloparin and RO-14 (p <0.05). 
In the 5U Ca
2+
 TT assay, differences in the anticoagulant activities of UFH and 
enoxaparin after supplementation in PPP and PRP were noted. However, at 
concentrations above 3.125 µg/ml, the anticoagulant effects of UFH were not affected by 
supplementation in PRP. At concentrations < 3.125 µg/ml, supplementation of UFH in 
PRP produced a 2.5-fold decrease in the clotting times compared to supplementation in 
PPP. The only noticeable effect produced by supplementation in PRP on enoxaparin was 
observed at the 12.5 µg/ml concentration. Supplementation in PRP produced a 2.75-fold 
decrease in the clotting time compared to supplementation in PPP. The overall 
anticoagulant effects of all other heparins in the 5U Ca
2+
 TT assay were so low, 
supplementation in PRP did not affect the outcomes. 
 
1.3.2 Antiprotease profile 
The inhibition of factor Xa and thrombin by UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 was evaluated by supplementation in PPP and PRP at a
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concentration range from 0 to 25 µg/ml. Antiprotease actions of these agents were 
determined by amidolytic assays, which utilized substrates for factor Xa (Spectrozyme 
Xa) and thrombin (Spectrozyme TH). Optical density changes were used to determine the 
percent inhibition by each agent as compared to PPP or PRP. The potency of each agent 
is presented in terms of IC50 (Table 19). Briefly, concentration verses percent inhibition 
was plotted and the linear portion of each curve was used to determine the IC50 value by 
extrapolating the concentration required to produce 50% inhibition. However, if the IC50 
value was not calculable at the highest concentration tested, it was presented as greater 
than the highest concentration (>25.0 µg/ml). Statistically significant differences between 
agents when supplemented in PPP versus PRP were determined by an unpaired t test. 
Statistical differences between supplementation of each agent to PPP and PRP were 
determined using a one-way ANOVA followed by Tukey’s multiple comparison test. 
Results were considered to be statistically significant if p <0.05. 
 
1.3.2.1 Anti-Xa assay 
As seen in Figure 27, UFH and semuloparin, when supplemented in PPP 
exhibited the highest potency with IC50 values of 1.0 ± 0.2 µg/ml and 1.0 ± 0.3 µg/ml, 
respectively. UFH (1.0 ± 0.2 µg/ml) was significantly more potent than enoxaparin (2.4 ± 
0.4 µg/ml) and RO-14 (4.5 ± 0.3 µg/ml) when supplemented in PPP (p <0.01) and was 
only able to inhibit factor Xa more potently than RO-14 when supplemented in PRP (p 
<0.001). Enoxaparin was determined to have a more potent inhibition of factor Xa than
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Figure 27. The inhibition of factor Xa by heparin and its derivatives as measured by the 
amidolytic anti-Xa assay. UFH was a more potent inhibitor of factor Xa than enoxaparin 
and RO-14 when supplemented in PPP (p <0.01) and was only able to inhibit factor Xa 
more potently than RO-14 when supplemented in PRP (p <0.001). Enoxaparin was 
determined to have a more potent inhibition of factor Xa than RO-14 when supplemented 
in both PPP and PRP (p <0.05). Semuloparin and bemiparin were able to significantly 
inhibit factor Xa more potently than enoxaparin and RO-14 when supplemented in PPP 
(p <0.05). In PRP, semuloparin was still more potent than both enoxaparin and RO-14 (p 
<0.01), but bemiparin was only stronger than RO-14 (p <0.001) when inhibiting factor 
Xa. Only UFH had a significantly different effect on the inhibition of factor Xa when 
supplemented in PPP or PRP (*p <0.01). The data represents the mean IC50 value ± the 
standard deviation of three individual experiments. Statistically significant differences 
between each agent when it was supplemented in PPP versus PRP were determined by an 
unpaired t test. Statistical differences between agents were determined using a one-way 
ANOVA followed by Tukey’s multiple comparison test. Results were considered to be 
statistically significant if p <0.05. 
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RO-14 when supplemented in both PPP and PRP (p <0.05). Semuloparin (1.0 ± 0.3 
µg/ml) and bemiparin (1.5 ± 0.2 µg/ml) significantly inhibited factor Xa to a greater 
extent than enoxaparin (2.4 ± 0.4 µg/ml) and RO-14 (4.5 ± 0.3 µg/ml) when 
supplemented in PPP (p <0.05). In PRP, semuloparin (1.4 ± 0.6 µg/ml) was still 
significantly (p <0.01) more potent than both enoxaparin (3.3 ± 0.4 µg/ml) and RO-14 
(4.8 ± 0.5 µg/ml), but bemiparin (2.3 ± 0.6 µg/ml) was only stronger than RO-14 (p 
<0.001) when inhibiting factor Xa. 
Only UFH had a significantly different effect on the inhibition of factor Xa when 
supplemented in PPP or PRP (p <0.01). However, the LWM and ULMW heparins 
demonstrated a similar trend, as the potency of each drug was greater when supplemented 
in PPP compared to PRP even though statistical significance was not reached. All IC50 
values are compiled in Table 19. 
 
1.3.2.2 Anti-IIa assay 
Figure 28 shows the effect of UFH, enoxaparin, bemiparin, semuloparin, and RO-
14 on the inhibition of thrombin after supplementation in PRP. UFH was (0.7 ± 0.0 
µg/ml) significantly (p <0.05) more potent than bemiparin (9.3 ± 2.8 µg/ml), semuloparin 
(21.6 ± 5.9 µg/ml), and RO-14 (>25.0 ± 0.0 µg/ml) when supplemented in PPP. In PRP, 
UFH exhibited the highest potency with and IC50 value of 1.9 ± 0.1 µg/ml compared to all 
other agents (p <0.001). Enoxaparin and bemiparin exhibited a stronger inhibition of 
thrombin compared to both semuloparin and RO-14 when supplemented in PPP (p
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Figure 28. The inhibition of thrombin by heparin and its derivatives as measured by the 
amidolytic anti-IIa assay. UFH was able to significantly inhibit thrombin to a greater 
extent than bemiparin, semuloparin, and RO-14 when supplemented in PPP (p <0.05) 
and was able to inhibit thrombin more potently than all other agents when supplemented 
in PRP (p <0.001). Enoxaparin and bemiparin exhibited a stronger inhibition of thrombin 
compared to both semuloparin and RO-14 when supplemented in PPP (p <0.01) and PRP 
(p <0.001). However, enoxaparin was stronger than bemiparin when supplemented in 
PRP (p <0.05). When supplemented in PPP, UFH and enoxaparin had a significantly 
more potent inhibition of thrombin compared to supplementation in PRP (*p <0.01). If 
the percent inhibition did not reach 50% at the highest concentration, the IC50 value was 
presented as greater than 25 µg/ml and was considered to be a supermax concentration. 
The data represents the mean IC50 value ± the standard deviation of three individual 
experiments. Statistically significant differences between each agent when it was 
supplemented in PPP versus PRP were determined by an unpaired t test. Statistical 
differences between agents were determined using a one-way ANOVA followed by 
Tukey’s multiple comparison test. Results were considered to be statistically significant if 
p <0.05.  ǂ 
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 <0.01) and PRP (p <0.001). However, enoxaparin (9.2 ± 0.8 µg/ml) was stronger than 
bemiparin (11.6 ± 0.5 µg/ml) when supplemented in PRP (p <0.05).  
When supplemented in PPP, UFH (0.7 ± 0.0 µg/ml) and enoxaparin (4.2 ± 0.6 
µg/ml) had a significantly (p <0.01) more potent inhibition of thrombin compared to 
supplementation in PRP (1.9 ± 0.1 µg/ml and 9.2 ± 0.8 µg/ml, respectively). A similar 
trend was observed for bemiparin. The anti-IIa effects of semuloparin and RO-14 were so 
low, supplementation in PPP or PRP had no effects. All IC50 values are compiled in 
Table 19. 
The overall results from these studies demonstrate that the release of PF4 from 
platelets may play a role in neutralizing the anticoagulant and antiprotease actions of 
heparins. However, these effects are MW and assay dependent. UFH was consistently the 
most affected by supplementation in PRP compared to the LMW and ULMW heparins. 
 
1.4 The effects of heparin and its derivatives on thrombin generation 
Figure 29 shows the comparative effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 on the inhibition of thrombin generation as measured by the 
thrombin generation assay. All agents were supplemented in NHP over a concentration 
range of 0 to 10.0 µg/ml. Results are expressed in terms of % inhibition of thrombin. 
UFH, enoxaparin, and semuloparin significantly (p <0.05) inhibited thrombin generation 
at all concentrations compared to baseline. RO-14 exhibited significant (p <0.05)
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Figure 29. Comparative effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 
on the inhibition of thrombin generation. All agents were supplemented in NHP over a 
concentration range of 0 to 10.0 µg/ml. UFH, enoxaparin, and semuloparin exhibited 
significant (*p <0.05) inhibition of thrombin generation at all concentrations compared to 
control. At concentrations above 0.625 µg/ml, RO-14 significantly (*p <0.05) inhibited 
thrombin generation compared to baseline. Bemiparin was only able to inhibit thrombin 
generation at concentrations above 1.25 µg/ml when compared to control (*p <0.05). At 
concentrations between.0.31 and 2.5 µg/ml, UFH was able to inhibit thrombin generation 
to a greater degree than enoxaparin and bemiparin (p <0.001). At concentrations between 
0.31 and 5.0 µg/ml, UFH was stronger than semuloparin at inhibiting thrombin 
generation (p <0.01). Moreover, UFH and semuloparin were consistently stronger than 
RO-14 at all concentrations (p <0.01). Enoxaparin and bemiparin were significantly 
stronger (p <0.001) at inhibiting thrombin generation compared to RO-14 at 
concentrations between 1.25 and 10.0 µg/ml; however, enoxaparin was still stronger even 
at the 0.625 µg/ml concentration (p <0.01). Semuloparin and enoxaparin were stronger 
than bemiparin at inhibiting thrombin generation between the 0.31 and 1.25 µg/ml 
concentrations (p <0.05).The data represent the mean ± standard deviation (n=3). 
Statistically significant differences between treatment and control for each agent were 
determined by one-way ANOVA followed by Dunnett’s multiple comparison test. 
Statistical difference between agents was determined using a two-way ANOVA followed 
by Bonferroni’s multiple comparison test. Results were considered to be statistically 
significant if p <0.05. 
173 
 
 
 
inhibition of thrombin generation compared to baseline only at concentrations above 
0.625 µg/ml. Compared to baseline, bemiparin was only able to inhibit thrombin 
generation at concentrations above 1.25 µg/ml (p <0.05). At concentrations between 0.31 
and 2.5 µg/ml, UFH was able to inhibit thrombin generation to a greater extent than 
enoxaparin and bemiparin (p <0.001). At concentrations between 0.31 and 5.0 µg/ml, 
UFH significantly inhibited thrombin generation to a greater extent than semuloparin (p 
<0.01). Moreover, UFH and semuloparin were consistently stronger at inhibiting 
thrombin generation than RO-14 at all concentrations (p <0.01). At concentrations 
between 1.25 and 10.0 µg/ml, enoxaparin and bemiparin significantly (p <0.001) 
inhibited thrombin generation to a greater extent than that of RO-14; however, 
enoxaparin was still significantly stronger than RO-14 at the 0.625 µg/ml concentration 
(p <0.01). Semuloparin and enoxaparin produced stronger inhibition of thrombin 
compared to bemiparin between the concentration range of 0.31 and 1.25 µg/ml (p 
<0.05). Essentially, all agents, besides RO-14, equally inhibited thrombin generation at 
the highest concentration. Differences between agents were only noticeable at lower 
concentrations. Individual data from these assays is presented in Table 20. 
Potency comparisons between UFH and its derivatives on the ability to inhibit 
thrombin generation are shown in Figure 30. All agents were able to inhibit thrombin 
generation, with UFH (0.19 ± 0.02 μg/ml) having the smallest IC50 value compared to all 
other agents (p <0.01). Enoxaparin (1.33 ± 0.15 µg/ml), bemiparin (1.11 ± 0.24 µg/ml), 
and semuloparin (1.01 ± 0.13 µg/ml) were significantly (p <0.001) more potent at
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Figure 30. Potency comparison between UFH and its derivatives on the ability to inhibit 
thrombin generation. All agents were able to inhibit thrombin generation, with UFH (0.19 
± 0.02 μg/ml) having the smallest IC50 value compared to all other agents (*p <0.01). 
Enoxaparin (1.33 ± 0.15), bemiparin (1.11 ± 0.24), and semuloparin (1.01 ± 0.13) were 
able to significantly (^, #, +p <0.001) inhibit thrombin generation to a greater extent than 
RO-14 (4.39 ± 0.37). The data represents the mean IC50 value ± the standard deviation of 
three individual experiments. Statistical differences between agents were determined 
using a one-way ANOVA followed by Tukey’s multiple comparison test. 
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inhibiting thrombin generation than RO-14 (4.39 ± 0.37 µg/ml). Compiled IC50 values 
can be found in Table 21. Based on these results, the ability to inhibit thrombin 
generation in vitro appears to be MW-dependant.  
 
1.5 The effects of heparin and its derivatives on the inhibition of TAFI activation in NHP 
UFH, enoxaparin, bemiparin, semuloparin and RO-14 were evaluated for their 
ability to inhibit TAFI generation in vitro after supplementation in NHP at concentration 
ranges of 0 to 10 µg/ml for UFH and 0 to 100 µg/ml for all other agents. Functional TAFI 
activity was determined using the Pefakit

 TAFI assay (Pentapharm, Inc, Basel 
Switzerland) as described in the ‘Materials and Methods’ section. Prior to all studies, the 
accuracy of the Pefakit

 TAFI assay in NHP was validated (see Materials and Methods). 
Statistical differences between agents were determined using a one-way ANOVA 
followed by Tukey’s multiple comparison test. Results were considered to be statistically 
significant if p <0.05. For these experiments, individual data is compiled in Tables of 
Appendix 1. 
 
1.5.1 Validation studies 
 Figure 31A shows the TAFI activation in NHP. The calibration curve was 
constructed by diluting the NHP 50, 25, 12.5, 6.25, and 3.12% with 5% albumin. The 
change in OD was measured at 5 minutes. TAFI generation activity was detectable and 
the calibration curve was linear with an r
2
 value greater than 0.99. 
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Figure 31A. TAFI activation in normal human plasma (NHP). The change in OD for 
NHP was calculated after 5 min. The calibration curve was linear with an r
2
 value greater 
than 0.99. 
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Figure 31B. The effect of heparin and its derivatives on the inhibition of TAFI functional 
activity when supplemented in NHP. All agents were able to inhibit TAFI functional 
activity. The rank order potency was UFH > enoxaparin > bemiparin > semuloparin > 
RO-14 (*, ^, +, # p < 0.001). The data represent the mean ± SEM (n=3). 
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1.5.2 Studies using heparin and its derivatives supplemented in NHP 
Figure 31 B shows the effects of heparin and its derivatives on the inhibition of 
TAFI generation when supplemented in NHP. All agents were able to inhibit TAFI 
generation, with UFH having the strongest effect reaching over 70% inhibition at a 
concentration of 1.25 µg/ml. The rank order potency was UFH > enoxaparin > bemiparin 
> semuloparin > RO-14 (p < 0.001). Although RO-14 had an IC50 value greater than 100 
µg/ml, it was capable of inhibiting TAFI generation up to 39.2% at this concentration. 
UFH exhibited the most potent IC50 value (0.57 ± 0.01 µg/ml), which was significantly 
higher (p < 0.001) than that of all other agents. Data from this study indicates that the 
inhibition of TAFI generation in NHP by these heparins was clearly molecular weight 
dependent.  
 
1.6 The effects of AT and HCII on antiprotease actions 
Serpin (serine protease inhibitor) mediated inhibition of factor Xa and thrombin 
was determined by using a SERPIN-deficient plasma system and a purified-SERPIN 
plasma free system. The various heparins were supplemented in AT deficient plasma 
(AT-DP), HCII deficient plasma (HCII-DP), or normal human plasma (NHP) at a 
concentration range of 0 to 10 µg/ml, and then their inhibitory effects on factor Xa and 
thrombin were measured using the Heptest
®
, Anti-Xa, and Anti-IIa assays, as previously 
discussed. The purified SERPIN systems contained purified AT (FC = 1U) or HCII (FC = 
8 µg/ml), purified factor Xa or thrombin, and amidolytic substrates (Spectrozyme Xa or
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TH). Heparin and its derivatives were supplemented in either AT at a concentration range 
of 0 to 10 µg/ml or HCII at a concentration range of 0 to 100 µg/ml. In the purified 
systems, the inhibitory effects of each heparin on factor Xa and thrombin were measured 
using the anti-Xa and anti-IIa assays, as previously discussed. The IC50 values were 
calculated as described in the ‘Material and Methods’ section and are compiled in Table 
22. 
 
1.6.1 AT and HCII depletion studies 
The anticoagulant effect of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 
following supplementation in AT-DP, HCII-DP, and NHP as measured by the Heptest
®
 
assay are shown in Figure 32. No agents had a significant anticoagulant effects when 
supplemented in the AT depleted plasma (A-E). When supplemented in HCII-DP or NHP 
(A-E), all agents produced significant anticoagulant effects compared to control (p 
<0.001). At different varying concentrations, UFH, semuloparin, and RO-14 were 
significantly more potent when supplemented in NHP compared to HCII-DP (p <0.05). 
At all concentrations tested, enoxaparin and bemiparin showed the strongest 
anticoagulant effect when supplemented in NHP versus HCII-DP (p <0.05). Individual 
data from these assays is presented in Table 23. 
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Figure 32. The anticoagulant effect of UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 following supplementation in AT depleted, HCII depleted, and normal human 
plasma as measured by the Heptest
®
 assay. All agents had no significant anticoagulant 
effects when supplemented in the AT depleted plasma (A-E). When supplemented in 
HCII depleted plasma or NHP (A-E), all agents produced significant anticoagulant effects 
compared to control (*p <0.001). At different varying concentrations, all agents produced 
stronger anticoagulant effects when supplemented in NHP compared to HCII depleted 
plasma (+p <0.05). Enoxaparin and bemiparin showed the strongest effect, at all 
concentrations, when supplemented in NHP versus HCII. The data represent the mean ± 
standard deviation (n=3). Statistically significant differences between treatment and 
control for each agent were determined by one-way ANOVA followed by Tukey’s 
multiple comparison test. Statistical differences for each agent when supplemented in 
each of the plasma systems were determined using a two-way ANOVA followed by 
Bonferroni’s multiple comparison test. Results were considered to be statistically 
significant if p <0.05. 
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Figure 33. The effect of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 on the 
inhibition of factor Xa following supplementation in AT depleted, HCII depleted, and 
NHP. The ability to inhibit factor Xa was remarkably reduced for all agents when 
supplemented in AT depleted plasma (A-E). The IC50 for all agents was greater than 10 
µg/ml, which was the highest concentration tested. UFH, enoxaparin, bemiparin, and RO-
14 demonstrated significant differences in their ability to inhibit factor Xa when 
supplemented in each of the plasma systems. For each of the agents, supplementation in 
HCII depleted plasma produced the greatest effect on factor Xa inhibition. However, 
semuloparin produced similar inhibitory responses in both HCII depleted plasma and 
NHP. The data represents the mean IC50 value ± the standard deviation of three 
individual experiments. Statistical differences between agents were determined using a 
one-way ANOVA followed by Tukey’s multiple comparison test. *p <0.001 vs. AT 
depleted, +p <0.05 vs. NHP, ^p <0.001 vs. AT depleted. 
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1.6.1.1 Effects of AT and HCII depletion on the inhibition of factor Xa 
The comparison of each heparin on the inhibition of factor Xa following 
supplementation in AT-DP, HCII-DP, and NHP are shown in Figure 33. The ability to 
inhibit factor Xa was reduced for all agents when supplemented in AT-DP (A-E). The 
IC50 for all agents was greater than 10 µg/ml, which was the highest concentration tested. 
UFH, enoxaparin, bemiparin, and RO-14 demonstrated significant differences in their 
ability to inhibit factor Xa when supplemented in either NHP or HCII-DP. For each of the 
agents, supplementation in HCII-DP resulted in the most potent effect on factor Xa 
inhibition when compared to supplementation in NHP and AT-DP (p <0.05). However, 
semuloparin produced similar inhibitory responses of factor Xa when supplemented in 
both HCII-DP (1.6 ± 0.08 µg/ml) and NHP (2.0 ± 0.35 µg/ml). The compiled IC50 values 
can be found in Table 22. Individual data from these assays is presented in Table 23. 
 
1.6.1.2 Effects of AT and HCII depletion on thrombin  
The effect of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 on the 
inhibition of thrombin following supplementation in AT-DP, HCII-DP, and NHP are 
shown in Figure 34. The ability to inhibit thrombin was remarkably reduced for all agents 
when supplemented in AT-DP (A-E). The IC50 for all agents was greater than 10 µg/ml, 
which was the highest concentration tested. Only UFH and enoxaparin demonstrated 
significant differences in their ability to inhibit thrombin when supplemented in the HCII-
DP and NHP systems. For enoxaparin, supplementation in HCII-DP (4.8 ± 0.29 µg/ml) 
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Figure 34. The effect of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 on the 
inhibition of thrombin following supplementation in AT depleted, HCII depleted, and 
normal human plasma. The ability to inhibit thrombin was considerably reduced for all 
agents when supplemented in AT depleted plasma (A-E). The IC50 for all agents was 
greater than 10 µg/ml, which was the highest concentration tested. Only UFH and 
enoxaparin demonstrated significant differences in their ability to inhibit thrombin when 
supplemented in each of the plasma systems. For enoxaparin, supplementation in HCII 
depleted plasma produced the greatest effect on thrombin inhibition. Conversely, UFH 
produced similar inhibitory responses in both HCII depleted plasma and NHP.  
The data represents the mean IC50 value ± the standard deviation of three individual 
experiments. Statistical differences between agents were determined using a one-way 
ANOVA followed by Tukey’s multiple comparison test. *p <0.001 vs. AT depleted, +p 
<0.001 vs. NHP, ^p <0.001 vs. AT depleted. 
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produced the greatest effect on thrombin inhibition (p <0.001) compared to 
supplementation in either NHP or AT-DP. Conversely, UFH produced similar inhibitory 
responses in both HCII-DP (1.6 ± 0.06 µg/ml) and NHP (1.9 ± 0.33 µg/ml). The 
compiled IC50 values can be found in Table 22. Individual data from these assays is 
presented in Table 23. 
These studies demonstrate that AT is the main cofactor required for heparin and 
its derivatives to produce their anticoagulant and antiprotease effects. The role of HCII in 
facilitating the anticoagulant effects of these agents was minimal and test dependent. In 
the Heptest
®
 assay, supplementation of the various heparins in HCII-DP produced only a 
slight decrease in the anticoagulant response compared to supplementation in NHP. 
Conversely, in both the anti-Xa and IIa assays, supplementation in HCII-DP produced a 
more potent antiprotease effect compared to supplementation in NHP for most heparins. 
However, the overall differences between HCII-DP and NHP were minimal.  
 
1.6.2 Purified AT and HCII mediated antiprotease actions 
1.6.2.1 Purified AT mediated antiprotease actions 
The AT-mediated inhibition (1 U) of factor Xa and thrombin by UFH and its 
derivatives are shown in Figure 35 A. All agents exhibited potent AT-mediated inhibition 
of factor Xa (A), with UFH (0.57 ± 0.02 µg/ml) and semuloparin (0.65 ± 0.08 µg/ml) 
having the smallest IC50 values compared to all other agents (p <0.01). Enoxaparin (2.0 ± 
0.47 µg/ml) and bemiparin (1.5 ± 0.22 µg/ml) significantly (p <0.001) inhibited factor
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Figure 35. AT mediated inhibition of factor Xa (A) and thrombin (B) by UFH and its 
derivatives. All agents were able to inhibit factor Xa, with UFH (0.57 ± 0.02) and 
semuloparin (0.65 ± 0.08) having the smallest IC50 values compared to all other agents 
(*p <0.001; +p <0.01). Enoxaparin and bemiparin were able to significantly inhibit 
factor Xa to a greater extent than RO-14 (^p <0.001; #p <0.001). Only UFH (0.51 ± 
0.18) and enoxaparin (3.08 ± 1.2) were able to significantly inhibit thrombin compared to 
all other agents (*p <0.001; ^p <0.001); however, UFH was more potent than enoxaparin 
(*p <0.001). If the percent inhibition did not reach 50% at the highest concentration, the 
IC50 value was presented as greater than 10 μg/ml. The data represents the mean IC50 
value ± the standard deviation of three individual experiments. Statistical differences 
between agents were determined using a one-way ANOVA followed by Tukey’s multiple 
comparison test. 
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Xa to a greater extent than RO-14 (3.6 ± 0.09 µg/ml). The AT-mediated inhibition of 
thrombin is seen in Figure 35 B. Only UFH (0.51 ± 0.18 µg/ml) and enoxaparin (3.08 ± 
1.2 µg/ml) significantly potentiated AT-mediated inhibition of thrombin compared to all 
other agents (p <0.001); however, UFH was more potent than enoxaparin (p <0.001). 
Bemiparin, semuloparin, and RO-14 were unable, significantly, to inhibit thrombin via 
AT. If the percent inhibition did not reach 50% at the highest concentration, the IC50value 
was presented as greater than 10 μg/ml. All IC50 are compiled in Table 24. Additionally, 
individual data from these assays are presented in Table 25. 
 
1.6.2.2 Purified HCII mediated antiprotease actions 
Figure 36 shows the HCII-mediated inhibition of thrombin by UFH and its 
derivatives. All agents were able to potentiate HCII-mediated inhibition of thrombin, 
with UFH (2.02 ± 0.16 μg/ml) having the smallest IC50 value compared to all other agents 
(p <0.01), including enoxaparin (5.19 ± 0.35 µg/ml). Enoxaparin (5.19 ± 0.35 µg/ml), 
bemiparin (11.61 ± 2.75 µg/ml), and semuloparin (8.53 ± 1.51 µg/ml) produced a 
significantly (p <0.01) more potent inhibition of thrombin compared to RO-14 (94.70 ± 
2.34 µg/ml). Additionally, enoxaparin was significantly more potent than bemiparin (p 
<0.01). Compiled IC50 values can be found in Table 24. Individual data from these assays 
is presented in Table 25. 
These studies help delineate the role that AT and HCII play in mediating the 
antiprotease effects of the various heparins. Results show that UFH and semuloparin are 
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Figure 36. HCII mediated inhibition of thrombin by UFH and its derivatives. All agents 
were able to inhibit thrombin, with UFH (2.02 ± 0.16 μg/ml) having the smallest IC50 
value compared to all other agents (*p <0.01) except enoxaparin. Enoxaparin, bemiparin, 
and semuloparin were able to significantly inhibit thrombin to a greater extent than RO-
14 (^, #, +p <0.01). Additionally, enoxaparin was significantly more potent than 
bemiparin (^p <0.01). The data represents the mean IC50 value ± the standard deviation 
of three individual experiments. Statistical differences between agents were determined 
using a one-way ANOVA followed by Tukey’s multiple comparison test. 
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more potent inhibitors of factor Xa in a purified AT system. Thus, AT may contribute to 
the antiprotease effects of UFH and semuloparin to a greater extent than enoxaparin, 
bemiparin, or RO-14. Conversely, the role of AT appears to be less important for 
semuloparin compared to UFH and enoxaparin in inhibiting thrombin. The role that HCII 
plays in mediating the inhibition of thrombin for UFH, enoxaparin, bemiparin, and 
semuloparin was similar. Only RO-14 had an IC50 value that was markedly greater than 
all other agents. 
 
1.7 High-AT AF semuloparin, semuloparin, and non-AT AF semuloparin studies 
Three different AT affinity fractions of semuloparin were used to determine to 
what extent enrichment with AT binding sequences plays a role in the anticoagulant and 
antiprotease effects of semuloparin. In order to delineate the role of enrichment with AT 
binding sequences, high-AT AF semuloparin (HAS), semuloparin, and non-AT AF 
semuloparin (NAS) were supplemented in NHP, HCII and AT purified and deficient 
systems, as well as in the thrombin generation assay at various concentrations.
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1.7.1 Supplementation in normal human plasma 
1.7.1.1 Global anticoagulant effects 
The global anticoagulant effects of high-AT AF semuloparin (HAS), semuloparin, 
and non-AT AF semuloparin (NAS) were determined following supplementation in NHP, 
over a concentration range of 0 to 25.0 µg/ml, using the APTT, TT (5U Ca
2+
), and 
Heptest
®
 assays. If the clotting time of any test exceeded 300 sec the test was stopped, as 
the values would be outside the linear sensitivity of the assay. Statistically significant 
differences between treatment and control for each agent were determined by one-way 
ANOVA followed by the Tukey multiple comparison test. Statistical differences between 
agents were determined using a two-way ANOVA followed by the Bonferroni multiple 
comparison test. Results were considered to be statistically significant if p <0.05. 
The comparative anticoagulant effects of high-AT AF semuloparin (HAS), 
semuloparin, and non-AT AF semuloparin (NAS) as measured by the APTT assay are 
shown in Figure 37. All three AT affinity versions of semuloparin exhibited significant (p 
<0.01) anticoagulant effects at concentrations above 12.5 µg/ml compared to baseline; 
however, HAS and semuloparin produced significantly longer clotting times compared to 
NAS at the same concentrations (p <0.05). At the highest concentration, HAS and 
semuloparin produced a clotting time that was approximately 2.5 times that of the 
baseline value. In the concentration range measured, both HAS and semuloparin 
produced comparable anticoagulant effects when measured by the APTT assay; which 
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Figure 37. Comparative anticoagulant effects of high-AT AF semuloparin (HAS), 
semuloparin, and non-AT AF semuloparin (NAS) as measured by the APTT assay. All 
agents were supplemented in NHP over a concentration range of 0 to 25.0 µg/ml. All 
three versions of semuloparin exhibited significant (*p <0.01) anticoagulant effects at 
concentrations above 12.5 µg/ml compared to control; however, HAS and semuloparin 
produced longer clotting times compared to NAS at the same concentrations (p <0.05). 
The data represent the mean ± standard deviation (n=3). Statistically significant 
differences between treatment and control for each agent were determined by one-way 
ANOVA followed by Tukey’s multiple comparison test. Statistical difference between 
agents was determined using a two-way ANOVA followed by Bonferroni’s multiple 
comparison test. Results were considered to be statistically significant if p <0.05. 
 
 
190 
 
 
may indicate that the anticoagulant effects that occur due to AT binding, at least in this 
assay, are limited. Individual data from this assay is presented in Table 26. 
Figure 38 shows the comparative anticoagulant effects of HAS, semuloparin, and 
NAS as measured by the thrombin time (5U Ca
2+
) assay. HAS exhibited significant (p 
<0.05) anticoagulant effects at concentrations above 3.125 µg/ml compared to baseline; 
conversely, semuloparin appreciably increased the time to clot at concentrations above 
12.5 µg/ml (p <0.05). NAS was the least effective and only significantly (p <0.05) 
increased the clotting time at a concentration of 25.0 µg/ml. HAS and semuloparin were 
significantly stronger (p <0.05) than NAS at concentrations above 12.5 µg/ml. At the 
25.0 µg/ml concentration, HAS (17.5 ± 0.3 sec) produced a statistically (p <0.001) 
stronger anticoagulant effect compared to semuloparin (14.9 ± 0.2 sec); overall, the effect 
was moderate. Individual data from this assay is presented in Table 26. 
The comparative anticoagulant effects of HAS, semuloparin, and NAS as 
measured by the Heptest
®
 assay are shown in Figure 39. All three versions of 
semuloparin exhibited significant (p <0.01) concentration dependent anticoagulant 
effects compared to baseline values. At all concentrations, a statistically significant (p 
<0.001) difference between the effects of HAS, semuloparin, and NAS was observed. 
HAS was decidedly the most potent agent, as the concentration required to reach a 
clotting time of 100 sec was less than 1.56 µg/ml. In order to reach the same effect, 
semuloparin and NAS required a concentration of approximately 4 and 12 times that of 
HAS, respectively. Additionally, HAS achieved clotting times greater than 300 seconds 
at concentrations > 12.5 µg/ml. Consequently, the results indicate that AT binding plays a 
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Figure 38. Comparative anticoagulant effects of high-AT AF semuloparin (HAS), 
semuloparin, and non-AT AF semuloparin (NAS) as measured by the thrombin time (5U 
Ca
2+
) assay. All agents were supplemented in NHP over a concentration range of 0 to 
25.0 µg/ml. HAS exhibited significant (*p <0.05) anticoagulant effects at concentrations 
above 3.125 µg/ml compared to control; however, semuloparin was only able to produce 
increased clotting times at concentrations above 12.5 µg/ml (*p <0.05). At the 25.0 
µg/ml concentration, NAS significantly increased the clotting time (*p <0.05) compared 
to control. HAS and semuloparin were significantly stronger (p <0.05) than NAS at 
concentrations above 12.5 µg/ml. At the 25.0 µg/ml concentration, HAS was 
significantly (p < 0.001) stronger than semuloparin. The data represent the mean ± 
standard deviation (n=3). Statistically significant differences between treatment and 
control for each agent were determined by one-way ANOVA followed by Tukey’s 
multiple comparison test. Statistical difference between agents was determined using a 
two-way ANOVA followed by Bonferroni’s multiple comparison test. Results were 
considered to be statistically significant if p <0.05. 
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Figure 39. Comparative anticoagulant effects of high-AT AF semuloparin (HAS), 
semuloparin, and non-AT AF semuloparin (NAS) as measured by the Heptest
®
 assay. All 
agents were supplemented in NHP over a concentration range of 0 to 25.0 µg/ml. All 
three versions of semuloparin exhibited significant (*p <0.01) anticoagulant effects at 
concentrations above 1.56 µg/ml compared to control. Additionally, at all concentrations, 
HAS, semuloparin, and NAS were significantly different from each other (p <0.001) in 
terms of their anticoagulant effects. The data represent the mean ± standard deviation 
(n=3). Statistically significant differences between treatment and control for each agent 
were determined by one-way ANOVA followed by Tukey’s multiple comparison test. 
Statistical difference between agents was determined using a two-way ANOVA followed 
by Bonferroni’s multiple comparison test. Results were considered to be statistically 
significant if p <0.05. 
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significant role in the anticoagulant effect of these agents when measured by the Heptest
®
 
assay. Individual data from this assay is presented in Table 26. 
 
1.7.1.2 Antiprotease effects 
The inhibition of factor X and thrombin by high-AT AF semuloparin (HAS), 
semuloparin, and non-AT AF semuloparin (NAS) was evaluated by the amidolytic factor 
Xa and IIa assays after supplementation in NHP at a concentration range of 0 to 25 
µg/ml. Optical density changes were used to determine the percent inhibition of each 
agent as compared to NHP. The potency of each agent was presented in terms of IC50. If 
the IC50 value was not calculable at the highest concentration, it was presented as greater 
than 25 µg/ml. Statistical differences between agents were determined using a one-way 
ANOVA followed by Tukey’s multiple comparison test. Results were considered to be 
statistically significant if p <0.05. 
The comparative effects of HAS, semuloparin, and NAS on the inhibition of 
factor Xa and thrombin following supplementation in NHP are shown in Figure 40. As 
seen in Panel A, all agents were able to produce a measurable anti-Xa effect; however, 
semuloparin (1.47 ± 0.49 µg/ml) and HAS (1.00 ± 0.19 µg/ml) produced a more potent 
inhibition (p <0.001) of factor Xa than NAS (5.78 ± 0.22 µg/ml). In Panel B, only HAS 
(16.33 ± 2.97 µg/ml) was significantly able to inhibit thrombin generation (p <0.01) 
compared to semuloparin and NAS. If the percent inhibition did not reach 50% at the 
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Figure 40. The comparative effects of high-AT AF semuloparin (HAS), semuloparin, and 
non-AT AF semuloparin (NAS) on the inhibition of factor Xa (A) and thrombin (B) 
following supplementation in NHP. As seen in Panel A, semuloparin (1.47 ± 0.49) and 
HAS (1.00 ± 0.19) produced a more potent inhibition (p <0.001) of factor Xa than NAS 
(5.78 ± 0.22); however all agents were able to produce a measurable anti-Xa effect. In 
Panel B, only HAS (16.33 ± 2.97) was able to significantly inhibit thrombin (*p <0.01) 
compared to semuloparin and NAS. If the percent inhibition did not reach 50% at the 
highest concentration, the IC50 value was presented as greater than 25 µg/ml. The data 
represents the mean IC50 value ± the standard deviation of three individual experiments. 
Statistical differences between agents were determined using a one-way ANOVA 
followed by Tukey’s multiple comparison test. 
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highest concentration in the anti-IIa assay, the IC50 value was presented as greater than 25 
µg/ml. The compiled IC50 can be found in Table 27.  
 
1.7.1.3 Thrombin Generation  
To determine the role that AT binding plays on the inhibition of thrombin 
generation HAS, semuloparin, and NAS were supplemented in NHP over a concentration 
range of 0 to 5.0 µg/ml and evaluated using the thrombin generation assay. The results 
were presented as both % inhibition of thrombin and IC50 values. If the percent inhibition 
did not reach 50% at the highest concentration, the IC50 value was presented as greater 
than 5.0 µg/ml. The compiled individual results and IC50 values can be found in Table 28. 
Shown in Figure 41 are the comparative effects of HAS, semuloparin, and NAS 
on the inhibition of thrombin generation. HAS significantly (p <0.001) inhibited 
thrombin generation at all concentrations compared to baseline and all other agents (p 
<0.001). At concentrations above 0.625 µg/ml, semuloparin significantly (p <0.05) 
inhibited thrombin generation compared to baseline and NAS (p <0.01). NAS was 
unable, significantly, to inhibit thrombin generation at any concentration tested. Potency 
comparisons of HAS, semuloparin, and NAS on thrombin generation following 
supplementation in NHP are shown in Figure 42. HAS (0.70 ± 0.07 µg/ml) produced a 
more potent inhibition (p <0.001) of thrombin generation than semuloparin (3.68 ± 0.24 
µg/ml) and NAS (>5.0 ± 0.0 µg/ml). Semuloparin was more potent than NAS at 
inhibiting thrombin generation (p <0.001). Taken together, these results indicate that AT 
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Figure 41. Comparative effects of high-AT AF semuloparin (HAS), semuloparin, and 
non-AT AF semuloparin (NAS) on the inhibition of thrombin generation. All agents were 
supplemented in NHP over a concentration range of 0 to 5.0 µg/ml. HAS exhibited 
significant (*p <0.001) antithrombin effects at all concentrations compared to control and 
all other agents (p <0.001). At concentrations above 0.625 µg/ml, semuloparin was able 
to significantly (*p <0.05) inhibit thrombin generation compared to baseline and NAS (p 
<0.01). NAS had no significant effects at any concentration. The data represent the mean 
± standard deviation (n=3). Statistically significant differences between treatment and 
control for each agent were determined by one-way ANOVA followed by Dunnett’s 
multiple comparison test. Statistical differences between agents were determined using a 
two-way ANOVA followed by Bonferroni’s multiple comparison test. Results were 
considered to be statistically significant if p <0.05. 
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Figure 42. Potency comparison of high-AT AF semuloparin (HAS), semuloparin, and 
non-AT AF semuloparin (NAS) on thrombin generation following supplementation in 
NHP. HAS (0.70 ± 0.07) produced a more potent inhibition (*p <0.001) of thrombin than 
semuloparin (3.68 ± 0.24) and NAS (>5.0 ± 0.0). Semuloparin was more potent than 
NAS at inhibiting thrombin generation (^p <0.001). If the percent inhibition did not reach 
50% at the highest concentration, the IC50 value was presented as greater than 5.0 µg/ml. 
The data represents the mean IC50 value ± the standard deviation of three individual 
experiments. Statistical differences between agents were determined using a one-way 
ANOVA followed by Tukey’s multiple comparison test. 
 
 
198 
 
 
 
binding plays a significant role in the ability of semuloparin to inhibit thrombin 
generation. 
 
1.7.2 Supplementation into a purified SERPIN assay system 
1.7.2.1 AT-mediated antiprotease actions 
To further elucidate the function of AT binding on the ability to inhibit proteases, 
factor Xa and thrombin, HAS, semuloparin, and NAS were supplemented in a purified 
amidolytic AT system at a concentration range of 0 to 10 µg/ml. The potency of the 
various agents was expressed in terms of IC50 values. If the percent inhibition did not 
reach 50% at the highest concentration, the IC50 value was presented as greater than 10 
μg/ml. Compiled IC50 values can be found in Table 28 . 
AT mediated inhibition of factor Xa and thrombin by HAS, semuloparin, and 
NAS are shown in Figure 43. As shown in panel A, all agents were able to inhibit factor 
Xa, with HAS (0.49 ± 0.01 μg/ml) and semuloparin (1.62 ± 0.11 μg/ml) having the 
smallest IC50 values (p <0.001) compared to NAS (8.34 ± 0.30 µg/ml). Moreover, HAS 
was significantly more potent than semuloparin (p <0.001). As seen in Panel B, only 
HAS (4.50 ± 0.18 µg/ml) significantly (p <0.001) inhibited thrombin generation 
compared to semuloparin (>10.0 µg/ml) and NAS (>10.0 µg/ml), indicating that a higher 
degree of AT binding is required to produce a significant inhibition of thrombin at the 
concentrations tested.  
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Figure 43. AT mediated inhibition of factor Xa (A) and thrombin (B) by high-AT AF 
semuloparin (HAS), semuloparin, and non-AT AF semuloparin (NAS). As shown in 
Panel A, all agents were able to inhibit factor Xa, with HAS (0.49 ± 0.01 μg/ml) and 
semuloparin (1.62 ± 0.11 μg/ml) having the smallest IC50 values (*p <0.001) compared 
NAS (8.34 ± 0.30 μg/ml). Moreover, HAS was significantly more potent than 
semuloparin (^p <0.001). Only HAS (4.50 ± 0.18 μg/ml) was able to significantly (p 
<0.001) inhibit thrombin generation compared to semuloparin and NAS (B). If the 
percent inhibition did not reach 50% at the highest concentration, the IC50 value was 
presented as greater than 10 μg/ml. The data represents the mean IC50 value ± the 
standard deviation of three individual experiments. Statistical differences between agents 
were determined using a one-way ANOVA followed by Tukey’s multiple comparison 
test. 
200 
 
 
 
Overall results from these studies indicate that AT binding plays a significant role 
in the anticoagulant and antiprotease effects of semuloparin; however, the effects are 
assay dependent. Interestingly, a higher degree of AT binding was required to produce a 
significant inhibition of thrombin as measured by the anti-II, thrombin time, and 
thrombin generation assays. These results indicate that AT binding plays a significant 
role in the ability of semuloparin to inhibit thrombin generation. 
 
1.8 Studies in platelet based systems 
1.8.1 Agonist-induced platelet aggregations studies 
The role of platelets in hemostasis is of considerable importance because of their 
ability to form platelet plugs after vessel injury and to localize coagulation reactions that 
eventually form thrombin. Adenosine diphosphate (ADP), collagen, arachidonic acid 
(AA), and thrombin are just a few agents that physiologically activate platelets in vivo 
because receptors for these agents are located on their surface. This study examined the 
effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 on agonist-induced 
platelet aggregation in a platelet rich plasma (PRP) system. All agents were 
supplemented into the PRP of 5 individual donors at a final concentration of 10 µg/ml. 
Agonists were used at concentrations listed in the ‘Materials and Methods’ section. 
Maximal percent aggregation as well as the slope of the aggregation response was 
determined by the tracings. The results for this study are tabulated in Tables 29. 
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In Figure 44, the effects of UFH , enoxaparin, bemiparin, semuloparin, and RO-
14 on thrombin (5U)-induced platelet aggregation are shown. In panel A, a comparison of 
the aggregation response is displayed. UFH (7.0 ± 4.9 % aggregation), enoxaparin (3.6 ± 
2.7 % aggregation), and bemiparin (3.4 ± 2.9 % aggregation) significantly (p < 0.001) 
inhibited the aggregation response compared to saline control (95.6 ± 10.5% 
aggregation), semuloparin (89.0 ± 12.4% aggregation), and RO-14 (98.6 ± 7.3% 
aggregation). Notably, at 10 µg/ml, UFH, enoxaparin, and bemiparin almost inhibited the 
proaggregatory actions of thrombin entirely. Similar to the aggregation response, in panel 
B, UFH, enoxaparin, and bemiparin displayed an approximately 80-fold reduction in the 
slope of the aggregation response compare to control, semuloparin, and RO-14 (p < 
0.05). Additional studies were performed using ADP, AA, and collagen as agonists (data 
not shown); however, none of the heparins affected the agonist-induced aggregations at a 
final concentration of 10 µg/ml. 
 In conclusion, semuloparin and RO-14 were shown to not have any significant 
effects on thrombin-induced platelet aggregation. On the other hand, UFH, enoxaparin, 
and bemiparin strongly inhibited the thrombin-induced platelet aggregation. Since UFH, 
enoxaparin, and to a lesser extent, bemiparin are strong inhibitors of thrombin in vivo, 
their ability to inhibit thrombin-mediated platelet aggregation in vitro makes sense. This 
coincides with the inability of semuloparin and RO-14 to normally inhibit thrombin in 
vivo.   
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Figure 44. The effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 on 
agonist-induced platelet aggregation. All agents were supplemented into the platelet rich 
plasma of 5 individual donors at a final concentration of 10 µg/ml. Platelet aggregation 
was induced by 5U thrombin. UFH, enoxaparin, and bemiparin significantly (*p < 0.001) 
inhibited platelet aggregation compared to saline control, semuloparin, and RO-14 (A). 
As with the aggregation response, UFH, enoxaparin, and bemiparin significantly (*p < 
0.05) reduced the slope of the aggregation response compare to control, semuloparin, and 
RO-14 (B). The data represent the mean ± standard deviation of five individual 
experiments. Statistical analysis of the data was performed using a one-way ANOVA 
followed by Tukey’s multiple comparison test. Data are compiled in Table 29. 
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1.8.2 Heparin induced thrombocytopenia screening 
Heparin induced thrombocytopenia (HIT) is a clinical event where antibody 
mediated platelet aggregation occurs due to the presence of antibodies reactive against 
the platelet factor 4 (PF4)/heparin complex. The reactive antibodies occur due to current 
or previous exposure to heparin. Activation of platelets induces the release of 
microparticles and ultimately leads to a reduction in the number of platelets, which is 
termed thrombocytopenia. The purpose of this study was to examine the effects of 
different heparin derivatives on HIT antibody-mediated aggregation of platelets and how 
molecular weight differences among these agents may contribute to their HIT potential. 
Platelet rich plasma (PRP) was incubated with the different heparin agents (final 
concentration of 2.5 µg/ml) and pooled serum from known HIT positive patients. 
Aggregation of platelets upon addition of the various heparins indicated a positive HIT 
potential. Results from these studies are compiled in Table 30. 
The effects of heparin and its derivates on HIT+ antibody mediated platelet 
aggregation are depicted in Figure 45. In control PRP, which was only supplemented 
with HIT + serum, 11.8 ± 7.4 % aggregation was observed. All agents produced 
significant platelet aggregation compared to control (p < 0.01); however, UFH (84.5 ± 
5.3 % aggregation), enoxaparin (74.8 ± 2.4 % aggregation), and bemiparin (72.8 ± 3.5 % 
aggregation) elicited significantly (p < 0.001) more HIT+ antibody mediated aggregation 
of platelets compared to semuloparin (46.8 ± 4.6 % aggregation) and RO-14 (33.5 ± 11.1 
% aggregation). These results suggest that antibodies to UFH may cross-react with other 
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Figure 45. The effects of heparin and its derivates on HIT antibody mediated platelet 
aggregation. Agents were tested at a final concentration of 2.5 µg/ml. All agents 
produced significant platelet aggregation compared to control (*p < 0.01). UFH, 
enoxaparin, and bemiparin elicited significantly more HIT+ antibody mediated 
aggregation of platelets compared to semuloparin and RO-14 (^, + p < 0.001). The data 
represent the mean ± standard deviation of four individual experiments. Statistical 
analysis of the data was performed using a one-way ANOVA followed by Tukey’s 
multiple comparison test. Data are compiled in Table 30. 
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LMW and ULMW heparins causing aggregation. However, semuloparin and RO-14 
showed the least cross-reactivity 
 
1.9 Neutralization studies 
The objective of this study was to determine the neutralization profiles of various 
heparin antagonists, such as heparinase, protamine sulfate (PS), platelet factor 4(PF4), 
polybrene (PB), and PMX 60056 (PMX) on UFH, enoxaparin, bemiparin, semuloparin, 
and RO-14. In addition, the role that MW plays on the ability of heparin antagonists to 
produce their effects was also examined. Briefly, for the PS, PF4, PB, and PMX studies, 
all heparins were supplemented in NHP at a concentration range of 0 to 25 µg/ml. The 
various heparin antagonists were added to the heparin solutions to obtain a final 
antagonist concentration of 25 μg/ml. For the heparinase digestions study, agents were 
supplemented in NHP at a concentration range of 0 to 10 µg/ml. The heparin solutions 
were then supplemented with heparinase to obtain a final heparinase concentration of 1U. 
The neutralization effects were measured using the APTT, Heptest
®
, TT (5U Ca
2+
), anti-
Xa and anti-IIa assays, which were previously discussed in the ‘Materials and Methods’ 
section. However, since the ULMW heparins were unable sufficiently to inhibit thrombin 
activity, and thus % neutralization was incalculable, the TT and anti-IIa data were 
excluded from analysis. 
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For each test using PS, PF4, PB, and PMX, the % neutralization was calculated 
using baseline corrected µg/ml concentrations by the following formula: % 
Neutralization (%NT) = 1-(post antagonist µg/ml/pre antagonist µg/ml) * 100 
Since UFH was effectively neutralized by the various antagonists tested, it was used as 
the standard for which to select an appropriate concentration to calculate the % 
neutralization. As such, the 6.25 µg/ml concentration was selected because it was the 
lowest heparin concentration that still allowed for maximal neutralization but did not 
exceed the ability for the antagonist to exert an effect. The 5.0 µg/ml concentration was 
selected to calculate % neutralization for the heparinase digestion study. The data 
represent the mean ± standard deviation of three to four independent experiments. 
Statistical analysis of the data was performed using a one-way ANOVA followed by 
Tukey’s multiple comparison test. All compiled data for this section is compiled in 
Tables 31 to 48. 
 
1.9.1Heparinase digestion 
The neutralization effects of heparinase (HP) on heparin and its derivatives as 
measured by the APTT, Heptest
®
, and anti-Xa assays are shown in Figure 46. When 
determined by the APTT assay (A), HP strongly neutralized the anticoagulant effects of 
UFH (98.8 ± 0.3 %NT) to a greater extent than all other agents (p < 0.01). Neutralization 
of the heparin derivatives by HP, as determined by APTT, appeared to follow a molecular 
weight dependent manner. The anticoagulant effects of enoxaparin (83.6 ± 2.9 %NT) 
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Figure 46. The neutralization effects of heparinase (HP) on heparin and its derivatives as 
measured by the APTT, Heptest
®
, and anti-Xa assays. All agents were supplemented in 
NHP at a concentration range of 0 to 10 µg/ml. HP was added to the heparin solutions to 
obtain a final concentration of 1U. HP was able to strongly neutralize the anticoagulant 
and antiprotease effects of UFH, as measured by the APTT (A), Heptest (B), and anti-Xa 
assays (C). The % neutralization of UFH was statistically stronger than for all other 
agents in both the APTT and Heptest
®
 assays (*p < 0.01). As determined by the anti-Xa 
assay (C), the antiprotease activity of UFH was significantly more neutralized compared 
to bemiparin, semuloparin, and RO-14 (*p < 0.01). In the APTT assay (A), the 
anticoagulant activity of enoxaparin was neutralized to a greater extent than all other 
agents (^ p < 0.001). In the Heptest assay (B), the anticoagulant activity of semuloparin 
and enoxaparin were neutralized to a greater extent than bemiparin and RO-14 (^ p < 
0.05). The anti-Xa activity (C) of enoxaparin was significantly reduced compared to 
bemiparin, semuloparin, and RO-14 (^ p < 0.01). Similarly, semuloparin and RO-14 were 
neutralized by HP to a greater extent than bemiparin (# p < 0.05). The data represent the 
mean ± standard deviation (n=3). Statistical analysis of the data was performed using a 
one-way ANOVA followed by Tukey’s multiple comparison test. 
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were also significantly reduced compared to all other agents (p < 0.001) in the same 
assay.  
In the Heptest assay (B), the anticoagulant activity of semuloparin (58.6 ± 6.3 
%NT), enoxaparin (51.2 ± 1.4 %NT) and UFH (88.1 ± 0.9 %NT) were neutralized to a 
greater extent (p < 0.05) than both bemiparin (35.2 ± 1.3 %NT) and RO-14 (42.3 ± 2.9  
%NT). However, HP neutralized the anticoagulant effects of UFH to a greater extent than 
both enoxaparin and semuloparin (p < 0.001). The anti-Xa activity (C) of UFH (93.6 ± 
4.3 %NT) and enoxaparin (92.2 ± 6.2 %NT) was significantly (p < 0.01) reduced by HP 
compared to bemiparin (60.0 ± 0.6 %NT), semuloparin (77.0 ± 1.6 %NT), and RO-14 
(70.0 ± 1.7 %NT). Similarly, semuloparin and RO-14 were neutralized by HP to a greater 
extent than that of bemiparin (p < 0.01). These results indicate that HP neutralizes the 
effects of heparins in a molecular weight and test dependent manner.  
 
1.9.2 Protamine sulfate neutralization 
Figure 47 shows the in vitro neutralization effects of protamine sulfate (PS) on 
UFH, enoxaparin, bemiparin, semuloparin, and RO-14 as determined by the APTT, 
Heptest
®
, and anti-Xa assays. In the APTT assay (A), PS was able to neutralize the 
anticoagulant effects of the different agents in a molecular weight dependant manner. 
However, PS was unable to inhibit the anticoagulant effects of RO-14 in this assay.
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Figure 47. The neutralization effects of protamine sulfate (PS) on UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 as measured by the APTT, Heptest
®
, and anti-Xa 
assays. All agents were supplemented in NHP at a concentration range of 0 to 25 µg/ml. 
PS was added to the heparin solutions to obtain a final PS concentration of 25 μg/ml. PS 
was able to strongly neutralize the anticoagulant and antiprotease effects of UFH, as 
measured by the APTT (A), Heptest (B), and anti-Xa assays (C). The percent 
neutralization of UFH was statistically stronger than for all other agents (*p < 0.001). 
The percent neutralization of enoxaparin was significantly greater than bemiparin, 
semuloparin, and RO-14 (^p < 0.01) in the APTT assay (A). Additionally, bemiparin was 
more neutralized than semuloparin and RO-14 (#p < 0.001), and semuloparin more so 
than RO-14 (+p < 0.01). In the Heptest assay (B), the anticoagulant activity of 
enoxaparin was neutralized to a greater extent than bemiparin, semuloparin, and RO-14 
(^p < 0.001). The anti-Xa activity (C) of enoxaparin was significantly reduced compared 
to bemiparin, semuloparin, and RO-14 (^p < 0.001). The data represent the mean ± 
standard deviation (n=3-4). Statistical analysis of the data was performed using a one-
way ANOVA followed by Tukey’s multiple comparison test.
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In the Heptest
®
 assay (B), PS strongly neutralized the anticoagulant effects of 
UFH (98.3 ± 1.4 %NT) and enoxaparin (47.3 ± 13.8 %NT) to a greater extent (p <0.001) 
than bemiparin (18.3 ± 2.2 %NT), semuloparin (14.3 ± 7.8 %NT) and RO-14 (11.7 ± 6.0 
%NT). Similarly, the anti-Xa activity (C) of UFH (98.3 ± 3.4 %NT) and enoxaparin (24.5 
± 6.0 %NT) was significantly reduced (p <0.001) compared to all other agents. These 
results indicate that PS neutralizes the effects of heparins in a molecular weight and test 
dependent manner.        
 
1.9.3 Platelet factor 4 neutralization 
The neutralization effects of platelet factor 4 (PF4) on UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 as determined by the APTT, Heptest
®
, and anti-Xa 
assays are shown in Figure 48. PF4 strongly neutralized the anticoagulant effects of all 
the agents as measured by the APTT assay (A). However, the percent neutralization of 
UFH (97.5 ± 2.5 %NT) was statistically greater than for all other agents (p <0.01). 
Similar results were observed for UFH (90.3 ± 1.9 %NT) in the Heptest
®
 assay (B) when 
compared to all other agents (p <0.01). Although bemiparin (29.7 ± 4.9 %NT) and 
enoxaparin (17.5 ± 4.9 %NT) were neutralized to a greater extent than semuloparin (8.2 ± 
2.9 %NT) and RO-14 (3.5 ± 1.4 %NT); in comparison to UFH, their overall 
neutralization by PF4, in the Heptest
®
 assay, was relatively low. As determined by the 
anti-Xa assay (C) the antiprotease effect of UFH was markedly reduced by PF4 (97.1 ± 
1.8 %NT), and this effect was significantly greater than for all other agents (p <0.01). In 
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Figure 48. The neutralization effects of platelet factor 4 (PF4) on UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 as measured by the APTT, Heptest
®
, and anti-Xa 
assays. All agents were supplemented in NHP at a concentration range of 0 to 25 µg/ml. 
PF4 was added to the heparin solutions to obtain a final PF4 concentration of 25 μg/ml. 
PF4 was able to strongly neutralize the anticoagulant and antiprotease effects of UFH, as 
measured by the APTT (A), Heptest (B), and anti-Xa assays (C). The percent 
neutralization of UFH was statistically stronger than for all other agents (*p < 0.01). In 
the Heptest assay (B), the anticoagulant activity of bemiparin was neutralized to a greater 
extent than enoxaparin, semuloparin, and RO-14 (#p < 0.05). Moreover, the percent 
neutralization of enoxaparin was significantly (^p < 0.05) more than RO-14. The anti-Xa 
activity (C) of enoxaparin was significantly reduced compared to bemiparin, 
semuloparin, and RO-14 (^p < 0.001). Similarly, bemiparin was neutralized by PF4 to a 
greater extent than semuloparin (#p < 0.05). The data represent the mean ± standard 
deviation (n=3-4). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test. 
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addition, the anti-Xa activity (C) of enoxaparin was significantly reduced compared to 
bemiparin, semuloparin, and RO-14 (p <0.001). Similarly, bemiparin was neutralized by 
PF4 to a greater extent than semuloparin (p <0.05). These results indicate that PF4 
neutralizes the effects of heparins in a molecular weight and test dependent manner.  
 
1.9.4 Polybrene neutralization 
Figure 49 shows the neutralization effects of polybrene (PB) on UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 as measured by the APTT, Heptest
®
, and anti-Xa 
assays. Compared to all other agents (p <0.01), PB strongly neutralized (greater than 
90%) the anticoagulant and antiprotease effects of UFH, as measured by the APTT (A), 
Heptest (B), and anti-Xa assays (C). In the APTT assay (A), the percent neutralization of 
enoxaparin (64.5 ± 11.4 %NT) was significantly greater (p <0.05) than bemiparin (37.4 ± 
2.7 %NT), semuloparin (32.1 ± 17.0 %NT), and RO-14 (8.1 ± 10.2 %NT). Additionally, 
bemiparin and semuloparin were more neutralized than RO-14 (p <0.05).  
In the Heptest assay (B), PB neutralized the anticoagulant activity of enoxaparin 
(27.7 ± 5.6 %NT) and bemiparin (26.7 ± 7.8 %NT) to a similar extent; yet, both were 
neutralized to a greater extent (p <0.05) than semuloparin (12.8 ± 5.0 %NT) and RO-14 
(4.3 ± 3.9 %NT). The anti-Xa activity (C) of enoxaparin (16.9 ± 5.3 %NT) was 
significantly reduced (p <0.05) compared to bemiparin (5.1 ± 1.9 %NT), semuloparin 
(0.6 ± 0.7 %NT), and RO-14 (8.4 ± 5.0 %NT). Similarly, RO-14 was neutralized by PB 
(p <0.05) to a greater extent than semuloparin (C). Interestingly, when determined by the 
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Figure 49. The neutralization effects of polybrene (PB) on UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 as measured by the APTT, Heptest
®
, and anti-Xa assays. All 
agents were supplemented in NHP at a concentration range of 0 to 25 µg/ml. PB was 
added to the heparin solutions to obtain a final PB concentration of 25 μg/ml. PB was 
able to strongly neutralize the anticoagulant and antiprotease effects of UFH, as measured 
by the APTT (A), Heptest (B), and anti-Xa assays (C). The percent neutralization of UFH 
was statistically stronger than for all other agents (*p < 0.01). The percent neutralization 
of enoxaparin was significantly greater than bemiparin, semuloparin, and RO-14 (^p < 
0.05) in the APTT assay (A). Additionally, bemiparin and semuloparin were more 
neutralized than RO-14 (#, +p < 0.05). In the Heptest assay (B), the anticoagulant 
activity of enoxaparin and bemiparin were neutralized to a greater extent than 
semuloparin and RO-14 (^, #p < 0.05). The anti-Xa activity (C) of enoxaparin was 
significantly reduced compared to bemiparin, semuloparin, and RO-14 (^p < 0.05). 
Similarly, RO-14 was neutralized (#p < 0.05).by PB to a greater extent than semuloparin 
(C).The data represent the mean ± standard deviation (n=3-4). Statistical analysis of the 
data was performed using a one-way ANOVA followed by Tukey’s multiple comparison 
test. 
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APTT assay, PB’s neutralizing effects seemed to be molecular weight dependent. 
Conversely, in the Heptest
®
 and anti-Xa assays, neutralization of the clotting and 
antiprotease activities of these agents seemed less dependent on molecular weight and 
more dependent on some other factor. 
 
1.9.5 PMX 60056 neutralization 
The neutralization effects of PMX 60056 (PMX) on UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 as measured by the APTT, Heptest
®
, and anti-Xa assays are 
shown in Figure 50. PMX powerfully neutralized the anticoagulant effects of all the 
agents, as measured by the APTT (A) and Heptest
®
 assays (B). In the APTT assay (A), 
the neutralization of UFH (98.8 ± 1.1 %NT) was two-fold greater (p <0.05) compared to 
semuloparin (47.7 ± 7.7 %NT). When determined by the Heptest
®
 assay (B), the 
neutralization of UFH (99.9 ± 0.1 %NT) was significantly greater (p <0.05) than 
bemiparin (72.3 ± 1.4 %NT), semuloparin (70.7 ± 8.9 %NT), and RO-14 (63.5 ± 15.3 
%NT). Moreover, PMX neutralized the anticoagulant effects of enoxaparin (90.3 ± 2.2 
%NT) to a greater extent (p <0.05) than RO-14 (63.5 ± 15.3 %NT). As shown in panel C, 
the antiprotease effects of UFH (98.1 ± 3.1 %NT) and enoxaparin (57.4 ± 3.8 %NT) were 
significantly more neutralized than all other agents (p <0.001 and p <0.05, respectively); 
although, PMX still moderately neutralized the effects of bemiparin (37.7 ± 5.6 %NT), 
semuloparin (25.2 ± 1.8 %NT), and RO-14 (30.2 ± 12.4 %NT). Notably, the ability of 
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Figure 50. The neutralization effects of PMX 60056 (PMX) on UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 as measured by the APTT, Heptest
®
, and anti-Xa 
assays. All agents were supplemented in NHP at a concentration range of 0 to 25 µg/ml. 
PMX was added to the heparin solutions to obtain a final PMX concentration of 25 
μg/ml. PMX was able to strongly neutralize the anticoagulant effects of all the agents, as 
measured by the APTT (A) and Heptest assays (B). Neutralization of UFH was 
significantly (*p < 0.05) greater compared to semuloparin, when determined by the 
APTT assay (A), and to a greater extent than bemiparin, semuloparin, and RO-14 (*p < 
0.05), when determined by the Heptest
®
 assay (B). Moreover, PMX neutralized the 
anticoagulant effects of enoxaparin to a greater extent than RO-14 (^p < 0.05). As shown 
in panel C, the antiprotease effects of UFH and enoxaparin were significantly more 
neutralized than all other agents (*p < 0.001 and ^p < 0.05, respectively). The data 
represent the mean ± standard deviation (n=3-4). Statistical analysis of the data was 
performed using a one-way ANOVA followed by Tukey’s multiple comparison test.
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PMX to neutralize the anticoagulant and antiprotease properties of the various heparins 
appears to be molecular weight dependent.  
 The overall results from these studies indicate that the various heparin antagonists 
differ with regards to their ability to neutralize the anticoagulant and antiprotease effects 
of UFH and its derivates. Neutralization by each of the antagonists was determined to be 
assay and MW dependent. At equigravimetric concentrations, all of the antagonists 
produced a > 90% neutralization of the anticoagulant and antiprotease effects of UFH. 
However, a greater degree of variation in terms of the neutralization of the LMW and 
ULMW heparins was noted. At equigravimetric concentrations, PMX and HP produced 
the greatest neutralization out of all the pharmacologic antagonists tested; however, their 
effectiveness was assay dependent. Both produced similar neutralization profiles when 
measured by the APTT assay. Interestingly, the anticoagulant activity of each LMW and 
ULMW heparin, as measured by the Heptest® assay, was neutralized to a greater extent 
by PMX. Conversely, when measured by the anti-Xa assay, the antiprotease activity was 
more neutralized by HP. Neutralization by PF4 was assay dependent. Neutralization of 
the anticoagulant effects of each agent by PF4 was most noted in the APTT assay. Of all 
the antagonists tested, PS and PB were considered the least efficacious for neutralization 
of the LMW and ULMW heparins. Both demonstrated a MW and assay dependent 
neutralization effect. Similarly to PF4, neutralization of the anticoagulant effects of each 
agent by PS and PB was most noted in the APTT assay. Overall, this data suggest that 
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PMX and HP may be potentially effective antagonists for the neutralization of LMW and 
ULMW heparins.  
 
2.0 Fibrinokinetics  
The differential effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 
on the rate of fibrin formation were compared. The fibrinokinetic profile of each agent 
was compared across a concentration range of 0 to 10 µg/ml in citrated normal human 
plasma (NHP). Thrombin (5U) and CaCl2 (0.25 mM) were added to the supplemented 
NHP and the rate of fibrin formation was recorded at 405 nM. The rate kinetics and % 
inhibition of fibrin clot formation for each drug were calculated at the varying 
concentrations. Results represent the mean and standard deviations of three independent 
experiments. Statistical analysis of the % inhibition data was performed using a two-way 
ANOVA followed by a Bonferroni multiple comparison test. Results were considered 
significant if p < 0.05. The compiled data are shown in Table 49. 
The differential inhibition of fibrinokinetics by UFH and its derivatives is shown 
in Figure 51. All agents produced a concentration dependent inhibition of fibrin clot 
formation. At all concentrations, UFH was consistently the most potent inhibitor of fibrin 
clot formation compared to all other agents. 
Figure 52 shows the comparative inhibitory effects of UFH and its derivatives on 
fibrin clot formation. UFH was significantly more efficacious at inhibiting fibrin clot 
formation compared to bemiparin, semuloparin, and RO-14 at all concentrations (p < 
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Figure 51. Differential inhibition of fibrinokinetics by UFH and its derivatives. All agents 
produced a concentration-dependent inhibition of fibrin clot formation. UFH was 
consistently the most potent inhibitor of fibrin clot formation. The data represent the 
means of three individual experiments. 
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Figure 52. The comparative inhibitory effects of UFH and its derivatives on fibrin clot 
formation. Drugs were supplemented in citrated NHP at a concentration range of 0 –10 
µg/mL. Results were given in terms of % inhibition. UFH produced a significantly more 
potent inhibition of fibrin clot formation compared to bemiparin, semuloparin, and RO-
14 at all concentrations (p < 0.01). At all concentrations tested, enoxaparin exhibited a 
significantly stronger inhibition of fibrin clot formation compared to semuloparin and 
RO-14 (p < 0.001). Bemiparin demonstrated a significantly stronger inhibition of fibrin 
clot formation compared to semuloparin and RO-14 at a concentration range of 0.6125 to 
5.0 µg/ml (p <0.05). The data represent the mean ± standard deviation of three individual 
experiments. Statistical analysis of the data was performed using a two-way ANOVA 
followed by Bonferroni’s multiple comparison test. Results were considered significant if 
p < 0.05. Data are compiled in Table 49. 
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0.01). Similarly, enoxaparin, at all concentrations, exhibited a significantly stronger 
inhibition of fibrin clot formation compared to semuloparin and RO-14 (p < 0.001). 
Bemiparin demonstrated a significantly inhibited fibrin clot formation to a greater degree 
than that of semuloparin and RO-14 at a concentration range of 0.61 to 5.0 µg/ml (p 
<0.05). Although semuloparin and RO-14 have a lower inhibitory effect on thrombin, 
both were able to inhibit fibrin clot formation induced by thrombin, albeit to a much 
lower extent than the other agents. 
 
C. In vivo studies in animal models 
1. The effects of heparin and its derivatives in a rat-tail bleeding model 
1.1 The hemorrhagic effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 
The next set of studies was employed to determine if the different MWs or AT 
binding properties of the various heparins played a role in their hemorrhagic effects in a 
rat model. The hemorrhagic effects of UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 were determined using a rat-tail bleeding model in male Sprague-Dawley rats as 
described in the ‘Materials and Methods’ section. The test agents were administered 
intravenously (IV) via the femoral vein with a circulation time of 5 min or 
subcutaneously (SC) under the scruff of the neck with a circulation time of 120 min. 
Three doses per route of administration were given as previously described in the 
‘Materials and Methods’ section. The hemorrhagic effect of each drug was determined by 
the time it took, after tail tip transaction, for the tip to form a thrombosis and bleeding to 
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stop. Statistical significance (p <0.05) between groups was determined using a one-way 
ANOVA followed by Tukey’s multiple comparison test. Compiled data for these studies 
can be found in Tables 50 to 54.  
 
1.1.1 Intravenous administration 
UFH, enoxaparin, bemiparin, semuloparin, and RO-14 were administered IV at 
dosages of 250, 500, and 1000 µg/kg (Figure 53). At the lowest dose (250 µg/kg), rats 
treated with UFH (17.0 ± 1.4 min), enoxaparin (13.0 ± 0.3 min), and bemiparin (15.6 ± 
2.1 min) exhibited prolonged bleeding compared to saline control (7.2 ± 0.6 min) (p 
<0.01). At the lowest dose, UFH and bemiparin prolonged the bleeding time to a greater 
extent than that of semuloparin and RO-14 (p <0.01). The increased bleeding time 
produced by enoxaparin, on the other hand, was only significantly greater than that of 
RO-14 at the lowest dose (p <0.01). Similar results were seen for UFH, enoxaparin, and 
bemiparin at the 500 µg/kg dose (p <0.05); although, prolongation in the bleeding time 
was only significantly different for UFH vs. RO-14 (p < 03.05). At the 1.0 mg/kg dose, 
rats administered UFH (22.0 ± 1.9 sec), enoxaparin (19.7 ± 1.4 sec), bemiparin (15.2 ± 
1.5 sec), and RO-14 (14.0 ± 2.2 sec) exhibited prolonged bleeding compared to control 
(7.2 ± 0.6 sec) (p <0.05). UFH significantly prolonged the bleeding time compared to 
bemiparin, semuloparin, and RO-14 at the highest dose (p < 0.05). Additionally, 
enoxaparin prolonged the bleeding time to a greater extent than semuloparin (p < 0.05). 
Semuloparin showed no significant prolongation in bleeding time. Out of all the agents, 
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Figure 53. The hemorrhagic effect of UFH, enoxaparin, bemiparin, semuloparin, and RO-
14 in a rat-tail bleeding model after IV administration. At a dose of 250 µg/kg, UFH, 
enoxaparin, and bemiparin exhibited prolonged bleeding compared to saline control (*p 
< 0.01). Similar results were seen for UFH, enoxaparin, and bemiparin at the 500 µg/kg 
dose (*p < 0.05). At the 1.0 mg/kg dose, all agents, except semuloparin, exhibited 
prolonged bleeding compared to control (*p < 0.05). The data represent the mean ± 
standard error of the mean (n=5). Statistical analysis of the data was performed using a 
one-way ANOVA followed by Tukey’s multiple comparison test. Exact p values for all 
statistically significant effects can be found in Tables 55 of the appendix. 
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UFH produced the largest prolongation of bleeding at all doses. Exact p values for all 
statistically significant effects can be found on Table 55. 
 
1.1.2 Subcutaneous administration 
 
UFH, enoxaparin, bemiparin, semuloparin, and RO-14 were administered SC at 
doses of 0.5, 1.0, and 2.5 mg/kg to rats (Figure 54). No significant bleeding was exhibited 
for any of the agents at the 500 µg/kg dose. At a dose of 1.0 mg/kg, UFH (12.5 ± 0.7 
sec), bemiparin (13.2 ± 1.2 sec), and RO-14 (12.0 ± 1.1 sec) exhibited prolonged 
bleeding compared to saline control (7.1 ± 0.9 sec) (p <0.05). No differences in bleeding 
between agents were observed. Similar results were seen for UFH, enoxaparin, 
bemiparin, and RO-14 at the 2.5 mg/kg dose (p <0.05). Similarly to IV administration, 
semuloparin did not exhibit any significant prolongation in bleeding when administered 
SC at any of the doses. Exact p values for all statistically significant effects can be found 
in Table 56. 
 These studies suggest that after IV administration, there is a MW dependent 
increase in the bleeding effects. For UFH, enoxaparin, and RO-14, increases in dose 
corresponded to increases in bleeding times when administered intravenously. This dose-
dependent increase was not as evident for bemiparin and semuloparin. After SC 
administration, the MW dependency was not as evident. However, a dose-dependent 
increase in the bleeding time was observed for all agents. The almost negligible anti-IIa 
activity of semuloparin most likely contributed to the low hemorrhagic effects observed 
for this agent. 
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Figure 54. The hemorrhagic effect of UFH, enoxaparin, bemiparin, semuloparin, and RO-
14 in a rat-tail bleeding model after SC administration. At a dose of 1.0 mg/kg, UFH, 
bemiparin, and RO-14 exhibited prolonged bleeding compared to saline control (*p < 
0.05). Similar results were seen for UFH, enoxaparin, bemiparin, and RO-14 at the 2.5 
mg/kg dosage (*p < 0.05). The data represent the mean ± standard error of the mean 
(n=5). Statistical analysis of the data was performed using a one-way ANOVA followed 
by Tukey’s multiple comparison test. Exact p values for all statistically significant effects 
can be found in Table 56 of the appendix. 
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2. Antithrombotic effects in a rat jugular vein clamping model 
2.1 The antithrombotic effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 
The next set of studies was employed to determine if the different MWs or 
structural characteristics of the various heparins played a role in their antithrombotic 
effects in a rat model. The rat jugular vein clamping model was used to evaluate the anti-
thrombotic effects of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 after SC 
(0.5, 1.0, and 2.5 mg/kg) and IV (0.25, 0.5, and 1.0 mg/kg) administration. Following the 
completion of the rat-tail transaction bleeding model, the rat jugular vein clamping model 
was performed. Although the bleeding time varied between animals, the clamping 
protocol was started at the same time point (50 minutes after IV administration or 160 
minutes after SC administration) in order to reduce any plasma drug concentration 
variability between animals. Additionally, after both the bleeding and clamping protocols 
were performed, the blood was drawn at a similar time point for all the IV animals and all 
the SC animals; this allowed for a more accurate comparative ex vivo analysis between 
drugs. The effectiveness of the antithrombotic agent was determined by the number of 
clampings required to cause complete vascular occlusion. Statistical significance (p 
<0.05) between groups was determined using a one-way ANOVA followed by Tukey’s 
multiple comparison test. Exact p values for all statistically significant effects can be 
found on Tables 57 and 58. 
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2.1.1 Intravenous administration  
At a dose of 250 µg/kg, UFH (4.4 ± 0.2 clampings), enoxaparin (4.6 ± 0.2 
clampings), bemiparin (5.0 ± 0.3 clampings), and semuloparin (4.2 ± 0.2 clampings) 
produced measurable antithrombotic effects compared to control (3.0 ± 0.3 clampings) (p 
<0.05), as demonstrated by the increase in the number of clampings required to occlude 
the jugular vein entirely (Figure 55). Similar results were seen for all agents at the 500 
µg/kg dose (p <0.01); however, there were no considerable differences between drugs at 
either of the low doses. All agents were able to produce significant antithrombotic effects 
compared to control at the 1.0 mg/kg dose (Figure 55). UFH (10.0 ± 0.8 clampings), 
enoxaparin (7.7 ± 0.4 clampings), bemiparin (9.6 ± 0.7 clampings), and semuloparin (8.0 
± 0.3 clampings) had significantly stronger (p <0.05) antithrombotic activity compared to 
RO-14 (5.2 ± 0.6 clampings) at the 1.0 mg/kg dose. Moreover, UFH had significantly 
stronger antithrombotic activity compared to enoxaparin (p <0.05). A dose-dependent 
increase in the antithrombotic activity of each agent was observed after IV 
administration. 
 
2.1.2 Subcutaneous administration 
At a dose of 500 µg/kg SC, enoxaparin (5.0 ±0.0 clampings) and semuloparin (5.0 
± 0.3 clampings) produced measurable antithrombotic effects compared to control (3.6 ± 
0.2 clampings) (p <0.05), as demonstrated by the increase in the number of clampings 
required to occlude the jugular vein entirely (Figure 56). The antithrombotic effects of 
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Figure 55. The antithrombotic effect of UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 in a rat jugular vein clamping model after IV administration. At a dose of 250 
µg/kg, UFH, enoxaparin, bemiparin, and semuloparin produced measurable 
antithrombotic effects compared to control (*p < 0.05), as demonstrated by the increase 
in the number of clampings required to completely occlude the jugular vein. Similar 
results were seen for all agents at the 500 µg/kg (*p < 0.01) and 1.0 mg/kg (*p < 0.05) 
doses. The data represent the mean ± standard error of the mean (n=5). Statistical analysis 
of the data was performed using a one-way ANOVA followed by Tukey’s multiple 
comparison test. Exact p values for all statistically significant effects can be found in 
Table 57 of the appendix. 
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Figure 56. The antithrombotic effect of UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 in a rat jugular vein clamping model after SC administration. At a dose of 500 
µg/kg, enoxaparin and semuloparin produced measurable antithrombotic effects 
compared to control (*p < 0.05), as demonstrated by the increase in the number of 
clampings required to completely occlude the jugular vein. Similar results were seen for 
all agents, except RO-14, at the 1.0 mg/kg (*p < 0.001). Moreover, all agents produced 
an antithrombotic effect at the 2.5 mg/kg dose (*p < 0.01). The data represent the mean ± 
standard error of the mean (n=5). Statistical analysis of the data was performed using a 
one-way ANOVA followed by Tukey’s multiple comparison test. Exact p values for all 
statistically significant effects can be found in Table 58 of the appendix. 
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enoxaparin and semuloparin were considered significantly greater than that of UFH at the 
500 µg/kg SC (p < 0.05). At the 1.0 mg/kg dose, all agents, except RO-14, produced 
measurable antithrombotic effects compared to control (p <0.001). The antithrombotic 
effects of enoxaparin (6.2 ± 0.4 clampings), bemiparin (6.4 ± 0.4 clampings), and 
semuloparin (6.6 ± 0.2 clampings) were significantly greater than that of RO-14 (4.8 ± 
0.2 clampings) at the same dose (p < 0.05). At the 2.5 mg/kg dose, all agents produced a 
significant antithrombotic effect compared to control (p <0.01). However, all agents 
demonstrated stronger antithrombotic activity compared to RO-14 at the same dose (p 
<0.05). A dose-dependent increase in the antithrombotic activity of each agent was 
observed after SC administration.  
These studies suggest that after both SC and IV administration, increases in dose 
corresponded to increases in the antithrombotic effects of these agents. Moreover, MW 
did not seem to affect the overall antithrombotic effects of these agents. After SC 
administration, the antithrombotic effects of UFH were not as strong compared to 
enoxaparin, bemiparin, and semuloparin, although this was not always considered 
significant. Most likely, this is due to the fact that UFH is not as readily absorbed after 
SC administration compared to the other LMW and ULMW heparins. 
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3. Ex vivo analysis of rat whole blood and plasma  
3.1 Intravenous administration 
 Blood samples were collected from each rat approximately 110 minutes 
after IV treatment with UFH, enoxaparin, bemiparin, semuloparin, or RO-14 in order to 
run ex vivo analysis using aPTT, TT, Heptest
®
, anti-Xa, and anti-IIa assays as described 
in the ‘Materials and Methods’ section. When the clotting time exceeded 300 sec for any 
assay, the test was stopped, as the values were out of the linear range of the assay. 
Statistical significance (p <0.05) between groups was determined using a one-way 
ANOVA followed by Tukey’s multiple comparison test. Exact p values for all 
statistically significant effects for these studies can be found on Tables 59 to 64. 
. 
3.1.1 Whole Blood aPTT assay 
 The global anticoagulant effects of UFH, enoxaparin, bemiparin, semuloparin and 
RO-14 (IV) were determined in rat whole blood using the aPTT assay (Figure 57). No 
significant differences were observed at the 250 µg/kg dose. At the 500 µg/kg and 1.0 
mg/kg IV doses, UFH produced prolonged clotting times compared to control (p <0.001) 
and all other agents (p <0.001). No other agent produced any significant prolongation of 
clotting times at any of the doses used.  
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Figure 57. The whole blood anticoagulant effect of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 as measured by aPTT after IV administration. At the 500 µg/kg 
and 1.0 mg/kg doses, UFH produced prolonged clotting times compared to control (*p < 
0.001). The data represent the mean ± standard error of the mean (n=5). Statistical 
analysis of the data was performed using a one-way ANOVA followed by Tukey’s 
multiple comparison test. Exact p values for all statistically significant effects can be 
found in Table 59 of the appendix. 
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3.1.2 Plasma aPTT assay 
The global anticoagulant effects of UFH, enoxaparin, bemiparin, semuloparin and 
RO-14 (IV) were determined in rat plasma using the aPTT assay (Figure 58). No 
significant differences were observed at the 250 µg/kg IV dose. At the 500 µg/kg and 1.0 
mg/kg doses, only UFH produced prolonged clotting times (34.9 ± 3.9 and 163.9 ± 40.1, 
respectively) compared to control (22.7 ± 2.0; p <0.01). Additionally, UFH demonstrated 
a significantly stronger effect compared to all other agents at the highest dose (p <0.001).  
 
3.1.3 Heptest
®
 assay 
The global anticoagulant effects of UFH, enoxaparin, bemiparin, semuloparin and 
RO-14 were determined in rat plasma using the Heptest
®
 assay (Figure 59). Semuloparin, 
UFH, enoxaparin, and bemiparin significantly prolonged the clotting time at the 250 
µg/kg IV dose (p <0.01); semuloparin (223.3 ± 19.7 sec) produced a significantly longer 
clotting time compared to enoxaparin (140.9 ± 24.3 sec; p <0.05) and RO-14 (123.2 ± 7.1 
sec; p <0.01). At both the 500 µg/kg and 1.0 mg/kg doses, all agents demonstrated 
prolonged clotting times compared to saline control (p <0.05). No differences between 
the agents were observed.  
 
3.1.4 Thrombin Time (5U Ca2+) assay 
The global anticoagulant effects, as measured by the TT (5 U Ca2+) assay, of 
UFH, enoxaparin, bemiparin, semuloparin and RO-14 in rat plasma are shown in Figure 
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Figure 58. The plasma anticoagulant effect of UFH, enoxaparin, bemiparin, semuloparin, 
and RO-14 as measured by aPTT after IV administration. At the 500 µg/kg and 1.0 
mg/kg doses, UFH produced prolonged clotting times compared to control (*p < 0.01). 
The data represent the mean ± standard error of the mean (n=5). Statistical analysis of the 
data was performed using a one-way ANOVA followed by Tukey’s multiple comparison 
test. Exact p values for all statistically significant effects can be found in Table 60 of the 
appendix. 
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Figure 59. The anticoagulant effect of UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 as measured by the Heptest
®
 assay after IV administration. Semuloparin, UFH, 
enoxaparin, and bemiparin were able to significantly prolong the clotting time at the 250 
µg/kg dose (*p < 0.01) compared to baseline; semuloparin had the strongest effect 
compared to enoxaparin and RO-14 (p < 0.05). At both the 500 µg/kg and 1.0 mg/kg 
doses, all agents demonstrated prolonged clotting times (*p < 0.05 and *p < 0.01, 
respectively) compared to baseline. The data represent the mean ± standard error of the 
mean (n=5). Statistical analysis of the data was performed using a one-way ANOVA 
followed by Tukey’s multiple comparison test. Exact p values for all statistically 
significant effects can be found in Table 61 of the appendix. 
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Figure 60. The anticoagulant effect of UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 as measured by the 5 U Ca2+ TT assay after IV administration. UFH, enoxaparin, 
and bemiparin were able to significantly prolong the clotting time at the 250 µg/kg dose 
compared to baseline (*p < 0.05). At the 500 µg/kg, only UFH demonstrated a prolonged 
clotting time compared to baseline (*p < 0.01) and all other agents (p < 0.05). All agents, 
except bemiparin, were able to prolong the clotting time at the 1.0 mg/kg dose; UFH 
demonstrated the greatest effect compared to all other agents (p < 0.001). The data 
represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was 
performed using a one-way ANOVA followed by Tukey’s multiple comparison test. 
Exact p values for all statistically significant effects can be found in Table 62 of the 
appendix. 
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60. UFH, enoxaparin, and bemiparin significantly prolonged the clotting time at the 250 
µg/kg dose (p <0.05). At the 500 µg/kg dose, only UFH demonstrated a prolonged 
clotting time (164.3 ± 26 sec) compared to baseline (25.3 ± 1.1 sec; p <0.01) and all 
other agents (P <0.05). All agents, except bemiparin, were able to prolong the clotting 
time at the 1.0 mg/kg dose; UFH demonstrated the greatest effect compared to all other 
agents (p <0.001).  
 
3.1.5 Amidolytic anti-Xa assay 
The inhibition of factor Xa in rat plasma was evaluated for UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 using the anti-Xa assay (Figure 61). Optical density 
changes were used to determine the percent inhibition of the agents. Semuloparin, 
bemiparin, and RO-14 significantly inhibited factor Xa at the 250 µg/kg dose compared 
to control (p <0.05). Semuloparin demonstrated the greatest inhibition (25.8 ± 3.4 % Inh) 
compared to all other agents (p <0.001). At both the 500 µg/kg and 1.0 mg/kg IV doses, 
all agents showed significant inhibition of factor Xa (p <0.001 and p <0.01, 
respectively). At the 500 µg/kg dose, UFH, enoxaparin, and semuloparin significantly 
inhibited factor Xa to a greater extent than RO-14 (p < 0.01). At the 1.0 mg/kg dose, 
semuloparin demonstrated stronger inhibition of factor Xa (63.8 ± 1.6 % Inh) than 
enoxaparin (33.2 ± 4.8 % Inh; p <0.01) and RO-14 (31.4 ± 2.9 % Inh; p <0.01).  
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Figure 61. The inhibition of factor Xa by UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 as measured by the amidolytic anti-Xa assay after IV administration. 
Semuloparin, bemiparin, and RO-14 were able to significantly inhibit factor Xa 
compared to baseline at the 250 µg/kg dose (*p < 0.05). Semuloparin demonstrated the 
greatest inhibition compared to all other agents at this dose (p < 0.001). At both the 500 
µg/kg and 1.0 mg/kg doses, all agents showed significant inhibition of factor Xa (*p < 
0.001 and p < 0.01, respectively) compared to baseline. The data represent the mean ± 
standard error of the mean (n=5). Statistical analysis of the data was performed using a 
one-way ANOVA followed by Tukey’s multiple comparison test. Exact p values for all 
statistically significant effects can be found in Table 63 of the appendix. 
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3.1.6 Amidolytic anti-IIa assay  
The inhibition of thrombin in plasma was evaluated using the anti-IIa assays from 
rats treated with UFH, enoxaparin, bemiparin, semuloparin, and RO-14 (Figure 62). 
Optical density changes were used to determine the percent inhibition of thrombin. No 
significant differences were observed at the 250 µg/kg dose. At both the 500 µg/kg and 
1.0 mg/kg doses, all agents showed significant inhibition of thrombin (p <0.001). UFH 
showed the greatest inhibition of thrombin (75.5 ± 2.9 % Inh) compared to all other 
agents at both doses (p <0.001).       
 
3.2 Subcutaneous Administration 
Blood samples were collected approximately 210 minutes after SC administration 
of UFH, enoxaparin, bemiparin, semuloparin, and RO-14 from each rat at the end of the 
experiments in order to run ex vivo analysis using aPTT, TT, Heptest
®
, anti-Xa, and anti-
IIa assays as described in the ‘Materials and Methods’ section. When the clotting time 
exceeded 300 sec for any assay, the test was stopped, as the values were out of the linear 
range of the assay. Statistical significance of differences between groups was determined 
using a one-way ANOVA followed by Tukey’s multiple comparison test. Exact p values 
for all statistically significant effects for these studies can be found on Tables 65 to 70. 
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Figure 62. The inhibition of thrombin by UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 as measured by the amidolytic anti-IIa assay after IV administration. At both the 
500 µg/kg and 1.0 mg/kg doses, all agents showed significant inhibition of thrombin 
compared to baseline (*p < 0.001). UFH showed the greatest inhibition of thrombin 
compared to all other agents at both doses (p < 0.001). The data represent the mean ± 
standard error of the mean (n=5). Statistical analysis of the data was performed using a 
one-way ANOVA followed by Tukey’s multiple comparison test. Exact p values for all 
statistically significant effects can be found in Table 64 of the appendix. 
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3.2.1 Whole Blood aPTT assay 
The anticoagulant effects of UFH, enoxaparin, bemiparin, semuloparin and RO-
14 (SC) were determined in whole blood from treated rats using the aPTT assay (Figure 
63). At the 500 µg/kg and 1.0 mg/kg doses, UFH, enoxaparin, bemiparin, and 
semuloparin produced prolonged clotting times compared to control (p <0.01). No 
significant differences between agents were observed. All agents produced significantly 
prolonged clotting times at the 2.5 mg/kg dose (p <0.001). Interestingly, semuloparin, at 
the 2.5 mg/kg dose, demonstrated the strongest anticoagulant effect (31.0 ± 1.3 sec) 
compared to all other agents (p <0.001).  
 
3.2.2 Plasma aPTT assay 
The global anticoagulant effects of UFH, enoxaparin, bemiparin, semuloparin and 
RO-14 (SC) were determined in plasma from treated rats using the aPTT assay (Figure 
64). Contrary to the whole blood aPTT, only UFH was able to prolong the clotting time 
(21.3 ± 1.2 sec) at the 2.5 mg/kg dose, compared to baseline (16.4 ± 0.1 sec; p <0.001) 
and all other agents (p <0.01). No significant differences were observed at the lowest 
doses for any agent.  
 
3.2.3 Heptest
® 
assay 
The global anticoagulant effects of UFH, enoxaparin, bemiparin, semuloparin and 
RO-14 (SC) were determined in plasma from treated rats using the Heptest
®
 assay 
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Figure 63. The whole blood anticoagulant effect of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 as measured by aPTT after SC administration. At the 500 µg/kg 
and 1.0 mg/kg doses, UFH, enoxaparin, bemiparin, and semuloparin produced prolonged 
clotting times compared to control (*p < 0.01). All agents produced prolonged clotting 
times compared to baseline at the 2.5 mg/kg dose (*p < 0.001). The data represent the 
mean ± standard error of the mean (n=5). Statistical analysis of the data was performed 
using a one-way ANOVA followed by Tukey’s multiple comparison test. Exact p values 
for all statistically significant effects can be found in Table 65 of the appendix. 
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Figure 64. The plasma anticoagulant effect of UFH, enoxaparin, bemiparin, semuloparin, 
and RO-14 as measured by aPTT after SC administration. Only UFH was able to prolong 
clotting compared to baseline at the 2.5 mg/kg dose (*p < 0.001). The data represent the 
mean ± standard error of the mean (n=5). Statistical analysis of the data was performed 
using a one-way ANOVA followed by Tukey’s multiple comparison test. Exact p values 
for all statistically significant effects can be found in Table 66 of the appendix. 
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(Figure 65). Semuloparin was the only agent able to prolong the Heptest
®
 clotting time 
(109.6 ± 5.7 sec) significantly compared to control (79.8 ± 2.7 sec), at the 500 µg/kg dose 
(p <0.01). At the 1.0 mg/kg dose, semuloparin, enoxaparin, and bemiparin demonstrated 
prolonged clotting times compared to control (p <0.01). All agents showed measurable 
anticoagulant effects as seen by the significant increases in clotting time at the 2.5 mg/kg 
dose (p <0.001). However, both semuloparin (253.6 ± 12.3 sec) and UFH (251.6 ± 20.9 
sec) significantly prolonged the clotting time to a greater extent than enoxaparin (174.2 ± 
11.7 sec; p < 0.05). All agents demonstrated a dose-dependent increase in Heptest
® 
clotting times.    
 
3.2.4 Thrombin Time (5U Ca2+) assay 
 The global anticoagulant effects, as measured by the TT (5 U Ca2+) assay, of 
UFH, enoxaparin, bemiparin, semuloparin and RO-14 (SC) in plasma from treated rats 
are shown in Figure 66. At the 1.0 mg/kg dose, UFH and enoxaparin showed significant 
inhibition of thrombin (p <0.05). UFH demonstrated the strongest inhibition of thrombin 
(216.1 ± 31.6 sec), at the 2.5 mg/kg dose, compared to baseline (26.4 ± 0.3 sec) and all 
other agents (p <0.001). No significant inhibition of thrombin at the lowest dose was 
observed for any of the agents.  
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Figure 65. The anticoagulant effect of UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 as measured by the Heptest
®
 assay after SC administration. Semuloparin was the 
only agent able to significantly prolong the clotting time compared to baseline at the 500 
µg/kg dose (*p < 0.01). At the 1.0 mg/kg dose, semuloparin, enoxaparin and bemiparin 
demonstrated prolonged clotting times compared to baseline (*p < 0.01). All agents were 
able to significantly increase the clotting time compared to baseline at the 2.5 mg/kg dose 
(*p < 0.001). The data represent the mean ± standard error of the mean (n=5). Statistical 
analysis of the data was performed using a one-way ANOVA followed by Tukey’s 
multiple comparison test. Exact p values for all statistically significant effects can be 
found in Table 67 of the appendix. 
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Figure 66. The inhibition of thrombin by UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 as measured by the thrombin time assay after SC administration. At the 1.0 mg/kg 
dose, UFH and enoxaparin showed significant inhibition of thrombin compared to 
baseline (*p < 0.05). UFH demonstrated a strong inhibition of thrombin at the 2.5 mg/kg 
dose compared to baseline and all other agents (*p < 0.001). The data represent the mean 
± standard error of the mean (n=5). Statistical analysis of the data was performed using a 
one-way ANOVA followed by Tukey’s multiple comparison test. Exact p values for all 
statistically significant effects can be found in Table 68 of the appendix. 
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3.2.5 Amidolytic anti-Xa assay 
The inhibition of factor Xa in plasma from rats treated with UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 (SC) was evaluated using the anti-Xa assay (Figure 
67). Optical density changes were used to determine the percent inhibition of factor Xa. 
Semuloparin, enoxaparin, bemiparin, and RO-14 significantly inhibited factor Xa at the 
500 µg/kg dose compared to saline control (p <0.01). At that dose, all agents produced a 
stronger inhibition of factor Xa than UFH (p <0.05). Additionally, inhibition of factor Xa 
by semuloparin was approximately 1.2-fold greater than RO-14 (p <0.05). At the 1.0 
mg/kg dose, all agents showed significant inhibition of factor Xa compared to saline 
control (p <0.05); semuloparin (41.0 ± 2.0 % Inh), enoxaparin (38.7 ± 2.6 % Inh), and 
bemiparin (36.9 ± 2.3 % Inh), demonstrated stronger inhibition compared to UFH (10.8 ± 
2.0 % Inh) and RO-14 (19.2 ± 3.9 % Inh) (p <0.001). All agents demonstrated a 
significant inhibition of factor Xa at the 2.5 mg/kg dose (p <0.001); however, 
semuloparin (67.7 ± 1.8 % Inh), bemiparin (56.3 ± 8.1 % Inh), and RO-14 (59.3 ± 3.6 % 
Inh) were more efficacious compared to UFH (36.6 ± 1.8 % Inh) (p <0.05). All agents 
demonstrated a dose-dependent inhibition of factor Xa compared to control. 
 
3.2.6 Amidolytic anti-IIa assay 
The inhibition of thrombin in plasma from rats treated with UFH, enoxaparin, 
bemiparin, semuloparin, and RO-14 (SC) was evaluated using the anti-IIa assay (Figure 
68). Optical density changes were used to determine the percent inhibition of thrombin. 
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Figure 67. The inhibition of factor Xa by UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 as measured by the amidolytic anti-Xa assay after SC administration. Compared 
to baseline, semuloparin, enoxaparin, bemiparin, and RO-14 were able to significantly 
inhibit factor Xa at the 500 µg/kg dose (*p < 0.01). At both the 1.0 mg/kg and 2.5 mg/kg 
doses, all agents showed significant inhibition of factor Xa compared to baseline (*p < 
0.05 and *p < 0.001, respectively). The data represent the mean ± standard error of the 
mean (n=5). Statistical analysis of the data was performed using a one-way ANOVA 
followed by Tukey’s multiple comparison test. Exact p values for all statistically 
significant effects can be found in Table 69 of the appendix. 
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Figure 68. The inhibition of thrombin by UFH, enoxaparin, bemiparin, semuloparin, and 
RO-14 as measured by the amidolytic anti-IIa assay after SC administration. At the 0.5 
mg/kg dose, enoxaparin, bemiparin, and semuloparin significantly inhibited thrombin 
compared to baseline (*p < 0.05). At the 1.0 mg/kg dose, all agents, except RO-14, 
showed significant inhibition of thrombin compared to baseline (*p < 0.01). All agents 
demonstrated a strong inhibition of thrombin at the 2.5 mg/kg dose compared to baseline 
(*p < 0.01). The data represent the mean ± standard error of the mean (n=5). Statistical 
analysis of the data was performed using a one-way ANOVA followed by Tukey’s 
multiple comparison test. Exact p values for all statistically significant effects can be 
found in Table 70 of the appendix. 
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At the 500 µg/kg SC dose, enoxaparin (10.5 ± 1.1 % Inh), bemiparin (8.0 ± 0.9 % Inh), 
and semuloparin (8.1 ± 2.1 % Inh) produced a significant inhibition of thrombin 
compared to saline control (p < 0.05). UFH, enoxaparin, bemiparin, and semuloparin 
significantly inhibited thrombin at the 1.0 mg/kg dose (p < 0.01). UFH and bemiparin 
inhibited thrombin to a greater extent than RO-14 (p < 0.01). The inhibition of thrombin 
by enoxaparin was significantly greater than for UFH, semuloparin, and RO-14 (p < 
0.05). All agents significantly inhibited thrombin at 2.5 mg/kg doses (p <0.01). UFH had 
a significantly stronger anti-IIa effect (36.3 ± 1.8 % Inh) than all other agents at the 2.5 
mg/kg dose (p <0.05). Additionally, enoxaparin (27.0 ± 1.3 % Inh) significantly inhibited 
thrombin to a greater extent than that of semuloparin (12.8 ± 3.7 % Inh) and RO-14 (14.6 
± 3.4 % Inh) (p <0.05). In conclusion, ex vivo measurements of the clotting and 
antiprotease effects after SC administration of each agent showed a dose-dependent 
increase in response. After SC administration, the anti-Xa activity of the LMW and 
ULMW heparins appeared to be stronger than that of UFH. However, as determined by 
the TT (5 U Ca2+) and anti-IIa assays, UFH still produced a more profound inhibition of 
thrombin compared to all other agents.  
 
4. Pharmacokinetics and pharmacodynamics in primates 
 Non-human primates were used to study the pharmacodynamic and 
pharmacokinetic properties of various heparins in an in vivo model similar to humans. To 
elucidate how molecular weight and AT binding contribute to the pharmacodynamic and 
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pharmacokinetic properties of heparins, UFH, enoxaparin, and semuloparin were given to 
primates, both intravenously (IV) and subcutaneously (SC), at doses previously described 
in the ‘Materials and Methods’ section. The pharmacokinetic and pharmacodynamic 
profiles of UFH, enoxaparin, and semuloparin were assessed using a variety of clotting 
and amidolytic assays (results shown in Appendix 1). However, the evaluation of their 
anti-Xa activity using the anti-Xa and Heptest
®
 assays are shown below. The plasma 
samples were also evaluated for their ability to inhibit thrombin generation and thrombin 
activatable fibrinolysis inhibitor (TAFI) functional activity. Additionally, tissue factor 
pathway inhibitor (TFPI) antigen and functional levels in the plasma were determined.
 Concentration-response curves were made by supplementing UFH, enoxaparin, 
and semuloparin in pooled baseline primate plasma over a concentration range of 0 to 20 
µg/ml. Best-fit curves were made and the drug concentration in each primate blood 
sample was determined by extrapolation using the measured Heptest clotting times, 
percent inhibition of factor Xa or thrombin generation, or TFPI antigen and functional 
levels.  
 Results are presented as the mean ± SEM. A one-way ANOVA followed by a 
Dunnett post-hoc analysis was carried out to determine differences between treatment 
and control, and a two-way ANOVA followed by a Bonferroni–Dunn post-hoc analysis 
was carried out to determine whether differences between treatments were statistically 
significant. p-values < 0.05 were considered to be statistically significant. Compiled data 
for the individual experiments can be found in Tables 71 through 81. 
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4.1 Comparative pharmacodynamic investigation of heparin and its derivatives 
4.1.1 Intravenous administration 
 Figure 69 A depicts the Heptest
®
 time response curves after 250 µg/kg IV 
administration of UFH, enoxaparin, and semuloparin to primates. Semuloparin and 
enoxaparin significantly prolonged the clotting time compared to baseline at 1, 4, and 6 
hours (p < 0.001). Maximal effects for semuloparin (90.4 ± 2.5 sec) and enoxaparin (82.7 
± 4.5 sec) were seen at 1 hour post drug administration (PDA). UFH demonstrated 
significant anticoagulant effects only at 1 (53.4 ± 10.1 sec) and 4 (54.0 ± 15.8 sec) hours 
compared to baseline (p < 0.05). Semuloparin and enoxaparin were significantly more 
potent than UFH at 1 and 6 hours (p < 0.01). Moreover, as the clotting time of UFH 
returned to baseline at 28 hours PDA, semuloparin still significantly prolonged the 
clotting time compared to UFH (p < 0.05).  
 The plasma concentration-time courses for each agent as determined by effects on 
Heptest
®
 prolongation are shown in panel B. At 1 hour, the rank order of the plasma 
concentrations of each agent were enoxaparin > semuloparin > UFH, which were 
significantly different from one another (p < 0.001). Although the plasma concentrations 
of semuloparin (1.7 ± 0.13 µg/ml) and enoxaparin (2.7 ± 0.25 µg/ml) were significantly 
different from one another at 1 hour PDA, the anticoagulant effects, as measured by 
prolongation in the clotting time, were not.  
 The time courses of the amidolytic anti-Xa activity of UFH, enoxaparin, and 
semuloparin (250 µg/kg IV) are shown in Figure 70. In panel A, the anti-Xa activity 
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Figure 69. The pharmacodynamic effects of 250 µg/kg IV UFH, enoxaparin, and 
semuloparin administered to primates as measured by the Heptest
®
 assay. As seen in 
panel A, semuloparin and enoxaparin significantly prolonged the clotting time compared 
to baseline (*p < 0.001) at 1, 4, and 6 hours. UFH demonstrated significant anticoagulant 
effects at 1 and 4 hours compared to baseline (*p < 0.05). Enoxaparin and semuloparin 
were significantly more potent than UFH at 1 and 6 hours (p < 0.01). Moreover, 
semuloparin was still more potent than UFH at 28 hours (p < 0.05). Panel B shows the 
plasma concentration-time courses for each agent as determined by effects on Heptest
®
 
prolongation. At 1 hour, the plasma concentrations of each agent were significantly 
different from one another (p < 0.001). The data represent the mean ± SEM (n=6). 
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Figure 70. The pharmacodynamic effects of 250 µg/kg IV UFH, enoxaparin, and 
semuloparin administered to primates as measured by the anti-Xa assay. Semuloparin and 
enoxaparin significantly inhibited factor Xa activity compared to baseline (*p < 0.01) at 
1, 4, and 6 hours (A). At 28 hours post drug administration (PDA), anti-Xa activity was 
still measured in primates treated with semuloparin (*p < 0.01). UFH significantly 
inhibited (*p < 0.001) anti-Xa activity at only 1 hour PDA. Semuloparin had 
significantly more potent anti-Xa activity than UFH and enoxaparin at 1, 4, and 6 hours 
(p < 0.001). Enoxaparin was more potent than UFH at 4 and 6 hours (p < 0.05). Panel B 
shows the plasma concentration-time courses for each agent as determined by effects on 
anti-Xa activity. At 1 hour, the plasma concentrations of semuloparin and enoxaparin 
were significantly greater than UFH (p < 0.001). Moreover, semuloparin had 
significantly greater plasma concentrations than UFH at both 4 and 6 hours (p < 0.05). 
The data represent the mean ± SEM (n=6).  
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expressed as % inhibition at various time points is shown. At 1, 4 and 6 hours PDA, 
semuloparin and enoxaparin significantly inhibited factor Xa activity compared to 
baseline (p < 0.01). At 28 hours post drug administration (PDA), anti-Xa activity was 
still measurable in primates treated with semuloparin. The anti-Xa activity of UFH 
peaked (58.9 ± 5.9 % Inh) at 1 hour PDA (p < 0.001) and rapidly returned to near 
baseline levels at 4 hours. Peak anti-Xa activity for semuloparin (74.3 ± 3.2 % Inh) and 
enoxaparin (58.2 ± 5.0 % Inh) also occurred at 1 hour. For enoxaparin, anti-Xa activity 
decreased 2-fold between 1 and 4 hours, with a gradual decline towards baseline at 28 
hours. However, at 4 and 6 hours, enoxaparin was still able to inhibit factor Xa to a 
greater extent than UFH (p < 0.05). Although there was a slight decrease in the anti-Xa 
activity of semuloparin between the 1 and 4 hour time points, the anti-Xa activity 
remained substantially elevated over 28 hours. Consequently, semuloparin had 
significantly more anti-Xa activity compared to UFH and enoxaparin at 1, 4, and 6 hours 
(p < 0.001).  
 Panel B shows the plasma concentration-time courses for each agent as 
determined by their effects on anti-Xa activity. At 1 hour, the plasma concentrations of 
semuloparin (5.1 ± 0.76 µg/ml) and enoxaparin (4.5 ± 1.1 µg/ml) were significantly 
greater (p < 0.001) than that of UFH (1.98 ± 0.53 µg/ml). Moreover, semuloparin had 
significantly higher plasma concentrations than UFH at both 4 and 6 hours (p < 0.05). 
Overall, the plasma concentration of semuloparin remained elevated over the 28 hour 
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period which coincided with its elevated anti-Xa activity. Correspondingly, the sizeable 
decline in the plasma concentration of UFH as with other agents after 1 hour coincided 
with the decline in its antiprotease activity.  
 The time courses for the inhibition of thrombin generation, after IV administration 
of 250 µg/kg UFH, enoxaparin, and semuloparin, are shown in Figure 71A. At 1, 4, and 6 
hours PDA, UFH, enoxaparin, and semuloparin were equally effective at inhibiting 
thrombin generation compared to baseline (p < 0.01). The peak inhibition of IIa 
generation by UFH (82.2 ± 6.2 % Inh), enoxaparin (81.5 ± 6.4 % Inh), and semuloparin 
(75.7 ± 6.1 % Inh) was observed at 1 hour. After 1 hour, the % thrombin inhibition 
decreased in a similar fashion for all three agents. Although not statistical significant 
from baseline, all three agents had some remaining activity even at 28 hours PDA. No 
significant differences between agents were noted at any of the time points.  
 The plasma concentration-time courses for each agent as determined by effects on 
thrombin generation are shown in panel B. At 1 hour PDA, the plasma concentrations of 
enoxaparin (4.22 ± 0.91 µg/ml) and semuloparin (2.82 ± 0.71 µg/ml) were significantly 
greater (p < 0.001) than for UFH (0.72 ± 0.26 µg/ml). This data suggests that a lesser 
amount of circulating UFH in plasma is required to inhibit thrombin generation equal to 
enoxaparin and semuloparin. 
 The time course of the anticoagulant effects, as determined by the Heptest
®
 assay, 
after IV administration of 500 µg/kg UFH, enoxaparin, and semuloparin to primates is 
shown in Figure 72A. UFH (268.4 ± 20.2 sec) significantly prolonged the clotting time at 
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Figure 71. The effects of 250 µg/kg IV UFH, enoxaparin, and semuloparin administered 
to primates on thrombin generation. As seen in panel A, UFH, enoxaparin, and 
semuloparin significantly inhibited thrombin generation compared to baseline at 1, 4, and 
6 hours (*p < 0.01). No statistical differences between agents were observed. Panel B 
shows the plasma concentration-time courses for each agent as determined by effects on 
thrombin generation. At 1 hour, the plasma concentrations of enoxaparin and 
semuloparin were significantly greater than UFH (p < 0.001). The data represent the 
mean ± SEM (n=6). 
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Figure 72. The pharmacodynamic effects of 500 µg/kg IV UFH, enoxaparin, and 
semuloparin administered to primates as measured by the Heptest
®
 assay. As seen in 
panel A, semuloparin and enoxaparin significantly prolonged the clotting time compared 
to baseline (*p < 0.01) at all time points. UFH demonstrated significant anticoagulant 
effects at 1 hour compared to baseline, enoxaparin, and semuloparin (*p < 0.001). 
However, enoxaparin and semuloparin were significantly more potent than UFH at 4 and 
6 hours PDA (p < 0.01), while semuloparin had more potent anticoagulant effects 
compared to enoxaparin at 6 hours PDA (p < 0.05). Panel B shows the plasma 
concentration-time courses for each agent as determined by effects on Heptest 
prolongation. At 1 hour, the plasma concentration of UFH was significantly higher than 
enoxaparin and semuloparin (p < 0.001), while enoxaparin was higher than semuloparin 
(p < 0.01). Conversely, at 4 and 6 hours the plasma concentrations of semuloparin and 
enoxaparin were significantly higher than UFH (p < 0.05). The data represent the mean ± 
SEM (n=6). 
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1 hour compared to baseline, enoxaparin, and semuloparin (p < 0.001). Interestingly, 
increasing the dose of UFH by 2-fold produced a near 5-fold increase in the clotting time 
compared to the clotting time shown in Figure 72A. Again, the clotting time effect of 
UFH decreased dramatically after 1 hour and completely returned to baseline between 4 
and 6 hours. On the other hand, semuloparin and enoxaparin significantly prolonged the 
clotting time compared to baseline (p < 0.01) at all time points. Maximal activity for 
semuloparin (115.4 ± 3.6 % sec) and enoxaparin (116.9 ± 9.6 % sec) was observed at 1 
hour PDA. Compared to UFH, enoxaparin and semuloparin had significantly more 
activity at 4 and 6 hours PDA (p < 0.01), while semuloparin had significantly more 
activity compared to enoxaparin at 6 hours PDA (p < 0.05). 
 Panel B shows the plasma concentration-time courses for each agent as 
determined by effects on Heptest prolongation. At 1 hour, the plasma concentrations 
followed the rank order of UFH > enoxaparin > semuloparin, with each being 
significantly different from one another (p < 0.01) Conversely, at 4 and 6 hours, the 
plasma concentrations of semuloparin and enoxaparin were significantly higher than 
UFH  
 The time courses of the amidolytic anti-Xa activity of UFH, enoxaparin, and 
semuloparin (500 µg/kg IV) are shown in Figure 73. In panel A, the anti-Xa activity 
expressed as % inhibition at various time points is shown. UFH significantly inhibited (p 
< 0.001) factor Xa activity (84.6 ± 4.8 % Inh) at 1 hour PDA and then progressively 
declined to near baseline levels at subsequent tome points. Semuloparin, on the other 
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Figure 73. The pharmacodynamic effects of 500 µg/kg IV UFH, enoxaparin, and 
semuloparin administered to primates as measured by the anti-Xa assay. 
As seen in panel A, semuloparin and enoxaparin expressed significant anti-Xa activity 
compared to baseline at 1, 4, and 6 hours (*p < 0.01). Moreover, semuloparin still had 
significant anti-Xa activity at 28 hours (*p < 0.001) UFH demonstrated significant anti-
Xa activity at 1 hour compared to baseline (*p < 0.001). At 4 and 6 hours, the rank order 
potency for anti-Xa activity was semuloparin < enoxaparin < UFH (p < 0.001). At 28 
hours PDA, semuloparin still exhibited potent anti-Xa activity compared to UFH (p < 
0.05). Panel B shows the plasma concentration-time courses for each agent as determined 
by effects on anti-Xa activity. At 1, 4, and 6 hours PDA, the plasma concentrations of 
semuloparin and enoxaparin were significantly higher than UFH (p < 0.001). The data 
represent the mean ± SEM (n=6).  
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hand, expressed significant anti-Xa activity at all time points (p < 0.001) compared to 
baseline, and was significantly higher at 4 and 6 hours compared to enoxaparin and UFH 
(p <0.001) and at 28 hours compared to UFH alone (p < 0.05). Similarly, enoxaparin 
exhibited significant anti-Xa activity compared to baseline at 1, 4, and 6 hours (p < 
0.001) and had significantly more activity compared to UFH at 4 and 6 hours PDA (p < 
0.001).  
 Panel B shows the plasma concentration-time courses for each agent as 
determined by effects on anti-Xa activity. At 1, 4, and 6 hours PDA, the plasma 
concentrations of semuloparin and enoxaparin were significantly higher than UFH. Peak 
plasma concentrations for semuloparin (9.06 ± 0.95 µg/ml), enoxaparin (8.61 ± 1.07 
µg/ml), and UFH (7.07 ± 0.95 µg/ml) occurred at 1 hour PDA. 
 Figure 74A depicts the effects of 500 µg/kg IV UFH, enoxaparin, and 
semuloparin administered to primates on the time course of thrombin generation. As seen 
in panel A, all three agents dramatically inhibited the generation of thrombin nearly 
100% (p < 0.001). By 4 hours, the anti-thrombin activity of UFH decreased 3-fold (27.4 
± 5.2 % Inh), although it was still significant compare to baseline (p < 0.001). 
Conversely, the antithrombin generation activity of semuloparin and enoxaparin was still 
significantly elevated at 4 and 6 hours compared to baseline and UFH (p < 0.01). 
Moreover, semuloparin had significantly more anti-thrombin generation activity than 
enoxaparin at 6 hours PDA (p < 0.01). At 28 hours, semuloparin still exhibited residual 
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Figure 74. The effects of 500 µg/kg IV UFH, enoxaparin, and semuloparin administered 
to primates on thrombin generation. As seen in panel A, semuloparin and enoxaparin 
significantly inhibited thrombin generation compared to baseline at 1, 4, and 6 hours (*p 
< 0.01). Moreover, semuloparin still significantly inhibited thrombin generation at 28 
hours (*p < 0.01) UFH significantly inhibited thrombin generation at 1 and 4 hours 
compared to baseline (p < 0.001). At 4 and 6 hours PDA, the rank order potency was 
semuloparin, enoxaparin, and UFH (p < 0.01). At 28 hours, semuloparin still 
demonstrated a strong inhibition of thrombin compared to UFH (p < 0.01). Panel B 
shows the plasma concentration-time courses for each agent as determined by effects on 
thrombin generation. At 1 and 4 hours, the plasma concentrations of enoxaparin and 
semuloparin were significantly greater than UFH (p < 0.01). Semuloparin had a 
significantly higher plasma concentration compared to enoxaparin and UFH at both 4 and 
6 hours PDA (p < 0.01). The data represent the mean ± SEM (n=6). 
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anti-thrombin generation activity (37.2 ± 10.7 % Inh) that was significant from baseline 
and UFH (p < 0.01). 
  Panel B shows the plasma concentration-time courses for each agent as 
determined by effects on thrombin generation. The plasma concentration of semuloparin 
was significantly greater than UFH at 1 hour (p < 0.001) and both UFH and enoxaparin 
at 4 and 6 hours PDA (p < 0.01). Compared to UFH, higher levels of enoxaparin in the 
plasma were observed at both 1 and 4 hours (p < 0.01). 
 
4.1.2 Subcutaneous administration 
 Figure 75A depicts the Heptest
®
 time response curves after 1.0 mg/kg SC 
administration of UFH, enoxaparin, and semuloparin to primates. At 1, 4, and 6 hours 
PDA, all agents demonstrated significant anticoagulant effects compared to baseline. At 
the same time points, the rank order potency was semuloparin > enoxaparin > UFH, with 
all agents being significantly different from one another (p < 0.001). The maximal 
response for semuloparin (141.5 ± 2.5 sec), enoxaparin (109.2 ± 3.7 sec), and UFH (83.9 
± 3.4 sec) was observed at the 4 hour time point. Moreover, the maximal response for 
semuloparin was 1.7 and 1.3-fold greater than UFH and enoxaparin, respectively. After 4 
hours, all agents demonstrated similar gradual declines in their anticoagulant effects. 
However, at 28 hours PDA, semuloparin still exhibited significant anticoagulant effects 
compared to baseline, UFH, and enoxaparin (p < 0.001).  
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Figure 75. The pharmacodynamic effects of 1.0 mg/kg SC UFH, enoxaparin, and 
semuloparin administered to primates as measured by the Heptest
®
 assay. As seen in 
panel A, UFH, semuloparin, and enoxaparin demonstrated significant anticoagulant 
effects compared to baseline at 1, 4, and 6 hours (*p < 0.01). Moreover, semuloparin still 
exhibited significant anticoagulant effects at 28 hours (*p < 0.001). At 1, 4, and 6 hours 
PDA, the rank order potency was semuloparin < enoxaparin < UFH (p < 0.001). At 28 
hours PDA, semuloparin significantly prolonged the clotting time compared to 
enoxaparin and UFH (p < 0.001). Panel B shows the plasma concentration-time courses 
for each agent as determined by effects on Heptest prolongation. Semuloparin had 
significantly higher plasma concentrations at 1, 4, and 6 hours compared to enoxaparin 
and UFH (p < 0.001). The plasma concentrations of enoxaparin were significantly higher 
compared to UFH at 4 and 6 hours (p < 0.001). The data represent the mean ± SEM 
(n=6). 
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 Panel B shows the plasma concentration-time courses for each agent as 
determined by effects on Heptest prolongation. Semuloparin had significantly higher 
circulating plasma concentrations at 1, 4, and 6 hours compared to enoxaparin and UFH 
(p < 0.001); whereas, the plasma concentrations of enoxaparin were significantly higher 
compared to UFH at only 4 and 6 hours (p < 0.001). Peak plasma concentrations for 
semuloparin (5.03 ± 0.24 µg/ml), enoxaparin (3.99 ± 0.26 µg/ml), and UFH (1.29 ± 0.07 
µg/ml) coincide with their peak maximal responses described above. 
 The time courses of the amidolytic anti-Xa activity of UFH, enoxaparin, and 
semuloparin (1.0 mg/kg SC) are shown in Figure 76. In panel A, the anti-Xa activity 
expressed as % inhibition at various time points are shown. Semuloparin exhibited the 
most robust and prolonged response, with significant anti-Xa activity detected at all time 
points compared to baseline, enoxaparin, and UFH (p <0.001). Similarly, at 1, 4, and 6 
hours, enoxaparin significantly inhibited factor Xa activity compared to baseline (p < 
0.001). UFH was only able to significantly inhibit factor Xa activity at 4 and 6 hours 
PDA (p < 0.001). At 1, 4, and 6 hours after drug administration, enoxaparin produced a 
more potent (p < 0.001) anti-Xa response compared to UFH.  
 Panel B shows the plasma concentration-time courses for each agent as 
determined by effects on anti-Xa activity. At 1, 4 and 6 hours, the circulating plasma 
concentrations of semuloparin were dramatically higher than UFH and enoxaparin (p < 
0.01). Moreover, enoxaparin had a significantly higher circulating plasma concentration 
than UFH at 4 and 6 hours (p < 0.001). 
265 
 
0 4 8 12 16 20 24 28
0
20
40
60
80
100
UFH
Enoxaparin
Semuloparin
*
*
*
* *
*
*
*
*
Time (Hours)
%
 In
h
ib
it
io
n
0 4 8 12 16 20 24 28
0
15
30
45
60
75
UFH
Enoxaparin
Semuloparin
Time (Hours)

g
/m
l
A.
B.
Figure 76. The pharmacodynamic effects of 1.0 mg/kg SC UFH, enoxaparin, and 
semuloparin administered to primates as measured by the anti-Xa assay. Semuloparin and 
enoxaparin significantly inhibited factor Xa activity compared to baseline (*p < 0.001) at 
1, 4, and 6 hours (A). At 28 hours PDA, anti-Xa activity was still measured in primates 
treated with semuloparin (*p < 0.001). UFH significantly inhibited (*p < 0.001) anti-Xa 
activity at 4 and 6 hours PDA. Semuloparin had significantly more potent anti-Xa activity 
than UFH and enoxaparin at all time points (p < 0.001). Enoxaparin was more potent 
than UFH at 1, 4, and 6 hours (p < 0.001). Panel B shows the plasma concentration-time 
courses for each agent as determined by effects on anti-Xa activity. At 1, 4 and 6 hours, 
the plasma concentrations of semuloparin were significantly greater than UFH and 
enoxaparin (p < 0.001). Moreover, enoxaparin had a significantly greater plasma 
concentration than UFH at 4 and 6 hours (p < 0.001). The data represent the mean ± 
SEM (n=6).  
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 Figure 77 depicts the effects of 1.0 mg/kg SC UFH, enoxaparin, and semuloparin 
administered to primates on thrombin generation. As seen in panel A, all agents 
demonstrated a moderate inhibition of thrombin generation starting at 1 hour (p < 0.05). 
Maximal inhibition (> 90%) was seen at 4 hours for all agents (p <0.001), followed by a 
decline in the antithrombin generation response which was back to baseline by 28 hours. 
However, at 6 hours, the effects were still significant for all agents compared to baseline 
(p < 0.01). No significant differences between agents were observed at any of the time 
points. Panel B shows the plasma concentration-time courses for each agent as 
determined by effects on thrombin generation. Enoxaparin had a significantly higher 
circulating plasma concentration (3.39 ± 0.79 µg/ml) compared to UFH (0.15 ± 0.07 
µg/ml) at 1 hour PDA (p < 0.01). At 4 and 6 hours PDA, both the plasma concentrations 
of enoxaparin and semuloparin were significantly greater than that of UFH (p < 0.01). 
 Figure 78A depicts the Heptest
®
 time response curves after 2.5 mg/kg SC 
administration of enoxaparin and semuloparin to primates. UFH was not included in 
these studies because 2.5 mg/kg was deemed to be too high of a concentration to safely 
inject in primates for fear of bleeding. Enoxaparin significantly increased the clotting 
time starting at 1 hour (153.8 ± 33.1 sec) PDA (p < 0.001) and were near assay threshold 
at 6 hours (275.7 ± 16.9 sec), which was statistically significant compared to baseline and 
semuloparin (p < 0.001). However, the clotting times were considerably lower at 28 (42.1 
± 1.6 sec) and 32 hours (36.2 ± 1.5 sec). Similarly, the anti-clotting activity of 
semuloparin rose substantially at 1 hour (131.7 ± 17.3 sec) PDA (p < 0.001); although, 
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Figure 77. The effects of 1.0 mg/kg SC UFH, enoxaparin, and semuloparin administered 
to primates on thrombin generation. As seen in panel A, UFH, enoxaparin, and 
semuloparin significantly inhibited thrombin generation compared to baseline at 1, 4, and 
6 hours (*p < 0.05). No statistical differences between agents were observed. Panel B 
shows the plasma concentration-time courses for each agent as determined by effects on 
thrombin generation. Enoxaparin had a significantly higher plasma concentration 
compared to UFH at 1 hour PDA (p < 0.01). At 4 and 6 hours PDA, both the plasma 
concentrations of enoxaparin and semuloparin were significantly greater than UFH (p < 
0.01). The data represent the mean ± SEM (n=6). 
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Figure 78. The pharmacodynamic effects of 2.5 mg/kg SC enoxaparin and semuloparin 
administered to primates as measured by the Heptest
®
 assay. As seen in panel A, 
semuloparin and enoxaparin significantly prolonged the clotting time compared to 
allbaseline (*p < 0.01) at 1, 4, and 6 hours. Enoxaparin was significantly more effective 
than semuloparin at prolonging the clotting time at 6 hours (p < 0.001). Contrastingly, 
semuloparin still exhibited significant anticoagulant activity at 28 hours PDA (*p < 
0.01). Panel B shows the plasma concentration-time courses for each agent as determined 
by effects on Heptest prolongation. At 6 hours, the plasma concentration of enoxaparin 
was significantly higher than semuloparin (p < 0.001). The data represent the mean ± 
SEM (n=6).  
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the maximal response for semuloparin was at 4 hours (218 ± 9.1 sec) compared to 6 
hours for enoxaparin (p < 0.001). Compared to enoxaparin, the anticoagulant activity of 
semuloparin was still significantly above baseline even at 28 hours PDA (p < 0.01). 
 Panel B shows the plasma concentration-time courses for each agent as 
determined by effects on Heptest prolongation. At 6 hours, the circulating plasma 
concentration of enoxaparin (17.5 ± 1.3 µg/ml) was significantly higher (p < 0.001) than 
semuloparin (6.1 ± 0.6 µg/ml), which corresponded to the peak maximal anticoagulant 
response of enoxaparin. The time courses of the amidolytic anti-Xa activity of enoxaparin 
and semuloparin (2.5 mg/kg SC) are shown in Figure 79. In panel A, the anti-Xa activity 
expressed as % inhibition at various time points are shown. At all time points measured, 
semuloparin and enoxaparin had significant anti-Xa activity compared to baseline (p < 
0.001). At 1 hour, the anti-Xa activity of semuloparin was significantly greater than 
enoxaparin (p < 0.05). After 6 hours, the anti-Xa activity of semuloparin only slightly 
decreased and was still highly elevated at 28 and 32 hours PDA. Similar results were 
observed for enoxaparin. However, the anti-Xa activity of semuloparin was significantly 
greater than enoxaparin at both 28 and 32 hours PDA (p < 0.001). 
 Panel B shows the plasma concentration-time courses for each agent as 
determined by effects on anti-Xa activity. The plasma concentrations for enoxaparin and 
semuloparin were similar at 1 hour, though semuloparin had significantly greater anti-Xa 
activity than enoxaparin at the same time point. At 6 hours, the plasma concentration of 
enoxaparin (57.2 ± 7.8 µg/ml) was significantly higher (p < 0.01) than semuloparin (39.2 
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Figure 79. The pharmacodynamic effects of 2.5 mg/kg SC enoxaparin and semuloparin 
administered to primates as measured by the anti-Xa assay. Semuloparin and enoxaparin 
significantly inhibited factor Xa activity compared to baseline (*p < 0.01) at all time 
points (A). At 1, 28, and 32 hours PDA, semuloparin exhibited significantly more robust 
anti-Xa activity compared to enoxaparin (p < 0.01). Panel B shows the plasma 
concentration-time courses for each agent as determined by effects on anti-Xa activity. At 
6 hours, the plasma concentration of enoxaparin was significantly higher than 
semuloparin (p < 0.01). The data represent the mean ± SEM (n=6).  
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± 5.2 µg/ml). Interestingly, the plasma concentrations for both agents dramatically 
decreased to near baseline levels at 28 and 32 hours even though their anti-Xa activity 
was still substantially elevated compared to baseline. 
 Figure 80 depicts the effects of 2.5 mg/kg SC enoxaparin and semuloparin 
administered to primates on thrombin generation. As seen in panel A, the anti-thrombin 
activity of enoxaparin and semuloparin was near assay threshold up to 6 hours PDA (p < 
0.001) and still significantly greater than baseline until 28 hours (p < 0.01). No statistical 
differences between agents were observed. Panel B shows the plasma concentration-time 
courses for each agent as determined by effects on thrombin generation. At 1, 4, and 6 
hours, the plasma concentrations of semuloparin were significantly greater than the 
concentration of enoxaparin (p < 0.001). 
 
4.2 TFPI measurements in primate plasma  
 In addition to the anticoagulant and antiprotease effects produced by heparins in 
non-human primates, the modulation of the endogenous mediator tissue factor pathway 
inhibitor (TFPI) was also evaluated. The release of TFPI following IV (0.25 and 0.5 
mg/kg) and SC (1.0 and 2.5 mg/kg) administration of UFH, enoxaparin, and semuloparin 
to non-human primates was determined using both immunologic and functional assays on 
baseline and post-drug plasma samples. Baseline corrected concentrations of both 
immunologic (ng/ml) and functional TFPI (U/ml) levels are shown. 
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Figure 80. The effects of 2.5 mg/kg SC enoxaparin and semuloparin administered to 
primates on thrombin generation. As seen in panel A, enoxaparin, and semuloparin 
significantly inhibited thrombin generation compared to baseline at 1, 4, 6, and 28 hours 
PDA (*p < 0.01). No statistical differences between agents were observed. Panel B 
shows the plasma concentration-time courses for each agent as determined by effects on 
thrombin generation. At 1, 4, and 6 hours, the plasma concentrations of semuloparin were 
significantly greater than enoxaparin (p < 0.001). The data represent the mean ± SEM 
(n=6). 
273 
 
 
 
4.2.1 Intravenous administration 
 Figure 81 shows the immunologic and functional TFPI levels following IV 
administration of 250 µg/kg UFH, enoxaparin, and semuloparin to primates. At 1 and 4 
hours PDA (A), UFH, semuloparin, and enoxaparin significantly increased TFPI antigen 
levels compared to baseline (p < 0.001). UFH (71.9 ± 2.6 ng/ml) increased TFPI antigen 
levels 1.5 times more than enoxaparin (46.1 ± 3.8 ng/ml) and semuloparin (42.7 ± 4.0 
ng/ml) at 1 hour PDA (p < 0.001). Panel B shows the effects of each agent on functional 
TFPI levels. At 1, 4, and 6 hours PDA, semuloparin and enoxaparin significantly 
increased functional TFPI levels compared to baseline (p < 0.05). UFH demonstrated 
similar results to that of semuloparin and enoxaparin; however, the results were not 
considered statistically significant from either agent. No significant differences between 
agents were observed. 
 The immunologic and functional TFPI levels following IV administration of 500 
µg/kg UFH, enoxaparin, and semuloparin to primates are shown in Figure 82. As seen in 
panel A, TFPI antigen levels peaked at 1 hour PDA for UFH (110.4 ± 6.0 ng/ml), 
enoxaparin (61.3 ± 3.4 ng/ml), and semuloparin (52.7 ± 1.6 ng/ml). For all agents, the 
TFPI antigen levels were still significantly elevated at 4 and 6 hour compared to baseline 
(p < 0.01). UFH significantly increased TFPI antigen levels to a greater extent than 
enoxaparin and semuloparin at 1 and 4 hours PDA (p < 0.001). By 28 hours, TFPI 
antigen levels were near baseline levels for all agents. Panel B shows the effects of each 
agent on functional TFPI levels. At 1 and 4 hours PDA, all three agents significantly 
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Figure 81. Immunologic and functional TFPI levels following IV administration of 250 
µg/kg UFH, enoxaparin, and semuloparin to primates. UFH, semuloparin, enoxaparin 
significantly increased TFPI antigen levels compared to baseline (*p < 0.001) at 1 and 4 
hours (A). UFH was significantly more potent than enoxaparin and semuloparin at 
increasing TFPI antigen levels at 1 hour PDA (p < 0.001). Panel B shows the effects of 
each agent on functional TFPI levels. At 1, 4, and 6 hours PDA, semuloparin and 
enoxaparin significantly increased functional TFPI levels compared to baseline (*p < 
0.05). No significant differences between agents were observed. The data represent the 
mean ± SEM (n=6).  
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Figure 82. Immunologic and functional TFPI levels following IV administration of 500 
µg/kg UFH, enoxaparin, and semuloparin to primates. UFH, semuloparin, enoxaparin 
significantly increased TFPI antigen levels compared to baseline (*p < 0.01) at 1, 4, and 
6 hours (A). UFH was significantly more potent than enoxaparin and semuloparin at 
increasing TFPI antigen levels at 1 and 4 hours PDA (p < 0.001). Panel B shows the 
effects of each agent on functional TFPI levels. At 1 and 4 hours PDA, all three agents 
significantly increased functional TFPI levels compared to baseline (*p < 0.01). At 1 
hour, UFH was significantly increased functional TFPI levels compared to semuloparin 
and enoxaparin (p < 0.001). Moreover, semuloparin significantly increased functional 
TFPI levels compared to enoxaparin at both 1 and 4 hours PDA (p < 0.05). The data 
represent the mean ± SEM (n=6).  
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increased functional TFPI levels compared to baseline (p < 0.01). At 1 hour, UFH (1.24 
± 6.0 U/ml) significantly increased (p < 0.001) functional TFPI levels to a greater extent 
compared to semuloparin (0.90 ± 0.05 U/ml) and enoxaparin (0.71 ± 0.03 U/ml). 
Moreover, semuloparin was able to significantly increase functional TFPI levels to a 
greater extent than that of enoxaparin at both 1 and 4 hours PDA (p < 0.05). These results 
indicate that UFH, enoxaparin, and semuloparin are able to dose-dependently increase 
TFPI antigen and functional levels after IV administration. However, the increase in TFPI 
levels was not directly proportional to the increase in dose. With a 2-fold increase in 
dose, UFH, enoxaparin, and semuloparin produced a 1.5, 1.3, and 1.2-fold increase, 
respectively, in TFPI antigen levels at 1 hour PDA, which corresponded to the peak 
maximal response at both concentrations. The increase in dose did, however, produce a 
more sustained increase in TFPI antigen levels up to 6 hours PDA. TFPI functional levels 
followed the same trend at the 1 hour time point; conversely, the increase in dose did not 
produce the same sustained increase in TFPI functional levels as that seen with the 
antigen levels.  
 
4.2.2 Subcutaneous administration 
 The immunologic and functional TFPI levels following SC administration of 1.0 
mg/kg UFH, enoxaparin, and semuloparin to primates are shown in Figure 83. All three 
agents significantly increased TFPI antigen levels compared to baseline (p < 0.05) at 1, 4, 
and 6 hours (A). No significant differences between agents were observed.  
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Figure 83. Immunologic and functional TFPI levels following SC administration of 1.0 
mg/kg UFH, enoxaparin, and semuloparin to primates. UFH, semuloparin, enoxaparin 
significantly increased TFPI antigen levels compared to baseline (*p < 0.05) at 1, 4, and 
6 hours (A). No significant differences between agents were observed. Panel B shows the 
effects of each agent on functional TFPI levels. At 1, 4, and 6 hours PDA, UFH and 
semuloparin significantly increased functional TFPI levels compared to baseline (*p < 
0.05). Enoxaparin significantly increased functional TFPI levels at only 1 and 4 hours (p 
< 0.001). At 4 and 6 hours PDA, UFH significantly increased functional TFPI levels to a 
greater extent than enoxaparin (p < 0.05). Moreover, semuloparin significantly increased 
functional TFPI levels more so than enoxaparin at 4 hours PDA (p < 0.05). The data 
represent the mean ± SEM (n=6).  
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 Panel B shows the effects of each agent on functional TFPI levels. UFH and 
semuloparin similarly increased functional TFPI levels compared to baseline at 1, 4, and 
6 hours PDA (p < 0.05). The increase in functional TFPI levels after SC administration 
of enoxaparin was only significant over baseline at 1 and 4 hours (p < 0.001). The 
increase in functional TFPI levels produced by UFH was significantly greater than 
enoxaparin at 4 and 6 hours PDA (p < 0.05). Moreover, semuloparin significantly 
increased functional TFPI levels more so than enoxaparin at 4 hours PDA (p < 0.05).
 Figure 84 shows the immunologic and functional TFPI levels following SC 
administration of 2.5 mg/kg enoxaparin and semuloparin to primates. Compared to 
baseline (A), semuloparin and enoxaparin produced a sharp increase in TFPI antigen 
levels (p < 0.001) at 1 hour (56.0 ± 7.5 ng/ml and 70.1 ± 5.8 ng/ml, respectively) and 
maximal levels at 4 hours (68.3 ± 2.7 ng/ml and 80.0 ± 6.7 ng/ml, respectively). 
Immunologic TFPI levels started to decrease at 6 hours but were still considered 
significant from baseline (p < 0.001) for both agents. No significant differences between 
agents were observed. 
 Panel B shows the effects of each agent on functional TFPI levels. At 1, 4, and 6 
hours PDA, semuloparin and enoxaparin significantly increased functional TFPI levels 
compared to baseline (p < 0.001); however, the increase in functional TFPI levels by 
enoxaparin were significantly higher than those of semuloparin at 4 and 6 hours PDA (p 
< 0.01). 
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Figure 84. Immunologic and functional TFPI levels following SC administration of 2.5 
mg/kg enoxaparin and semuloparin to primates. Semuloparin and enoxaparin 
significantly increased TFPI antigen levels compared to baseline (*p < 0.001) at 1, 4, and 
6 1  hours (A). No significant differences between agents were observed. Panel B shows 
the effects of each agent on functional TFPI levels. At 1, 4, and 6 hours PDA, 
semuloparin and enoxaparin significantly increased functional TFPI levels compared to 
baseline (*p < 0.001). At 4 and 6 hours PDA, enoxaparin significantly increased 
functional TFPI levels compared to semuloparin (p < 0.01). The data represent the mean 
± SEM (n=6).  
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 These results indicate that enoxaparin and semuloparin are able to dose-
dependently increase TFPI antigen and functional levels after SC administration. The 
increase in TFPI antigen levels was directly proportional to the increase in dose after SC 
administration of enoxaparin at 1, 4, and 6 hours PDA. Interestingly, increasing the SC 
dose of enoxaparin disproportionally increased the amount of functioning TFPI levels in 
the plasma. After a 2-fold increase in dose, at 4 and 6 hours PDA, enoxaparin produced a 
3- and 5- fold increase, respectively, in the TFPI functional levels. Conversely, while 
semuloparin did show a dose-dependent increase in both TFPI antigen and 
functional.levels at 1, 4, and 6 hours PDA, the increase was not directly proportional to 
the increase in dose.  
 
4.3 Effects on TAFI activation  
 Plasma samples taken from non-human primates treated with UFH, enoxaparin, 
and semuloparin either SC or IV, were evaluated for their ability to inhibit TAFI to 
TAFIa. Functional TAFI activity was determined using the modified Pefakit

 TAFI assay 
(Pentapharm, Inc, Basel Switzerland) as described in the ‘Materials and Methods’ 
section. Additionally, TAFI generation was measured in normal monkey plasma (NMP) 
supplemented with UFH, enoxaparin, and semuloparin at concentration ranges of 0 to 10 
µg/ml for UFH and 0 to 100 µg/ml for enoxaparin and semuloparin. Prior to all studies, 
the accuracy of the Pefakit

 TAFI assay in NMP was validated (see Materials and 
Methods), as the method was developed for use in human plasma. Statistically significant 
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differences between treatment and control for each agent were determined by one-way 
ANOVA followed by Dunnett’s multiple comparison test. Statistical differences between 
agents were determined using a two-way ANOVA followed by Bonferroni’s multiple 
comparison test. Results were considered to be statistically significant if p <0.05. 
 
4.3.1 Validation studies 
 Figure 85A shows the TAFI activation in normal monkey plasma. The calibration 
curve was constructed by diluting the NMP 50, 25, 12.5, 6.25, and 3.12% with 5% 
albumin. The change in OD was measured at 5 and 30 minutes. The change in OD at 5 
minutes was not sufficient to calculate TAFI activation; therefore, the results were given 
as the change in OD after 30 minutes. Functional TAFI activity was detectable and the 
calibration curve was linear with an R
2
 value greater than 0.99.  
 
The effect of UFH, enoxaparin, and semuloparin on the inhibition of the 
conversion of TAFI to TAFIa when supplemented in NMP is shown in Figure 85B. 
Results are expressed in terms of IC50 (µg/ml) values. All three agents were able to 
inhibit TAFI generation. The inhibition of TAFI generation by UFH (3.0 ± 0.05 µg/ml) 
was significantly (p < 0.001) more potent than both enoxaparin (5.3 ± 0.03 µg/ml) and 
semuloparin (5.8 ± 0.03). Enoxaparin was significantly more potent than semuloparin (p 
< 0.001). 
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Figure 85A. TAFI activation in normal monkey plasma (NMP). The change in OD for the 
non-human primate plasma was calculated after 30 min. The calibration curve was 
relatively linear with an R
2
 value greater than 0.99. 
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Figure 85B. The effect of UFH, enoxaparin, and semuloparin on the inhibition of TAFI 
activation when supplemented in NMP. All three agents were able to inhibit TAFI 
activation, with UFH being significantly more potent than both enoxaparin and 
semuloparin (*p < 0.001). Enoxaparin was significantly more potent than semuloparin 
(+p < 0.001). The data represent the mean ± SEM (n=3). 
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4.3.2 Ex vivo analysis using non-human primate plasma 
Figure 86 shows the effects of 250 µg/kg IV UFH, enoxaparin, and semuloparin 
administered to primates on the inhibition of TAFI generation. UFH and semuloparin 
significantly inhibited TAFI activation at 1 and 4 hours compared to baseline NMP (p < 
0.05). Enoxaparin produced a modest inhibition of TAFI generation starting at 1 hour 
PDA (20.0 ± 9.2 % Inh); however, no statistical significance was reached when compared 
to baseline. Inhibition of TAFI activation by UFH was significantly greater than for 
enoxaparin at both 1 and 4 hours (p < 0.05). Peak inhibition for UFH (58.5 ± 11.9 % Inh) 
and enoxaparin (20.0 ± 9.2 % Inh) was at 1 hour PDA. The inhibition of TAFI activation 
by semuloparin peaked at 4 hours PDA (40.0 ± 14.8 % Inh). However, semuloparin had 
high inhibitory activity starting at 1 hour (33.5 ± 8.8 % Inh) compared to baseline. 
The effects of 500 µg/kg IV UFH, enoxaparin, and semuloparin administered to 
primates on TAFI activation inhibition is shown in Figure 87. UFH (72.9 ± 14.6 % Inh) 
and enoxaparin (39.2 ± 13.6 % Inh) significantly inhibited TAFI activation at 1 hour 
PDA compared to baseline NMP (p < 0.01). UFH still produced a moderate inhibition of 
TAFI activation at 4 hours PDA (45.8 ± 23.2 % Inh), although it was not considered to be 
statistically significant. Semuloparin exhibited significant inhibition of TAFI activation at 
1, 4, and 6 hours PDA compared to baseline NMP (p < 0.05). Inhibition of TAFI 
generation by UFH was significantly greater than for semuloparin at 1 hour PDA (p < 
0.05). Peak inhibition of TAFI activity by semuloparin occurred at 4 hours PDA (54.5 ± 
6.0 % Inh).  
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Figure 86. The effects of 250 µg/kg IV UFH, enoxaparin, and semuloparin administered 
to primates on the inhibition of TAFI activation. UFH and semuloparin significantly 
inhibited TAFI activation at 1 and 4 hours compared to baseline NMP (*p < 0.05). 
Inhibition of TAFI activation by UFH was significantly greater than for enoxaparin at 
both 1 and 4 hours (p < 0.05). The data represent the mean ± SEM (n=4-5).  
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Figure 87. The effects of 500 µg/kg IV UFH, enoxaparin, and semuloparin administered 
to primates on the inhibition of TAFI activation. UFH and enoxaparin significantly 
inhibited TAFI activation at 1 hour PDA compared to baseline NMP (*p < 0.01). 
Semuloparin exhibited significant inhibition of TAFI activation at 1, 4, and 6 hours PDA 
compared to baseline NMP (p < 0.05). Inhibition of TAFI activation by UFH was 
significantly greater than for semuloparin at 1 hour PDA (p < 0.05). The data represent 
the mean ± SEM (n=3-5).  
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Figure 88 shows the effects of 1.0 mg/kg SC UFH, enoxaparin, and semuloparin 
administered to primates on TAFI activation inhibition. All three agents similarly 
inhibited TAFI activation at the lowest SC dose. Compared to baseline NMP, UFH and 
enoxaparin significantly inhibited TAFI activation at 4 and 6 hours PDA (p < 0.01). 
Inhibition of TAFI activation at 4 and 6 hours by semuloparin was similar to the 
inhibition by UFH and enoxaparin; however, no statistical significance was observed. No 
differences between agents were observed. Peak inhibition of TAFI activation by UFH 
(46.9 ± 7.0 % Inh), semuloparin (44.4 ± 10.8 % Inh), and enoxaparin (39.0 ± 10.4 % Inh) 
occurred at 4 hours PDA.  
The effects of 2.5 mg/kg SC enoxaparin and semuloparin administered to primates 
on the inhibition of TAFI activation are shown in Figure 89. As previously noted, UFH 
was not included at the highest SC dose. Semuloparin significantly inhibited TAFI 
activation at 4, 6, and 28 hours PDA compared to baseline NMP (p < 0.05). Peak 
inhibition of TAFI activation by semuloparin occurred at 6 hours PDA (57.0 ± 13.1 % 
Inh). A dose dependent increase in the inhibition of TAFI activation by semuloparin after 
SC administration was noted. Compared to the 1 mg/kg dose, the higher SC dose of 
semuloparin still produced significant inhibition of TAFI activation at 28 hours PDA 
(32.6 ± 7.8 % Inh). Compared to baseline NMP, enoxaparin significantly inhibited (p < 
0.01) TAFI activation at 4 and 6 hours (37.6 ± 8.1 % Inh and 48.0 ± 5.6 % Inh, 
respectively). No differences between agents were observed. 
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Figure 88. The effects of 1.0 mg/kg SC UFH, enoxaparin, and semuloparin administered 
to primates on the inhibition of TAFI activation. UFH and enoxaparin significantly 
inhibited TAFI activation at 4 and 6 hours PDA compared to baseline NMP (*p < 0.01). 
Inhibition of TAFI activation at 4 and 6 hours by semuloparin was similar to the 
inhibition by UFH and enoxaparin; however, no statistical significance was observed. No 
differences between agents were observed. The data represent the mean ± SEM (n = 4-6).  
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Figure 89. The effects of 2.5 mg/kg SC enoxaparin and semuloparin administered to 
primates on the inhibition of TAFI activation. Semuloparin significantly inhibited TAFI 
activation at 4, 6, and 28 hours PDA compared to baseline NMP (*p < 0.05). Enoxaparin 
significantly inhibited TAFI activation at only 4 and 6 hours PDA compared to baseline 
NMP (*p < 0.01). No differences between agents were observed. The data represent the 
mean ± SEM (n = 3-6).  
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These studies demonstrate that UFH, enoxaparin, and semuloparin are able to 
inhibit the conversion of TAFI to TAFIa in vivo after both SC and IV administration. The 
inhibition of TAFI activation after IV administration appeared to be stronger for UFH at 
1 hour PDA compared to enoxaparin and semuloparin. Differences between drugs were 
negligible after SC administration.  
 
4.4 Comparative pharmacokinetic investigation of heparin and its derivatives 
 The extrapolated plasma concentrations (described above) were used to calculate 
values for pharmacokinetic parameters (Simoneau, 1992). The elimination rate constant 
(ke) was determined by calculating the slope of the linear portion of the natural log 
concentration vs. time curve. Elimination Half-life (T1/2) was calculated as 0.693/ke. Area 
under the plasma concentration time curve (AUC0 - ∞) was determined from the 
concentration vs. time curve using the trapezoidal rule and was extrapolated to infinity by 
adding a value equal to the last measured concentration divided by the slope of the 
elimination curve. Systemic clearance (Clsys) was calculated as dose/AUC. Volume of 
distribution (Vd) was calculated as Clsys/ke.  
 
4.4.1 Intravenous administration 
 The estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the Heptest
®
 assay after IV administration of 250 µg/ml 
heparins are shown in Figure 90. At the indicated dose, no differences in T1/2 were noted 
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Figure 90. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the Heptest
®
 assay after IV administration of 250 µg/kg 
heparins. No differences in half-life were noted between each agent (A). In panel B, 
enoxaparin and semuloparin demonstrated significantly larger AUCs compared to UFH 
(*, # p < 0.05). In panel C, UFH exhibited an increased plasma clearance (CLsys) 
compared to enoxaparin and semuloparin (p < 0.05). No differences in volume of 
distribution (Vd) were noted between each agent (D) The data represent the mean ± SEM 
(n=6). 
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between each agent when determined by the Heptest
®
 assay (A). Enoxaparin (10.5 ± 0.6 
µg*hr/ml) and semuloparin (9.0 ± 1.0 µg*hr/ml) demonstrated significantly larger (p < 
0.05) AUCs (B) compared to UFH (5.9 ± 0.6 µg*hr/ml), whereas UFH exhibited a nearly 
2-fold increase in CLsys (C) compared to the other agents (p < 0.05). Although UFH 
appeared to have a larger Vd, no significant differences were noted between each agent 
(D). Figure 91 shows the estimation of pharmacokinetic parameters calculated from 
plasma concentration-time curves using the anti-Xa assay after IV administration of 250 
µg/ml heparins. Similar to the Heptest
®
 results, no differences in T1/2 were noted between 
each agent at the indicated dose when determined by the anti-Xa assay (A). However, a 
great deal of variation was noted for the AUC (B). Semuloparin had an AUC that was 
nearly 2-fold larger than that of enoxaparin (p < 0.001) and 7-fold larger than that of 
UFH (p < 0.001). Similarly, enoxaparin (22.0 ± 2.5 µg*hr/ml) demonstrated a 
significantly larger (p < 0.001) AUC compared to UFH (5.6 ± 1.2 µg*hr/ml). 
Conversely, the CLsys rate (C) of UFH was 9-fold higher than that of semuloparin (p < 
0.001) and 4.7-fold higher than that of enoxaparin (p < 0.01). Additionally, the Vd (D) of 
UFH (480.83 ± 103.66 ml/kg) was significantly larger (p < 0.01) than for enoxaparin 
(156.2 ± 12.4 ml/kg) and semuloparin (66.6 ± 8.9 ml/kg). 
The estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the TGA assay after IV administration of 250 µg/ml 
heparins are shown in Figure 92. As determined by the TGA assay, UFH (4.97 ± 0.53 
hrs) had a significantly longer T1/2 (A) than enoxaparin (2.64 ± 0.6 hrs) and semuloparin 
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Figure 91. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the anti-Xa assay after IV administration of 250 µg/kg 
heparins. No differences in half-life were noted between each agent (A). In panel B, 
enoxaparin demonstrated a significantly larger AUC compared to UFH (*p < 0.001). The 
AUC for semuloparin was significantly larger than UFH and enoxaparin (# p < 0.001). In 
panel C and D, UFH exhibited an increased CLsys and larger Vd compared to enoxaparin 
and semuloparin (p < 0.01). The data represent the mean ± SEM (n=6). 
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Figure 92. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the TGA assay after IV administration of 250 µg/kg 
heparins. UFH had a significantly longer half-life than enoxaparin and semuloparin (* p 
< 0.05). In panel B, enoxaparin and semuloparin demonstrated significantly larger AUCs 
compared to UFH (*,# p < 0.05). In panels C and D, UFH exhibited an increased CLsys 
and larger Vd compared to enoxaparin and semuloparin (p < 0.01). The data represent the 
mean ± SEM (n=6). 
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(1.7 ± 0.51 hrs) (p < 0.05). Interestingly, the AUCs (B) for enoxaparin (19.3 ± 2.7 
µg*hr/ml) and semuloparin (13.4 ± 1.3 µg*hr/ml) were dramatically larger (p < 0.05) 
compared to UFH (3.1 ± 0.99 µg*hr/ml). UFH exhibited a CLsys rate (C) that was 
increased 7-fold over enoxaparin and semuloparin (p < 0.01). The Vd (D) for UFH 
(655.6 ± 134.3 ml/kg) was 13 times larger than that of the other agents (p < 0.01). Only 
T1/2 and AUC were calculated for the immunologic and functional TFPI assays. At a dose 
of 250 µg/kg IV, no differences in the pharmacokinetic parameters between UFH, 
enoxaparin, and semuloparin were noted in either assay (Figure 93). Figure 94 shows the 
estimation of pharmacokinetic parameters calculated from plasma concentration-time 
curves using the Heptest
®
 assay after IV administration of 500 µg/ml heparins. 
Intravenous administration of enoxaparin resulted in a T1/2 of 8.2 ± 0.9 hrs, which was 
significantly longer (p < 0.05) than that of UFH (5.7 ± 0.3 hrs) as measured by Heptest 
prolongation (A).  No other significantly different pharmacokinetic parameters were 
observed between the drugs when measured by the Heptest assay (B, C, and D). 
 The estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the anti-Xa assay after IV administration of 500 µg/ml 
heparins are shown in Figure 95. Similar to the results obtained at the lower IV dose, no 
differences in T1/2 between agents were observed (A). When measuring anti-Xa activity, 
the AUC (B) for semuloparin and enoxaparin was 3.5- and 2.5-fold larger, respectively 
compared to the AUC of UFH (p < 0.001). Conversely, UFH exhibited an increased 
CLsys (C) and larger Vd (D) compared to semuloparin and enoxaparin (p < 0.001).
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Figure 93. Estimation of pharmacokinetic parameters calculated from TFPI immunologic 
and functional concentration-time curves after IV administration of 250 µg/kg heparins. 
No significant differences in any of the pharmacokinetic parameters were noted. The data 
represent the mean ± SEM (n=6). 
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Figure 94 Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the Heptest
®
 assay after IV administration of 500 µg/kg 
heparins. Enoxaparin had a significantly longer half-life than UFH (* p < 0.05). No 
significant differences were observed for AUC, Clsys, and Vd between the different 
agents. The data represent the mean ± SEM (n=6). 
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Figure 95. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the anti-Xa assay after IV administration of 500 µg/kg 
heparins. No differences in half-life between agents were observed (A). In panel B, 
semuloparin and enoxaparin demonstrated a significantly larger AUC compared to UFH 
(*, # p < 0.001). In panels C and D, UFH exhibited an increased CLsys and larger Vd 
compared to semuloparin and enoxaparin (* p < 0.001). The data represent the mean ± 
SEM (n=6). 
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 Figure 96 shows the estimation of pharmacokinetic parameters calculated from 
plasma concentration-time curves using the TGA assay after IV administration of 500 
µg/ml heparins. No differences in T1/2 were noted (A). The AUC for semuloparin was 32 
times greater than that of UFH (3.30 ± 0.07 µg*hr/ml). The CLsys for UFH (C) was 
increased 10-fold over enoxaparin and 23-fold over semuloparin (p < 0.001). UFH also 
had a significantly larger Vd compared to all other agents (p < 0.001). The estimation of 
pharmacokinetic parameters calculated from TFPI immunologic and functional 
concentration-time curves after IV administration of 500 µg/ml heparins are shown in 
Figure 97. No significant differences in T1/2 and AUC were observed between agents for 
the TFPI immunological effects (A and B). In the functional TFPI assay, compared to 
enoxaparin, semuloparin exhibited a T1/2 that was 2 times longer (p < 0.05) and an AUC 
nearly 3 times larger (p < 0.01). 
 
4.4.2 Subcutaneous administration 
After SC administration (1.0 mg/kg), semuloparin demonstrated a longer T1/2 (6.1 
± 0.2 hrs) and significantly increased exposure in terms of AUC (70.1 ± 1.5 µg*hr/ml) 
compared to UFH and enoxaparin (p < 0.05), as determined by the Heptest assay (Figure 
98). Similarly, enoxaparin, when compared to UFH, exhibited an approximate 1.5-fold 
longer T1/2 and a 3-fold larger AUC (p < 0.01) in the same assay (A and B). UFH, on the 
other hand, had an increased plasma Clsys rate (62.2 ± 4.2 ml/kg*hr) and a larger Vd 
(320.0 ± 28.9 ml/kg) compared to enoxaparin and semuloparin (C and D) (p < 0.001). 
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Figure 96. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the TGA assay after IV administration of 500 µg/kg 
heparins. No differences in half-life were noted A). In panel B, semuloparin 
demonstrated a significantly larger AUC compared to UFH (* p < 0.01). In panels C and 
D, UFH exhibited an increased clearance and a larger Vd compared to enoxaparin and 
semuloparin (p < 0.001). The data represent the mean ± SEM (n=6). 
300 
 
UFH Enoxaparin Semuloparin
0
3
6
9
12
15
H
a
lf
-L
if
e
; 
H
rs
UFH Enoxaparin Semuloparin
0
200
400
600
800
1000
A
U
C
; 
(n
g
*h
rs
)/
m
l
UFH Enoxaparin Semuloparin
0
5
10
15
20
25
*
H
a
lf
-L
if
e
; 
H
rs
UFH Enoxaparin Semuloparin
0
5
10
15
20
25
*
A
U
C
; 
(U
*h
rs
)/
m
l
A. B.
C. D.
TFPI Antigen
TFPI Functional
 
Figure 97. Estimation of pharmacokinetic parameters calculated from TFPI immunologic 
and functional concentration-time curves after IV administration of 500 µg/kg heparins. 
In panels A and B, no differences in half-life and AUC were observed between agents for 
the TFPI immunological effects. In panels C and D, semuloparin exhibited a longer half-
life and larger AUC compared to enoxaparin (p < 0.01). The data represent the mean ± 
SEM (n=6). 
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Figure 98. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the Heptest
®
 assay after SC administration of 1.0 mg/kg 
heparins. Semuloparin had a significantly longer (# p < 0.05) half-life compared to 
enoxaparin and UFH (A). Similarly, enoxaparin demonstrated a significantly longer (*p 
< 0.05) half-life compared to UFH. In panel B, semuloparin demonstrated a significantly 
larger AUC compared to UFH and enoxaparin (#p < 0.001). Enoxaparin displayed a 
significantly larger (*p < 0.001) AUC compared to UFH (B). In panels C and D, UFH 
exhibited an increased CLsys and larger Vd compared to enoxaparin and semuloparin (p 
< 0.001). The data represent the mean ± SEM (n=6). 
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 As measured by anti-Xa activity, the AUC (Figure 99) for semuloparin (1.0 
mg/kg SC) was 396.6 ± 38.2 µg*hr/ml, which was significantly greater than that of 
enoxaparin (206.1 ± 27.8 µg*hr/ml) and UFH (10.1 ± 3.7 µg*hr/ml) (p < 0.001). The 
AUC for enoxaparin (1.0 mg/kg SC) was also significantly greater than UFH (p < 0.001). 
Conversely, UFH (1.0 mg/kg SC) had a Clsys rate of 236.5 ± 91.3 ml/kg*hr and a Vd of 
1676.0 ± 761.3 ml/kg (C and D); both were significantly greater than the Clsys rate and 
Vd for enoxaparin and semuloparin (p < 0.01). Figure 100 shows the estimation of 
pharmacokinetic parameters calculated from plasma concentration-time curves using the 
TGA assay after SC administration of 1.0 mg/ml heparins. Enoxaparin (6.0 ± 0.5 hrs) had 
a significantly longer T1/2 (A) compared to UFH (3.5 ± .04 hrs) and semuloparin (3.5 ± 
0.6 hrs) (p < 0.05). The AUC for semuloparin was 121.9 ± 8.9 µg*hr/ml, which was 
significantly greater than that of enoxaparin (75.4 ± 7.4 µg*hr/ml) and UFH (20.9 ± 1.2 
µg*hr/ml) (p < 0.01). The AUC for enoxaparin was also significantly greater than that of 
UFH (p < 0.01). In panel C, UFH exhibited an increased CLsys rate (48.1 ± 2.8 
ml/kg*hr) compared to enoxaparin (13.7 ± 1.4 ml/kg*hr) and semuloparin (8.3 ± 0.6 
ml/kg*hr) (p < 0.001). The Vd (D) for UFH was 220.5 ± 20.7 ml/kg which was 5-fold 
greater than the Vd for semuloparin and 2-fold greater than that of enoxaparin (p <0.01). 
Moreover, the Vd for enoxaparin (115.3 ± 8.7 ml/kg) was considered significantly greater 
(p < 0.05) than semuloparin (44.5 ± 9.8 ml/kg). 
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Figure 99. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the anti-Xa assay after SC administration of 1.0 mg/kg 
heparins. No differences in half-life between each agent were observed (A). In panel B, 
semuloparin demonstrated a significantly larger AUC compared to UFH and enoxaparin 
(#p < 0.001). Enoxaparin displayed a significantly larger (*p < 0.001) AUC compared to 
UFH (B). In panels C and D, UFH exhibited an increased CLsys and larger Vd compared 
to enoxaparin and semuloparin (p < 0.01). The data represent the mean ± SEM (n=6). 
304 
 
UFH Enoxaparin Semuloparin
0
2
4
6
8
10
*
H
a
lf
-l
if
e
; 
h
rs
UFH Enoxaparin Semuloparin
0
50
100
150
200
*
#
A
U
C
; 
(
g
*h
rs
)/
m
l
UFH Enoxaparin Semuloparin
0
15
30
45
60
*
C
L
s
y
s
; 
m
l/
k
g
/h
rs
UFH Enoxaparin Semuloparin
0
50
100
150
200
250 *
#
V
d
; 
m
l/
k
g
A. B.
C. D.
 
Figure 100. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the TGA assay after SC administration of 1.0 mg/kg 
heparins. Enoxaparin had a significantly longer half-life compared to UFH and 
semuloparin (* p < 0.05). In panel B, the rank order for AUCs was semuloparin < 
enoxaparin < UFH (#,* p < 0.01). In panel C, UFH exhibited an increased CLsys 
compared to enoxaparin and semuloparin (p < 0.001). The rank order for Vd (D) was 
UFH < enoxaparin < semuloparin (*, # p < 0.05). The data represent the mean ± SEM 
(n=6). 
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 Only T1/2 and AUC were calculated for the immunologic and functional TFPI 
assays. At a dose of 1.0 mg/kg SC, no differences in the pharmacokinetic parameters 
between UFH, enoxaparin, and semuloparin were noted in either assay (Figure 101). 
 The estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the Heptest
®
 assay after SC administration of 2.5 mg/ml 
enoxaparin and semuloparin are shown in Figure 102. The T1/2 of semuloparin (A), as 
determined by the Heptest
®
 assay, was 5.2 ± 0.1 hrs, which was significantly longer (p < 
0.001) than the T1/2 of enoxaparin (4.3 ± 0.04 hrs). Similarly, the Clsys rate (C) for 
semuloparin was increased 2-fold over that of enoxaparin (p < 0.001). Semuloparin also 
exhibited a significantly (p < 0.001) larger Vd (154.7 ± 6.0 ml/kg) compared to 
enoxaparin (60.4 ± 5.9 ml/kg), as seen in panel D. Conversely, enoxaparin had 
significantly increased exposure in terms of AUC (269.8 ± 22.9 µg*hr/ml) compared to 
semuloparin (121.8 ± 6.0 µg*hr/ml) (p < 0.001), 
 As measured by anti-Xa activity, the T1/2 (Figure 103) for semuloparin (2.5 mg/kg 
SC) was 6.2  ±  0.2 hrs, which was significantly longer than enoxaparin (4.37 ± 0.1 hrs) 
(p < 0.001). The Vd (D) was significantly larger (p < 0.001) for enoxaparin (33.8 ± 3.6 
ml/kg) compared to semuloparin (18.9 ± 1.8 ml/kg). No significant differences were 
noted in terms of AUC (B) and Clsys (C). Once again, pharmacokinetic parameters 
calculated using immunologic and functional TFPI levels were not considered 
significantly different between enoxaparin and semuloparin at the 2.5 mg/kg dose (Figure 
104). 
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Figure 101. Estimation of pharmacokinetic parameters calculated from TFPI 
immunologic and functional concentration-time curves after SC administration of 1.0 
mg/kg heparins. No differences in any of the pharmacokinetic parameters for both the 
immunologic and functional TFPI data were seen. The data represent the mean ± SEM 
(n=6). 
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Figure 102. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the Heptest
®
 assay after SC administration of 2.5 mg/kg 
enoxaparin and semuloparin. Semuloparin demonstrated a significantly (*p < 0.001) 
longer half-life, increased Clsys, and larger Vd compared to enoxaparin (A, C, and D). 
However, enoxaparin exhibited a significantly (*p < 0.001) larger AUC (B). The data 
represent the mean ± SEM (n=6). 
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Figure 103. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the anti-Xa assay after SC administration of 2.5 mg/kg 
enoxaparin and semuloparin. Semuloparin had a significantly longer half-life (A) 
compared to enoxaparin (* p < 0.001). Enoxaparin had a significantly larger Vd (D) 
compared to semuloparin (* p < 0.001). The data represent the mean ± SEM (n=6). 
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Figure 104. Estimation of pharmacokinetic parameters calculated from TFPI 
immunologic and functional concentration-time curves after SC administration of 2.5 
mg/kg enoxaparin and semuloparin. No differences were observed. The data represent the 
mean ± SEM (n=6). 
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Figure 105 shows the estimation of pharmacokinetic parameters calculated from 
plasma concentration-time curves using the TGA assay after SC administration of 2.5 
mg/ml enoxaparin and semuloparin. In panel B, semuloparin demonstrated a significantly 
larger AUC (173.9 ± 4.5 µg*hr/ml) compared to enoxaparin (135.2 ± 2.2 µg*hr/ml) (p < 
0.001). Enoxaparin, on the other hand, exhibited a significantly increased CLsys (C) and 
larger Vd (D) compared to semuloparin (p < 0.05). 
 
D. Lewis lung carcinoma (LLC) tumor model 
1. In vivo LLC tumor model 
1.1 Heparin and its derivatives effects on tumor growth 
Preclinical evidence consistently supports the ability of heparin and related drugs 
to affect cancer progression beyond their anticoagulant activity. The following study was 
conducted to determine whether heparin and its derivatives, with or without adjunctive 
treatment of paclitaxel (taxol), were able to augment the inhibition of tumor growth in 
vivo. The primary endpoint included the tumor volume, tumor weight, spleen length, 
spleen weight and mortality. Furthermore, this study also attempted to demonstrate any 
potential interaction between heparins and paclitaxel in terms of anti-tumor effects. The 
following heparins were tested as monotherapy and in combination with paclitaxel (7.5 
and 15 mg/kg): UFH, non-AT AF UFH, enoxaparin, bemiparin, semuloparin, and non-
AT AF semuloparin at dosages of 0.25, 0.5, and 1.0 mg/kg SC (n = 10-14 mice/group). 
 In the first set of experiments paclitaxel was given at a dosage of 15 mg/kg IP.
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Figure 105. Estimation of pharmacokinetic parameters calculated from plasma 
concentration-time curves using the TGA assay after SC administration of 2.5 mg/kg 
enoxaparin and semuloparin. In panel B, semuloparin demonstrated significantly larger 
AUCs compared to enoxaparin (*p < 0.001). In panel C and D, enoxaparin exhibited an 
increased CLsys and larger Vd compared to semuloparin (p < 0.05). The data represent 
the mean ± SEM (n=6). 
 
 
 
312 
 
 
 
Figure 106 shows the result of the tumor volumes in mice treated with 1.0 mg/kg SC 
semuloparin, enoxaparin, bemiparin, non-AT AF semuloparin, or non-AT AF UFH. In 
the heparin groups, 5/6 mice died due to bleeding; therefore, the heparin group was 
discontinued at this dosage. However, non-AT AF UFH was included because the 
anticoagulant effects of this heparin fraction were minimal, and thus less bleeding in 
these animals was observed. The tumor volumes of the saline/paclitaxel group as well as 
the tumor volumes of each heparin/saline and heparin/paclitaxel group (Table 82) were 
extensively reduced compared to the saline/saline group, and these reductions of tumor 
volume which were statistically significant (p < 0.01) versus the saline/saline group. 
Interestingly, on a descriptive level, the heparins themselves without paclitaxel had as 
strong an effect as the paclitaxel alone at the highest studied dosages, and combining the 
heparins with paclitaxel did not produce any considerable differences compared to 
paclitaxel alone. These differences in the heparin groups versus the saline/paclitaxel 
group were not statistically significant.  
Figure 107 B shows these results calculated as % inhibition from the saline/saline 
control. The % inhibition was calculated since the murine LLC tumor model is a biologic 
model, and variations in the saline/saline controls may occur due to the tumor cells and 
how quickly they multiply. Since there were some variations observed in the controls 
between the different experiments, the % inhibition for the tumor volume was calculated 
from the saline/saline controls that were run with each group of animals. Similar results 
were observed as in the calculated value of tumor volume (Table 82).  Figure 107 C 
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Figure 106. Heparins and its derivatives, with and without taxol (15 mg/kg), effects on tumor growth at a dose of 1.0 mg/kg. All 
heparins, with and without taxol, demonstrated a significant decrease in tumor volume compared to saline control (A). Similar results 
were observed for tumor weight (C). Panel B shows these results calculated as % inhibition of tumor volume from the saline/saline 
control. All data points are presented as mean ± SEM. Statistical analysis of the data was performed using a Kruskal-Wallis test 
followed by Kruskal-Wallis multiple comparison test versus the saline/saline (S/S) group or saline/taxol (S/T) group. *p < 0.05, ** p < 
0.01, ***p < 0.001. S, saline; T, taxol; E, enoxaparin; B, bemiparin; A, semuloparin; non-AT AF A or H; non-antithrombin affinity 
semuloparin or UFH. 
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Figure 107. Heparins and its derivatives, with and without taxol (7.5 mg/kg), effects on tumor growth at a dose of 500 µg/kg. All 
heparins, with and without taxol, demonstrated a significant decrease in tumor volume compared to saline control (A). 
Semuloparin/saline (A/S) was significantly stronger at inhibiting tumor volume compared to the saline/taxol (S/T) control. Similar 
results were observed for tumor weight (C). Panel B shows these results calculated as % inhibition from the saline/saline control. All 
data points are presented as mean ± SEM. Statistical analysis of the data was performed using a Kruskal-Wallis test followed by 
Kruskal-Wallis multiple comparison test versus the saline/saline (S/S) group or saline/taxol (S/T) group. *p < 0.05, ** p < 0.01, ***p 
< 0.001. S, saline; T, taxol; H, UFH; E, enoxaparin; B, bemiparin; A, semuloparin; non-AT AF A; non-antithrombin affinity 
semuloparin. 
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shows the results of the tumor weight in this group of animals. Again the saline/paclitaxel 
group as well as the heparins without paclitaxel and the heparins with paclitaxel 
treatment (Table) showed a statistical significant difference from the saline/saline control 
(p < 0.05). No differences between the different heparins were observed. These results 
demonstrate that heparins have a substantial anti-tumor effect. 
 Since there were no significant differences between the heparins/saline and 
heparins/paclitaxel groups in the previous experiment, the dosage of paclitaxel was 
reduced in order to prevent the masking of heparin effects. Therefore, in the next set of 
experiments, the paclitaxel dosage was decreased to 7.5 mg/kg IP, and the heparin 
dosages were decreased to 500 µg/kg SC. Figure 107 shows the results of heparin and its 
derivatives on tumor volume. All agents showed a statistically significant decrease (p < 
0.001) in tumor volume from the saline/saline control (Table 83). Additionally, the mean 
tumor volumes of the saline/paclitaxel group (1128.5 ± 344.6 mm
3
) were significantly 
reduced (p < 0.05) compared to the saline/saline control (2060.1 ± 276.0 mm
3
). 
Semuloparin (A/S) alone (202.7 ± 68.1 mm
3
) significantly inhibited tumor growth to a 
greater extent (p < 0.05) than that of the paclitaxel control group (1128.5 ± 344.6 mm
3
). 
Reducing the doses of paclitaxel and heparins by a factor of 2 in the second set of 
experiments still yielded extensively reduced tumor volumes compared to the 
saline/saline group. There were no significant differences between the saline/paclitaxel 
group and the heparin/saline groups, except for the A/S group, and combining the 
heparins with paclitaxel as well did not produce any significant differences compared to 
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paclitaxel alone. No statistically significant differences between the heparins were 
observed.  Figure 107 B shows these results calculated as % inhibition from the 
saline/saline control. All agents, including paclitaxel alone, showed a significant % 
inhibition of tumor growth compared to the saline/saline control group (p < 0.001). 
Figure 107 C shows the results of the tumor weights. Similarly, the heparins without 
paclitaxel and the heparins with paclitaxel treatment, except the saline/paclitaxel group, 
were significantly different from the saline/saline group (p < 0.001). To determine if 
there was a dose response in the anti-tumor effects of the various heparins, groups of 
mice were treated with 250 µg/kg SC followed by saline or paclitaxel at a dose of 7.5 
mg/kg IP. At the lower dose, the heparin groups yielded reduced anti-tumor effects 
compared to the strong effects observed at the higher doses. The tumor volume was 
reduced in all groups compared to the saline/saline treated group as shown in Figure 108. 
However, statistical significance was observed only for the saline/paclitaxel, 
enoxaparin/paclitaxel, bemiparin/saline, bemiparin/paclitaxel, and semuloparin/saline 
groups (p < 0.05) as shown in Table 84. Descriptively, the heparins/saline groups, except 
UFH/saline, produced an effect that was as strong as paclitaxel (S/T) alone; combining 
the heparins with paclitaxel did not produce any considerable differences compared to 
paclitaxel (S/T) alone. There were no significant differences between the heparin groups 
and the saline/paclitaxel group. Figure 109 B shows these results calculated as % 
inhibition from the saline/saline control. Lower inhibition was noted in the group of 
animals treated with heparins at a dosage of 250 µg/kg SC compared to the higher 
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Figure 108. Heparins and its derivatives, with and without taxol (7.5 mg/kg), effects on tumor growth at a dose of 250 µg/kg. Various 
heparins, with and without taxol, demonstrated a decrease in tumor volume compared to saline control (A). Similar results were 
observed for tumor weight (C). Panel B shows these results calculated as % inhibition from the saline/saline control. All data points 
are presented as mean ± SEM. Statistical analysis of the data was performed using a Kruskal-Wallis test followed by Kruskal-Wallis 
multiple comparison test versus the Saline/Saline group. *p < 0.05, ** p < 0.01, ***p < 0.001. S, saline; T, taxol; H, UFH; E, 
enoxaparin; B, bemiparin; A, semuloparin; non-AT AF A; non-antithrombin affinity semuloparin. 
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dosages of heparins. Figure 109 C shows the results of the tumor weight at 250 µg/kg SC 
heparins and 7.5 mg/kg IP paclitaxel. Similar to the results obtained for the tumor 
volumes, heparins without paclitaxel and heparins with paclitaxel treatment significantly 
reduced tumor weight compared to the saline/saline group.  
 
1.2 Gross Pathology 
A common observation in the LLC mouse model is splenomegaly. Spleens were 
removed, grossly observed, and then weighed to determine any effect of heparin 
treatment or LLC cell injections on spleen length or weight. The LLC mouse model is 
also noted for rapid tumor growth and thus, tumor surface necrosis. Tumor surface 
necrosis was determined by visual estimates of approximate necrotic surface area as 
compared to the total surface area. 
Figure 109 shows the effects of heparin and its derivatives on spleen length in the 
murine LLC tumor model. UFH and its derivatives had no effect on spleen length 
compared to the saline control (S/S). However, the injection of LLC cells into mice (S/S) 
and subsequent tumor formation produced a significant (p < 0.05) increase in spleen 
length at both the 0.5 (16.2 ± 1.0 mm) and 1.0 mg/kg SC dosages (15.8 ± 0.8 mm) 
compared to mice that were not injected (CT) with tumor cells (12.6 ± 0.52 mm) (B and 
C). Although the results for the 0.25 mg/kg SC experiment (A) were not statistically 
significant, the CT group spleen lengths were still smaller than the S/S group.
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Figure 109. Murine LLC tumor model and UFH and its derivatives effects on spleen 
length. UFH and its derivatives had no effect on spleen length compared to the saline 
control (S/S). However, the injection of LLC cells into mice and subsequent tumor 
formation (S/S) produced an increase in spleen length (B and C) compared to mice that 
were not injected (CT) with tumor cells (^p < 0.05). Although, the results in A were not 
statistically significant, the CT group spleen lengths were still smaller than the S/S group. 
All data points are presented as mean ± SEM. Statistical analysis of the data was 
performed using a one-way ANOVA followed by a Dunnett multiple comparison test 
versus the saline/saline (S/S) group. S, saline; T, taxol; CT, control no tumor; H, UFH; E, 
enoxaparin; B, bemiparin; A, semuloparin; non-AT AF A; non-antithrombin affinity 
semuloparin. 
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The effects of the murine LLC tumor model and UFH and its derivatives on 
spleen weight are shown in Figure 110. At all doses tested (A, B, and C), UFH and its 
derivatives had no significant effect on spleen weight compared to the saline control 
(S/S), except for non-AT AF semuloparin and non-AT AF UFH (p < 0.05) (Table). 
However, the injection of LLC cells into mice (S/S) and subsequent tumor formation 
produced a significant increase in spleen weight (A, B and C) compared to mice that were 
not injected (CT) with tumor cells (p < 0.05) (Table). 
One of the observations noted in rapid tumor growth is central tumor necrosis, 
which can be visually observed by the naked eye. However, in the LLC tumor model, 
there was no necrosis observed in any of the tumors when examined by a trained 
pathologist (data not shown). 
 
2. In vitro and ex vivo assays 
2.1 Cell viability assay 
To test whether UFH and its derivatives inhibit cell proliferation in vitro, 
proliferation of LLC cells, treated with UFH, enoxaparin, bemiparin, semuloparin, and 
non-AT AF semuloparin (0.1 to 100 µg/ml), was measured using the CellTiter 96
®
 
AQueous One Solution Cell Proliferation Assay (Promega Corporation, Madison, WI), as 
previously described in the ‘Materials and Methods’ section. Saline was used as a 
control. From the results of the proliferation assay, cells treated with the various heparins 
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Figure 110. Murine LLC tumor model and UFH and its derivatives effects on spleen 
weight. At all concentrations tested (A, B, and C), UFH and its derivatives had no 
significant effect on spleen weight compared to the saline control (S/S), except for non-
AT AF semuloparin and non-AT AF UFH (*p < 0.05). However, the injection of LLC 
cells into mice and subsequent tumor formation produced a significant increase in spleen 
weight (A, B and C) compared to mice that were not injected (CT) with tumor cells (^p < 
0.05). All data points are presented as mean ± SEM (n= 5-11). Statistical analysis of the 
data was performed using a one-way ANOVA followed by a Dunnett multiple 
comparison test versus the saline/saline (S/S) group or control no tumor (CT) group. S, 
saline; T, taxol; CT, control no tumor; H, UFH; E, enoxaparin; B, bemiparin; A, 
semuloparin; non-AT AF A; non-antithrombin affinity semuloparin. 
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were found to have a similar viability when compared to control cells at all 
concentrations tested (data not shown). These data suggest that heparin and its derivatives 
do not inhibit cell proliferation in LLC cells.  
 
2.2 Mitotic Figure analysis 
Light microscopic evaluation of mitotic activity has long served as a reasonable 
assessment of cell proliferation or rate of turnover of cells in that tissue. In order to 
confirm the results of the in vitro cell proliferation assay, H&E stained slices of Lewis 
lung tumors removed from mice treated with various heparins at a dose of 500 µg/kg, 
were evaluated for the number of mitotic figures present in 3 high-powered microscopic 
fields. A single-blind quantitation of mitotic figures was performed by an independent 
observer. Counts of mitotic spheres were used as a proliferation index. In accordance 
with the in vitro proliferation results, there were no statistically significant differences 
observed between treatment groups and the saline control groups (data not shown). 
However, Figure 111 shows a representative control slide under a 10 X microscopic field 
with at least 8 mitotic figures present. 
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Figure 111. Mitotic figures: representative control slide under a 10 X microscopic field 
with at least 8 mitotic figures present. Arrows point to mitotic figures. 
 
2.2 BCL-2 analysis  
Anti-apoptotic B-cell lymphoma 2 (BCL-2) is the leading member of the Bcl-2 
family of apoptosis regulator proteins. Apoptosis
 
(or programmed cell death) is the last 
critical phase of a cell's life. A failure of cells to fulfill their destiny has catastrophic 
consequences on an organism. BCL-2 is found to be highly overexpressed in certain 
types of cancer and thus, is known to enhance the survival of cancer cells. In order to 
determine a possible mechanism for the observed heparin-mediated decrease in tumor 
volumes previously described, BCL-2 expression was examined in tumor slices removed 
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from mice treated with 0.5 mg/kg SC heparins and 7.5 mg/kg IP paclitaxel. A single blind 
quantification of BCL-2 expression was performed by an independent observer as 
previously described in the ‘Materials and Methods’ section. Figure 112 shows 
representatives of groups considered to have 3, 1-2, and 0 levels of BCL-2 staining as 
shown under a 10 X (or 40X for the inset) microscopic field. Statistical significance was 
determined by a Chi-square analysis followed by a Fisher’s exact test for nonparametric 
data. Results were considered significant if p < 0.05. 
BCL-2 expression in LLC tumors removed from mice treated with 0.5 mg/kg SC 
heparins and 7.5 mg/kg IP paclitaxel is shown in Figure 113. Enoxaparin/saline (p = 
0.023), bemiparin/paclitaxel (p = 0.003), and semuloparin/saline (p = 0.002) significantly 
decreased BCL-2 expression compared to saline control. Notably, semuloparin/saline and 
bemiparin/paclitaxel groups were exceptionally strong at inhibiting BCL-2 expression; 
which was demonstrated by the fact that they had no positive BCL-2 staining as 
determined by our scoring criterion. Additionally, on close examination of the data, 
enoxaparin/saline and bemiparin/saline appeared to be close to significance threshold. 
Semuloparin/paclitaxel demonstrated a similar trend; however, lack of statistical 
significance for these groups may be dependent on the overall sample sizes. Interestingly, 
the non-antithrombin affinity semuloparin fraction had significant BCL-2 staining on 
every slide examined. Together these results suggest that heparins decrease BCL-2 
expression in LLC tumors. These findings may explain one possible mechanism for the 
ability of heparins to slow tumor progression in the murine LLC tumor model.
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Figure 112. BCL-2 staining shown under a 10x microscopic field. Inset shows staining under a 40x microscopic field.  
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Figure 113. BCL-2 expression in LLC tumors treated with 0.5 mg/kg SC heparins and 7.5 
mg/kg IP taxol. Statistical significance was determined by a Chi-square analysis followed 
by a Fisher’s exact test for nonparametric data (χ2 = 35.26, df = 9, p < 0.001). 
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2.4 Matrigel tubular formation assay 
 Tumors induce blood vessel growth (angiogenesis) by secreting various growth 
factors (e.g. VEGF). Growth factors such as FGF-β and VEGF can induce capillary 
growth into the tumor. Angiogenesis is a necessary and required step for transition from a 
small harmless cluster of cells to a large tumor. Angiogenesis is also required for the 
spread of a tumor metastasis. Moreover, studies have shown that heparins are able to 
inhibit tumor growth; therefore, heparins may be able to inhibit tumor growth by 
inhibiting angiogenesis. To test the hypothesis that heparins are able to suppress 
angiogenesis, UFH, enoxaparin, bemiparin, semuloparin, high-AT AF semuloparin, non-
AT AF semuloparin, and RO-14 were used in an in vitro angiogenesis assay system as 
described in the ‘Materials and Methods’ section. 
 Figure 114 shows the incubation of endothelial cells with saline. Controls from 
three different individual wells are shown. The tubular structures first appeared after 12 h 
of incubation and developed into a well organized capillary-like network after 24 hours 
of incubation. With the saline control, there was formation of 33 ± 2.0 capillary-like 
tubules/well. Microphotographs of tubular formation of human microvascular endothelial 
cells (HMVECs) cultured in the presence of semuloparin at concentrations of 1, 50, and 
100 µg/ml are shown in Figure 115. Semuloparin exhibited a strong inhibition of tubular 
formation compared to control (p < 0.001), even at the lowest concentration.  
Figure 116 shows the tubular formation of HMVECs cultured in the presence of 
UFH and other heparin derivatives, including non and high-antithrombin affinity
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Figure 114. Endothelial cell tube formation control wells. Controls from three different individual wells are shown above. Extensive 
tubular formation was observed. Conditions: 10
5
 endothelial cells, 250 µl matrigel, 24h at 37 °C, and 2.5% CO2. Scale: 100 µm. 50 X 
magnification. 
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Figure 115. The inhibitory effects of semuloparin on endothelial cell tube formation. Endothelial cell (10
5
) were seeded on Matrigel 
(250 µl, 24h at 37 °C, and 2.5% CO2) in cell culture medium containing 10% FBS and semuloparin (1, 50, and 100 µg/ml). Each 
column represents one experiment. Semuloparin demonstrated a dose-dependent inhibition of tubular formation. Scale: 100 µm. 50 X 
magnification. 
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Figure 116. The inhibitory effects of heparin and its derivatives on endothelial cell tube formation. Endothelial cell (10
5
) were seeded 
on Matrigel (250 µl, 24h at 37 °C, and 2.5% CO2) in cell culture medium containing 10% FBS and the various agents (100, 50, and 1 
µg/ml). All agents demonstrated a strong ability to inhibit tubular formation. Scale: 100 µm. 50 X magnification.
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fractions of semuloparin. All agents were tested at concentrations of 1, 50, and 100 
µg/ml.  Treatment with the various heparins produced an almost complete abolishment of 
tubular formation compared to control (p < 0.001). Quantification of the results is shown 
in Figure 117. These results suggest that heparins or the enzymes inhibited by heparins 
may play a role in the regulation of endothelial cell differentiation/tubule formation. 
Additionally, since the non-AT AF semuloparin fraction produced similar inhibition of 
tubular formation compared to the other heparins, it was speculated that the ability of 
heparins to inhibit tubular formation and thus angiogenesis, is independent of their 
anticoagulant activities. 
 
2.5 VEGF and TGF-β assay 
VEGF and TGF-β are known to play a critical role in tumor angiogenesis. 
Therefore, since tubular formation was inhibited by heparins in the matrigel assay, the 
possible modulation of VEGF and TGF-β by UFH and its derivatives was investigated. 
The effects of UFH, enoxaparin, bemiparin, semuloparin, and non-AT affinity 
semuloparin (0.1, 10, and 100 µg/ml) on VEGF and TGF-β levels in the supernatant and 
lysates of cultured LLC-LN7 cells were measured using the commercially available 
Quantikine
®
 ELISA kits for mouse VEGF (R&D Systems, Minneapolis, MN). In vitro, 
VEGF protein levels in culture medium containing LLC cells were significantly (p < 
0.05) reduced by all agents at the 100 µg/ml concentration (Figure 118). At the 10 µg/ml 
concentration, enoxaparin was still significantly able to reduce VEGF protein levels. All 
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Figure 117. Quantification of the inhibitory effects of heparin and its derivatives on endothelial cell tube formation. Endothelial cell 
(10
5
) were seeded on Matrigel (250 µl, 24h at 37 °C, and 2.5% CO2) in cell culture medium containing 10% FBS and the various 
agents (100, 50, and 1 µg/ml). All agents significantly (p < 0.001) inhibited tubular formation compared to saline control (A). Tubular 
perimeter and perimeter/area of controls were similar across wells (B and C).  Statistical significance was obtained by using a one-way 
ANOVA followed by a Tukey post-hoc test: Sem, semuloparin; bemi, bemiparin; enox, enoxaparin; HA, high-AT AF semuloparin; 
NA, non-AT AF semuloparin; UFH, unfractionated heparin.  
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Figure 118. In vitro effects of heparin and its derivatives on VEGF protein levels in LLC 
cell culture medium. The data represent the mean ± standard error of the mean from three 
independent experiments. Statistical analysis was performed for each dosage using a one-
way ANOVA followed by a Tukey post hoc test. * p < 0.05 vs. control, ** p < 0.01 vs. 
control. 
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agents appeared to reduce VEGF protein levels in a concentration-dependent manner. In 
LLC cell lysates (Figure 119), VEGF protein levels were significantly reduced by UFH 
and its derivatives in a concentration-dependent manner (p < 0.05). UFH and its 
derivatives had no significant effects on TGF-β protein expression levels in either the cell 
culture medium or cell lysates (data not shown). 
 
2.6 VEGF levels in LLC mouse plasma samples 
 Since VEGF expression was inhibited by heparins in LLC cell lysates and 
cultured medium in vitro, the systemic effects of heparins on VEGF expression were 
analyzed. The amount of VEGF in plasma samples collected from heparin-treated (1.0 
and 0.5 mg/kg SC) LLC tumor bearing mice was measured using the commercially 
available Quantikine
®
 ELISA kits for mouse VEGF (R&D Systems, Minneapolis, MN). 
Compared to the saline controls, no significant differences in VEGF expression in the 
mouse plasma were observed after the various heparin treatments at either the 1.0 or 0.5 
mg/kg SC dosages (data not shown).  
 
2.6 Endothelium binding assay 
 The ability of heparins to inhibit vessel formation (shown above) and 
subsequently angiogenesis may be dependent on multiple mechanisms. Previous studies 
have shown that heparin binds to the extracellular matrix (ECM) of endothelial cells (EC) 
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Figure 119. In vitro effects of heparin and its derivatives on VEGF protein levels in LLC 
cell lysates. The data represent the mean ± standard error of the mean from three 
independent experiments. Statistical analysis was performed for each dosage using a one-
way ANOVA followed by a Tukey post hoc test. * p < 0.05 vs. control, ** p < 0.01 vs. 
control. 
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derived from rabbit thoracic aorta (Trindade et al., 2008). Binding of heparin to the ECM 
of ECs may inhibit tubular formation. Since LMW and ULMW heparins are also capable 
of inhibiting tubular vessel formation in vitro, the ability of various heparin derivatives to 
compete with heparin binding to ECs was examined. 
In the present study, biotinylated heparin (BiotHep) was incubated in the presence 
or absence of 100 times molar excess of UFH, enoxaparin, bemiparin, semuloparin, non-
AT AF semuloparin, and high-AT AF semuloparin and examined using a scanning 
confocal microscope (Figure 120). When the cells were exposed to BiotHep and detected 
using streptavidin conjugated with Texas Red, a fiber-like pattern of binding was 
observed (Figure 120, control). As shown in Figure 121, heparin and its derivatives were 
able to strongly compete with BiotHep (1µg/ml) on ECs. Bemiparin was the least 
effective at competing with BiotHep. However, no statistical differences between agents 
were observed. The ability to compete with BiotHep on ECs appeared to be independent 
of the amount of antithrombin binding sites present in each semuloparin fraction (Figure 
121). 
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Figure 120. Heparin and its derivatives compete with biotinylated heparin (BiotHep) on rabbit thoracic aorta endothelial cells. 
BiotHep was incubated in the presence or absence of 100 times molar excess of different heparin preparations. BiotHep heparin (1 
µg/ml) was detected after incubation with streptavidin conjugated to Texas Red. The nuclei were stained with DAPI. Slides were 
examined using a scanning confocal microscope. 
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Figure 121. Quantification of biotinylated heparin (BiotHep) competition assay. Heparin 
and its derivatives were able to strongly compete with BiotHep (1µg/ml) on rabbit 
thoracic aorta endothelial cells. The data represent the mean ± the standard error of the 
mean from three independent experiments. Statistical analysis was performed using a 
one-way ANOVA followed by a Tukey post hoc test. * p < 0.05 vs. control, *** p < 
0.001 vs. control. 
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CHAPTER FIVE 
DISCUSSION 
 
For over 80 years, heparin has been effectively used as an anticoagulant and 
antithrombotic agent. It was the first systemic anticoagulant used in the management of 
thrombotic disorders. Heparin is a heterogeneous agent in terms of its molecular weight 
(MW), structural and molecular composition, and its biological actions. Preparations of 
heparin can contain fractions that vary in molecular weight from 1.5 kDa to 30 kDa 
(Nader et al., 1974). In addition to MW, these fractions can exhibit differences in their 
chemical structure such as in their degree of sulfation. 
The primary mechanism of action of heparin is to indirectly inhibit the 
coagulation proteases. This process involves the binding of heparin to its main 
endogenous cofactors, antithrombin (AT), and to a lesser extent, heparin cofactor II 
(HCII). Interestingly, the specific sequence of heparin required for high affinity binding 
to AT is only present in approximately 20% of its chains (Casu, 1989). The main targets 
of the heparin-AT complex are factor Xa and thrombin. By inhibiting the proteolytic 
action of these coagulation factors, heparin also acts to limit further generation of these 
enzymes. While heparin was initially thought to exhibit only anticoagulant activities, it is 
now well known that heparin produces several other biologic actions including  
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Interactions with endogenous proteins and cells, and may have signal transduction 
properties (Fareed et al., 2003). Most likely, this is a result of the large percentage of non-
anticoagulant fractions heparin possesses. However, heparin is still associated with 
several side effects such as bleeding, heparin-induced thrombocytopenia (HIT), and 
osteoporosis. The use of UFH also has disadvantages such as the need to be given 
intravenously, due to its low bioavailability after SC administration, and the need for 
continuous monitoring. 
Recently, low molecular weight (LMW) and ultra low molecular weight (ULMW) 
heparins have been introduced as possible replacements of unfractionated (UF) heparin 
for certain indications. The LMWHs and ULMWHS are derivatives produced by 
depolymerization of porcine or bovine heparin. These agents exhibit a lower mean MW 
in the range of 2.5 to 6.0 kDa. Because of the difference in MW composition, LMW and 
ULMW heparins exhibit different biochemical and pharmacological profiles from UFH, 
such as higher bioavailability, prolonged plasma half life, different protein and vascular 
binding, weaker antithrombin effects, and more predictable anticoagulant responses 
(Fareed et al., 1998). In addition, these lower MW heparins exhibit different interactions 
with AT and HCII. The degree to which these compounds exert their effects through AT 
and HCII, as well as other endogenous proteins, determines how well they inhibit various 
targets of the coagulation system and the severity of side effects. 
It has been proposed that heparin-derived oligosaccharides with ultra-low 
molecular weight may present different features from both heparin and LMWHs (Fareed, 
1985). Semuloparin is a novel ULMWH with a MW <3.0 kDa. Semuloparin is prepared 
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by controlled chemical heparin depolymerization by a phosphazene base. This method of 
preparation gives it a unique characteristic of having its high-affinity AT binding 
sequences preserved relative to ULMWHs produced using other depolymerization 
methods. This preservation of AT binding sites, along with its low molecular weight, 
gives semuloparin a higher anti-FXa/FIIa ratio (>30:1) than other LMW and ULMW 
heparins (Viskov et al., 2009). By selectively inhibiting factor Xa, semuloparin is 
expected to have a greater antithrombotic effect and to provide a better safety profile. 
In this dissertation, the differences among UF, LMW, and ULMW heparins were 
investigated by comparing the biochemical and pharmacological effects of these heparins 
in a variety of in vitro assays and in vivo animal models. This dissertation primarily 
focuses on the MW, composition, and activity relationship of heparin and its 
depolymerized derivatives, with focus on the novel ULMW heparin, semuloparin. As 
such, the agents included in this dissertation vary in MW from 2.6 to 17.0 kDa. The 
relative distribution of different molecular components also varies in these agents. One of 
the major objectives of this research was to investigate the pharmacological actions of 
semuloparin, and to determine how AT affinity enrichment influences these actions in 
comparison to other heparins of various MWs and structures. Therefore, the addition of 
well-defined fractions of semuloparin that exhibit both high and low AT affinity has 
provided a novel approach to determine both the AT and non-AT mediated effects of 
these agents. 
The initial studies were a comprehensive molecular and compositional analysis 
which provided crucial data on the physicochemical behavior of these agents. A 
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comprehensive biochemical analysis included extensive testing of the in vitro 
anticoagulant and antiprotease actions in different whole blood and plasma systems. The 
in vitro systems were chosen to characterize the physicochemical properties of these 
agents and their effects on various steps of the coagulation cascade. In this study, the 
relative role that SERPIN (AT and HCII) activation contributes to the anticoagulant, 
antiprotease, and protease generation effects of heparin and its derivatives were also 
investigated in various in vitro systems.  
The ability to inhibit thrombosis without increasing the risk of bleeding is an 
important concern related to heparin therapy. As such, the antithrombotic and 
hemorrhagic effects of these agents were studied in two rodent animal models, namely, 
the rat-tail bleeding model and the rat jugular vein clamping model. The pharmacokinetic 
and pharmacodynamic profiles of some of these agents were also investigated. In 
particular, the pharmacokinetic profile of UFH, semuloparin, and enoxaparin was 
extensively investigated in a primate colony solely dedicated for the investigation of the 
pharmacokinetics of heparin (Fareed et al., 1985). In these models, the various heparins 
were utilized as they not only exhibited different MWs, but also contained compositional 
differences (as discussed earlier in this discussion) since they were prepared by different 
methods. As such, any effects that MW or composition plays on any of these systems 
would be evident. 
It is widely accepted that heparins have a wide range of activity that are 
dependent and independent of their anticoagulant effects. In fact, UFH and different 
LMWHs are used for the prevention and treatment of thrombosis in cancer patients, and 
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have been shown to increase survival in patients (Kakkar, 2009). Since semuloparin is an 
ULMWH with unique oligosaccharide sequences, it was used in a mouse model of lung 
cancer to study the effect of this agent on tumor growth compared to UFH and other 
LMWHs. In addition, the role of AT enhancement and molecular weight in the ability to 
inhibit tumor growth were elucidated, thus contributing to making an improved 
anticoagulant for the treatment of cancer associated thrombosis. 
Thus, this dissertation provides a comprehensive pharmacological investigation in 
which not only the MW dependence, but also the effect of different depolymerization 
processes on the production of heparin and its derivatives have been investigated. In 
addition, these studies aid in the understanding of the pharmacological actions of a novel 
ULMW heparin, where limited information is available. To date, no such comprehensive 
study comparing the actions of so many various heparins has been undertaken. The 
discussion section of this dissertation is divided into several major sub-sections to 
provide an integrated account of the results and to highlight the role MW and AT binding 
play on the pharmacological actions of heparins. Together, the integrated information 
discussed provides clear answers to the questions raised in this dissertation. 
 
A. Physicochemical characterization of various heparins 
1. Gel-permeation chromatography 
1.1 Molecular weight profiles 
As UFH, enoxaparin, bemiparin, semuloparin, and RO-14 are heterogeneous in 
nature, their average molecular weights can be determined by using size exclusion 
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chromatography (SEC). SEC separates the components of the different heparins based on 
MW, while offering the advantages of minimal sample preparation and a rapid 
turnaround time (Ahsan et al., 1995). This technique has been previously used to 
characterize the molecular weight profiles of UFH and different LMW heparins (Ahsan et 
al., 1995). In this dissertation, it has been demonstrated that GPC can be readily applied 
to prolife the molecular size of heparin-derived oligosaccharides. However, in order to 
obtain MW data from the HPLC elution profiles, calibration of the columns is required. 
Two different sets of molecular weight standards were used in these studies. They 
included the narrow range calibrators (NRC-I) and the modified European 
Pharmacopoeia (EP) calibrators. The first consisted of thirteen fractions of heparin with 
varying MWs ranging from 1.1 to 32 kDa. The MWs of these calibrators have been 
previously reported (Ahsan et al., 1994). The EP method was based on a theory by van 
Dedem et al (1991), in which a mixture of partially depolymerized heparins was used as 
the molecular weight calibration standard. The heparinase depolymerization results in the 
generation of double bond chromophores which can be detected by UV methods (Ahsan 
et al., 1994). 
In the NRC-I method, with a few minor exceptions, the MWs determined by the 
UV and RI detectors compared fairly well. Therefore, MW determination discussed here 
will be from those collected by the UV detector. Using the NRC-1 method, the mean 
MW of UFH was determined to be 16.5 kDa. The Gaussian distribution pattern evident in 
its elution profile denotes the presence of multiple species. The polydispersity, which is a 
measure of heterogeneity, was higher for UFH (1.31) than for all other agents. 
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Enoxaparin (4.2 kDa), bemiparin (3.8 kDa), semuloparin (2.9 kDa), and RO-14 (2.6 kDa) 
exhibited lower molecular weights compared to UFH. These MWs were comparable to 
their known formula weights. For each of these agents, multiple oligosaccharide 
components were present. This multi-component property was indicated by their 
polydispersity values. However, being that the LMW and ULMW heparins have 
relatively low polydispersity values, ranging from 1.06 to 1.18, it can be determined that 
their degree of heterogeneity is substantially lower than that of UFH. The degree of 
heterogeneity also decreased with the decreases in MW for each agent. The peak 
absorption at 232 nm resulted primarily from the double bonds incorporated into each 
heparin fraction during the depolymerization process. As such, the relative degree by 
which each of these agents was depolymerized can be assessed by the amplitude of each 
elution profile. RO-14 shows the greatest degree of depolymerization. Although the MW 
of RO-14 is not substantially lower than that of semuloparin, the fact that it is 
manufactured using a unique ammonia hydroxide degradation method, probably 
contributed to its markedly different elution profile (Rico et al., 2011).  
In addition to the heparins already mentioned, various non and high-AT affinity 
fractions of semuloparin and UFH were also analyzed using the NRC-I method. The 
fractions with and without AT binding sequences had slightly increased and decreased 
MW, respectively. For semuloparin, the high-AT AF fraction has the highest MW (3.3 
kDa). Interestingly, the polydispersity for the standard semuloparin was greater (1.10) 
than that of the high- (1.06) and non (1.06)-AT AF fractions. The fraction of heparin with 
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non-AT AF binding sequences had a lower MW (13.5 kDa) than the standard UFH (16.5 
kDa); however, the polydispersity did not change. 
Determinations of the mean MWs for heparin and its derivatives were also made 
using the EP method. The mean MW for UFH was similar between the two methods. 
However, for the LMW and ULMW heparins, the calculated mean MWs varied between 
the two methods. The EP method produced higher MWs for these agents. These 
differences are most likely due to the difference in composition of the calibrants (Ahsan 
et al., 1994). In addition, it has been shown that the EP method has too narrow of a range 
to allow for the accurate MW determinations of LMW and ULMW heparins (Ahsan et 
al., 1994).  
In summary, these studies compared two calibration methods in the molecular 
profiling of UFH and its derivatives and demonstrated the applicability of the NRC-I 
method for this profiling.  
 
1.2 Heparinase-I depolymerization of heparins 
Heparinase-I cleaves heparins between the 2-sulfo-iduronate and 2,6-disulfo-
glucosamine residues (Nader et al., 1999; Xiao et al., 2011). Depolymerization of 
heparins by heparinase-I generates an unsaturated uronic acid at the non-reducing ends 
which absorbs UV light. The ability to measure this absorption allows the degradation 
process to be easily followed (Xiao et al., 2011). By using heparinase-I (1U/ml) in 
conjunction with GPC, the oligosaccharide ‘finger-print’ profile of heparin and its 
derivatives could be obtained. For example, the relative amounts of disaccharides and 
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tetrasaccharides noticeable on the elution profiles (Figure 11) after heparinase-I cleavage 
were different for each agent. The amount of disaccharides and tetrasaccharides present 
were not inversely proportional to the MWs of the heparins. In particular, the amount of 
disaccharides derived from UFH, enoxaparin, bemiparin, and semuloparin was relatively 
high, whereas for RO-14 the amount was markedly lower. The amount of 
tetrasaccharides present was greater for both bemiparin and semuloparin compared to 
enoxaparin, UFH, and RO-14. Overall, heparinase-I was clearly capable of 
depolymerizing the various heparins as evident by the shift to the right of each peak and 
subsequent decrease in mean molecular weight for all agents. Additionally, the similar 
post-digested mean molecular weights (ranging from 2.13 to 2.26 kDa) for each heparin 
demonstrates a similar degree of heparinase-I digestion. The heparinase-I 
depolymerization of the various heparins gave chromatographic profiles similar to that 
described by Linhardt et al (1988). In the future, using heparinase-I, II and III, as these 
cleave heparins in different locations than that of type I (Linhardt et al., 1988), would be 
beneficial to further characterize the various sulfated disaccharide units. In the present 
studies, heparinase-I degradation of heparins has provided some useful information on 
the digestibility and MW of the various study agents. 
 
2. Scanning UV spectroscopy and circular dichroism 
 There are several methods used for the production of LMW and ULMW heparins, 
and each one of them leads to the formation of new structures; therefore, these heparins 
are a quite complex group of pharmacological agents. LMWHs are considered not 
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interchangeable in antithrombotic therapy (Hirsh et al., 2001), and each one of them must 
be treated as a unique pharmacological agent. LMWHs possess higher anti-Xa activity 
than anti-IIa activity typically. Nevertheless, the different preparations still possess chains 
that are able to simultaneously bind AT and thrombin, resulting in quite high residual 
anti-IIa activity. ULMWHs are being designed to specifically inhibit Xa with a very low 
residual anti-IIa activity, as a residual anti-IIa activity could be beneficial for effective 
prevention of thromboembolism without having an influence on an increased bleeding 
liability (Viskov et al., 2009). Therefore, the search for differences among the various 
LMW and ULMW heparins is attracting great attention 
 The purpose of these dissertation studies was to characterize the chemical 
composition of semuloparin to better understand its biological/pharmacological 
differences in comparison to other heparins. As such, UFH, enoxaparin, bemiparin, 
semuloparin and RO-14 were submitted to fine chemical characterization using scanning 
UV scanning spectroscopy and circular dichoism. 
The features in the UV spectra of glycosaminoglycans arise predominantly from 
electronic transitions of the carboxylate groups of the uronate residues and the N-acetyl 
chromophores of the glucosamine residues, the carboxylate chromophore being 
responsible for the majority of the spectral features (Lima et al., 2011). As a result of -
eliminative methods used in the production of certain types of low and ultra-low 
molecular mass heparin preparations, a new chromophore, unsaturated uronic acid 
residues, is introduced within the heparin chain (Lima et al., 2011). 
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Typical UV spectra of samples containing carboxylic acid groups were observed 
with the highest band around 190 nm, arising from carboxylate chromophores of 
iduronate and glucuronate as well as N-acetyl chromophores of the glucosamine residues. 
Also, all LMW and ULMW heparins presented an extra broad band from 215 to 255 nm 
indicating that they are produced by -eliminative methods. However, each LMW and 
ULMW heparin had a slightly different UV spectrum indicating a possible difference in 
the type of β-elimination reactions used in their production. The ratio of the maximum 
absorbances at 190 and 230 nm were used as a molecular weight comparison parameter 
for compounds produced by -elimination reactions. Indeed, RO-14, the agent with the 
lowest MW, presented the lowest 190/230 nm ratio, making scanning UV spectroscopy a 
quick and reliable approach to infer the degree of depolymerization of the preparations. 
The CD spectra features arose from the electronic transition occurring in the 
oxygen atoms (ring, glycosidic linkage, and hydroxyl group), with a maxima around 190 
nm, as well as from electronic transition occurring on the carboxylate and N-acetyl 
chromophores, maxima around 210 nm. The introduction of a 4,5 double bond (C=C) 
into the non-reducing end of the uronate residue, as a result of the β-elimination reaction 
used in the production of the various heparins, resulted in an additional negative band 
with its maxima at 230 nm (Rudd et al., 2009; Lima et al., 2011). The observed 
differences in the CD spectrums of the LMW and ULMW heparins may indicate 
variations in the structural characteristics of each agent that occur during the 
depolymerization process such as the introduction of the double bonds in the uronic acid 
residue. 
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B. Comparative in vitro studies 
The therapeutic actions of heparin and its derivatives are predominately the result 
of their interactions with a diversity of plasma proteins including factor Xa and thrombin. 
The ability of heparins to bind to and inhibit various serine proteases is predominately 
mediated by the cofactors, AT and HCII. The binding of heparins with its cofactors and 
subsequent anticoagulant actions are strongly influenced by MW, content of AT-binding 
sequences, sulfation type, and charge density (Casu, 1985). Although the focus of this 
section is to elucidate how anticoagulant activity is influenced by MW and AT-binding, it 
should be kept in mind that due to the multi-component nature of heparin and its 
derivatives, collectively, the factors described above might influence the anticoagulant 
activities of these agents and complicate their underlying mechanisms.  
The anticoagulant and antiprotease actions of heparin and its derivatives were 
studied following supplementation in normal human whole blood and plasma systems. 
More extensive studies including characterizing the neutralization profile of the different 
study agents were also performed using human plasma. 
 
1. Anticoagulant effects in human whole blood 
The anticoagulant effects of heparin and its derivatives can be measured using 
several widely used methods. One of these methods is known as the celite activated 
clotting time (ACT). This is one of several modified versions of whole blood clotting 
time assays regularly used for monitoring heparins during cardiopulmonary bypass 
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surgery and interventional cardiology. In this assay, celite is used as an activator of the 
factor XIIa-mediated intrinsic pathway of coagulation. Heparin and its derivatives were 
tested on an equal gravimetric basis at two different concentrations (10 and 25 mg/ml). 
At both concentrations, these agents exhibited a clear MW dependence with UFH 
producing the strongest anticoagulant effect. The difference in the mean clotting times for 
bemiparin and enoxaparin were not statistically significant. Most likely, this could have 
resulted from two things: 1) donor variability or 2) the MW difference between 
enoxaparin and bemiparin being rather low negates any differences that might otherwise 
be seen. All agents significantly prolonged the clotting time at the lower concentration 
compared to the saline control, except for RO-14. RO-14 only prolonged the clotting time 
significantly when its concentration was increased 2.5-fold; even still, the resultant 
increase in clotting time was rather low. 
It is evident that the ability to strongly inhibit factor Xa is not a major 
contributing factor in the ability to prolong the whole blood ACT. This is evident by the 
fact that the prolongation of the whole blood ACT was not proportional to the 
corresponding increased anti-Xa potency of semuloparin. This observation is consistent 
with previous studies that suggested in whole blood, factor Xa inhibition plays a 
relatively minor role in the mediation of clot formation (Greiber et al., 1997). In contrast, 
the agents with greater anti-IIa activity were able to prolong the whole blood ACT more 
effectively. These observations support the hypothesis that the effect of heparins on the 
ACT is correlated to their activity against thrombin more so than with their activity 
against factor Xa (Linkins et al., 2002). 
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1.1 Supplementation in whole blood and retrieved platelet poor plasma 
 The anticoagulant and antiprotease effects of heparins can be significantly 
different in whole blood compared to their effects in plasma due to a variety of reasons. 
Firstly, platelet poor plasma (PPP) used for coagulation assays is prepared from citrated 
whole blood. The addition of citrate removes calcium ions from blood which prevents the 
calcium-dependent formation of various activated coagulation factors (Davie et al., 
1991). Secondly, plasmatic coagulation factors can be diluted during the recalcification 
of plasma in the global clotting assays. Thirdly, PPP contains very few platelets, red 
blood cells (RBC), or white blood cells (WBC) which are normally found in whole blood. 
This system can detect whether heparins bind to WBCs, RBCs, or platelets, and therefore 
demonstrate a lower anticoagulant activity in whole blood compared to retrieved plasma. 
Lastly, granules from platelets are known to contain heparin neutralizing agents such as 
platelet factor 4 (PF4) and procoagulant materials such as phosphatidyl serine (Davie et 
al., 1991; Dasgupta et al., 2009). Overall, when observed in this framework, the more 
true pharmacological effects of heparins may be evident in the whole blood-based assay 
systems.  
 To determine the extent of which heparins bind to or are inactivated by different 
cellular components, the global anticoagulant effects of the study agents were determined 
following supplementation in whole blood (WB) and retrieved platelet poor plasma (PPP) 
using the activated partial thromboplastin time (APTT) and Heptest
®
 assays. APTT is 
used clinically to monitor heparin therapy as the heparin-AT complex inhibits most of the 
intrinsic pathway enzymes including thrombin (Kitchen, 2000). The Heptest
®
 assay is an 
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anti-Xa clotting assay, which is designed to measure the inhibition of factor Xa, 
prothrombin activation, and thrombin inhibition by heparins (Yin et al., 1973).  
 As the agent with the highest MW, UFH exhibited the broadest anticoagulant 
effect, prolonging clotting times in both assays when supplemented in PPP. The ability of 
heparin to exert anticoagulant activity is dependent on it binding to AT. The heparin/AT 
complex not only inhibits factors Xa and thrombin, but also inactivates factors VIIa, 
XIIa, XIa, and IXa mainly in the intrinsic pathway of coagulation (Mourey et al., 1990; 
Pike et al., 2005). Therefore, heparin would be expected to have strong effects in assays 
in which intrinsic pathway enzymes are inhibited. This idea is clearly evident by the fact 
that in the APTT assay, UFH significantly increased the clotting time compared to all 
other agents in both WB and PPP. Whereas, in the APTT assay UFH limits thrombin 
formation by inhibiting the upstream intrinsic pathway enzymes in addition to directly 
inhibiting formed thrombin, the other agents, due to their lower MW, may only achieve 
these effects at significantly higher concentrations.  
When supplemented in PPP, all agents exhibited varying degrees of anticoagulant 
activity in both assays and a clear MW dependence was noted. The Heptest
®
 assay was 
the most sensitive to all of the different heparins. In fact, the Heptest
®
 assay was able to 
detect anticoagulant activity for all the agents at a concentration as low as 0.31 µg/ml, 
whereas the APTT assay only detected significant activity at concentrations above 1.25 
µg/ml. 
Supplementation of the various heparins in WB compared to PPP attenuated their 
anticoagulant effects. Interestingly, for the LMWH, this was only the case when their 
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activity was measured by the Heptest
®
 assay. As measured by APTT, supplementation of 
UFH in WB decreased its anticoagulant activity 2.6-fold from PPP, but only at the 
highest concentration tested (2.5 µg/ml). Most likely, the concentrations of heparins used 
were too low to measure any substantial differences in clotting between supplementation 
in WB and PPP when measured by APTT. In the Heptest
®
 assay, the fold decreases in 
anticoagulant activity after supplementation in WB followed in a MW dependent manner. 
In fact, whereas UFH significantly prolonged the clotting time compared to all other 
agents when supplemented in PPP, in WB, semuloparin was significantly stronger than 
both UFH and enoxaparin. The preservation of the AT binding sites and subsequent 
higher degree by which semuloparin can bind to AT seemed to counter some of the 
inhibitory effects supplementation in WB produces.  
Overall, results from these studies suggest that the various cellular components 
exhibited in WB can have an effect on the anticoagulant effects of heparins. When the 
WBCs, RBCs, and platelets are present, binding of heparins to these cellular components 
may prevent them from being able to inhibit the coagulation factors as they do in the PPP 
system. Moreover, this effect is MW dependent. However, conferring LMW heparins 
with extra AT binding sequences may help to provide some compensatory properties that 
help to overcome these inhibitory actions. 
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2. Supplementation in plasma based systems 
2.1 Supplementation in platelet poor plasma and platelet rich plasma 
As stated previously, PF4 is one of the main components found in the α-granules 
of platelets. It is known to be a potent neutralizing agent of heparin. Neutralization of 
circulating heparin by PF4, secreted during platelet activation, could result in a reduction 
in heparin’s anticoagulant or antiprotease activity. In view of this, the potential 
significance of this release was investigated by supplementing heparins in platelet rich 
plasma (PRP) and platelet poor plasma (PPP) and measuring the anticoagulant and 
antiprotease activities of heparins. Differences in clotting time and antiprotease activity 
between the two plasma systems were considered to be a measurement of possible PF4 
activity. The anticoagulant and antiprotease effects were measured using the APTT, 
Heptest
®
, thrombin time (TT 5 U Ca
2+
), anti-Xa and anti-II assays. The APTT and 
Heptest
®
 assays have already been discussed. TT is a clot based assay, which is designed 
to measure the conversion of fibrinogen to fibrin following the addition of a known 
amount of thrombin into plasma (O’ Shea et al., 1971). This assay is primarily used to 
monitor antithrombin agents. The version of the assay used in these studies supplements 
thrombin with calcium chloride. The addition of calcium lowers the sensitivity of the 
assay allowing for strong antithrombin drugs to produce a measurable effect. The normal 
clotting time of normal human plasma (NHP) after the addition of 5 U thrombin is 
approximately 20 seconds, with the addition of calcium the clotting time is reduce to 
approximately 12 -15 seconds. Both the anti-Xa and IIa assays are chromogenic assays 
that use a factor Xa or IIa substrate onto which a chromophore has been linked. Factor Xa 
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or IIa cleaves the chromogenic substrate, releasing a colored compound that can be 
detected with a spectrophotometer and is directly proportional to the amount of factor Xa 
or IIa present (Walenga and Hoppensteadt, 2004). These assays are a direct measurement 
of the effects of heparins on factors Xa and thrombin only.  
When compared to measured activities after supplementation in PPP, the 
anticoagulant effects of all agents were attenuated when supplemented in PRP as 
measured by the three global clotting assays. The anticoagulant effects of UFH were the 
most affected; however, this was test and concentration dependent. In the APTT assay, 
the anticoagulant effects of UFH were not affected by supplementation in PRP at 
concentration of UFH above 12.5 µg/ml. However, starting at concentrations below 6.25 
µg/ml, the clotting times decreased approximately 2-fold following supplementation of 
UFH in PRP. This data implies that there is probably a concentration dependent effect 
that limits the heparin neutralizing activity of PF4. Essentially, high concentrations of 
UFH probably saturates the amount of PF4 in the system, leaving more than enough 
heparin left over to still produce measurable anticoagulant effects. Of course another 
possibility is that the high heparin concentration effectively inhibits thrombin and 
prevents platelet activation and PF4 release. The concentrations of LMW and ULMW 
heparins were not high enough to prevent the neutralizing effects of PF4. However, as the 
molecular weight of the heparins decreased, so did the decreases in the fold-changes 
between the clotting times after supplementation in PPP and PRP. This was true for all 
global clotting assays.  
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In the Heptest
®
 assay, at the highest concentration, the anticoagulant effects of all 
agents were not as affected by the presence of platelets as they were at lower 
concentrations. At concentrations < 12.5 µg/ml, supplementation of each heparin in PPP 
prolonged the clotting times to a greater extent compared to supplementation in PRP. 
Once again, a MW dependence was observed; although, when determined by the 
Heptest
®
 assay, the differences in fold-change between supplementation in PPP and PRP 
were not as great as those seen in the APTT assay. 
In the TT assay, once again high concentrations (>3.125 µg/ml) of UFH negated 
the possible neutralizing effects of PF4 on its antithrombin activity. However, at 
concentrations < 3.125 µg/ml, supplementation of UFH in PRP produced a 2.5-fold 
decrease in the clotting times compared to supplementation in PPP. The overall 
anticoagulant effects of all other heparins, with a minor exception for enoxaparin, in the 
TT assay were so low, supplementation in PRP did not affect the outcomes. 
The antiprotease activities of the heparins were measured in terms of their IC50. 
Interestingly, the potency of the LMW and ULMW heparins, in terms of the anti-Xa 
activity, were not significantly affected by supplementation in PRP. Only the anti-Xa 
potency of UFH was significantly reduced when supplemented in PRP. When measured 
by the anti-IIa assay, the potencies of UFH and enoxaparin were significantly reduced 
after supplementation in PRP.A similar trend was observed for bemiparin. However, the 
anti-IIa effects of semuloparin and RO-14 were so low, supplementation in PPP or PRP 
had no effects. 
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The overall results from these studies demonstrate that the release of PF4 from 
platelets plays a role in neutralizing the anticoagulant and antiprotease actions of 
heparins. However, these effects are MW and assay dependent. UFH was consistently the 
most affected by supplementation in PRP compared to the LMW and ULMW heparins. 
This is consistent with the literature which states that a heparin chain length greater than 
18 saccharides is required for optimal PF-4 binding (Lane et al., 1984). Therefore, 
heparin molecules above 18 saccharides with both anti-thrombin and anti-factor Xa 
activities can be completely neutralized by PF-4, whereas molecules below 18 
saccharides, which retain anti-factor Xa activity, are more resistant to neutralization by 
PF-4. Indeed, a weaker neutralization by PF-4 has been seen for LMWHs in comparison 
to that of heparin in these and other studies (Lane et al., 1984).  
 
2.2 The effects on thrombin generation 
The generation of thrombin is a fundamental part of the clotting cascade. It is a 
multifunctional enzyme that has many other roles apart from ﬁbrin formation, all of 
which influence hemostasis. Physiologically, the majority of thrombin generation occurs 
after the clot is formed (van ‘t Veer et al., 1997). The thrombin generation assay (TGA) 
can measure the time-dependent changes in thrombin concentrations in NHP (Hemker et 
al., 2003). It measures the whole kinetics of thrombin generation even after the clot 
formation, and thus assesses all activating and inactivating systems of coagulation. In this 
assay, thrombin generation is triggered by a low concentration of tissue factor, and the 
thrombin activity is measured continuously using a speciﬁc ﬂuorescence peptide 
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substrate, which is cleaved by thrombin and liberates a ﬂuorophore. The rate of 
development in the ﬂuorescence intensity can be converted to thrombin-equivalent 
concentrations (nM) using a reference curve prepared by measuring the rate of substrate 
conversion by a thrombin calibrator. Therefore, this assay is a good way to measure the 
overall antithrombin effects of heparin, not just the conversion of prothrombin to 
thrombin.  
In the current in vitro study, all heparins concentration-dependently inhibited 
thrombin generation. When comparing the potencies (IC50) of these agents, the parent 
compound, UFH (0.19 ± 0.02 μg/ml) was significantly more potent than all other agents. 
RO-14 (4.39 ± 0.37 µg/ml) was the least potent inhibitor of all the agents tested. A MW 
dependency was not as evident in this assay, as the IC50 value for semuloparin (1.01 ± 
0.13 µg/ml) was lower than enoxaparin (1.33 ± 0.15 µg/ml) and bemiparin (1.11 ± 0.24 
µg/ml), although these differences were not considered significant. This seems to counter 
the hypothesis that the inhibition of thrombin generation by heparins in vitro, corresponds 
to their anti-IIa activity (Padilla et al., 1992). However, as stated previously, TGA 
measures the entire kinetics of thrombin generation, even after clot formation, and thus 
assesses all activating and inactivating systems of coagulation. Although semuloparin has 
very low, direct anti-IIa activity, its overly strong anti-Xa activity may still inhibit 
thrombin generation more upstream in the coagulation pathway.  
Based on the fact that UFH produces such a potent inhibition of thrombin in this 
assay, while RO-14 does not, MW probably does play a role in the ability of these agents 
to inhibit thrombin generation. 
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2.3 The effects of heparins on TAFI activity 
As stated previously, thrombin-activatable fibrinolysis inhibitor (TAFI) is a 
powerful inhibitor of fibrinolysis. Fibrin is the natural substrate for the proteolytic effects 
of activated TAFI. TAFI can be activated by several serine proteases such as thrombin, 
plasmin, or trypsin. The catalytic activation of TAFI by thrombin is increased 1250-fold 
when thrombin is in a complex with thrombomodulin (Boffa et al., 1999; Bouma et al., 
2001).TAFI function may be affected by different drugs such as heparins and various low 
molecular weight heparins (LMWHs).  
In these studies, all agents were able to inhibit TAFI functional activity; with 
UFH having the strongest effect reaching over 70% inhibition at a concentration of 1.25 
µg/ml. The inhibition of TAFI by UFH was significantly more effective than that of the 
other heparins. The rank order potency clearly followed in a MW-dependent manner. 
This coincides with other studies that have linked the ability of heparins to inhibit TAFI 
with their anti-IIa activity, as thrombin play a major role in the activation of TAFI. 
Florian-Kujawski et al (2004) compared to the effects of heparin and various LMW 
heparins on TAFI activation in normal human plasma. In accordance with these 
dissertation studies, they found that heparin produced the strongest inhibition of TAFI 
functionality compared to different LMW heparins at equigravimetric concentrations. In 
addition, the authors reported that the ability of heparins to inhibit TAFI was strongly 
correlated to their anti-IIa activity. Overall, this ability of heparins to inhibit TAFI may 
be one of the many mechanisms by which they produce their therapeutic effects. In 
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addition, the weaker effect of semuloparin on TAFI inhibition may be one explanation for 
the decrease in bleeding observed in the rat-tail bleeding model (discussed later).  
 
3. AT and HCII dependence on the modulatory actions of heparins 
Heparin-mediated antiprotease activities are largely dependent on their ability to 
bind to their main cofactors AT and HCII. Using a SERPIN-deficient plasma system and 
a purified-SERPIN plasma free system in these studies, it was possible to examine 
distinct SERPIN-mediated anticoagulant effects of heparin and its derivatives.  
 
3.1 The effects of heparins in SERPIN-deficient plasma systems 
 In the first set of studies, the various heparins were supplemented in NHP or 
plasma depleted of AT (AT-DP) or HCII (HCII-DP) by immunoaffinity, and then the 
inhibitory effects of heparins on factor X and thrombin were measured using the 
Heptest
®
, anti-Xa, and anti-IIa assays, as previously discussed. The results from the 
chromogenic anti-Xa and anti-IIa assays are expressed as IC50 µg/ml. It was evident that 
heparins predominantly produce their anticoagulant and antiprotease effects via AT. At 
the concentrations tested, AT depletion resulted in an almost complete inhibition of 
anticoagulant effects of all agents when measured by the Heptest
®
 assay. AT depletion 
also resulted in a pronounced decrease in the anti-Xa and IIa activities of all heparins. In 
fact, in both antiprotease assays, all agents showed an IC50 of greater than 10 µg/ml. 
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Other studies in our lab have shown that this AT-mediated effect is still persistent at 
concentrations of heparins as high as 100 µg/ml. 
Conversely, the HCII-mediated effects were not as evident. As measured by the 
Heptest
®
 assay, all agents produced significant anticoagulant effects compared to control 
when supplemented in both NHP and HCII-DP. At all concentrations tested, enoxaparin 
and bemiparin showed the strongest anticoagulant effect when supplemented in NHP 
versus HCII-DP. However, only about a 1 to 1.2-fold decrease in the clotting times after 
supplementation in HCII-DP was noted. UFH, semuloparin, and RO-14 were 
significantly more potent when supplemented in NHP compared to HCII-DP, but once 
again only small differences were observed.  
 Interestingly, for all agents, supplementation in HCII-DP resulted in stronger 
factor Xa inhibition when compared to supplementation in NHP. One would expect that 
there would be no differences between these two plasma systems since HCII has no effect 
on the inhibition of factor Xa. However, one could speculate at a possible theory to 
explain this discrepancy. In normal human plasma AT and HCII are both present. In 
theory, they both would be competing to bind with heparin. Although it is known that 
heparin has a 5-fold higher affinity for AT than for HCII (Yamagishi et al., 1984; Griffith 
et al., 1985), still some heparin most likely binds to HCII even in the presence of AT. 
Therefore, supplementation of heparins in plasma that is HCII depleted could mean that 
more drug is available to bind to AT. As such, in a ‘closed’ assay where only the 
inhibition of factor Xa is being measured, increasing the amount of drug exposed to AT 
would most likely produce a more potent inhibition. Similar results were observed in the 
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anti-IIa assay for UFH, bemiparin, and enoxaparin, although the differences for UFH and 
bemiparin were not significant. Here again, one might expect that since HCII solely 
inhibits thrombin, having a plasma system with both AT and HCII present would lead to 
greater inhibition of thrombin compared to a system without HCII; however, this was not 
the case. The theory above may still hold true in this scenario as well. Previous data has 
shown that the apparent Km (affinity constant) for the thrombin-AT reaction is 35 nM, 
whereas it is 150 nM for the thrombin-HCII reaction (Griffith et al., 1983). Therefore, 
heparin more strongly inhibits thrombin via AT than by HCII. This is evident by the fact 
that UFH, as determined by the anti-IIa assay, had an IC50 value greater than 10 µg/ml 
when supplemented in AT-DP and an IC50 value of 1.56 ± 0.06 µg/ml when 
supplemented in HCII-DP plasma.  
 Only the anti-IIa activity seemed to be MW-dependent, and this occurred after 
both supplementation in HCII-DP and NHP. In the anti-Xa assay, semuloparin was 
equally as potent as UFH at inhibiting factor Xa activity when supplemented in HCII-DP. 
However, when supplemented in NHP, semuloparin was the most potent inhibitor. This 
discrepancy can also be explained using the theory described above. Unlike AT, which 
binds to a specific pentasaccharide sequence in heparin, HCII binds to most heparin 
oligosaccharides greater than 4 monosaccharide units in length. However, in order for 
HCII to maximally inhibit thrombin, at least 26 monosaccharide units are required (Sie et 
al, 1988). This is consistent with the data on the MW dependence of heparins’ 
potentiating effects on HCII (Scully et al., 1987). Kinetic studies have shown that a 
decrease in MW from 32 kDa to 6 kDa was associated with an 11-fold decrease in the 
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maximum rate constant (Scully et al., 1987). Since LMW and ULMW heparins have an 
average MW in the range of 2.5 to 6 kDa, the majority of their molecules would have 
only a weak ability to potential HCII (Tollefsen, 1994). Therefore, when UFH is 
supplemented in NHP it is competing with both HCII and AT, whereas the majority of 
semuloparin is most likely only binding to AT. However, in HCII-DP, UFH is able to 
solely bind to AT to produce its effects. This explains why in the anti-Xa assay 
semuloparin is more potent than UFH when supplemented in NHP and equally as potent 
when supplemented in HCII-DP. 
Overall, these studies demonstrate that AT is the main cofactor required for 
heparin and its derivatives to produce their anticoagulant and antiprotease effects. The 
role of HCII in facilitating the anticoagulant effects of these agents was minimal and test 
dependent.  
 
3.2 The effects of heparin in purified-SERPIN plasma free systems 
To further examine the effects of heparin and its derivatives on a distinct 
SERPIN-mediated event, the various heparins were supplemented in both AT and HCII 
purified plasma free systems.  
In these studies, both UFH (0.57 ± 0.02 µg/ml) and semuloparin (0.65 ± 0.08 
µg/ml) were the most potent inhibitors (IC50) of FXa in the AT purified system. The AT-
mediated anti-Xa effects of enoxaparin (2.0 ± 0.47 µg/ml) and bemiparin (1.5 ± 0.22 
µg/ml) were 2.3 to 3.5-fold lower than that of UFH and semuloparin. The IC50 value for 
RO-14 was 3.6 ± 0.09 µg/ml, which was considerably higher than that of all other agents. 
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These observations along with the previous data suggests that the presence of the specific 
binding sequences is a more important determinant than MW in AT-mediated factor Xa 
inhibition (Ellis et al., 1986) 
It was observed that UFH more strongly inhibited thrombin via AT than by 
heparin cofactor II. The IC50 value determined for AT mediated thrombin inhibition was 
approximately 4-fold lower than the value determined for the HCII system. Similar 
results were observed for enoxaparin and bemiparin. This is consistent with previous 
studies that were mentioned earlier (Griffith et al., 1983; Yamagishi et al., 1984; Griffith 
et al., 1985). Semuloparin, and RO-14 were unable to inhibit thrombin via AT at a 
concentration of 10 µg/ml. Interestingly, semuloparin and RO-14 could promote HCII-
mediated inhibition of thrombin with IC50 values of 8.5 ±1.5 µg/ml and 94.7 ±2.3 µg/ml, 
respectively. There is an overall MW-dependence for both AT and HCII-mediated 
inhibition of thrombin, which has been described above. However, in this study, the 
HCII-mediated inhibition of thrombin by semuloparin was stronger than that of 
bemiparin, although not statistically. This may be due to the fact that the activation of 
HCII by heparins has also been shown to be dependent on charge density as well as MW 
(Hurst et al. 1983); however, the charge densities of the two agents are not known. 
These studies help delineate the role that AT and HCII play in mediating the 
antiprotease effects of the various heparins. These studies demonstrate that AT is the 
main cofactor required for heparin and its derivatives to produce their anticoagulant and 
antiprotease effects. Additionally, the presence of the specific binding sequences is a 
more important determinant than MW in AT-mediated factor Xa inhibition. The role of 
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HCII in facilitating the anticoagulant effects of these agents was minimal and was both 
MW- and test-dependent.  
 
4.0 High-AT AF semuloparin, semuloparin, and non-AT AF semuloparin 
studies 
The main purpose of these studies was to determine to what extent the 
preservation of the AT binding sequences plays a role in the anticoagulant and 
antiprotease effects of semuloparin. In order to delineate the role of enrichment with AT 
binding sequences, high-AT AF semuloparin (HAS), semuloparin, and non-AT AF 
semuloparin (NAS) were supplemented in NHP, HCII, and in an AT purified system, as 
well as in the thrombin generation assay at various concentrations. Earlier studies 
determined that the mean MWs for HAS, semuloparin, and NAS were 3.3, 2.9, and 2.6 
kDa, respectively. 
 
4.1 Supplementation in normal human plasma 
In the concentration range tested, both HAS and semuloparin produced 
comparable anticoagulant effects when measured by the APTT assay. However, at 
concentrations above 12.5 µg/ml, NAS was also able to produce significant anticoagulant 
effects compared to baseline. At the same concentrations, HAS and semuloparin 
produced significantly greater prolongation of the clotting time compared to NAS. These 
results indicate that AT binding does play a role in mediating the effects of these agents 
in the APTT assay. However, the anticoagulant effects that occur due to AT binding, at 
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least in this assay, seem to have a maximal response. This is evident by the fact that the 
HAS and semuloparin produced almost identical concentration-time curves. This may be 
because the APTT is a clot based assay, and while these agents strongly inhibit factor Xa, 
their effects on thrombin are still minimal. Therefore, increased amounts of AT binding 
sequences may not correlate to increases in the anticoagulant response in this assay.  
Furthermore, at high concentrations of NAS, prolongation of the clotting time was 
still achievable. This seemed to be the case in all assays, although compared to both HAS 
and semuloparin, these effects were drastically lower. One might think that a heparin 
fraction devoid of AT binding properties would exhibit little to no anticoagulant activity; 
however, there may be a few possible explanations to consider and are discussed below.  
Firstly, semuloparin may have direct antiprotease effects that are AT-independent. 
This is supported by studies done by Barrow et al (1994) that showed that part of the 
antithrombotic action of heparin and LMW heparin was due to a AT-independent 
inhibition of the intrinsic factor IXa-factor VIIIa complex (intrinsic fXase) which is 
responsible for the activation of factor X. They state that the ability of heparins to inhibit 
intrinsic tenase in an AT-independent manner is most likely dependent on their charge. 
The authors suggest that this activity is usually masked by the capacity of heparins to 
activate AT (Barrow et al., 1994). Secondly, some residual AT binding sequences may be 
present in the non-AT affinity fraction which is contributing to its anticoagulant effect. 
Finally, some activity may be mediated through HCII as this cofactor does not require a 
specific binding sequence to produce its effects.  
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The ability to inhibit thrombin is usually pretty low for semuloparin when 
measured by the TT (5U Ca
2+
) assay. In these studies, standard semuloparin was able to 
significantly prolong the clotting time at concentrations above 12.5 µg/ml. NAS was only 
able to significantly prolong the clotting time at the highest concentration. Interestingly, 
increased propensity to bind to AT conferred semuloparin with a greater ability to 
prolong the TT, as the HAS fraction significantly prolonged the clotting time at 
concentrations above 3.125 µg/ml. At the highest concentration, the HAS fraction also 
significantly prolonged the clotting time to a greater extent than standard semuloparin. 
This data implies that in the TT assay, increased AT binding allows more residual 
thrombin inhibition.  
Whereas, in the APTT assay there is more generation of thrombin, in the Heptest
®
 
assay, there is more generation of factor Xa, although the Heptest
®
 does measure both 
activities (Bara et al., 1990). In this assay, all three semuloparin fractions significantly 
prolonged the clotting time compared to baseline at all concentrations tested. The rank 
order was HAS > semuloparin > NAS. HAS was decidedly the most potent agent, as the 
concentration required to reach a clotting time of 100 sec was less than 1.56 µg/ml. In 
order to reach the same effect, semuloparin and NAS required a concentration of 
approximately 4 and 12 times that of HAS, respectively. The AT-mediated actions are 
clearly evident in this assay, where each fraction has a clearly independent concentration-
time curve. The clotting time at the highest concentration for HAS was > 300 seconds, 
which was 17-fold greater than the clotting time as measured by TT. This implies that the 
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majority of the activity measured in this assay probably reflects these agents ability to 
inhibit factor Xa.   
In the anti-Xa and anti-IIa assay, potency for these agents was calculated and 
presented as an IC50 value. As would be expected, all agents produced a measurable anti-
Xa effect. However, HAS and semuloparin were considerably more potent then NAS, 
with IC50 values of 1.0 ± 0.2 µg/ml and 1.5 ±0.5 µg/ml versus 5.8 ± 0.2 µg/ml, 
respectively. Since this assay measured only anti-Xa activity, these results were to be 
expected. HAS was the only fraction to have any anti-thrombin activity as measured by 
the anti-IIa assay. Compared to the anti-Xa assay, the activity in this assay was 
dramatically lower for HAS, with an IC50 of 16.3 ± 3.0 µg/ml. Additional AT binding 
may increase the antithrombin effects of heparin.  
In addition to the anti-IIa and TT assays, the anti-thrombin actions of these 
fractions were also measured using the TGA. Interestingly, in this assay, only HAS and 
semuloparin were able to inhibit thrombin generation at the concentrations tested. HAS 
had a powerful effect at concentrations as low as 0.3125 µg/ml. Its IC50 value was 0.70 ± 
0.07 µg/ml, which was significantly more potent than that of semuloparin (3.68 ± 0.24 
µg/ml) and NAS (>5.0 µg/ml). The fact that NAS was unable to inhibit thrombin 
generation demonstrates the importance of AT binding in inhibiting thrombin generation, 
which is important to the overall anticoagulant activity of heparins. Once again, these 
results confirm that additional AT binding may increase the anti-thrombin effects of 
heparin.  
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4.2 Supplementation into a purified AT system 
The different fractions of semuloparin were also evaluated in a purified AT 
system using both the anti-Xa and anti-IIa assays. Compared to supplementation in NHP, 
the IC50 values for HAS were significantly lower when supplemented in AT, as measured 
by both assays. This is interesting, since the IC50 value for NAS was higher when 
supplemented in AT. The IC50 values for semuloparin when supplemented in AT and 
NHP were similar, although slightly higher in the AT purified system. For NAS, the more 
potent anti-Xa effect when supplemented in NHP helps support the theory that 
semuloparin has other AT-independent activities that were already stated above. In 
addition, the possibility of residual AT binding sequences could help to explain the fact 
that in an AT purified system, it still has antiprotease activity. Of course, this also could 
be a direct effect on the intrinsic FX-ase complex as previously discussed (Barrow et al., 
1994). The fact that HAS was significantly more potent in the AT purified system may 
have to do with the theory stated earlier regarding HCII. Since AT is the only cofactor in 
the purified system, HAS is not competing with HCII to produce its effects. Of course the 
amount of AT in the purified system may be more than that found in NHP, meaning that 
more AT would be present for HAS to produce its effects.   
Overall results from these studies indicate that AT binding plays a significant role 
in the anticoagulant and antiprotease effects of semuloparin; however, the effects are 
assay dependent. Interestingly, a higher degree of AT binding was required to produce a 
significant inhibition of thrombin or thrombin generation as measured by the anti-II, 
thrombin time, and thrombin generation assays. These results indicate that AT binding 
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play a significant role in the ability of semuloparin to inhibit factor Xa, thrombin and its 
generation. In addition, these studies suggest that semuloparin has other non-AT 
mediated effects that contribute to its overall anticoagulant activity.  
 
5. Studies in platelet based systems 
5.1 Agonist-induced platelet aggregations studies 
The role of platelets in hemostasis is of considerable importance because of their 
ability to form platelet plugs after vessel injury and to localize coagulation reactions that 
eventually form thrombin. Adenosine diphosphate (ADP), collagen, arachidonic acid 
(AA), and thrombin are just a few agents that physiologically activate platelets in vivo 
because receptors for these agents are located on their surface (Packham et al., 1994). 
The interaction of heparins with platelets has not been fully elucidated, in that both 
inhibition and promotion of platelet aggregation have been reported. These effects may 
relate to the concentrations of heparins used in these studies.  
The main purpose of these platelet studies was to investigate the influence of MW 
on the interaction of platelets and heparins. The effects of UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 on agonist-induced platelet aggregation were compared in 
platelet rich plasma (PRP) at a concentration of 10 µg/ml. In these studies, UFH, 
enoxaparin, and bemiparin significantly attenuated the proaggregatory response to 
thrombin. Neither semuloparin nor RO-14 was able to inhibit thrombin-induced 
aggregation. The platelet aggregation induced by the other agonists was not modulated by 
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any of the agents at the concentration tested. These results are consistent with the data 
from Westwick et al (1986) and Messmore et al (1989) which demonstrate that both 
heparin and LMWHs are capable of inhibiting thrombin-induced platelet aggregation. In 
these studies no apparent MW-dependence was observed. This may be due to the 
relatively high concentration of heparins used in these studies. The high concentration of 
heparins may also account for the lack of response with other agonist-induced platelet 
aggregation to these agents. In fact, heparin has been shown to augment platelet 
aggregation induced by ADP at a concentration of 2.5 µg/ml, but not at higher 
concentrations (Brace et al., 1986). 
While the agonist-induced platelet aggregation assay is a quick and easy method 
to determine the interactions between platelets and heparin, there are a few caveats to 
consider. Since different components of the ‘true’ aggregation response such as platelet 
activation, receptor expression, interaction with blood cells, or granule release cannot be 
studied, this assay may not represent the true physiologic response in vivo. Therefore, 
new techniques such as flow cytometric technology, which can measure the modulation 
of TF activation of platelets by heparins, would serve as a good supplement in future 
studies (Ahmad et al., 2001) 
 In conclusion, UFH, enoxaparin, and bemiparin strongly inhibited thrombin-
induced platelet aggregation in vitro. Since UFH, enoxaparin, and to a lesser extent, 
bemiparin are strong inhibitors of thrombin in vivo, their ability to inhibit thrombin-
mediated platelet aggregation in vitro is expected. This coincides with the inability of 
semuloparin and RO-14 to inhibit thrombin in vivo. 
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5.2 HIT antibody-mediated platelet aggregation studies 
Heparin induced thrombocytopenia (HIT) is a clinical event where antibody 
mediated platelet aggregation occurs due to the presence of antibodies reactive against 
the platelet factor 4 (PF4)/heparin complex (Chong et al., 1993). These reactive 
antibodies occur due to current or previous exposure to heparin. Essentially, heparin 
combines with endogenous PF4 to form an immune complex. This immune complex then 
binds to the FcγRII receptors on circulating platelets and induces platelet activation, 
promotes thrombin generation, and platelet aggregation (Alving, 2002). Activation of 
platelets induces the release of microparticles and ultimately leads to a reduction in the 
number of platelets, which is termed thrombocytopenia (Chong et al., 1993). HIT is a 
serious side-effect of heparin therapy. HIT patients rarely bleed, but rather present with 
arterial thrombi which can lead to the loss of a limb or even death (Walenga et al., 2004) 
There are several assays that are used to help in the clinical diagnosis of HIT. These 
include platelet aggregation, immunoblots, 
14
C-serotonin release assays, and ELISA 
(Walenga et al., 1996). In addition, some of these assays can be used to screen different 
MW heparins for their potential to induce HIT in vitro (Walenga et al., 1996). 
In these studies, the capacity of heparin and its derivatives to promote a HIT 
response was examined in a platelet aggregation assay in which PRP from normal donors 
was mixed with heparins and serum collected from known HIT positive patients. The 
aggregation response was used as an index for the potential to cause HIT. Among test 
agents, bemiparin, enoxaparin, and UFH produced the highest levels of HIT+ antibody 
mediated aggregation. There did not seem to be a clear MW dependence, although both 
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ULMW heparins had the lowest HIT response. Interestingly, this seems to counter reports 
in the literature that indicate that the size of the heparin chain is an important factor in 
determining whether a HIT response is generated (Greinacher et al., 1995). It has been 
hypothesized that heparin chains with higher MW would bind more readily to PF4, and 
therefore have the higher potential to cause HIT (Kelton, 2002). The results of this study 
may also reflect differences in the degree of sulfation, which has been shown to be 
another critical factor for the production of a HIT response by heparin-like agents (Jeske 
et al., 1999). It has been shown that agents with a higher degree of sulfation tend to 
produce higher amounts of HIT responses (Jeske et al., 1999). It should be mentioned 
that degrees of sulfation for the LMW and ULMWs used in these studies were similar.  
The fact that the LMW heparins and UFH had a similar HIT response cannot be 
readily explained at this time. However, the platelet aggregation assays for HIT are 
known to be effected by a number of variables. As such, plasmas from all volunteers do 
not react in the same manner to HIT serum. It has been proposed that individual 
differences may reflect differences in platelet Fc receptor genotype, although the exact 
reason is still not known (Warkentin et al., 1995). Also, the concentrations of heparins 
used in this study may not have been the optimal concentrations necessary to see a MW-
dependence effect.  
These results suggest that antibodies to UFH may cross-react with other LMW 
and ULMW heparins causing aggregation. However, semuloparin and RO-14 showed the 
least cross-reactivity. 
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6.0 Neutralization studies 
UFH and UFH-derived oligosaccharides are widely used anticoagulants for 
interventional and surgical use. As such, the ability to reverse the biological effects of 
heparins is of considerable importance. Presently, the anticoagulant and bleeding effects 
of heparin are neutralized by protamine sulfate. However, protamine sulfate is known to 
have a variety of side effects such as bradycardia, hypotension, allergic reactions, and 
causing heparin rebound. In addition, the molecular and structural differences seen in 
LMWHs prevents protamine sulfate from fully neutralizing their anticoagulant effects. 
Therefore, an effective replacement for protamine sulfate is needed. 
The objective of these studies was to determine the neutralization profiles of 
various heparin antagonists, such as heparinase-I, protamine sulfate (PS), platelet factor 
4(PF4), polybrene (PB), and PMX 60056 (PMX) on UFH, enoxaparin, bemiparin, 
semuloparin, and RO-14 in NHP. The neutralizing effects of these antagonists were 
measured by comparing various clotting and antiprotease activities of heparins pre- and 
post neutralization. Since the ULMW heparins were unable sufficiently to inhibit 
thrombin activity, only the APTT, Heptest
®
, and anti-Xa assays were used. In order to 
compare these differences, % neutralization was calculated using baseline corrected 
µg/ml concentrations by the following formula: 
% Neutralization (%NT) = 1-(post antagonist/pre antagonist) * 100 
Since UFH was effectively neutralized by the various antagonists tested, it was 
used as the standard for which to select an appropriate concentration to calculate the % 
neutralization. As such, the 6.25 µg/ml concentration was selected because it was the 
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lowest heparin concentration that still allowed for maximal neutralization but did not 
exceed the ability for the antagonist to exert an effect. The 5.0 µg/ml concentration was 
selected to calculate % neutralization for the heparinase-I digestion study.  
 
6.1 Heparinase-I digestion 
 Heparinase-I (HP) is an enzyme purified and characterized from Flavobacterium 
heparinum (Lohse and Lindardt, 1992). The cleavage of heparin by HP occurs at the 
linkage regions between the GlcNS6S (1 → 4) IdoA2S and GlcNS3S6S (1 → 4) IdoA2S 
residues (Xiao et al., 2011). Xiao et al (2011) demonstrated that the GlcNS3S6S (1 → 4) 
IdoA2S linkage, which is found mainly within the AT binding site, is more susceptible to 
cleavage by heparinase-I than the major heparin disaccharide repeating unit GlcNS6S (1 
→ 4) IdoA2S. The authors concluded that heparinase-I would not be very useful in the 
preparation of intact AT binding sites (Xiao et al., 2011). In addition, heparinase has a β-
eliminative mechanism which yields oligosaccharides with an unsaturated uronic acid at 
the non-reducing ends (Lohse and Lindardt, 1992). 
Heparinase-I was capable of neutralizing heparin and its derivatives, though 
differential neutralization of the activities of these agents was noted. All heparins were 
neutralized to varying degrees depending upon the assay. Semuloparin had only 33% 
residual activity remaining as measured by the anti-Xa assay. This was the greatest 
degree of neutralization of semuloparin’s anti-Xa activity by any antagonist tested 
(discussed below). The ability of heparinase to neutralize the anti-Xa activity of 
semuloparin most likely has to do with the fact that heparinase preferentially cleaves 
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glycosidic linkages located within the AT binding site (Xiao et al., 2011). The fact that 
the anti-Xa activity of UFH and enoxaparin was neutralized to a greater extent than all 
the other agents points to a MW-dependent effect as well. In fact, this correlates to an 
enzymatic kinetic study done by Rice and Linhardt (1989). This study demonstrated that 
LMW heparin derivatives are more resistant to heparinase-I digestion because they bind 
poorly to the enzyme. Rice and Linhardt (1989) showed that the Vmax values for heparin 
derivatives are lower than that for heparin, which indicates an ineffective substrate 
positioning within the active site. Therefore, in terms of catalytic efficiency, heparin is a 
better substrate for heparinase compared to heparin-derived oligosaccharides.  
All of the anticoagulant and antiprotease activities of UFH were readily 
neutralized by heparinase-I with % neutralizations ranging from 88.1 to 98.8%. The most 
notable residual activity was observed in the Heptest
®
 (11.9%) and anti-Xa (6.4%) 
assays. In addition, all other agents had some residual anti-Xa activity remaining. These 
results are consistent with previous studies showing that some anti-Xa activity remained 
after heparinase-I digestion (Linhardt et al., 1982). The residual activity may be due to 
the anticoagulant effects of cleavage products, such as hexasaccharides and 
oligosaccharides possessing anti-Xa but not anti-IIa activities (Linhardt et al., 1982). 
Although, these agents were not profiled in terms of their anti-IIa activities in this 
dissertation (since some of these agents are basically devoid of this), studies have shown 
that the activities in the anti-IIa and TT assays for various LMW heparins are more 
susceptible to heparinase-I neutralization than anti-Xa activity (Fareed et al., 1997). Since 
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heparinase-I cleavage of these heparins reduces the length of their polysaccharide chains, 
this make sense, as longer chain lengths are required for thrombin inhibition. 
 
6.2 Protamine sulfate neutralization 
 Protamine sulfate (PS) is the heparin antagonist that has been used clinically for 
many years. The interaction of protamine with UFH and LMWHs has been well studied 
(Racanelli et al., 1985). However, little is known about the interactions of PS with 
ULMW heparins.  
 All of the in vitro activities of heparin were neutralized by PS as evident by the > 
98% neutralization. For the other LMW and ULM heparins neutralization was much less 
and assay dependent. In both the anticoagulant and antiprotease assays, neutralization by 
PS was clearly MW-dependent. It has previously been shown that a heparin chain length 
greater than 18 saccharides is required for optimal PS binding to heparin and its 
neutralizing effects (Harenberg et al., 1985; Holst et al., 1994). Both semuloparin and 
RO-14 were predominately resistant to PS neutralization. However, this result is not 
unanticipated. Walenga et al (1987) demonstrated that the anti-Xa activity of a 
chemically synthesized pentasaccharide was found to be resistant to the in vitro 
neutralization of PS. This effect was evident even at a PS/pentasaccharide ratio of 
30:1(Walenga et al., 1987). There does seem to be something more than MW affecting 
the neutralization of these heparins. Curiously, the % neutralization for bemiparin in both 
the Heptest
®
 and anti-Xa assay were closer to the effects seen with semuloparin than that 
of enoxaparin. This seems strange since bemiparin is closer in MW to enoxaparin. One 
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possible explanation may have to do with the sulfate charge. A study by Crowther et al 
(2002) showed that reduced sulfate charge is more crucial than molecular mass for the 
partial neutralization of anti-Xa activity by PS. However, the sulfate ratio of the LMW 
and ULMW heparins used in this study do not differ that drastically. The exact reasons 
why lower MW heparins’ activity is not completely antagonized by PS may not be fully 
known.  
In these studies, significantly different neutralization profiles were noticed when 
heparinase-I and protamine were used as heparin antagonists. This may be due in part to 
the difference in their mechanisms of action. Heparinase-I causes enzymatic degradation 
and protamine produces a stoichiometric polycation-polyanion complex with heparin.  
 
6.3 Platelet factor 4 neutralization 
As stated previously, PF4 is one of the main components found in the α-granules 
of platelet. It is known to be a potent neutralizing agent of heparin. In these studies, 
neutralization by PF4 appeared to be MW-dependent. Interestingly, as observed in the PS 
studies, the anti-Xa activity of the LMW and ULMW heparins appeared to be resistant to 
PF4 neutralization. These results are consistent with the observations from previous 
studies on oligosaccharides, in which fragments below 18 saccharides had high anti-Xa 
activity but no anti-IIa activity (Lane et al., 1984). Moreover, their anti-Xa activity 
became increasingly resistant to PF4 neutralization with decreasing MW (Lane et al., 
1984). Other studies done on commercial LMWHs have confirmed these observations 
(Fareed et al., 1988; Walenga et al., 1985). In the current study, this is even more evident 
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by the fact that the anti-Xa activity of semuloparin was even more resistant than that of 
RO-14, most likely due to the high degree by which semuloparin binds to AT. The 
molecular weight dependence can be further explained by the fact that optimal binding of 
PF4 to heparin requires a chain length of at least 18 saccharides (Cowan et al., 1986).  
 
6.4 Polybrene neutralization 
Polybrene is a synthetic heparin antagonist used in clinical laboratories to 
neutralize the anticoagulant effects of heparin as well as to determine heparin activity in 
human plasma (Montalescot et al., 1990). Essentially, heparin and polybrene form a 
polyanion-polycation interaction similar to that of protamine sulfate. Therefore, 
polybrene neutralizes the intermolecular charge of heparin and renders it inactive 
(Montalescot et al., 1990).  
All of the various anticoagulant and antiprotease activities of heparin were readily 
neutralized by polybrene. The % neutralization of heparin in the various assays ranged 
from 93 to 99%. The neutralization of LMW and ULMW heparins by polybrene was 
similar to that exhibited by PS, in that the anti-Xa activity of these agents was resistant to 
polybrene antagonism. In the anti-Xa assay, semuloparin had nearly 99% residual activity 
remaining. This is in contrast to the APTT assay, where 68% of semuloparin’s activity 
remained intact. Few publications can be found on the interactions of polybrene with 
heparins. However, one could speculate that the mechanisms responsible for the 
neutralizing properties of polybrene, mirrors that of PS. 
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6.5 PMX 60056 neutralization 
PMX 60056 (PMX) is the clinical lead compound of a series of small molecule 
oligomers that interact strongly with heparin and LMWHs. PMX is designed to restore 
coagulation by binding non-specifically to heparins in a charge based manner and 
disrupting their interaction with antithrombin.  
PMX was found to strongly neutralize the anticoagulant effects of all the agents, 
as measured by the APTT and Heptest
®
 assays. For these assays the % neutralization of 
the various heparins ranged from 50% to nearly 100%, which was greater than that seen 
with any of the other antagonist tested, with the exception of heparinase-I. The actions of 
UFH were completely abolished by PMX as measured by all assays. This data coincides 
with studies done in animal models that demonstrate the ability of PMX to neutralize the 
hemorrhagic and antithrombotic effects of heparin and enoxaparin (Kuziej et al., 2010). 
Even the actions of RO-14, which remained mainly untouched by the other antagonist, 
were neutralized between 31% to 64%. 
Interestingly, the effects of PMX were associated with a MW-dependency. 
However, semuloparin, as measured by the anti-Xa assay, had the most residual activity 
(75%) compared to all other agents. This most likely reflects the fact that a higher 
concentration of PMX would be needed to counter the increased percentage of AT 
binding sites on semuloparin. 
Because bleeding is a common side effect that can occur from use of heparins, 
there is a significant unmet medical need for a pharmaceutical agent which can safely 
reverse their anticoagulation activity. Therefore, these studies were carried out to 
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determine the neutralization profiles of various heparin antagonists and to help delineate 
their possible mechanisms of action. The overall results from these studies indicate that 
the various heparin antagonists differ with regards to their ability to neutralize the 
anticoagulant and antiprotease effects of UFH and its derivates. Neutralization by each of 
the antagonists was determined to be assay and MW dependent. At equigravimetric 
concentrations, all of the antagonists produced a > 90% neutralization of the 
anticoagulant and antiprotease effects of UFH. However, a greater degree of variation in 
terms of the neutralization of the LMW and ULMW heparins was noted. At 
equigravimetric concentrations, PMX and heparinase-I produced the strongest 
neutralization out of all the pharmacologic antagonists tested; however, their 
effectiveness was assay dependent. Both produced relatively similar neutralization 
profiles when measured by the APTT assay. Interestingly, the anticoagulant activity of 
each LMW and ULMW heparin, as measured by the Heptest® assay, was neutralized to a 
greater extent by PMX. Conversely, when measured by the anti-Xa assay, the 
antiprotease activity was more neutralized by HP. Neutralization by PF4 was assay 
dependent. Neutralization of the anticoagulant effects of each agent by PF4 was most 
noted in the APTT assay. Of all the antagonists tested, PS and PB were considered the 
least efficacious for neutralization of the LMW and ULMW heparins. Both demonstrated 
a MW and assay dependent neutralization effect. Similarly to PF4, neutralization of the 
anticoagulant effects of each agent by PS and PB was most noted in the APTT assay. 
Overall, this data suggest that PMX and heparinase-I may be potentially effective 
antagonists for the neutralization of LMW and ULMW heparins. However, while 
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heparinase-I is found to be effective when supplemented in vitro, administration of 
heparinase-I to heparinized patients was associated with an unacceptable safety profile 
(Stafford-Smith et al., 2005).  
 
7.0 Fibrinokinetics  
Clot formation is the last important step in the hemostatic process and entails 
thrombin-mediated cleavage of fibrinogen to fibrin. The ability of heparins to inhibit this 
process is one of their main functions. Fibrinokinetic measurements represent a method 
for the monitoring of the rate of fibrin formation. The differential effects of heparin and 
its derivatives on the rate of fibrin formation were compared. The fibrinokinetic profile of 
each agent was compared across a concentration range of 0 to 10 µg/ml in citrated NHP. 
Thrombin (5U) and CaCl2 (0.25 mM) were added to the supplemented NHP and the rate 
of fibrin formation was recorded at 405 nM. The rate kinetics and % inhibition of fibrin 
clot formation for each drug were calculated at the varying concentrations. 
A concentration- and MW-dependent inhibition of fibrin clot formation was 
observed. At all concentrations, UFH was consistently the most potent inhibitor of fibrin 
clot formation compared to all other agents. Both UFH and LMWHs were determined to 
be more potent in inhibiting clot formation compared to the ULMWHs due to their higher 
inhibitory effects on thrombin. Although semuloparin and RO-14 have a lower inhibitory 
effect on thrombin, both were able to inhibit fibrin clot formation induced by thrombin, 
albeit to a much lower extent than the other agents. These studies suggest that 
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fibrinokinetics assays offer a trigger dependent approach to investigate the anticoagulant 
effects of heparins.  
 
C. In vivo studies in animal models 
1. Hemorrhagic effects in a rat-tail bleeding model 
One of the major side effects associated with anticoagulant therapy and heparin 
overdose is the propensity for patients to experience hemorrhagic complications. In a 
meta-analysis study of 34,146 patients with acute ischaemic coronary syndromes, 
anticoagulant-associated bleeding was associated with a 5-fold increased risk of death 
during the first 30 days and a 1.5-fold higher mortality between 30 days and six months 
(Eikelboom et al., 2006). However, the hemorrhagic tendencies of all anticoagulants are 
not the same. Some studies have shown a reduced risk of bleeding after treatment with 
lower MW heparins compared to UFH (Viskov et al., 2009; Silvain et al., 2012). To 
assess the hemorrhagic tendency of a wide variety of anticoagulant agents, animal 
bleeding models have been developed to mimic the clinical situation of hemorrhage 
(Dejana et al., 1979; Cade et al., 1984; Rodgers and Levin, 1990). In these studies, a 
transectional rat-tail bleeding model was employed to measure arterial/venous bleeding. 
This method has previously been used to measure the hemorrhagic tendency of a wide 
variety of anticoagulant agents (Dejana et al., 1979; Gustafsson et al., 1996; Wienen et 
al., 2007). In this model, the various heparins were administered intravenously (IV) via 
the femoral vein with a circulation time of 5 min or subcutaneously (SC) under the scruff 
of the neck with a circulation time of 120 min. Heparins were given at doses of 0.25, 0.5, 
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and 1.0 mg/kg IV and 0.5, 1.0, and 2.5 mg/kg SC to rats. The hemorrhagic effect of each 
drug was determined by the time it took, after tail tip transection, for a thrombus to form 
and bleeding to stop. 
After IV administration, UFH, enoxaparin, semuloparin, and RO-14 were 
observed to dose-dependently increase blood loss. However, the dose-dependent increase 
for semuloparin was only observed between 0.25 and 0.5 mg/kg and was not considered 
significant. No additional increase in bleeding time was observed when the dose was 
increased to 1.0 mg/kg. Bemiparin caused a 2-fold increase in bleeding from baseline 
starting at 0.25 mg/kg, but remained steady at increasing doses. For UFH, enoxaparin, 
and bemiparin, a significantly increased bleeding effect was seen at all doses. Although 
the bleeding times increased from baseline for both of the ULMWHs, these effects were 
not considered statistically significant. Of the two ULMWHS, only RO-14 significantly 
increased bleeding loss at the highest dose. UFH and both LMWHs produced increases in 
bleeding at the lowest dose (0.25 mg/kg) that was greater than that of semuloparin at its 
highest dose (1.0 mg/kg). UFH (at 0.25 mg/kg) had already more than doubled the 
amount of blood loss relative to saline treatment. UFH exhibited the longest bleeding 
time at all doses compared to the other agents. 
Overall bleeding times were lower for the various heparins after SC 
administration when compared to the same IV dose. None of the heparins produced a 
measurable hemorrhagic effect at the lowest SC dose (0.5 mg/kg). The increase in 
bleeding times was dose-dependent for all agents. At a dose of 1.0 mg/kg, UFH, 
bemiparin, and RO-14 exhibited prolonged bleeding compared to saline control. Similar 
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results were observed for UFH, enoxaparin, bemiparin, and RO-14 at the 2.5 mg/kg dose. 
Interestingly, after SC administration, a 5-fold increase in dose was required to produce 
the same bleeding time for UFH as seen after IV administration. This most likely reflects 
the inability of UFH to be readily absorbed after SC administration at the concentrations 
tested.  
 Semuloparin did not significantly increase the amount of blood loss in this model 
even though the trend of blood loss was found to be dose-dependent over the dose range 
studied. These results were similar to a study done by Viskov et al (2009). They 
demonstrated that at equigravimetric doses (1.0 mg/kg SC), enoxaparin showed increased 
hemorrhage in rats, rabbits, and dogs, whereas semuloparin did not affect bleeding 
parameters.  
In these comparative hemorrhagic studies, heparin was found to be the strongest 
in terms of bleeding effect. The relative effect of semuloparin was minimal. The bleeding 
effects seemed to follow in a MW-dependent manner for all agents. This may be due to 
the proportionally lower ability of the LMW and ULMHs to inhibit thrombin. In addition, 
the bleeding plateau observed after IV administration by the LMW and ULMW heparins, 
may reflect an AT saturation mechanism. Despite additional AT binding sites at the 
higher dosages of heparins, there may be a saturation of the AT present in the blood of 
the rats and therefore even when higher dosages are given, there is no additional effect. 
It should be kept in mind that the use of bleeding time measurements as surrogate 
markers for clinical bleeding tendency remains controversial. Often times there are large 
variabilities in these models which can result in contradictory results. No single model is 
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considered optimal for predicting bleeding risks of anti-hemostatic agents in humans. In 
the future, testing these study agents in other bleeding models may help to create a better 
overall clinical assessment of the bleeding tendencies of these agents.  
 
2. Antithrombotic effects in a rat jugular vein clamping model 
 Normally, the intact endothelium provides an antithrombogenic surface over 
which blood flows freely. These antithrombogenic properties of the endothelium are in 
part due to the release of prostacyclin, nitric oxide, and TFPI (Radomski et at., 1987). 
When disruption of the endothelium occurs, the antithrombogenic properties of the 
endothelium are disrupted and subendothelial TF and collagen, which serve to activate 
the coagulation and platelet processes, are exposed. The rat jugular vein clamping model 
is a widely used animal models to test the antithrombotic actions of heparins and new 
antithrombotic drugs (Raake and Elling, 1989; Hayes et al., 1996). This model is used to 
mimic the events that take place during endothelial disruption by injury. In this model, 
repeated clamping of the jugular vein with a hemostat causes endothelial damage, and 
subsequent exposure of the underlying tissue leads to the formation of a prothrombotic 
locus. This vessel damage has been previously shown histologically (Raake et al., 1989). 
Thrombosis is initiated after TF, which is present subendothelially, is exposed to the 
flowing blood where it can complex with factor VII. In addition, platelets can become 
activated after exposure to collagen from the vessel wall. In this model, the number of 
clampings required to cause vascular occlusion is an index of antithrombotic activity.  
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 The treatment protocols were identical to the ones discussed for the rat-tail 
bleeding model. The antithrombotic properties of the various heparins were evaluated in 
response to the thrombogenic trigger after both IV and SC administration. The first 
clamping was made 50 minutes after IV drug administration or 160 minutes after SC 
administration in order to standardize the protocol.  
 Following IV administration, each agent exhibited a dose-dependent increase in 
the number of vascular clampings required to induce thrombus formation. At the lowest 
dose (0.25 mg/kg), UFH, enoxaparin, bemiparin, and semuloparin were able to 
significantly increase the number of clampings required to occlude the jugular vein 
entirely. Similar results were observed when the dose was doubled to 0.5 mg/kg. At this 
higher dose, RO-14 was also able to significantly inhibited thrombosis. A dose of 1.0 
mg/kg was required to double the number of baseline clampings. At this dose, all agents 
were able to significantly increase the number of vascular clampings required to induce 
thrombus formation. Only at the 1.0 mg/kg dose was any differences between the agents 
noted. UFH was able to inhibit vascular occlusion to a greater extent that both enoxaparin 
and RO-14. All other agents were more potent inhibitors of thrombosis than RO-14, as 
RO-14 failed to produce a two-fold increase in clampings at 1.0 mg/kg.  
 Bleeding seemed to disproportionally increase compared to the antithrombotic 
effects for these agents. This was evident by the fact that bleeding for all agents increased 
significantly after the lowest IV dose was doubled, but the antithrombotic effects only 
minimally increased. However this trend seemed to level off at the highest dose. For 
semuloparin, a 2-fold increase in the number of clampings required to occlude the vessel 
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was noted after the dose increased from 0.5 to 1.0 mg/kg; however, the bleeding time for 
this agent did not change. A similar result was noted for bemiparin. For all other agents, 
the increase in dose only increased the bleeding time by approximately 2 minutes after IV 
administration.  
 After SC administration, all agents produced dose-dependent antithrombotic 
effects; however, these effects were weaker compared to the results seen after IV 
administration. The dose of each agent which doubled the baseline clamping number 
following SC administration was 5-fold higher than the dose determined following IV 
administration. When an antithrombotic agent is administered SC, pharmacokinetic and 
bioavailability considerations become important in assessing the observed antithrombotic 
and hemorrhagic effects. Plasma drug levels are influenced by the extent of drug 
absorption as well as the time needed for the absorption to occur. Drug absorption and 
drug metabolism may occur simultaneously following drug administration. UFH is 
known to have a lower bioavailability after SC administration compared to the lower 
MW heparins (Hull et al., 1986). This may explain why at equal IV and SC doses, UFH 
had a 1.3- to 1.8-fold lower antithrombotic effect after SC administration compared to IV 
administration. When the ratios of the SC and the IV antithrombotic effects at the 0.5 
mg/kg dose were calculated, only enoxaparin and semuloparin had stronger 
antithrombotic effects after SC administration. However, at 1.0 mg/kg this effect was no 
longer seen. Interestingly, at this same dose, the ratios for the lower MW heparins were 
smaller than that of UFH. While these ratios do not predict bioavailability, they may 
suggest that the lower MW heparins were absorbed to a greater degree than UFH.  
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These studies suggest that after both SC and IV administration, increases in dose 
corresponded to increases in the antithrombotic effects of these agents. Moreover, MW 
did not seem to affect the overall antithrombotic effects of these agents at the doses 
studied. After SC administration, the antithrombotic effects of UFH were not as strong 
compared to enoxaparin, bemiparin, and semuloparin, although this was not always 
considered significant. Most likely, this is due to the fact that UFH is not as readily 
absorbed after SC administration compared to the other LMW and ULMW heparins.  
Based on the assumption that even with very effective factor Xa inhibition trace 
amounts of thrombin will be generated during thrombosis, a residual anti-thrombin 
activity could be highly beneficial for effective prevention of thromboembolism without 
having an influence on an increased bleeding liability. This may explain why 
semuloparin had equipotent antithrombotic effects but produced considerably lower 
bleeding times compared to the other heparins. 
 The hemorrhagic and antithrombotic effects of these agents vary widely. In 
addition to the ability of heparins to inhibit thrombin, other factors such as effects on 
platelets, duration of action, and metabolic processes are important to remember when 
evaluating their global actions. Other studies have shown that the endogenous release of 
TFPI may also play a role in the pharmacodynamic interactions of these heparins. 
Therefore, future studies may want to evaluate the effects of these study heparins by 
other non-plasmatic methodologies to further characterize their overall antithrombotic 
and anticoagulant effects. 
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3. Ex vivo analysis of rat whole blood and plasma  
 Ex vivo anticoagulant responses using the global clotting assays were also 
determined on whole blood and retrieved plasma samples obtained after cardiac puncture 
of the rats following both the bleeding and thrombosis protocols.  
 In whole blood, all agents produced dose-dependent increases in clotting time 
after both IV and SC administration when measured by the APTT assay. However, only 
UFH produced a significant increase in the clotting time after IV administration and only 
at the 0.5 and 1.0 mg/kg doses. The whole blood APTT was not a sensitive measure of 
the activity of the lower MW heparins after IV administration. In contrast, all agents, 
except for RO-14, were able to produce a significant dose-dependent increase in the 
clotting time after SC administration. RO-14 was only able to do so at the highest SC 
dose, but the increase was approximately only 1.2 times that of baseline. Interestingly, 
the anticoagulant response of semuloparin was significantly greater than that of the all 
other agents at the 2.5 mg/kg dose. This increase in APTT following SC administration 
correlated well to the antithrombotic activity of all agents except RO-14 (r
2
 >0.90). This 
was not the case after IV administration.  
 In plasma after IV administration, the anticoagulant effect for UFH, when 
measured using APTT, was similar to that seen in the whole blood assay. Only at the two 
higher doses was UFH able to significantly increase the clotting time. These effects were 
also significantly greater than that of the other agents. The plasma APTT clotting time for 
UFH was 3.5-fold higher compared to that seen in whole blood at the 1.0 mg/kg dose. 
The prolongation of clotting time by UFH after IV administration was correlated with its 
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antithrombotic activity (r = 0.95). After SC administration, only UFH significantly 
increased the clotting time compared to control and all other agents at a dose of 2.5 
mg/kg. It seems that the whole blood APTT, after SC administration, is a better measure 
of the anticoagulant effects of lower MW heparins.  
 In the Heptest
® 
assay, coagulation is initiated by the addition of activated factor X 
to the test plasma. Agents capable of inhibiting this factor Xa would be expected to 
prolong the clotting time. Following both IV and SC administration of the various 
heparins, the Heptest
® 
clotting time was dose-dependently prolonged. At the 0.25 mg/kg 
IV dose, semuloparin significantly increased the clotting time to a greater extent than 
enoxaparin and RO-14. Although, not statistically significant, the Heptest
® 
clotting times 
produced by semuloparin were greater than those of the other agents at all IV doses. This 
is interesting since the antithrombotic effects between the different agents were not 
significantly different at the doses studied. This implies that in the Heptest
® 
assay, the 
higher anti-Xa activity of semuloparin is not necessarily correlated with an increased 
antithrombotic response. After SC administration, only semuloparin significantly 
increased the Heptest
® 
clotting time at the 0.5 mg/kg dose. This response was 
significantly greater than that of UFH and RO-14. At the 1.0 mg/kg dose, only 
enoxaparin, bemiparin, and semuloparin were able to significantly increase the clotting 
times from baseline. Although UFH had a significant antithrombotic response at this 
dose, it was unable to significantly increase the Heptest
® 
clotting time. All agents were 
able to significantly increase the Heptest
® 
clotting time at the 2.5 mg/kg dose. The 
Heptest
® 
clotting times were considerably lower after SC administration than those 
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produced by these heparins at the same IV dose. The dose-dependent anticoagulant state 
was correlated to the antithrombotic activity of enoxaparin, bemiparin, and semuloparin 
after SC administration (r
2
 > 0.90). 
 The inhibition of thrombin as measured by the 5.0 U thrombin time (TT) was 
correlated with the antithrombotic activity of UFH but only after IV administration (r
2
 > 
0.90). At the highest IV dose, UFH produced a clotting time (> 300 seconds) that was 
greater than the linear range of the assay. Following both IV and SC administration, all 
heparins dose-dependently increased thrombin inhibition. However, this increased 
thrombin inhibition was not considered significant for all agents. At the lowest IV dose, 
only UFH, enoxaparin, and bemiparin significant increased the TT. At higher doses 
bemiparin no longer had a significant effect. This most likely had to do with the 
variability in the individual clotting times for each rat. The same was true for enoxaparin 
at the 0.5 mg/kg IV dose. However, at 1.0 mg/kg, enoxaparin once again significantly 
increased the TT. Only UFH was able to significant increased the TT at the 0.5 mg/kg 
dose, and this effect was significantly greater than for all other agents. Only at the highest 
IV dose was semuloparin and RO-14 able to significantly increase the TT.  
 After SC administration, only UFH was able to significantly increase the clotting 
time and only at concentrations above 1.0 mg/kg. At the 2.5 mg/kg dose, UFH was able 
to significantly inhibit the clotting time to a greater extent than all other agents. 
Interestingly, the inhibition of thrombin by UFH did not correlate well with its 
antithrombotic activity. This was evident by the fact that the clotting increased 
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approximately 6-fold between the 1.0 and the 2.5 mg/kg SC dose while the number of 
vascular clampings required to induce thrombus formation only increased by 1.2-fold.  
 The inhibition of factor X by the various heparins, as measured by the anti-Xa 
assay, was considered to be dose-dependent after both IV and SC administration. After 
the 0.25 mg/kg IV dose, only bemiparin, semuloparin, and RO-14 significantly inhibited 
factor Xa compared to control and UFH. At this dose, semuloparin was significantly 
stronger than all other agents. At both higher doses, all agents significantly inhibited 
factor Xa compared to control. After IV administration, the inhibition of factor Xa by, 
bemiparin, semuloparin, and RO-14 when measured by the anti-Xa assay strongly 
correlated (r
2 
> 0.92) with their antithrombotic activity. This correlation was not as strong 
for UFH and enoxaparin (r
2
 = 0.88 and 0.70, respectively).  
 The ability to inhibit factor Xa was lower after SC administration than the 
inhibition produced by these heparins at the same IV dose. However, at all SC doses, 
each agent was able to significantly inhibit factor Xa, except UFH at the lowest dose. All 
of the LMW and ULMW heparins were able to inhibit factor Xa to a greater extent than 
UFH at 0.5 mg/kg. Even at the highest gravimetric dose, semuloparin had a 1.9-fold 
greater anti-Xa activity than UFH. After SC administration, the inhibition of factor Xa by 
enoxaparin, bemiparin, and semuloparin when measured by the anti-Xa assay strongly 
correlated (r
2
 > 0.96) with their antithrombotic activity. This correlation was not as strong 
for UFH and RO-14 (r
2
 = 0.84 and 0.80, respectively).  
 The inhibition of thrombin by the various heparins, as measured by the anti-IIa 
assay, was considered to be dose-dependent after both IV and SC administration. After 
395 
 
IV administration, no agent was able to inhibit thrombin at the lowest dose. However, at 
the 0.5 and 1.0 mg/kg IV dose, all agents significantly inhibited thrombin compared to 
baseline. UFH was significantly stronger at inhibiting thrombin at both of these doses. 
After IV administration, the ability to inhibit thrombin by all agents was not strongly 
correlated to their antithrombotic activity.  
 After SC administration, at the 0.5 mg/kg dose, enoxaparin, bemiparin, and 
semuloparin were able to significantly inhibited thrombin. UFH, normally being a strong 
thrombin inhibitor, was unable to significantly inhibit thrombin at this dose. This was the 
same for RO-14. However, at the highest doses, UFH was able to significantly inhibit 
thrombin, as did all other agents. In fact, at the 2.5 mg/kg dose, UFH was considered to 
be significantly stronger than all other agents. Interestingly, only the anti-thrombin 
activity of enoxaparin and bemiparin showed a strong correlation to their antithrombotic 
activity (r
2
 = 0.99 and r
2 
= 0.90, respectively).  
 These ex vivo pharmacologic studies performed on blood and plasma samples 
collected from rats treated with various heparins are suggestive of the relevance of 
plasmatic effects of each agent to their antithrombotic activity. The degree of factor Xa or 
thrombin inhibition was not always proportional to the expected anithrombotic activity 
using UFH as a reference drug. This data suggests that heparin is a polyfunctional drug 
targeting multiple sites while the various derivatives produce their actions at certain sites 
related to their affinity and specificity for various cofactors. For each derivative, a 
distinct ex vivo assay effect/antithrombotic response was obtained. This is evident by the 
fact that the correlation between the assay responses and the antithrombotic effects were 
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different depending on the assay and route of administration. The strongest correlations 
for the LMW and ULMW heparins between activity and antithrombotic effects were seen 
in the anti-Xa assay and after SC administration. The antithrombotic effects observed in 
these studies were not observed to be MW-dependent; however, the hemorrhagic effects, 
especially at the highest doses, did appear to be MW-dependent. Based on these studies, 
it seems that the higher Xa/II ratio of semuloparin may allow trace amounts of thrombin 
to be generated during thrombosis. This residual anti-thrombin activity could be highly 
beneficial for effective prevention of thromboembolism without having an influence on 
an increased bleeding liability, as demonstrated in these studies. 
 
4. Pharmacodynamics and pharmacokinetics in non-human primates 
4.1 Comparative investigation of heparin and its derivatives 
 The main objective of this study was to evaluate the influence of MW and 
increased AT binding on the pharmacodynamic (PD) and pharmacokinetic (PK) profiles 
of UFH, enoxaparin, and semuloparin in non-human primates. UFH, enoxaparin, and 
semuloparin were administered to primates, both IV and SC, at doses previously 
described in the ‘Materials and Methods’ section. The PK and PD profiles of UFH, 
enoxaparin, and semuloparin were determined using the anti-Xa and Heptest
®
 assays. 
The plasma samples were also evaluated in terms of thrombin generation capacity and 
thrombin activatable fibrinolysis inhibitor (TAFI) activation. Additionally, tissue factor 
pathway inhibitor (TFPI) antigen and functional levels in the plasma were determined. 
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 Concentration-response curves were made by supplementing UFH, enoxaparin, 
and semuloparin in pooled baseline primate plasma over a concentration range of 0 to 20 
µg/ml. Best-fit curves were made and the drug concentration in each monkey blood 
sample was determined by extrapolation using the measured Heptest clotting times, 
percent inhibition of factor Xa and thrombin, or TFPI antigen and functional levels.  
The pharmacokinetic profile of these agents was analyzed using a standard non-
compartment model based on statistical moment theory (Gibaldi, 1984). This type of 
modeling has been used to investigate the pharmacokinetics of heparin and LMWHs 
previously (Estes, 1971; McAvoy, 1979; Cornelli and Fareed, 1999).  
 Since heparin and its derivatives (i.e. enoxaparin and semuloparin) have different 
molecular compositions, differences in pharmacokinetics can be expected. In fact, 
enoxaparin and semuloparin have different manufacturing processes, mean MWs, MW 
distributions, and amounts of AT-binding oligosaccharides. Enoxaparin, for example, 
undergoes benzylation followed by alkaline depolymerization. Semuloparin is produced 
by partial and controlled chemical depolymerization by a phosphazene base. The mean 
MW difference between enoxaparin and semuloparin is approximately 1.3 kDa. In 
addition, semuloparin has significantly more AT-binding material in fractions ranging 
from hexa to hexadecasaccharides compared to enoxaparin (Viskov et al., 2009). These 
differences may affect the overall pharmacokinetic behavior of heparins. Previous studies 
have alluded to this, since a relation between MW and half-life has been reported (Palm 
et al., 1990). 
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 Heparin and heparin-like compounds can either be compared on a gravimetric 
basis or in terms of functional activity In the present investigation, the heparins were 
compared on a gravimetric basis for the following reason. Some of the new indications 
for heparin derivatives are independent of their anticoagulant activity (e.g. an anti-
inflammatory effect is obtained by molecules with both low and high affinity for AT) 
(Ekre et al., 1986), and a dose based on the total weight of the drug (mg) is usually 
recommended for these indications. In fact, enoxaparin is known to be dosed on a 
gravimetric weight basis. In the clinical trials already performed, dosing of semuloparin 
was on a gravimetric basis.  
 In these studies the PK parameters were calculated from drug concentrations 
determined using a clot based and amidolytic assays. The pharmacokinetic behavior of 
heparins needs to be quantified in terms of their biological activity since they are multi-
component entities. This is common practice for determining pharmacokinetic parameters 
for heparins since chemical means of measuring plasma heparin levels do not exist. For 
this reason, the kinetic values were relative to the circulating anticoagulant actions of the 
different heparins. While potency measures for heparins typically measure anti-Xa 
activities, comparing PK data in terms of one activity does not ensure a complete biologic 
picture. This is reflected by the fact that various oligosaccharide components in UFH, 
LMW, and ULMW heparins have different biologic activities outside of their anti-Xa 
activity. Therefore, in the current study, multiple functional parameters were used to 
assess the PK profiles of these agents. However, with that in mind, to describe the 
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pharmacokinetic profiles of these agents in terms of the literature, the anti-Xa assay was 
considered the hallmark measure by which these agents’ activities will be discussed here.  
 Before discussing the PD and PK of these drugs, a few experimental limitations 
should be mentioned. One of the major drawbacks of this study was having suboptimal 
time points. Since absorption happens immediately after IV administration, the peak 
activity for each assay may have been missed since the first blood draw was not until one 
hour after injection. Furthermore, non-compartmental PK analysis is highly dependent on 
estimation of total drug exposure. Total drug exposure is most often estimated by the area 
under the concentration-time curve (AUC). In these studies, the trapezoidal rule 
(numerical integration), which is the most common method for determining AUC, was 
used to determine the AUCs for the various heparins. Due to the dependence on the 
length of 'x' in the trapezoidal rule, the area estimation is highly dependent on the 
blood/plasma sampling schedule. That is, the closer time points are, the closer the 
trapezoids reflect the actual shape of the concentration-time curve. The results may also 
have been influenced by practical limitations on the number of blood samples that could 
be collected and by the number of primates that could be included in each treatment 
group. The sample size may not have been high enough to offset the inter-animal 
variability (i.e. hepatic function, age, sex, and weight).  
 With the previously defined limits enumerated above, the results of these studies 
along with others (Frydman et al., 1988) have shown that the PD and PK behavior of the 
various heparins is different when the drug levels are determined using distinct biological 
activities. There was a dose-dependent increase in peak plasma concentrations (Cmax) 
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and AUC for all agents after both IV and SC administration. All three agents reached the 
circulation after IV and SC administration, where they exerted rapid and long-lived 
inhibitory effects on both factor X and thrombin.  
 At the lowest IV dose (0.25 mg/kg), all three drugs significantly prolonged the 
Heptest
®
 clotting time with peak activity at 1 hour. The peak plasma concentrations also 
correlated with this time point. This peak anticoagulant activity was stronger for 
semuloparin and enoxaparin than for UFH. While the Heptest
®
 clotting time was similar 
between semuloparin and enoxaparin at 1 hour, the plasma concentrations of each agent 
were not. In fact, more enoxaparin was needed to produce the same effect. When the IV 
dose was increased, all agents dose-dependently prolonged the Heptest
®
 clotting time. 
This time the peak anticoagulant effect was produced by UFH at 1 hour post drug 
administration (PDA) and was significantly greater than for enoxaparin and semuloparin. 
However, this effect quickly decreased after 1 hour for UFH and returned to near baseline 
levels by 4 hours. On the other hand, the effects of semuloparin and enoxaparin were still 
elevated at 28 hours. The plasma concentration-time courses followed the activity in the 
assay; however, similar to the effects seen at the lower IV dose, higher circulating levels 
of enoxaparin were required to have similar anticoagulant effects as semuloparin during 
peak activity.  
 Administration of the various heparins at an IV dose of 0.25 mg/kg produced a 
significant inhibition of factor Xa at 1 hour. This effect dramatically decreased at 4 hours 
for UFH and enoxaparin, where the anti-Xa effect of semuloparin was still measurable at 
28 hours. Semuloparin had a significantly stronger anti-Xa effect compared to UFH and 
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enoxaparin up to 6 hours PDA. The plasma concentration-time courses followed the 
activity in the assay. Similar trends were observed in this assay at the higher IV dose. The 
only major difference was that at 1 hour, which corresponded to peak activity for all 
agents, there were no differences between them. 
 The results from the TGA assay were interesting after both IV dosages. 
Considering that semuloparin has such a low anti-IIa activity, one would expect that it 
would exhibit lower thrombin generation inhibition compared to the other agents; 
however, this was not the case. All three agents dose-dependently inhibited thrombin 
generation. In fact, at the 0.5 mg/kg dose, this effect was near maximal inhibition (98%) 
for all three agents at 1 hour PDA. While this effect was once again near baseline levels 
at 6 hours for UFH, semuloparin was still able to significantly inhibit thrombin 
generation even at 28 hours. Moreover, this inhibition of thrombin generation was 
significantly greater than for enoxaparin and UFH at 4 and 6 hours and remained stronger 
than UFH at 28 hours.  
 When administered SC, all three drugs showed a significant prolongation of the 
Heptest
®
 clotting time with peak activity at 4 hours. The peak plasma concentrations also 
correlated with this time point. At 1, 4, and 6 hours PDA, the rank order of 
activity/concentration was semuloparin > enoxaparin > UFH. Semuloparin was still able 
to significantly prolong the clotting time even at 28 hours. At the higher SC dose (2.5 
mg/kg), semuloparin and enoxaparin significantly increased the clotting time, although 
the peak effects were seen at 4 hours for semuloparin and 6 hours for enoxaparin. This 
may mean that enoxaparin was absorbed slower after SC administration compared to 
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semuloparin. Their peak plasma concentrations also correlated with these time points. At 
this dose, enoxaparin was significantly more effective than semuloparin at prolonging the 
clotting time at 6 hours. However, semuloparin still exhibited significant anticoagulant 
activity at 28 hours PDA. 
 At 1.0 mg/kg SC, semuloparin strongly inhibited factor Xa at all time points. Peak 
inhibition occurred at 4 hours for all agents. Enoxaparin also significantly inhibited factor 
Xa at 1, 4, and 6, hours, but this activity had returned to baseline by 28 hours. The time 
course for enoxaparin was similar to that of UFH. However, to have the same anti-Xa 
effect as UFH, more enoxaparin was needed in the plasma circulation. When the dose 
was increased to 2.5 mg/kg SC, both semuloparin and enoxaparin significantly inhibited 
factor Xa at all time points. At 4 and 6 hours, the anti-Xa effects were indistinguishable 
between semuloparin and enoxaparin. However, semuloparin was significantly stronger 
than enoxaparin at 1, 28 and 32 hours. Interestingly, the plasma concentrations of 
semuloparin and enoxaparin were near baseline levels at 28 hours, but both still exhibited 
strong antiprotease effects at 32 hours. 
 Consistent with to the IV studies, all agents were able to strongly inhibit thrombin 
generation at 1.0 mg/kg SC. There were no differences noted between agents. While the 
plasma concentration for enoxaparin and semuloparin were relatively similar, the plasma 
concentration for UFH was remarkably lower at all time points. This indicates that lower 
concentrations of UFH are required to produce equipotent effects as enoxaparin and 
semuloparin. At 2.5 mg/kg SC, the inhibitory effects of semuloparin and enoxaparin were 
indistinguishable. Both exhibited near maximal inhibition of thrombin generation for 6 
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hours after PDA. In addition, both had anti-thrombin generation activity up to 28 hours 
later. The plasma concentration-time curves followed the assay activity. Although at 1, 4, 
and 6 hours, the plasma concentrations of semuloparin were significantly greater than 
enoxaparin. Similarly to that seen in the anti-Xa assay, the plasma concentrations of 
semuloparin and enoxaparin were near baseline levels at 28 hours, but both still exhibited 
strong anti-thrombin generation effects at this time. 
 In the present study, a clear non-linear pharmacokinetic profile was found for 
heparin in primates based on its anti-Xa and anti-IIa activity. Both peak plasma 
concentration (Cmax) and area under the plasma concentration time curve (AUC0-inf) 
increased with the administration of each escalating dose, in a non-linear fashion. The 
total clearance rate and Vd values varied with increasing doses. This finding is similar to 
previous studies using increasing doses of heparins in rats (Bjornsson and Levy, 1979). 
The non-linear kinetics of heparin has been explained to be MW-dependent. This is 
caused by a lower absorption of high MW molecules as well as higher affinity of these 
molecular to the vascular endothelium and neutralizing plasma proteins (i.e. PF4) 
(Glimelius et al., 1978). The critical length for affinity to the endothelium and 
neutralizing plasma proteins is the same as needed for expressing anti-thrombin activity. 
Therefore, the high affinity to the endothelium and low bioavailability of anti-thrombin 
components in heparin may account for its overall non-linear pharmacokinetics. 
Experimental work on heparin has indicated that its half-life increases with dose 
(Bjornsson and Levy, 1979). In the current study, this was found to be the case, however, 
only in the anti-Xa assay. The fact that the half-life did not change in the Heptest
®
 assay 
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is not completely understood. Since the Heptest
®
 assay measures anti-FXa and anti-FIIa 
activities, lower absorption of high MW molecules and thus low bioavailability of anti-
thrombin components may be masking the change in its half-life. 
 Unlike heparin, enoxaparin and semuloparin exhibited linear or first-order 
kinetics in non-human primates. This was reflected in a proportional increase in both 
Cmax and AUC0-inf values with increasing doses based on the Heptest
®
, anti-Xa, and 
TGA activity. In addition, the total clearance rate and Vd values did not vary statistically 
with increasing doses. Any minor variations noted most likely reflected the various study 
limitation already mentioned. However, it was noted that the majority of the variations 
occurred in the Heptest
®
 assay. Other studies have reported that the PKs of the anti-FXa 
and the anti-FIIa activities of LMWHs are quite different (Briant et al., 1989; Frydman et 
al., 1988). Since the Heptest
®
 assay uses a factor Xa activation system with a clot based 
endpoint, the PK parameters determined using this assay should have reflected both 
circulating anti-FXa and anti-FIIa actions. This might explain the variations noted 
between this assay and the anti-Xa assay. The same could be true for differences noted in 
the TGA. These findings agree with previous results on other LMWHs in humans 
(Kandrotas, 1992; Frydman, 1996).  
 Although bioavailability was not a PK parameter investigated here, previous 
studies have shown that lower MW heparins display better bioavailability characteristics 
compared to heparin (Hirsh et al., 2001). In fact, the bioavailability of UFH has been 
determined to be approximately 30% after SC administration at lower doses, while 
enoxaparin was about 92% (Boneu et al., 1990). However, it is worthy to note that the 
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bioavailability of UFH after SC injection has been shown to be as high as 92% when it is 
given at very high doses (Boneu et al., 1990). 
 It has been demonstrated that LMW heparins typically have a longer plasma half-
life than UFH and this is most likely due to a slower clearance of the smaller 
oligosaccharide chains. It has been suggested that the high clearance rate of UFH is due 
to the combined effect of a potent cellular clearance and a less efficient renal clearance, 
while the LMWHs are mainly eliminated by renal clearance (Caranobe et al., 1985; Palm 
and Mattsson, 1987). One possible mechanism that helps to explain these discrepancies in 
elimination routes has been discussed by Barzu et al (1985). They determined in vitro 
that binding and incorporation of heparin molecules into endothelial cells decrease with 
decreasing MW. It has also been shown that other cellular systems, e.g. the reticulo-
endothelial system, which are responsible for the elimination of heparin, have a similar 
MW dependency (Palm and Mattsson, 1987). While in these studies, the half-lives of 
enoxaparin and semuloparin were not always statistically greater than UFH, there still 
was a clear trend in this direction. The lower half-life of UFH was accompanied by 
higher rates of clearance compared to both enoxaparin and semuloparin, which based on 
previous research, was an expected outcome (Caranobe et al., 1985; Palm and Mattsson, 
1987).  
 Since heparin is known to bind with a high degree to various plasma proteins, 
endothelial cells, and macrophages, it is often reported that UFH has a low Vd (Barzu et 
al., 1985). In these studies, the Vd of for UFH was often times significantly larger than 
for enoxaparin and semuloparin. However, some drugs may exhibit both a high degree of 
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plasma protein binding and a large volume of distribution (Altamura et al., 1994). While 
drug bound to plasma proteins is not able to cross biological membranes, it is important 
to remember that binding of drugs to plasma proteins is a dynamic equilibrium (between 
bound and unbound drug). If the unbound (or free) drug is able to cross biological 
membranes, the drug may exhibit an extensive volume of distribution, despite a high 
degree of protein binding. As free drug moves across membranes and out of vascular 
space, the equilibrium will shift, in essence drawing drug off plasma protein to 
‘replenish’ the free drug lost from vascular space. This free drug is now also able to 
traverse membranes and leave vascular space. In this way, a drug with a very low free 
fraction (i.e., a high degree of plasma protein binding) can exhibit a large volume of 
distribution. Many examples of such drugs exist (e.g., tricyclic antidepressants). This may 
be a possible explanation as to why in these studies UFH was shown to have such a high 
Vd. Of course most of the PK studies done on heparin have been completed in humans or 
rats; it may be that the observed differences in the current study reflect the fact that the 
PK parameters were calculated in monkeys rather than humans.  
 One of the major finding of these studies was that the overall kinetics of ultra low 
molecular weight semuloparin was similar to that of enoxaparin and other lower 
molecular weight compounds (Frydman, 1996). The kinetics of the elimination phase did 
not suggest saturable processes for semuloparin. In addition, these data demonstrated that 
semuloparin is most likely cleared linearly by a renal mechanism. Moreover, semuloparin 
was observed to have a predictable anti-factor Xa effect. Overall, semuloparin showed 
favorable PD and PK characteristics in the present study.  
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4.2 TFPI measurements in primate plasma  
 The anticoagulant effects of heparin and its derivatives are mediated mainly 
through their direct interaction with AT and HCII (Hirsh et al., 2001). Studies have 
shown that heparins can release the Kunitz-type protease inhibitor, tissue factor pathway 
inhibitor (TFPI) from the endothelium, and this may contribute to their overall 
anticoagulant effect (Girard et al., 1989). The main purpose of these studies was to 
investigate the influence of MW and AT-binding affinity on the TFPI release in a non-
human primate model.  
 TFPI is a serine protease inhibitor, known to inhibit the tissue factor of the 
extrinsic coagulation pathway. Both heparin and LMWHs have been shown to release 
TFPI from vascular endothelium by displacing the TFPI from endothelial cell surface 
glycosaminoglycans (Sandset et al., 1988; Ariens et al., 1994). It has also been reported 
that heparins are capable of binding to TFPI and forming heparin-TFPI complexes which 
promote synergistic anticoagulant effects (Valentin et al., 1994). Based on these studies 
and others like it, it has been proposed that TFPI may be as important for the 
anticoagulant actions of heparin and its derivatives as AT and HCII (Valentin et al., 
1992). 
 In the present study, the effects of UFH, enoxaparin, and semuloparin on TFPI 
release were compared in non-human primates. Immunologic and functional TFPI levels 
were measured using ELISA and chromogenic assays, respectively. The ELISA measures 
TFPI using a monoclonal antibody directed against the first Kunitz domain (Ostergaard et 
al., 1997). This assay measures the total TFPI content in the plasma sample. The 
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functional assay measures the non-truncated form of TFPI present in the plasma through 
evaluating its antiprotease activity. The non-truncated form of TFPI is known to be the 
more active form. Another carboxy truncated version of TFPI exists, but this version is 
known express a reduced antiprotease activity (Nordfang et al., 1991). 
 After both IV and SC injection, circulating TFPI antigen and functional levels 
significantly increased in a dose-dependent manner for all agents. After IV administration 
of UFH, enoxaparin, and semuloparin, the functional TFPI activity was highly elevated at 
1 hour. Although at the 0.25 mg/kg dose the TFPI antigen level did not directly correlate 
to the functional levels, the two levels were both significantly increased from baseline at 
1 and 4 hours. This was probably an anomaly since at the higher dose, and after SC 
administration, the TFPI antigen levels correlated rather well with the functional TFPI 
activity. The correlation between the TFPI antigen levels and functional TFPI activity 
suggests that the full-length, functional TFPI is released upon heparin administration. 
After the 0.25 mg/kg dose, UFH produced significantly higher TFPI antigen levels at 1 
hour. No significant differences between these agents were noted in the functional TFPI 
activity levels at this dose.  
 At the higher IV dose, all three agents significantly increased TFPI antigen levels 
at 1, 4, and 6 hours. UFH significantly released more TFPI antigen compared to 
enoxaparin and semuloparin at 1 and 4 hours. Interestingly, the functional TFPI levels 
were only significantly increased at 1 and 4 hours for all agents. This could mean that 
while heparins are releasing TFPI even after 6 hours, not all of it may be the in the 
functional form, or it could mean that TFPI is being modified in the circulation following 
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release. At the 0.5 mg/kg IV dose, UFH increased the TFPI functional activity to a 
greater degree than semuloparin and enoxaparin at 1 hour. Semuloparin produced a 
greater degree of functional TFPI activity compared to enoxaparin at 1 and 4 hours. This 
was an interesting finding, since the TFPI antigens levels seemed to follow in a MW-
dependent manner. Although the specific structural features of heparin that contribute to 
this effect on TFPI release are still relatively unknown, a few suggestions have been 
made. A study by Ma et al (2007) demonstrated a molecular weight dependence of TFPI 
release by heparin and its low molecular weight fractions after intravenous and 
subcutaneous administration. Additionally, Valentin et al (1994) proposed that heparin 
displacing TFPI from the endothelium might depend on total sulfate content and 
localization of charge groups. Since semuloparin has a smaller MW than enoxaparin, if 
MW was the sole contributing factor to the release of TFPI, then the TFPI activity would 
not have been significantly higher for semuloparin compared to enoxaparin. While the 
sulfate content of semuloparin and enoxaparin determined in these studies were not 
significantly greater than each other, semuloparin did have a slightly higher amount. This 
may have contributed to the overall effect.  
 Administration of these agents at a dose of 1.0 mg/kg SC elevated the functional 
TFPI activity and plasma TFPI antigen levels at 1, 4, and 6 hours. No differences in the 
antigen levels were noted between these drugs. Whereas the peak concentrations for both 
levels were at 1 hour after IV administration, the peak levels were at 4 hours after SC 
injection. Interestingly, both UFH and semuloparin significantly increased TFPI activity 
compared to enoxaparin at 4 hours; once again implying that more than MW is 
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contributing to this effect. However, at the 2.5 mg/kg SC dose, this was not the case. 
While both enoxaparin and semuloparin significantly increased the TFPI antigen and 
activity levels at 1, 4, and 6 hours, the TFPI activity levels were greater for enoxaparin at 
4 and 6 hours. These time points correlated to the peak TFPI activity levels after SC 
administration. In terms of the pharmacokinetic data, there were no differences in the 
half-life and AUC except at the 0.5 mg/kg dose, where semuloparin had a longer half-life 
and greater AUC compared to enoxaparin. Since the pharmacokinetic parameters were 
determined by the TFPI antigen and functional levels and not on the plasma 
concentration-times curves of the various heparins, the clearance and Vd were not 
evaluated.  
 It has been suggested that the amount of TFPI released into the plasma is 
determined by the dose of heparin administered. Interestingly, Hansen et al., 1996; 
Hansen et al., 1998; and Bendz et al., 1999 demonstrated that continuous and repeated IV 
and SC administration of heparin causes the partial depletion of TFPI antigen and heparin 
releasable TFPI in man, but not during subcutaneous injections of LMWH. It would be 
interesting in the future to examine the effects of semuloparin after repeated IV and SC 
administration to determine whether it depletes endogenous TFPI stores.  
 The overall significance of the heparin releasable TFPI to the pharmacological 
effects of heparins still remains largely unknown. However, studies have indicated that 
the enhancement of TFPI activity may contribute to the antithrombotic effect of heparin 
and its derivatives (Sandset et al., 1988). Additionally, other studies have suggested that 
TFPI may be involved in the non-anticoagulant effects of heparins, such as their anti-
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inflammatory effects and modulation of arteriosclerosis (Esmon, 2002). However, how 
much TFPI contributes to these effects is still unknown. In these studies, it was shown 
that an ultra low molecular weight heparin was capable of dose-dependently releasing 
TFPI from the endothelium. Furthermore, semuloparin was shown to be as effective as 
both heparin and enoxaparin at increasing functional TFPI activity levels in the plasma, 
which may indicate a significant role of AT-binding affinity. This effect on TFPI may 
contribute to the anti-cancer effects demonstrated in this thesis. 
 
4.3 TAFI measurements in primate plasma 
Early in vitro studies demonstrated that heparin and its derivatives were able to 
inhibit TAFI activation in normal human plasma (NHP). Primates (Macaca mulatta) are 
widely believed to exhibit similar fibrinolytic responses in comparison to humans (Fareed 
et a., 1985) The main purpose of the present study was to investigate the influence of 
MW and AT binding affinity on the ability of heparins to inhibit TAFI ex vivo using a 
non-human primate model. Plasma samples taken from non-human primates treated with 
UFH, enoxaparin, and semuloparin either SC or IV, were evaluated for their ability to 
inhibit TAFI activation.  
Firstly, the modified Pefakit

 TAFI assay was validated in NMP as the method 
was developed for use in human plasma. NMP was supplemented with UFH, enoxaparin, 
and semuloparin at concentration ranges of 0 to 10 µg/ml for UFH and 0 to 100 µg/ml for 
enoxaparin and semuloparin. The calibration curve was constructed by diluting the NMP 
50, 25, 12.5, 6.25, and 3.12% with 5% albumin. Unlike in NHP, the change in OD at 5 
412 
 
min was not sufficient to calculate TAFI activation; therefore results were obtained from 
OD reading at 30 min. At this time point, the OD readings were similar to those seen at 5 
min for NHP. The in vitro supplementation studies clearly validated the use of the TAFI 
assay in non-human primates. In addition, UFH, enoxaparin, and semuloparin were able 
to inhibit TAFI activation when supplemented in NMP. UFH was the most potent of all 
three agent followed by enoxaparin.  
In these studies, all agents were able to inhibit TAFI activation in a dose-
dependent manner. After IV administration, at a dose of 0.25 mg/kg, UFH and 
semuloparin were able to significantly inhibited TAFI activation up to 4 hours. While 
some TAFI inhibition was exhibited by enoxaparin (20%) at 1 hour, the results were not 
considered significant. At an increased dosage, peak inhibition for UFH and enoxaparin 
occurred at 1 hour and was considered statistically significant from baseline. 
Semuloparin, on the other hand, had significantly inhibited TAFI activation up to 6 hours 
PDA. After SC administration, all three agents showed a similar inhibition of thrombin at 
a dose of 1.0 mg/kg. However, while inhibition of TAFI activation at 4 and 6 hours by 
semuloparin was similar to the inhibition by UFH and enoxaparin, it was not considered 
statistical significant. Again, all agents were able to dose-dependently inhibit TAFI 
activation after SC administration. Interestingly, when the dose was increased, 
semuloparin was able to strongly inhibit TAFI activation up to 28 hours after injection. 
The peak activity for both agents was at 6 hours.  
These data are interesting because other studies have linked the ability of heparins 
to inhibit TAFI with their anti-IIa activity, as thrombin play a major role in the activation 
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of TAFI. Florian-Kujawski et al (2004) reported that the ability of heparins to inhibit 
TAFI was strongly correlated to their anti-IIa activity. Here, semuloparin was able to 
strongly inhibit TAFI activation after both IV and SC administration even though it has a 
very low direct anti-IIa effect. Additionally, at some time points, this activity was equal 
to or even stronger than that of UFH. It should also be noted that this activity correlates to 
the inhibition of thrombin observed in primates when measured by the thrombin 
generation assay. Together these data suggest, that while semuloparin can strongly bind 
to AT and specifically inhibit factor Xa, a very low residual anti-IIa activity must remain. 
As such, this residual anti-IIa activity seems to be playing an important role in providing 
semuloparin with thrombin generation and TAFI inhibitory properties. In addition, 
semuloparin may have a direct effect on TAFI, causing its inhibition. TAFI’s role is to 
regulate fibrinolysis by protecting the clot from lysis. By inhibiting TAFI, the clot is 
more susceptible to fibrinolysis. This mechanism of inhibition of TAFI by semuloparin 
and other heparins may contribute to their therapeutic effect.  
 
D. Lewis lung carcinoma (LLC) tumor model 
1. In vivo LLC tumor model 
The coagulation system becomes activated in cancer, and this activation is further 
amplified by cancer treatments such as radiation, chemotherapy, and surgery (Rickles and 
Falanga, 2001). Thrombosis is associated with almost all cancer types, and it is the 
second leading cause of death in cancer patients (Khorana et al., 2007). Cancer patients 
are frequently treated with anticoagulants, including heparins, to treat and prevent 
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thrombosis that occurs due to a range of factors directly related to the cancer and its 
treatment. Since heparins are negatively charged polysaccharides they can bind to a 
whole host of proteins and molecules and affect their activity. As such, preclinical 
evidence consistently supports the ability of heparins to affect cancer progression beyond 
their normal anticoagulant activity.  
It is important to keep in mind that manufacturing differences between UF, LMW 
and ULMW heparins affect the biological and chemical properties of these agents. In 
particular, molecular weight, degree of sulfation (charge density), and the percentage of 
AT-binding sequences present varies between each of the agents. As a consequence, the 
various heparins may produce different anticancer effects. 
The goal of these studies was to determine whether heparin and its derivatives, 
with or without adjunctive treatment of paclitaxel (taxol), were able to augment the 
inhibition of tumor growth in vivo. The primary endpoint included the tumor volume, 
tumor weight, spleen length, and spleen weight. Furthermore, these studies also 
attempted to demonstrate any potential interaction between heparins and taxol in terms of 
anti-tumor effects. UFH, non-AT AF UHF, enoxaparin, bemiparin, semuloparin, and 
non-AT AF semuloparin were tested as monotherapy and in combination with taxol at 
concentrations of 0.25, 0.5, and 1.0 mg/kg. It was hypothesized that LMW and ULMW 
heparins would be able to attenuate tumor growth. 
The solid neoplasm used for these experiments was the Lewis lung carcinoma 
(LLC) model. This non-small cell lung carcinoma was discovered in 1951 by Dr. 
Margaret R. Lewis of the Wistar Institute (Mayo, 1972). The LLC tumor spontaneously 
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originated as a carcinoma of the lung of a C57BL mouse (Mayo, 1972). The use of 
subcutaneously implanted LLC tumors has been well documented (Mayo, 1972; Young 
et al., 2001). 
Among all malignancies, lung cancer has the greatest impact on mortality 
worldwide (Boing et al., 2007). Several studies have reported the effects of LMWHs 
against small cell lung cancer (SCLC), and the results are encouraging (Mellema et al., 
2011). However, the knowledge of the mechanisms of action is relatively incipient. Using 
the LLC tumor model in determining the effects of heparins on this tumor type is of 
importance. 
The adjunct chemotherapeutic agent taxol was selected since it is routinely used 
to treat lung cancer. Taxol belongs to a class of medications called antimicrotubule 
agents. It works by stabilizing microtubules which interferes with the normal breakdown 
of microtubules during cell division, thus stopping the growth and spread of cancer cells. 
These dissertation studies show that the various heparins are able to effectively 
inhibit experimental tumor growth in a dose-dependent manner. In addition, the heparins 
had no effect on tumor necrosis. In the first set of experiments, mice were treated with 
1.0 mg/kg SC of each agent daily along with bi-weekly doses of 15 mg/kg IP taxol. Mice 
treated with UFH experienced a high degree of mortality due to bleeding, and therefore 
were no longer injected with UFH at this dose. Instead, at the highest dosage, a non-AT 
AF fraction of UFH (non-AT AF UFH) was included. This prevented the drug from 
having any anticoagulant effects (as determined by global anticoagulant assays, data not 
shown) and subsequently reduced the bleeding effects seen with the standard UFH.  
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 At the 1.0 mg/kg dose, all agents, with and without adjunctive treatment of taxol, 
significantly attenuated the growth of the tumors compared to control (p < 0.01), with no 
discernible differences between each agent observed. The percent inhibition of tumor 
growth for all agents was between 55% and 83% compared to control. Additionally, the 
reduction in tumor weights correlated with the reduction in tumor volumes. Taxol alone 
was able to significantly inhibit tumor growth compared to the saline control. However, 
the drugs with adjunctive treatment of taxol showed no synergistic effects. With this, the 
high dose of taxol was thought to be masking the effects seen by the various heparins. 
Subsequently, at the lower doses of heparins, the taxol dose was reduced by half in order 
to tease out the individual effects of the heparins and taxol.  
 Decreasing the dosages of the various heparins (0.5 mg/kg) once again strongly 
attenuated the growth of the tumors compared to control. There were no significant 
differences between any of the agents. Mice treated with UFH alone had a high rate of 
mortality at the 0.5 mg/kg dosage and were excluded from this analysis. On the other 
hand, the use of taxol in conjunction with UFH increased the longevity of the mice 
allowing them to remain in the study. 
The % inhibition from the saline/saline control for all agents was between 50% 
and 90% at the 0.5 mg/kg dosage. Only the semuloparin/saline (A/S) group was 
significantly different from the taxol group, indicating that semuloparin has a more potent 
antitumor effect than taxol alone at this dose. Interestingly, the addition of taxol to the 
semuloparin treatment did not confer any additive effects. In fact, at all dosages of 
semuloparin, the addition of taxol seemed to slightly reduce the antitumor effects of 
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semuloparin. Differences between the semuloparin/saline and semuloparin/taxol (A/T) 
group, however, were not statistically significant. For all other agents, no differences 
between when given alone or in conjunction with taxol were observed. However, when 
comparing the drugs, with and without taxol present, to the taxol control group, the 
heparin groups appear to have a stronger inhibitory effect, although not significantly. 
This may imply that whatever mechanisms are inhibiting tumor growth by heparins at 
this dose (0.5 mg/kg) are actually outweighing the actions of taxol. Interestingly, when 
the dosage of heparin was decreased by half again (0.25 mg/kg), this effect was 
abolished.  
 Decreasing the dosage of heparin to 0.25 mg/kg prevented some of the heparin 
groups from significantly inhibiting tumor growth. Semuloparin alone, bemiparin alone 
and with taxol, and enoxaparin with taxol were still able to significantly (p <0.05) 
attenuate tumor growth as determined by the decrease in tumor volume and weight. This 
was also the case for taxol alone. When the % inhibition of tumor growth from the saline 
control was calculated, both semuloparin with taxol and enoxaparin with taxol were 
considered statistically significant as well (p < 0.05). The lower dose of UFH prevented 
the bleeding associated deaths that were evident at the higher doses, but did not produce 
any significant antitumor effects compared to control.  
 Interestingly, the ability to bind to AT and produce anticoagulant effects is not 
required to inhibit tumor growth in this model. This is evident by the fact that both 
semuloparin and the non-AT AF semuloparin fraction were able to significantly inhibit 
tumor growth to a similar degree. Only when given at the lowest dosage, did the standard 
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semuloparin and the non-AT affinity fraction differ, whereas semuloparin significantly 
inhibited tumor growth, the non-AT affinity fraction did not. The reason for this is 
unclear. Consistent with the non-AT AF semuloparin fraction, the non-AT UFH fraction 
at 1.0 mg/kg SC was also able to inhibit tumor growth. This data coincides with other 
studies that demonstrate that modified heparins with no anticoagulant activity still have 
antitumor and antimetastatic properties (Lapierre et al., 1996).  
 There did not appear to be any overall effect of molecular weight on inhibiting 
tumor growth. However, the fact that UFH was not able to significantly reduce tumor size 
indicates, at least after SC administration, smaller MW heparins are more efficacious. 
This is most likely due to the fact that smaller heparin molecules have a better 
bioavailability after SC administration. In addition, differences in the MW between the 
LMW and ULMW heparins (MW range of 2.6 to 5.0 kDa) used in this study are small; 
therefore, any effect of MW may not be easily seen using these agents. In the future, 
using agents with a greater degree of MW variability may help to further elucidate the 
role that MW may play. 
 These studies also examined at splenomegaly, a common occurrence associated 
with the LLC mouse model, to determine if heparins have any effect on spleen size. The 
length and weight of each spleen was measured and compared to saline treatment and 
mice that were not injected with tumor cells. Heparin and its derivatives were determined 
to have no effect on spleen length. However, the injection of the LLC cells and 
subsequent tumor formation was found to produce an increase in spleen lengths. The 
same was true for spleen weights, although both non-AT AF UFH and non-AT AF 
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semuloparin significantly increased spleen weight compared to saline treatment. This 
data indicates that the pentasaccharide AT binding sequence alone or the ability of 
heparins to bind to AT prevents further splenomegaly in LLC bearing mice. This suggests 
a role of AT-mediated SERPINs in this process. 
 Although, this study did not find any synergistic effects between heparin and 
taxol does not mean that overall, giving heparins in conjunction with anticancer therapies 
would not be beneficial. In fact, a growing body of data suggests that adjunctive therapy 
with heparin may improve prognosis in cancer patients (Kakkar et al., 1995; Kakkar, 
2003). In fact, a study by Altinbas et al (2001) showed that in patients with SCLC treated 
with LMWHs in conjunction with chemotherapy, the duration of progression-free 
survival was significantly longer with the addition of LMWH. On this matter, studies 
from this dissertation study are inconclusive. For one, these results are from a mouse 
model and may not truly reflect what might be seen in humans. Secondly, the dosages of 
heparin or taxol may be too high, thus creating a masking effect of one or the other. 
Finally, heparins might have a more additive effect with a different type of 
chemotherapy.  
 In conclusion, the LMW and ULMW heparins are strong inhibitors of tumor 
growth in a LLC tumor model. They were shown to be as effective as a traditional 
chemotherapy in reducing tumor burden. Most likely, heparins will never be used a sole 
anticancer treatment; however, in conjunction with other chemotherapeutic agents, they 
may prevent VTE, help to attenuate tumor growth, and ultimately prolong survival in 
420 
 
cancer patients. Additionally, the antitumor effects of heparins may be useful in patients 
were chemotherapy is not an option.  
 
2. Possible mechanisms of action 
An array of mechanisms has been proposed to explain the effects of heparin on 
tumors. Some of these mechanisms can be generally classified as direct antitumor effects 
and antiangiogenic effects. In these studies, the effects of heparins on cell proliferation, 
cell apoptosis, growth factors, and angiogenesis were examined 
 
2.1 Cell proliferation and apoptosis 
Cancer occurs when the homeostatic balance between cell growth and cell death 
is disturbed. Research in cancer biology has discovered that a variety of aberrations in 
gene expression of anti-apoptotic and pro-apoptotic proteins can contribute to the many 
forms of the disease; b-cell lymphoma (Bcl-2) is one such anti-apoptotic protein. 
Bcl-2 is the founding member of the Bcl-2 family of apoptosis regulatory proteins 
encoded by the Bcl-2 gene. Bcl-2 has been implicated in a number of cancers including 
lung carcinomas, breast, melanoma, prostate, and chronic lymphocytic leukemia 
(Colombel et al., 1993; Ramsay et al., 1995; Kitagawa et al., 1996; Plati et al., 2011). 
This suggests that decreased apoptosis may play a role in the development of cancer. 
Studies have shown that heparins can affect tumor growth via an array of different 
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mechanisms including decreases in cell proliferation or increased apoptosis of tumor cells 
(Li et al., 2001; Chen et al., 2008; Ueda et al., 2009).  
In these studies, the ability of heparins to affect proliferation of LLC cells was 
tested via two different methods. Firstly, LLC cells were cultured in vitro using a MTS 
assay to determine cell proliferation. Secondly, tumor slices were evaluated for the 
number of mitotic figures present. Neither of these measures showed a significant effect 
of heparin on the proliferation of LLC cells (data not shown). Next, the effect of heparins 
on the expression of Bcl-2, an anti-apoptotic protein, was examined in tumor tissue using 
immunohistochemistry. Although not statistically significant, there was a trend for the 
LMW heparins to reduce Bcl-2 expression when administered alone. The ULMW heparin 
semuloparin was the only agent capable of significantly reducing the expression of Bcl-2 
when administered without taxol. Interestingly, taxol administration appeared to attenuate 
the ability of semuloparin to reduce Bcl-2 expression. This follows the trend that was 
observed in the tumor model, where taxol seems to suppress the effects of semuloparin. 
Conversely, when taxol was administered in conjunction with the LMW heparins, there 
was significantly decreased Bcl-2 expression for enoxaparin and bemiparin. Interestingly, 
the non-AT AF semuloparin had no effect on Bcl-2 expression at all. This implies that the 
addition of AT binding sequences or the ability to bind to antithrombin has an effect on 
Bcl-2 expression. Therefore, the ability of the non-AT AF fractions of heparin to inhibit 
tumor growth may have little to do with inducing apoptosis and more to do with some 
other inhibiting mechanism. Overall, the anticoagulant and nonanticoagulant versions of 
heparins may be inhibiting tumor growth by completely different mechanisms.  
422 
 
The exact mechanisms responsible for heparins actions on Bcl-2 expression still 
need to be further examined. Normally, dephosphorylated Bcl-2-associated death 
promoter (BAD) protein forms a heterodimer with the pro-apoptotic Bcl-2 protein, 
inactivating it and thus allowing Bax/Bak (Bcl-2-associated X protein and Bcl-2 
homologous antagonist/killer, respectively) triggered apoptosis. However, when BAD is 
phosphorylated by Akt, it forms a BAD homodimer thus leaving Bcl-2 free to inhibit 
Bax-triggered apoptosis. Heparin treatment has been associated with significant decreases 
in phosphorylated Akt and consequent increases in apoptosis (Ueda et al., 2009). 
Therefore, significantly decreasing phosphorylated Akt may be one way in which heparin 
treatment in these studies is affecting Bcl-2 expression levels. In the future, studies 
looking at the amount of phosphorylated Akt in LLC tumors may help to further delineate 
the exact mechanism by which heparins produce their pro-apoptotic effects. Overall, 
these studies suggest that heparins, especially the LMW and ULMW heparin, may be 
inducing apoptosis in these tumor cells.  
 
2.2 Heparins effects on angiogenesis 
Several studies have described both stimulatory and inhibitory effects of heparin 
on tumor growth. These diverse effects may be due to the ability of these drugs to affect 
processes, such as angiogenesis, in addition to their anticoagulant properties. Tumors 
induce blood vessel growth (angiogenesis) by secreting various growth factors (e.g. 
vascular endothelial growth factor (VEGF)). Growth factors such as transforming growth 
factor (TGF-β) and VEGF can induce capillary growth into the tumor. Angiogenesis is a 
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necessary and required step for transition from a small harmless cluster of cells to a large 
tumor. Angiogenesis is also required for the spread of a tumor metastasis. The effects of 
heparins on inhibiting angiogenesis have been shown in a variety of studies in vivo and in 
vitro. The majority of these studies, however, have been conducted with UFH or LMWHs 
(Khorana et al., 2003; Norrby, 2006). In the present study, we describe the first in vitro 
characterization of the antiangiogenic activity of the ULMWH semuloparin in 
comparison with UFH and other routinely used LMWHs in a model of angiogenesis. In 
order to determine whether AT binding plays any role, high and non-AT AF fractions of 
semuloparin were also included. 
 In this study, Matrigel purified from Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma (EHS) (Kleinman, 2001) tumors was plated on the bottom of 24 well-plates for 
16 h. Endothelial cells (100,000 cells) were seeded on Matrigel in F12 medium 
containing 10% FBS, with the various heparins and a saline control. This approach was 
selected on the basis of other studies using heparins in this method (Dreyfuss et al., 
2010). The data shows that UFH and its derivatives, including non and high-antithrombin 
affinity fractions of semuloparin produced an almost complete abolishment of capillary-
like tubular formation compared to control in Matrigel at a concentration range of 0 to 
100 µg/ml. All heparins were equally effective at inhibiting the capillary formation. This 
data coincides with similar finding from other studies using some of these heparins 
(Vignoli et al, 2011; Khorana et al., 2003). In addition, no effect of molecular weight was 
evident at the concentrations of heparins used. This differs from a study done by 
Marchetti et al (2008) that reported a molecular weight- and dose-dependent inhibition by 
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UFH, dalteparin, and enoxaparin on EC capillary-like tube formation in matrigel when 
induced by human breast cancer and leukemia cells. However, in their study, they used 
concentrations of 0.01 to 1 IU/ml of each agent. The concentrations of heparins used in 
this study may have been too high to differentiate any effect of dose or molecular weight. 
Future studies should reduce the concentrations of the heparins in order to explore these 
effects.  
 One possible way in which heparins may be inhibiting angiogenesis is by causing 
the vascular endothelial cells (EC) to undergo apoptosis. However, a study by Dreyfuss et 
al (2010) using flow cytometry and the Annexin V-Propidium Iodine assay demonstrated 
that heparinoid did not induce ECs death in vitro. Similarly, preliminary studies done in 
our lab using the same method indicate that the various heparins used in these studies do 
not induce EC death (data not shown).  
In conclusion, these findings are of relevance as they show that heparins or the 
enzymes inhibited by heparins may play a role in the regulation of endothelial cell 
differentiation/tubule formation. The antiangiogenic activity of these heparin derivatives 
was found to be closely associated with the antitumoral activity in a mouse model. These 
results suggest that the suppression of tumor growth can be attributed to the inhibition of 
tumor angiogenesis, which coincides with results from previous studies (Vignoli et al, 
2011; Khorana et al., 2003). Additionally, since the non-AT AF semuloparin fraction 
produced similar inhibition of tubular formation compared to the other heparins, it can be 
speculated that the ability of heparins to inhibit tubular formation and thus angiogenesis, 
is independent of their anticoagulant activities. 
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2.3 Heparins effects on VEGF and TGF-β 
Heparins are known to bind and modulate the activities of heparin-binding growth 
factors and their receptors, such as VEGF, TGF-β, and FGF controlling various aspects 
of vascular development and angiogenesis (Dreyfuss et al., 2000). Studies have shown 
that heparins can interfere with the angiogenic growth factors by binding to specific 
domains located on the growth factor or its cellular receptor (Ashikari-Hada et al., 2005). 
These effects may exist because of their chemical resemblance to extracellular matrix 
(ECM) and cell-surface-associated heparin-sulfate glycoaminoglycans (HSGAGs). By 
interacting with growth factors, chemokines, enzymes, and matrix proteins at the 
interface of the cell and ECM, HSGAGs regulate the way in which cells perceive their 
environment in order to modulate signal transduction and thereby regulate malignant cell 
growth (Trindade et al., 2008). HSGAGs are found on the surface of every cell, including 
both tumor cells and cells that are imperative for tumor survival (Dietrich, 1984; 
Sasisekharan et al., 2002). These include the EC compartment that is proximate to a 
growing tumor, where HSGAGs modulate the process of angiogenesis (Sasisekharan et 
al., 2002). In accordance with other studies, the hypothesis of this study is that the 
antiangiogenic effect of heparins is related to their capacity to interfere with the binding 
of soluble proangiogenic molecules (i.e. VEGF) to their high-affinity signal-transducing 
receptors expressed by endothelial and tumor cell surfaces or ECMs (Norrby, 2006).  
VEGF and TGF-β are two of the most potent angiogenic factors produced by 
tumors (Ferrara et al, 2003). In its native form, VEGF is a 45 kDa heparin-binding 
homodimeric glycoprotein (Ferrara et al., 2003). TFG-β has been found to influence 
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carcinoma initiation, progression, and metastasis (Bierie and Moses, 2010). Since it was 
determined that heparins interfere with tumor-driven neoangiogenesis in a capillary-like 
tubular formation assay, the effects of heparins on VEGF and TGF-β expression in vitro 
were examined. These studies found that in vitro, the study heparins, at a concentration of 
100 µg/ml, suppressed VEGF protein levels in culture medium containing LLC cells. 
Additionally, in LLC cell lysates, VEGF protein levels were significantly reduced by 
UFH and its derivatives in an apparent dose-dependent manner. These results are 
consistent with a study by Takahashi et al (2005) that showed that UFH and another 
LMWH, dalteparin were able to dose-dependently inhibit VEGF protein levels in culture 
media containing LLCs. In the current study, UFH and its derivatives had no significant 
effects on TGF-β protein expression levels in either the cell culture medium or cell 
lysates. No apparent effect of MW or AT binding on the expression of VEGF was 
evident. However, at the doses studied, these effects may have been masked. In the 
future, lowering the concentration of all the heparins may help to better delineate these 
effects.  
The amount of VEGF in plasma samples collected from heparin-treated LLC 
tumor bearing mice was also measured. No significant differences in VEGF expression in 
the mouse plasma were observed after the various heparin treatments at either the 1.0 or 
0.5 mg/kg SC dosages. This may indicate that the effects of heparins on VEGF 
expression may be localized to the tumor. As such, VEGF mRNA has been shown to 
upregulated in many human tumors by in situ hybridization (Dvorak et al, 1995). Future 
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studies should be conducted to determine the effects of heparins on the expression of 
VEGF in LLC tumors. 
 The effects of the study heparins on tumor growth and angiogenesis may rely on a 
variety of mechanisms. Endothelial cells cultured in the presence of VEGF were found to 
induce the phosphorylation of Akt in a VEGF receptor 2 (VEGFR-2), PI3-kinase-
dependent manner, which subsequently lead to the VEGF-induced survival of endothelial 
cells (Gerber et al., 1998). This study indicated that VEGF may inhibit apoptosis of the 
vascular endothelium (Gerber et al., 1998). The two isoforms of VEGF (206 and 189) 
known to bind to heparin with high affinity (Houck et al., 1992) are also known to bind to 
VEGFR-2. VEGFR-2 is known to be the major mediator of the angiogenic effects of 
VEGF (Ferrara et al., 2003). Houch et al (1992) demonstrated that the isoforms VEGF206 
and VEGF189 are localized to the ECM are almost completely bound to the extracellular 
heparin containing proteoglycans. The competition binding assay performed for these 
dissertation studies showed that heparin and its derivatives were able to strongly compete 
with biotinylated heparin on ECs. Previous studies have shown that heparin binds to the 
ECM of ECs derived from rabbit thoracic aorta (Trindade et al., 2008). These studies 
imply that heparins may be binding to the ECM of ECs. 
Another study by Gerber et al (1998) showed that Bcl-2 plays an important role in 
mediating the survival activity of VEGF on endothelial cells. As discussed previously, 
Akt is known to phosphorylate the Bcl-2 associated protein BAD, thus leaving Bcl-2 free 
to inhibit the Bax-triggered apoptosis (Ueda et al., 2009). These studies along with this 
dissertation research point to a possible effect of heparins on tumor growth that may be a 
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VEGF/Akt/Bcl-2-dependent mechanism (Figure 123). Additionally, these effects may be 
related to the various heparins’ capacities to interfere with the binding of the soluble 
proangiogenic molecule, VEGF to its signal-transducing receptor, VEGFR-2 on 
endothelial and tumor cell surfaces or ECMs. 
Heparins may be inducing tumor cell apoptosis, inhibiting angiogenesis, or a 
combination of both. In addition, the antitumor effects of heparins seem to be 
independent of their anticoagulant effects. The effect of MW, however, has not been 
ruled out. Obviously, the data in these dissertation studies are preliminary and additional 
research needs to be performed to validate this hypothesis.  
Of course the effects of heparins on tumor growth are not limited to the above 
conclusion. Part of heparin’s anti-cancer properties may be related to release of the 
coagulation inhibitor TFPI from vascular endothelium. TFPI released by heparin 
sequentially inhibits TF signaling, which appears to suppress tumor growth (Versteeg et 
al., 2008). A study by Mousa et al (2004) has shown that the LMWH tinzaparin can 
inhibit FGF-2-induced tube formation by mascrovascular EC through the release of TFPI. 
Since it is known that certain heparins can induce the release of TFPI by endothelium 
(Westmuckett et al., 2001; Perez-Ruiz et al., 2002; Vignoli et al., 2006) 29), this may not 
be excluded as a possible mechanism by which these study heparins may also counteract 
angiogenesis.  
In addition, heparins have been shown to inhibit heparanase (Nadir et al., 2008). 
Heparanase is an endo-beta- D-glucuronidase that is capable of cleaving heparan sulfate 
side chains of heparan sulfate proteoglycans on cell surfaces and the extracellular matrix; 
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activity that is strongly implicated in tumor angiogensis and metastasis. Studies have 
shown that heparanase overexpression in human leukemia, glioma, and breast carcinoma 
cells results in a marked increase in tissue factor (TF) levels (Nadir et al., 2008). As 
heparins are strong inhibitors of heparanase, this may be another possible mechanism by 
which these agents produce their anti-tumor effects.  
Tumor type-speciﬁc oncogenic transformations cause constitutive and hypoxia-
dependent upregulation of tissue factor (TF) in cancer cells, but TF expressed by 
vascular, stromal and inﬂammatory cells also contributes to the procoagulant character of 
the tumor microenvironment (Contrino et al., 2006; Ruf et al., 1996; Camerer et al., 2004; 
Khorana et al., 2007). A growing body of genetic and pharmacological evidence 
implicates signaling by protease activated receptors (PARs) and specifically by tumor 
cell-expressed TF-VIIa-PAR2 in the induction of an array of proangiogenic and immune 
modulating cytokines, chemokines and growth factors (Ruf and Mueller, 2006). Studies 
have shown that specific inhibition of this pathway results in attenuated tumor growth 
and angiogenesis (Camerer et al., 2004; Ruf et al., 1996; Yu et al., 2010). It is possible in 
these studies that heparins could be inhibiting PARs which is contributing to their 
antitumor effects. 
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Figure 122. The effect of heparins on tumor growth and angiogenesis. The ability for 
heparin to inhibit angiogenesis may be a VEGF/PI3K/Akt/Bcl-2-dependent mechanism. 
Additionally, these effects may be related to the various heparins’ capacities to interfere 
with the binding of the soluble proangiogenic molecule, VEGF to its signal-transducing 
receptor, VEGFR-2 on endothelial and tumor cell surfaces or ECMs. 
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In conclusion, many studies have shown that LMWHs are comparable to some 
anticancer therapies in terms of adverse effects, survival, and burden, as reported for 
small-cell lung cancer. For the management of cancer, LMW and ULMW heparins are 
likely to be administered as adjuvant therapy. However, in patients who are not 
candidates for chemotherapy, there may still be a benefit for using LMW and ULMW 
heparins since data suggests they have additional antitumor effects independent of their 
anticoagulant actions. Furthermore, studies have shown that low and ULMWHs may be 
superior to UFH as prophylaxis and initial therapy for VTE. These heparins offer 
improved pharmacokinetic and pharmacodynamic profiles, a more predictable 
antithrombotic response, longer half-lives, increased bioavailability, variability in the 
number of AT binding sites, and a higher anti-Xa anti-IIa inhibitory ratio. In addition, 
compared with UFH, LMW and ULMW heparins offer greater ease of administration, as 
these agents can be given SC and may not require monitoring. Several of the 
characteristics of LMWH and ULMW heaprins suggest that these agents may have an 
important role to play in future research on new anticancer therapies. Through direct 
antitumor and antiangiogenic effects, LMWHs appear to have significant antineoplastic 
activity.  
 
432 
 
CHAPTER SIX 
SUMMARY 
 This dissertation addresses the compositional, biochemical, and pharmacological 
profiles of heparin and its derivatives, with particular reference to the ULMWH 
semuloparin. These studies explored their interactions with the coagulation system, their 
pharmacodynamic/pharmacokinetic behaviors, and their non-anticoagulant effects in 
cancer. A summary of results from the major experimental protocols included in this 
dissertation is provided below. 
 
A. Physiochemical characterization 
1. Heparin and its derivates exhibited different molecular weight (MW) profiles as 
determined by the size exclusion chromatography method. Each heparin exhibited 
specific elution profiles. The MWs profile of each heparin, in the range of 2.6 to 16.5 
kDa, was cross referenced utilizing the narrow range calibrators (NRC) and European 
Pharmacopeial (EP) methods. The NRC and EP methods represent reproducible 
approaches to profile the commercially available LMW and ULMW heparins. However, 
the results obtained with the EP method resulted in falsely measured higher MWs. In 
addition, these studies showed that all unfractionated (UF), low molecular weight
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(LMW), and ultra low molecular weight (ULMW) heparins are degradable by 
heparinase-I to similar degrees.  
2. Scanning UV spectroscopy analysis showed that spectral features of 
glycosaminoglycans predominantly arising from electronic transitions of the carboxylate 
groups of the uronate residues and the N-acetyl chromophores of the glucosamine 
residues. In addition, the LMW and ULMW heparins had an unsaturated uronic acid 
residue introduced into their saccharide chain which resulted from β-elimination methods 
used in their production.  
 
3. The CD spectra analysis showed that spectral features of the various heparins 
arose from electronic transition occurring in the oxygen atoms (ring, glycosidic linkage, 
and hydroxyl group), with a maxima around 190 nm, as well as from electronic transition 
occurring on the carboxylate and N-acetyl chromophores, maxima around 210 nm. In 
addition, the CD spectra indicated 4,5 double bonds (C=C) into the non-reducing end of 
the uronate residue, which resulted from the β-elimination reaction used in the production 
of the LMW and ULMW heparins. 
 
B. In vitro studies 
1. The global anticoagulant and antiprotease effects of heparin and its derivatives 
showed a MW dependence in both the native whole blood and the citrated plasma based 
assays. Heparin exhibited the broadest anticoagulant activity as measured by various 
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global clotting tests. This was due to its ability to directly and indirectly modulate the 
coagulation process at multiple sites in the coagulation cascade. However, the addition of 
AT binding sequences to semuloparin resulted in strong anticoagulant effects that rivaled 
that of heparin and the LMWHs. The MW dependent effects were mostly seen in assays 
that measured thrombin inhibition. In the assays that predominately depended on AT, 
semuloparin was often time stronger than its LMW counterparts.  
2. In the whole blood and retrieved plasma studies, results suggested that the 
various cellular components found in WB can have an effect on the anticoagulant effects 
of heparins. Moreover, this effect was determined to be MW-dependent. However, 
conferring LMW heparins with extra AT binding sequences was shown to provide some 
compensatory properties that helped to overcome these inhibitory actions, as semuloparin 
was shown to be less affected by binding to blood cells. 
3. In the platelet rich plasma and platelet poor plasma studies, results demonstrated 
that the assumed release of PF4 from platelets played a role in neutralizing the 
anticoagulant and antiprotease actions of heparins. However, these effects were MW and 
assay dependent. UFH was consistently the most affected by supplementation in PRP 
compared to the LMW and ULMW heparins. 
4. Inhibition of thrombin generation by all heparins was shown to concentration- 
and MW-dependent in vitro. UFH had the strongest inhibitory effect on thrombin 
generation while RO-14 had the overall weakest effect.  
5. The ability of the various heparins to affect the fibrinolytic system was measured 
by evaluating their inhibition of thrombin-activatable fibrinolysis inhibitor (TAFIa) 
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generation. The results showed that the various heparins inhibited TAFIa in MW-
dependent manner.  
6. AT was shown to be the main cofactor required for heparin and its derivatives to 
produce their anticoagulant and antiprotease effects. In addition, the presence of the 
specific binding sequences was determined to be a more important determinant than MW 
in AT-mediated factor Xa and IIa inhibition. The role of HCII in facilitating the 
anticoagulant effects of these agents was minimal and test dependent. In addition, the 
results showed that when supplemented in HCII-DP plasma, heparins were more potent 
inhibitors of factor Xa and IIa than when supplemented in NHP. These results suggest 
that heparins possible compete with AT and HCII in vivo. 
7. The results from the semuloparin AT affinity studies demonstrated that AT 
binding plays a significant role in the anticoagulant and antiprotease effects of 
semuloparin. Moreover, a higher degree of AT binding was required to produce a 
significant inhibition of thrombin or thrombin generation as measured by the anti-II, 
thrombin time, and thrombin generation assays. These results indicate that AT binding 
plays a significant role in the ability of semuloparin to inhibit factor Xa, thrombin and its 
generation. In addition, it may be possible that semuloparin has other non-AT mediated 
effects that contribute to its overall anticoagulant activity. 
8. UFH, enoxaparin, and bemiparin were capable of strongly inhibited thrombin-
induced platelet aggregation in vitro. Semuloparin and RO-14 were unable to inhibit 
thrombin- induced platelet aggregation. In the HIT studies, results showed that antibodies 
to UFH may cross-react with other LMW and ULMW heparins causing aggregation. 
However, semuloparin and RO-14 showed the least cross-reactivity. 
436 
 
9. Results from the neutralization studies showed that PMX 60056 and heparinase-I 
were the most effective antagonists for the neutralization of LMW and ULMW heparins. 
These studies indicate that the various heparin antagonists differ with regards to their 
ability to neutralize the anticoagulant and antiprotease effects of UFH and its derivates. 
Overall, the neutralization pattern of each of the antagonists was determined to be assay-
and MW-dependent. UFH was consistently neutralized the most by all antagonists 
compared to the LMW and ULMW heparins.  
10. All heparins were shown to concentration- and MW-dependently inhibit fibrin 
clot formation. UFH was consistently the most potent inhibitor of fibrin clot formation 
compared to all other agents. Although semuloparin and RO-14 have a lower inhibitory 
effect on thrombin, both were able to inhibit fibrin clot formation induced by thrombin, 
albeit to a much lower extent than the other agents. 
 
C. In vivo studies  
Hemorrhagic and antithrombotic studies in a rat model 
1. In the comparative hemorrhagic studies, heparin was found to be the strongest in 
terms of bleeding effect. The relative effect of semuloparin was minimal, indicating that 
strong inhibition of factor Xa and residual anti-IIa activity does not cause blood loss in 
this model. The bleeding effects seemed to follow in a MW-dependent manner for all 
agents. This may have been due to the proportionally lower ability of the LMW and 
ULMHs to inhibit thrombin. Overall bleeding times were lower for the various heparins 
after SC administration when compared to the same IV dose. 
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2. The antithrombotic studies demonstrated that after both SC and IV 
administration, increases in dose corresponded to increases in the antithrombotic effects 
of the various heparins. Moreover, MW did not seem to affect the overall antithrombotic 
effects of these agents at the doses studied. After SC administration, the antithrombotic 
effects of UFH were not as strong compared to enoxaparin, bemiparin, and semuloparin, 
although this was not always considered significant. Most likely, this was due to the fact 
that UFH was not as readily absorbed after SC administration compared to the other 
LMW and ULMW heparins. In these studies, semuloparin was as potent as heparin and 
LMW heparins in inhibiting thrombosis but produced considerably lower bleeding times. 
Although semuloparin demonstrated a lower MW, the preservation of AT binding sites 
contributed to its antithrombotic effect.  
3. These ex vivo pharmacologic studies performed on blood and plasma samples 
collected from rats treated with various heparins were suggestive of the relevance of 
plasmatic effects of each agent to their antithrombotic activity. The degree of factor Xa or 
thrombin inhibition was not always proportional to the expected anithrombotic activity 
using UFH as a reference drug. This data suggested that heparin is a polyfunctional drug 
targeting multiple sites while the various derivatives produce their actions at certain sites 
related to their affinity and specificity for various cofactors.  
4. For each derivative, a distinct ex vivo assay-dependent effect/antithrombotic 
response was obtained. The strongest correlations for the LMW and ULMW heparins 
between activity and antithrombotic effects were seen in the anti-Xa assay and after SC 
administration. Based on these studies, it seemed that the higher FXa/IIa ratio of 
semuloparin allowed trace amounts of thrombin to be generated during thrombosis. This 
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residual anti-thrombin activity may be highly beneficial for effective prevention of 
thromboembolism without having an influence on an increased bleeding liability, as 
demonstrated in these studies. 
 
Pharmacodynamics and pharmacokinetics in non-human primates 
1. The anti-Xa effects of semuloparin were prolonged, sometimes up to 28 hours 
after both IV and SC administration. Additionally, semuloparin significantly inhibited 
thrombin generation. At equal gravimetric concentrations, the overall anticoagulant and 
antiprotease effects of semuloparin were greater than or equal to UFH in the non-human 
primate model. 
2. The pharmacokinetic parameters in all studies were calculated from the 
concentrations derived from anti-Xa or anti-IIa activity using non-compartmental 
analyses. Non-linear pharmacokinetics of heparin was evident in primates from major 
variations in Vd and CL parameters between doses. In contrast, both enoxaparin and 
semuloparin exhibited linear pharmacokinetics in non-human primates, which was 
evident from dose-dependent increases in Cmax and AUC values, and no major 
variations in Vd and CL parameters between doses.  
3. One of the major finding of these studies was that the overall kinetics of ultra 
low molecular weight semuloparin was similar to that of enoxaparin. The kinetics of the 
elimination phase did not suggest saturable processes for semuloparin. In addition, these 
data demonstrated that semuloparin is most likely cleared linearly by a renal mechanism. 
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Moreover, semuloparin was observed to have a predictable anti-factor Xa effect. Overall, 
semuloparin showed favorable PD and PK characteristics in the present study. 
4. After both IV and SC injection, TFPI antigen and functional levels significantly 
increased in a dose-dependent manner for all agents. The correlation between the TFPI 
antigen levels and functional TFPI activity suggested that the full-length, functional TFPI 
was released upon administration of the various heparins. In these studies, semuloparin 
was shown to be as effective as both heparin and enoxaparin at increasing antigen and 
functional TFPI activity levels in the plasma. 
5. The influence of MW and AT binding affinity on the ability of heparins to inhibit 
TAFI generation ex vivo was evaluated using a non-human primate model. In vitro 
supplementation studies clearly validated the use of the TAFI assay in non-human 
primates. In these studies, all agents were able to inhibit TAFI activation in a dose-
dependent manner. Semuloparin was able to strongly inhibit TAFI activation after both 
IV and SC administration even though it has a very low direct anti-IIa effect. 
Additionally, at specific time points, this activity was equal to or even stronger than that 
of UFH. It should also be noted that this activity correlated to the inhibition of thrombin 
observed in primates when measured by the thrombin generation assay. Together these 
data suggest, that while semuloparin can strongly bind to AT and specifically inhibit 
factor Xa, a very low residual anti-IIa activity must remain. As such, this residual anti-IIa 
activity seems to be playing a role in providing semuloparin with TAFI inhibitory 
properties. This data could also suggest a direct effect of semuloparin on TAFI inhibition. 
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Lewis lung carcinoma (LLC) tumor model 
1. The LLC tumor studies showed that the various heparins were able to effectively 
inhibit experimental tumor growth in a dose-dependent manner. They were shown to be 
as effective as a traditional chemotherapy in reducing tumor burden.  No additive effects 
between heparins and taxol were noted. Most likely, the ability to bind to AT and 
produce anticoagulant effects was not required to inhibit tumor growth in this model. 
This was evident by the fact that both semuloparin and the non-AT AF semuloparin 
fraction were able to significantly inhibit tumor growth to a similar degree. 
2. There did not appear to be any overall effect of molecular weight on inhibiting 
tumor growth. However, the fact that UFH was not able to significantly reduce tumor size 
indicated, at least after SC administration, lower MW heparins are more efficacious. 
3. Heparin and its derivatives did not induce splenomegaly. The injection of the 
LLC cells and subsequent tumor formation was found to produce an increase in spleen 
lengths. The same was true for spleen weights, although both non-AT AF UFH and non-
AT AF semuloparin significantly increased spleen weight compared to saline treatment. 
This data indicates that the pentasaccharide AT binding sequence alone or the ability of 
heparins to bind to AT prevents further splenomegaly in LLC bearing mice.  
4. In these studies, the ability of heparins to affect proliferation of LLC cells was 
tested. No effect on cell proliferation was noted. The effects of heparins on apoptosis 
were measured by using an indirect marker of apoptosis. Although not statistically 
significant, there was a trend for the LMW heparins to reduce B-cell lymphoma 2 (Bcl-2) 
expression when administered alone. The ULMW heparin semuloparin was the only 
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agent capable of significantly reducing the expression of Bcl-2 when administered 
without taxol. Conversely, when taxol was administered in conjunction with the LMW 
heparins, there was significantly decreased Bcl-2 expression for enoxaparin and 
bemiparin. 
The ability of heparins to inhibit angiogenesis was tested in a capillary-like 
tubular formation assay. The data shows that UFH and its derivatives, including non- and 
high-antithrombin affinity fractions of semuloparin produced an almost complete 
abolishment of capillary-like tubular formation compared to control in Matrigel at a 
concentration range of 0 to 100 µg/ml. At these concentrations, all heparins were equally 
effective at inhibiting the capillary formation. No effect of molecular weight was evident. 
This data also suggested that the ability of heparins to inhibit tubular formation and thus 
angiogenesis was independent of their anticoagulant activities. 
5. These studies found that in vitro, the study heparins, at a concentration of 100 
µg/ml, suppressed VEGF protein levels in culture medium containing LLC cells. 
Additionally, in LLC cell lysates, VEGF protein levels were significantly reduced by 
UFH and its derivatives in an apparent dose-dependent manner. No apparent effect of 
MW or AT binding on the expression of VEGF was evident. UFH and its derivatives had 
no significant effects on TGF-β protein expression levels in either the cell culture 
medium or cell lysates.  
6. Heparins may be inducing tumor cell apoptosis, inhibiting angiogenesis, or a 
combination of both. In addition, the antitumor effects of heparins seem to be 
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independent of their anticoagulant effects. The effect of MW, however, has not been 
ruled out. 
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CHAPTER SEVEN 
CONCLUSIONS 
 
Unfractionated heparin (UFH) is one of the oldest anticoagulant drugs being 
successfully used clinically for over 80 years. However, it is associated with several side 
effects such as bleeding, heparin-induced thrombocytopenia (HIT), and osteoporosis. The 
use of UFH also has disadvantages such as the need to be given intravenously due to poor 
bioavailability and the need for continuous monitoring. More recently, the development 
of low molecular weight (LMW) and ultra low molecular weight (ULMW) heparins and 
have provided alternatives to UFHs. Their pharmacodynamic and pharmacokinetic 
properties allow a more convenient use than that of UFH with a comparable or superior 
efficacy. During the last few decades, numerous studies have been undertaken to 
understand the structural-activity relationships of these various heparin derivatives.  
All heparins produce their effects via interactions with various endogenous 
proteins such as antithrombin (AT) and heparin cofactor II (HCII). The degree to which 
these compounds exert their effects through AT and HCII, as well as other endogenous 
proteins, determines how well they inhibit various targets of the coagulation system and 
the severity of side effects. In addition, differences in structure and composition of these 
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agents, i.e. molecular weight and saccharide composition, affect the various 
anticoagulant effects of these agents. 
Semuloparin is a novel hemisynthetic, ultra low molecular weight heparin with a 
unique AT binding oligosaccharide profile compared to LMWHs. It is in clinical 
development for the prevention of venous thromboembolism. Semuloparin is prepared by 
a highly selective depolymerization of the heparin backbone by a phosphazene base 
which preserves the AT binding sequence. This unique compositional feature of 
semuloparin differentiates it from LMWHs. Unlike other depolymerized heparins where 
the antithrombin (AT) affinity components and anti-Xa activity is decreased with the 
decrease in the molecular weight, semuloparin exhibits a relatively higher proportion of 
AT-binding components which translates into a higher anti-Xa activity.  
In this dissertation, the ULMW heparin semuloparin was studied to determine if 
its MW and chemical structure would result in a better pharmacologic profile compared 
to UFH and LMWHs in terms of safety and efficacy. For these investigations, five 
different heparins with varying molecular weight and structural composition were 
utilized. They included UFH (16.5 kDa), enoxaparin (4.2 kDa), bemiparin (3.8 kDa), 
semuloparin (2.9 kDa), and RO14 (2.6 kDa). Their activities in biochemical and 
biological assays were compared in order to elucidate how their molecular composition 
and structural attributes affect their pharmacological actions. 
It was hypothesized that due to the preservation of the high-affinity AT 
binding sequences, which results in a higher anti-FXa/FIIa ratio, semuloparin 
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would exhibit a better antithrombotic and safety profile compared to non-enriched 
heparin derivatives.  
These studies have shown that ULMW heparins as well as UF and LMW heparins 
can be characterized by gel permeation chromatography, scanning UV spectroscopy, and 
circular dichroism. Results showed distinct MW and compositional attributes for each of 
the various heparins. The various studies of this dissertation also clearly demonstrate 
that AT appears important for the mediation of anticoagulant and antithrombotic 
effects whereas interactions with HCII play a relatively minor role in mediation of 
the pharmacologic actions of heparins.  
The main results from the in vitro studies in this dissertation support the 
hypothesis that high-affinity AT binding of semuloparin promotes as effective, if not 
better, anticoagulant and antiprotease effects compared to UF and LMW heparins. 
Moreover, the anti-Xa effects of semuloparin were often times found to be superior to all 
other heparins at equal gravimetric concentrations.  
Even with very effective FXa inhibition and low anti-thrombin activity, 
semuloparin was able to inhibit thrombin and thrombin generation in many assays. This 
data alludes to the fact that after treatment with semuloparin, trace amounts of thrombin 
will be generated during thrombosis, thus providing a residual anti-thrombin activity that 
may be found to be highly beneficial for the effective prevention of thromboembolism 
without having an influence on an increased bleeding liability. In fact, studies in this 
dissertation have shown that semuloparin had an equally as effective antithrombotic 
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effect and a substantially lower bleeding profile than other heparins as measured in 
the various animal models.  
 The pharmacodynamic and pharmacokinetic studies showed that LMW and ULM 
heparins have several advantages over the traditional UFH. Among these advantages was 
their strong effectiveness after SC administration, their greater circulating half-life, and 
their linear pharmacokinetics. The overall kinetics of semuloparin was similar to that of 
the other LMWHs. The kinetics of the elimination phase did not suggest saturable 
processes for semuloparin. In addition, these data demonstrated that semuloparin is most 
likely cleared linearly by a renal mechanism. Moreover, semuloparin was observed to 
have a predictable anti-factor Xa effect. Overall, semuloparin showed favorable PD 
and PK characteristics in the present study. In addition, semuloparin was shown to 
be as effective as both heparin and the other LMW heparins at increasing functional 
TFPI activity levels and inhibiting TAFI activity in the plasma of non-human 
primates. 
 In addition to the normal anticoagulant effects of these heparins, these studies 
showed that semuloparin as well as the other LMW heparins can strongly inhibit tumor 
growth in vivo in a dose-dependent manner. They were shown to be as effective as a 
traditional chemotherapy in reducing tumor burden. Moreover, these effects were 
determined to be mostly independent of MW; however, at least after SC administration, 
lower MW heparins, overall, were determined to be more efficacious. These studies 
showed that the effects of heparin on tumor growth may be mediated by their ability 
to induce tumor cell apoptosis, inhibiting angiogenesis, or a combination of both. 
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Overall, several of the characteristics of LMWH and ULMW heparins studied in 
this dissertation suggest that these agents may have an important role to play in 
future research on new anticancer therapies. 
Based on the integrated biochemical, molecular and pharmacological results from 
different studies reported in this dissertation, it is concluded that the different MW and 
affinity profiles of UF, LMW, and ULMW heparins contribute to the unique 
pharmacological effects of these agents. In addition, these studies validated the 
hypothesized that preservation of the high-affinity AT binding sequences, which results 
in a higher anti-FXa/FIIa ratio, would result in semuloparin exhibiting a better 
antithrombotic and safety profile compared to non-enriched heparin derivatives. 
Additionally, in these studies, ULMWHs were found to exert effects on tumor growth in 
a similar fashion to other LMWHs. The data in this dissertation will be of value in 
projecting the use of newer, ‘tailored’ ULMWHs in arterial and venous thrombosis as 
well as in other non-anticoagulant-mediated disorders.  
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TABLE 12. 
 
THE EFFECTS OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-
14 ON THE ACTIVATED CLOTTING TIME AFTER SUPPLEMENTATION IN 
WHOLE BLOOD 
 
Drug Concentration 
 10 ug/ml 25 ug/ml 
 Time (sec) Time (sec) 
Saline 123.8 ± 1.6 126.0 ± 1.5 
   
UFH 330.0 ± 8.1* 449.0 ± 7.5* 
   
Enoxaparin 177.0 ± 2.4* 234.7 ± 9.0* 
   
Bemiparin 167.8 ± 4.4* 225.0 ± 3.5* 
   
Semuloparin 153.6 ± 6.6* 186.7 ± 7.2* 
   
RO-14 147.2 ± 5.7 165.7 ± 3.5* 
   
 
All results represent the mean ± standard deviation (n=3-5). Sec; seconds. Statistically 
significant differences between treatment and control for each agent were determined by 
one-way ANOVA followed by Bonferroni’s multiple comparison test. *p <0.05 
compared to baseline values. 
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TABLE 13. IN VITRO ANTICOAGULANT ACTIVITY OF VARIOUS HEPARINS IN NORMAL HUMAN WHOLE BLOOD 
(WB) AND PLATELET POOR PLASMA (PPP) 
 
 WB  WB PPP PPP 
Drug / MW (kDa) Concentration APTT Heptest APTT Heptest 
 (µg/ml) (µM) (Sec) (Sec) (Sec) (Sec) 
UFH / 16.5 2.50 0.15 91.1±16.3* 71.2±16.9* 151.6±21.2* 182.3±27.5* 
 1.25 0.08 61.9±11.5 51.3±21.7* 58.8±6.4* 108.9±23.9* 
 0.63 0.04 51.4±10.9 36.2±15.4 41.4±7.4 83.2±21.8* 
 0.31 0.02 44.2±6.5 21.0±4.4 31.0±4.3 57.0±11.9* 
 0.00 0.00 42.6±5.7 16.8±1.0 24.7±2.7 20.0±1.9 
Enoxaparin / 4.2 2.50 0.60 51.3±7.1* 70.0±12.8* 44.3±6.1* 116.2±13.7* 
 1.25 0.30 47.0±5.1 51.9±15.2* 32.1±5.2 83.7±5.9* 
 0.63 0.15 43.6±5.0 42.0±12.3* 28.3±3.9 65.3±6.3* 
 0.31 0.07 40.8±5.5 28.5±9.7 26.2±3.4 44.9±12.3* 
 0.00 0.00 41.4±4.6 16.8±1.0 24.7±2.7 20.0±1.9 
Bemiparin / 3.8 2.50 0.66 53.0±7.5* 81.8±5.7* 41.3±5.9* 123.0±18.5* 
 1.25 0.33 48.2±5.4 69.6±11.7* 32.6±4.5* 91.7±11.2* 
 0.63 0.16 44.7±4.4 50.7±11.1* 29.1±3.8 73.7±13.6* 
 0.31 0.08 41.9±4.4 33.6±10.0* 26.8±3.4 58.8±10.0* 
 0.00 0.00 41.4±4.6 16.8±1.0 24.7±2.7 20.0±1.9 
Semuloparin / 2.9 2.50 0.86 48.9±4.6 97.6±19.4* 35.1±4.6* 112.2±11.2* 
 1.25 0.43 46.4±4.5 76.1±12.7* 31.0±3.9* 89.6±10.2* 
 0.63 0.22 44.3±3.6 57.1±15.2* 28.6±3.5 74.9±9.9* 
 0.31 0.11 42.1±4.5 39.9±11.9* 26.6±3.1 60.0±10.1* 
 0.00 0.00 41.4±4.6 16.8±1.0 24.7±2.5 20.0±1.9 
RO-14 / 2.6 2.50 0.96 47.3±4.8 72.5±11.2* 32.6±4.1* 82.7±14.7* 
 1.25 0.48 44.5±4.6 51.7±11.7* 29.0±3.6* 62.7±12.8* 
 0.63 0.24 42.5±4.6 35.3±8.7* 27.1±3.2 51.7±10.9* 
 0.31 0.12 40.6±4.6 25.3±5.6 25.7±3.1 38.6±10.2* 
 0.00 0.00 41.4±4.6 16.8±1.0 24.7±2.5 20.0±1.9 
All results represent the mean ± standard deviation (n=10). One-way ANOVA followed by Tukey’s multiple comparison test.  
*p <0.05 compared to baseline values. 
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TABLE 14. IN VITRO ANTICOAGULANT ACTIVITY OF UFH IN NORMAL HUMAN PLATELET POOR PLASMA AND 
PLATELET RICH PLASMA  
  PLATELET POOR PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 1.52 300.0±0.0* 300.0±0.0* 300.0±0.0* 95.3±1.4* 83.6±2.5* 
12.50 0.76 300.0±0.0* 300.0±0.0* 300.0±0.0* 93.0±1.8* 83.0±2.5* 
6.250 0.38 262.3±37.0* 223.8±2.5* 300.0±0.0* 92.3±0.8* 77.5±5.4* 
3.125 0.19 116.0±19.3* 130.6±5.3* 300.0±0.0* 84.8±3.8* 76.3±4.7* 
1.563 0.09 63.0±8.1 88.3±3.8* 63.0±12.2* 66.5±7.18 72.9±3.8* 
0.781 0.05 41.0±4.8 72.3±3.3* 45.4±1.6* 45.1±4.0* 56.6±4.0* 
0.000 0.00 25.0±1.3 24.7±3.1 15.4±3.0 0.0±0.0 0.0±0.0 
       
       
  PLATELET RICH PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 1.52 300.0±0.0* 300.0±0.0* 300.0±0.0* 95.6±0.4* 89.8±1.8* 
12.50 0.76 300.0±0.0* 263.7±3.7* 300.0±0.0* 93.6±0.6* 89.2±2.3* 
6.250 0.38 124.1±10.5* 128.8±5.7* 300.0±0.0* 90.2±0.8* 86.5±3.4* 
3.125 0.19 44.7±2.6* 122.7±50.7* 280.5±8.5* 67.8±2.9* 68.2±6.8* 
1.563 0.09 29.2±1.8 45.6±0.6* 24.6±4.2 36.8±5.2* 46.0±2.4* 
0.781 0.05 26.6±2.2 38.3±2.8* 17.7±2.0 13.9±4.6* 19.3±3.6* 
0.000 0.00 25.8±2.1 19.1±1.3 16.8±2.0 0.0±0.0 0.0±0.0 
       
All results represent the mean ± standard deviation (n=3). Molar values were calculated based on an average MW of 16.5 kDa.  
One-way ANOVA followed by Tukey’s multiple comparison test. *p <0.05 compared to baseline values. 
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TABLE 15. IN VITRO ANTICOAGULANT ACTIVITY OF ENOXAPARIN IN NORMAL HUMAN PLATELET POOR PLASMA 
AND PLATELET RICH PLASMA  
  PLATELET POOR PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 5.95 113.0±8.0* 262.5±1.8* 300.0±0.0* 92.9±1.8* 81.7±5.0* 
12.50 2.98 65.8±4.7* 169.1±2.6* 300.0±0.0* 88.8±3.6* 75.8±4.9* 
6.250 1.49 47.0±2.8* 119.1±1.1* 33.0±6.0* 78.9±4.8* 62.9±3.6* 
3.125 0.74 37.3±2.2 90.3±4.6* 18.3±3.2 59.2±5.4* 42.1±5.9* 
1.563 0.37 28.5±7.5 71.1±1.8* 16.6±3.4 40.1±4.0* 27.7±6.4* 
0.781 0.19 29.4±1.9 54.3±6.0* 15.7±3.7 22.6±6.2* 19.8±8.8* 
0.000 0.00 25.0±1.3 24.7±3.1 15.4±3.0 0.0±0.0 0.0±0.0 
       
       
  PLATELET RICH PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 5.95 74.5±8.7* 181.3±31.5* 300.0±0.0* 93.4±0.7* 83.6±0.8* 
12.50 2.98 46.1±3.7* 109.7±4.6* 109.3±32.0* 87.8±2.7* 62.6±7.7* 
6.250 1.49 35.8±2.6 73.7±1.5* 29.6±8.0 73.2±4.9* 39.5±3.9* 
3.125 0.74 30.7±2.3 55.2±2.38 18.7±2.3 49.2±4.1* 19.3±4.2* 
1.563 0.37 28.3±2.1 43.6±2.2* 17.7±2.0 26.1±6.4* 8.7±3.2 
0.781 0.19 26.8±2.1 36.1±0.4* 17.2±1.7 14.3±7.0* 8.0±3.3 
0.000 0.00 25.8±2.1 19.1±1.3 16.8±2.0 0.0±0.0 0.0±0.0 
       
All results represent the mean ± standard deviation (n=3). Molar values were calculated based on an average MW of 4.2 kDa.  
One-way ANOVA followed by Tukey’s multiple comparison test. *p <0.05 compared to baseline values.  
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TABLE 16. IN VITRO ANTICOAGULANT ACTIVITY OF BEMIPARIN IN NORMAL HUMAN PLATELET POOR PLASMA  
AND PLATELET RICH PLASMA  
  PLATELET POOR PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 6.58 100.8±8.7* 252.4±0.7* 53.9±18.7* 92.9±0.4* 72.9±5.0* 
12.50 3.29 60.8±4.5* 185.1±7.5* 44.1±19.7* 90.6±0.9* 59.5±7.7* 
6.250 1.64 43.6±2.7* 134.9±16.0* 21.6±3.5 82.1±2.1* 41.2±7.7* 
3.125 0.82 36.8±1.9 104.1±4.6* 19.0±3.5 69.3±2.7* 33.1±7.7* 
1.563 0.41 32.9±2.2 82.4±1.4* 17.4±2.9 51.5±3.8* 25.2±12.1 
0.781 0.21 29.3±2.1 72.2±0.2* 15.6±3.5 36.2±4.7* 20.9±10.6 
0.000 0.00 26.4±1.6 24.7±3.1 15.4±3.0 0.0±0.0 0.0±0.0 
       
       
  PLATELET RICH PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 6.58 80.6±6.3* 227.3±5.7* 56.6±12.6* 92.0±1.7* 68.0±2.6* 
12.50 3.29 49.0±3.7* 122.2±27.2* 48.8±13.5* 86.6±2.8* 53.3±3.2* 
6.250 1.64 37.5±2.8 89.4±8.6* 22.1±1.1 73.0±2.9* 29.5±3.8* 
3.125 0.82 32.2±2.5 65.2±1.8* 20.4±2.5 58.8±5.1* 20.0±4.4* 
1.563 0.41 29.3±2.4 53.7±3.0* 19.7±2.5 40.0±8.4* 13.0±4.8 
0.781 0.21 28.0±2.8 51.5±4.5* 18.5±1.5 28.1±9.4* 12.0±4.8 
0.000 0.00 25.7±2.0 19.1±1.3 16.8±2.0 0.0±0.0 0.0±0.0 
       
All results represent the mean ± standard deviation (n=3). Molar values were calculated based on an average MW of 3.8 kDa.  
One-way ANOVA followed by Tukey’s multiple comparison test. *p <0.05 compared to baseline values. 
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TABLE 17. IN VITRO ANTICOAGULANT ACTIVITY OF SEMULOPARIN IN NORMAL HUMAN PLATELET POOR 
PLASMA AND PLATELET RICH PLASMA  
  PLATELET POOR PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 8.62 62.3±6.1* 291.5±7.3* 24.2±1.6* 94.7±1.0* 53.4±5.7* 
12.50 4.31 47.4±4.3* 228.8±3.0* 21.9±3.0 94.2±0.4* 39.2±7.5* 
6.250 2.16 38.9±3.1* 152.0±8.1* 21.2±3.3 91.4±3.0* 30.8±9.9* 
3.125 1.08 33.5±2.8 116.3±1.6* 20.4±3.2 82.2±7.5* 21.1±10.1 
1.563 0.54 31.3±2.8 92.6±2.1* 19.8±2.9 66.8±11.3* 17.5±12.1 
0.781 0.27 28.9±2.1 73.5±4.4* 18.4±2.1 41.9±10.3* 13.0±13.9 
0.000 0.00 25.0±1.5 24.7±3.1 16.2±2.0 0.0±0.0 0.0±0.0 
       
       
  PLATELET RICH PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 8.62 54.6±5.2* 271.8±5.6* 18.5±1.6 95.2±0.2* 30.8±11.5* 
12.50 4.31 41.2±4.3* 166.0±49.2* 16.5±1.6 92.7±2.3* 19.0±4.4* 
6.250 2.16 35.2±3.8 105.9±15.5* 15.7±1.2 85.9±7.1* 10.7±5.0 
3.125 1.08 31.7±3.3 80.0±6.2* 15.0±1.8 71.4±10.8* 8.1±5.1 
1.563 0.54 29.8±3.1 62.9±4.0* 14.6±1.6 55.1±14.5* 6.1±5.2 
0.781 0.27 28.2±3.0 50.3±3.0* 13.1±0.7 35.9±14.9* 4.4±5.0 
0.000 0.00 25.7±2.0 19.1±1.3 15.6±3.2 0.0±0.0 0.0±0.0 
       
All results represent the mean ± standard deviation (n=3). Molar values were calculated based on an average MW of 2.9 kDa.  
One-way ANOVA followed by Tukey’s multiple comparison test. *p <0.05 compared to baseline values. 
  
 
[4
5
5
] 
TABLE 18. IN VITRO ANTICOAGULANT ACTIVITY OF RO-14 IN NORMAL HUMAN PLATELET POOR PLASMA AND 
PLATELET RICH PLASMA  
  PLATELET POOR PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 9.62 49.2±1.3* 174.6±13.5* 17.6±4.9 86.0±1.3* 14.0±9.2 
12.50 4.81 39.8±0.8* 129.3±8.0* 17.1±5.1 77.2±0.9* 7.4±7.9 
6.250 2.40 35.4±0.6* 96.6±4.7* 16.4±4.3 59.7±2.7* 6.9±8.1 
3.125 1.20 32.4±1.3 78.2±3.8* 15.7±4.8 42.2±2.4* 0.6±1.1 
1.563 0.60 30.4±0.9 62.4±8.1* 15.4±4.8 29.6±3.8* 0.4±0.7 
0.781 0.30 28.5±0.9 42.6±12.7 14.8±4.2 18.4±3.7* 0.0±0.0 
0.000 0.00 26.7±1.3 24.7±3.1 15.4±3.0 0.0±0.0 0.0±0.0 
       
       
  PLATELET RICH PLASMA 
       
Concentration  APTT Heptest 5U Ca
2+
TT Anti-Xa Anti-IIa  
(µg/ml) (µM) (Sec) (Sec) (Sec) (% Inhibition) (% Inhibition) 
25.00 9.62 48.0±5.7* 150.1±6.4* 13.8±0.9 84.0±1.8* 13.7±10.9 
12.50 4.81 39.1±3.6* 93.8±13.0* 13.0±0.3 74.3±1.7* 11.3±9.7 
6.250 2.40 34.3±3.1 70.8±3.0* 12.7±0.4 59.3±2.9* 10.2±8.5 
3.125 1.20 31.5±2.2 60.2±6.2* 12.3±0.4 39.3±3.1* 8.9±8.6 
1.563 0.60 29.9±2.5 50.6±5.4* 12.1±0.4 24.0±2.2* 6.6±9.7 
0.781 0.30 27.8±2.1 42.4±5.3* 11.7±0.6 15.9±5.2* 2.9±5.0 
0.000 0.00 26.7±2.3 19.1±1.3 16.8±2.0 0.0±0.0 0.0±0.0 
       
All results represent the mean ± standard deviation (n=3). Molar values were calculated based on an average MW of 2.6 kDa.  
One-way ANOVA followed by Tukey’s multiple comparison test. *p <0.05 compared to baseline values. 
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TABLE 19.  
 
POTENCY COMPARISON OF UFH, ENOXAPARIN, BEMIPARIN, 
SEMULOPARIN, AND RO-14 WHEN SUPPLEMENTED IN PPP AND PRP AS 
MEASURED BY THE AMIDOLYTIC ANTI-XA AND ANTI-IIA ASSAYS 
 
 
All results represent the mean IC50 value ± the standard deviation (n=3). If the percent 
inhibition did not reach 50% at the highest concentration, the IC50 value was presented as 
greater than the highest concentration tested and was considered to be a supramax 
concentration. Statistically significant differences between each agent when it was 
supplemented in PPP versus PRP were determined by an unpaired t test. *p <0.05 
compared to baseline values. Xa, factor Xa; IIa, thrombin; PPP, platelet poor plasma; 
PRP, platelet rich plasma.  
 PPP PRP 
Drug  Anti-Xa Anti-IIa Anti-Xa Anti-IIa 
 IC50 (µg/ml) IC50 (µg/ml) IC50 (µg/ml) IC50 (µg/ml) 
     
UFH  1.0±0.2* 0.7±0.0 2.2±0.2 1.9±0.1 
     
Enoxaparin  2.4±0.4 4.2±0.6 3.3±0.4 9.2±0.8 
     
Bemiparin  1.5±0.2 9.3±2.8 2.3±0.6 11.6±0.5 
     
Semuloparin  1.0±0.3 21.6±5.9 1.4±0.6 >25.0±0.0 
     
RO-14  4.5±0.3 >25.0±0.0 4.8±0.5 >25.0±0.0 
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TABLE 20. 
 
THE INHIBTION OF THROMBIN BY HEPARIN AND ITS DERIVATIVES AS 
MEASURED BY THE THROMBIN GENERATION ASSAY. 
  
All results represent the mean ± standard deviation (n=3). MW, mean molecular weight; 
% Inh, percent inhibition. Statistically significant differences between treatment and 
control for each agent were determined by one-way ANOVA followed by Dunnett’s 
multiple comparison test. *p <0.05 compared to baseline values. 
Drug / MW (kDa) Concentration Thrombin Inhibition 
 (µg/ml) (µM) % Inh 
UFH / 16.5 10.00 0.61 100.0±0.0* 
 5.00 0.30 100.0±0.0* 
 2.50 0.15 100.0±0.0* 
 1.25 0.08 98.2±1.3* 
 0.63 0.04 90.8±6.5* 
 0.31 0.02 76.5±3.6* 
 0.00 0.00 0.0±0.0 
Enoxaparin / 4.2 10.00 2.38 100.0±0.0* 
 5.00 1.19 97.2±0.6* 
 2.50 0.60 77.7±2.8* 
 1.25 0.30 48.3±5.3* 
 0.63 0.15 26.9±2.8* 
 0.31 0.07 14.8±9.7* 
 0.00 0.00 0.0±0.0 
Bemiparin / 3.8 10.00 2.63 100.0±0.0* 
 5.00 1.32 93.9±2.0* 
 2.50 0.66 81.0±8.6* 
 1.25 0.33 61.1±11.4* 
 0.63 0.16 13.6±2.6 
 0.31 0.08 4.8±4.5 
 0.00 0.00 0.0±0.0 
Semuloparin / 2.9 10.00 3.45 92.7±0.8* 
 5.00 1.72 87.4±0.2* 
 2.50 0.86 74.9±4.3* 
 1.25 0.43 58.9±6.7* 
 0.63 0.22 36.7±3.0* 
 0.31 0.11 19.5±4.5* 
 0.00 0.00 0.0±0.0 
RO-14 / 2.6 10.00 3.85 63.1±1.7* 
 5.00 1.92 53.7±4.0* 
 2.50 0.96 37.6±1.7* 
 1.25 0.48 30.8±6.9* 
 0.63 0.24 15.1±1.4* 
 0.31 0.12 6.5±0.8 
 0.00 0.00 0.0±0.0 
[458] 
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TABLE 21. 
 
POTENCY COMPARISON OF HEPARIN AND ITS DERIVATIVE ON THE 
INHIBITION OF TAFI ACTIVATION WHEN SUPPLEMENTED IN NORMAL 
HUMAN PLASMA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All results represent the mean ± standard error of the mean (n=3). Statistically significant 
differences between treatment and control for each agent were determined by one-way 
ANOVA followed by Tukey’s multiple comparison test. *p <0.05 compared to baseline 
values. 
 
Drug  Concentration 
 IC50 (µg/ml) 
  
UFH  0.6 ± 0.01* 
  
Enoxaparin  23.6 ± 0.20* 
  
Bemiparin  58.5 ± 0.20* 
  
Semuloparin  93.1 ± 0.41* 
  
RO-14  100.0 ± 0.00 
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TABLE 22. POTENCY COMPARISON OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 WHEN 
SUPPLEMENTED IN NHP, AT DEPLETED, AND HCII DEPLETED PLASMA AS MEASURED BY THE AMIDOLYTIC ANTI-
XA AND ANTI-IIA ASSAYS 
 
 
All results represent the mean IC50 value ± the standard deviation (n=3). If the percent inhibition did not reach 50% at the highest 
concentration, the IC50 value was presented as greater than the highest concentration tested and was considered to be a supramax 
concentration. Xa, factor Xa; IIa, thrombin; NHP, normal human plasma; AT, antithrombin; DP, depleted plasma. 
 NHP AT-DP HCII-DP 
Drug  Anti-Xa Anti-IIa Anti-Xa Anti-IIa Anti-Xa Anti-IIa 
 IC50 (µg/ml) IC50 (µg/ml) IC50 (µg/ml) IC50 (µg/ml) IC50 (µg/ml) IC50 (µg/ml) 
       
UFH 2.3 ± 0.33 1.9 ± 0.33 10.0 ± 0.00 10.0 ± 0.00 1.6 ± 1.55 1.6 ± 0.06 
       
Enoxaparin  3.6 ± 0.71 7.0 ± 0.76 10.0 ± 0.00 10.0 ± 0.00 2.2 ± 0.23 4.8 ± 0.29 
       
Bemiparin 2.3 ± 0.06 10.0 ± 0.00 10.0 ± 0.00 10.0 ± 0.00 1.9 ± 0.11 9.5 ± 0.46 
       
Semuloparin 2.0 ± 0.35 10.0 ± 0.00 10.0 ± 0.00 10.0 ± 0.00 1.5 ± 0.08 10.0 ± 0.00 
       
RO-14 6.3 ± 0.35 10.0 ± 0.00 10.0 ± 0.00 10.0 ± 0.00 3.83 ± 0.15 10.0 ± 0.00 
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TABLE 23.THE ANTICOAGULANT EFFECTS OF HEPARIN AND ITS DERIVATIVES FOLLOWING SUPPLEMENTATION 
IN AT DEPLETED, HCII DEPLETED, AND NORMAL HUMAN PLASMA.  
All results represent the mean ± standard deviation (n=4). AT, antithrombin; Xa, factor Xa, HCII, heparin cofactor II; IIa, thrombin; 
MW, mean molecular weight; % Inh, percent inhibition; sec, seconds.
  AT Depleted Plasma HCII Depleted Plasma Normal Human Plasma 
Drug / MW 
(kDa) 
Concentration Xa IIa Heptest Xa IIa Heptest Xa IIa Heptest 
 (µg/ml) (µM) % Inh % Inh (Sec) % Inh % Inh (Sec) % Inh % Inh (Sec) 
UFH / 16.5 10.0 0.61 1.1±1.6 10.5±2.9 24.0±1.0 95.7±0.2 94.3±0.7 300.0±0.0 90.5±0.5 88.4±3.3 300.0±0.0 
 5.00 0.30 0.7±1.2 6.3±0.7 14.5±0.2 92.4±1.3 92.3±2.9 214.3±2.6 80.1±3.9 86.1±5.1 252.2±5.5 
 2.50 0.15 0.5±0.9 2.2±2.0 12.7±0.3 79.9±3.5 79.5±3.8 114.6±0.6 56.0±7.6 67.9±11.9 113.0±2.5 
 0.00 0.00 0.0±0.0 0.0±0.0 13.0±1.2 0.0±0.0 0.0±0.0 19.7±5.4 0.0±0.0 0.0±0.0 19.2±1.8 
Enoxaparin / 4.2 10.0 2.38 2.3±4.0 0.9±1.3 14.6±0.4 90.0±2.6 74.3±6.2 217.3±3.1 80.2±2.9 66.4±4.4 241.2±0.8 
 5.00 1.19 1.3±2.3 0.3±0.5 13.0±0.1 78.6±1.4 51.1±3.3 124.5±7.6 60.2±6.4 38.8±6.2 128.9±0.7 
 2.50 0.60 0.3±0.5 0.4±0.7 12.2±0.1 58.7±6.4 26.2±3.5 51.3±1.0 42.4±4.0 15.8±6.6 75.4±3.9 
 0.00 0.00 0.0±0.0 0.0±0.0 13.0±1.2 0.0±0.0 0.0±0.0 19.7±5.4 0.0±0.0 0.0±0.0 19.2±1.8 
Bemiparin / 3.8 10.0 2.63 3.7±3.4 2.6±2.4 18.8±2.0 92.0±1.0 51.2±3.8 206.7±5.7 81.5±0.3 40.4±3.8 246.7±3.1 
 5.00 1.32 2.8±2.6 1.9±2.0 14.8±0.5 85.7±0.7 30.6±3.8 112.6±2.8 73.6±2.2 21.8±5.9 140.3±1.6 
 2.50 0.66 1.5±2.6 0.7±1.1 12.4±0.1 66.3±4.1 14.3±2.9 74.4±2.2 55.1±1.7 9.4±6.2 92.1±1.7 
 0.00 0.00 0.0±0.0 0.0±0.0 13.2±0.9 0.0±0.0 0.0±0.0 22.0±2.5 0.0±0.0 0.0±0.0 20.1±0.5 
Semuloparin / 
2.9 
10.0 
3.45 1.2±1.2 1.7±3.0 16.4±2.9 95.9±1.0 16.3±2.2 193.7±3.1 88.2±2.9 12.6±4.6 239.4±1.3 
 5.00 1.72 0.0±0.0 0.3±0.3 12.4±0.1 91.2±3.2 4.1±3.6 137.3±12.4 76.3±7.9 4.4±5.4 148.4±9.0 
 2.50 0.86 0.0±0.0 0.6±1.0 12.2±0.1 79.9±4.1 2.0±2.1 99.8±2.2 62.7±10.3 2.8±2.8 106.2±14.1 
 0.00 0.00 0.0±0.0 0.0±0.0 13.0±1.2 0.0±0.0 0.0±0.0 19.7±5.4 0.0±0.0 0.0±0.0 19.2±1.8 
RO-14 / 2.6 10.0 3.85 2.8±3.1 2.6±1.4 16.4±1.8 79.7±1.3 2.0±2.3 105.2±3.2 65.1±3.8 1.1±1.6 150.4±1.8 
 5.00 1.92 2.0±2.4 0.4±0.7 15.4±1.5 57.8±1.9 0.8±1.4 91.4±0.8 44.0±2.5 0.5±0.8 100.6±1.7 
 2.50 0.96 0.8±1.2 0.5±0.7 12.1±0.1 40.7±2.2 0.0±0.0 81.8±1.4 26.9±1.7 0.3±0.5 82.3±2.3 
 0.00 0.00 0.0±0.0 0.0±0.0 13.2±0.9 0.0±0.0 0.0±0.0 22.0±2.5 0.0±0.0 0.0±0.0 19.2±1.8 
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TABLE 24.  
 
POTENCY COMPARISON OF UFH, ENOXAPARIN, BEMIPARIN, 
SEMULOPARIN, AND RO-14 IN SERPIN ACTIVITY ASSAYS 
 
 
All results represent the mean IC50 value ± the standard deviation (n=4). If the percent 
inhibition did not reach 50% at the highest concentration, the IC50 value was presented as 
greater than the highest concentration tested and was considered to be a supramax 
concentration. AT, antithrombin; Xa, factor Xa, HCII, heparin cofactor II; IIa. 
Drug  AT/Xa AT/IIa HCII/IIa 
 IC50 (µg/ml) IC50 (µg/ml) IC50 (µg/ml) 
    
UFH  0.57±0.02 0.51±0.18 2.02±0.16 
    
Enoxaparin  2.00±0.47 3.08±1.20 5.19±0.35 
    
Bemiparin  1.50±0.22 9.50±0.58 11.61±2.75 
    
Semuloparin  0.65±0.08 >10.00±0.00 8.53±1.51 
    
RO-14  3.60±0.09 >10.00±0.00 94.70±2.34 
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TABLE 25. 
 
SERPIN MEDIATED INHIBTION OF FACTOR XA AND THROMBIN BY HEPARIN 
AND ITS DERIVATIVES 
 
All results represent the mean ± standard deviation (n=4). AT, antithrombin; Xa, factor 
Xa, HCII, heparin cofactor II; IIa, thrombin; MW, mean molecular weight; % Inh, 
percent inhibition. 
Drug / MW (kDa) Concentration AT/Xa AT/IIa Concentration HCII/IIa 
 (µg/ml) (µM) % Inh % Inh (µg/ml) (µM) % Inh 
UFH / 16.5 10.00 0.61 98.8±0.6 99.3±0.5 1.563 0.095 82.0±2.8 
 5.00 0.30 96.6±0.6 98.5±1.3 0.781 0.047 74.5±3.5 
 2.50 0.15 86.5±2.1 94.5±5.4 0.391 0.024 63.9±1.1 
 1.25 0.08 67.2±4.7 84.0±14.2 0.195 0.012 49.8±1.7 
 0.63 0.04 53.6±2.2 65.3±19.6 0.098 0.006 25.8±1.3 
 0.31 0.02 31.4±10.0 37.5±7.5 0.049 0.003 19.4±3.8 
 0.00 0.00 0.0±0.0 0.0±0.0 0.000 0.000 0.0±0.0 
Enoxaparin / 4.2 10.00 2.38 92.9±1.4 86.7±11.5 100.0 23.81 --- 
 5.00 1.19 82.9±3.1 69.6±17.4 50.00 11.90 88.3±1.4 
 2.50 0.60 62.4±8.6 50.3±17.6 25.00 5.95 84.1±2.0 
 1.25 0.30 44.8±12.2 24.0±8.7 12.50 2.98 74.9±1.1 
 0.63 0.15 29.3±11.6 12.4±5.9 6.250 1.49 55.1±2.3 
 0.31 0.07 20.6±9.7 8.7±4.0 3.125 0.74 40.4±1.9 
 0.00 0.00 0.0±0.0 0.0±0.0 0.000 0.00 0.0±0.0 
Bemiparin / 3.8 10.00 2.63 94.6±2.1 50.7±3.3 100.0 26.32 --- 
 5.00 1.32 81.1±3.3 31.9±5.3 50.00 13.16 81.1±3.5 
 2.50 0.66 64.4±2.5 15.3±6.4 25.00 6.58 63.0±3.2 
 1.25 0.33 45.7±5.4 11.0±3.7 12.50 3.29 51.4±3.7 
 0.63 0.16 30.5±9.1 4.4±4.3 6.250 1.64 40.7±5.3 
 0.31 0.08 15.8±11.1 3.6±3.1 3.125 0.82 22.8±2.1 
 0.00 0.00 0.0±0.0 0.0±0.0 0.000 0.00 0.0±0.0 
Semuloparin / 2.9 10.00 3.45 97.7±0.5 32.7±6.8 100.0 34.48 --- 
 5.00 1.72 92.1±6.0 18.9±3.4 50.00 17.24 88.6±5.3 
 2.50 0.86 78.2±11.9 9.6±2.5 25.00 8.62 79.7±7.1 
 1.25 0.43 58.0±13.9 5.0±5.1 12.50 4.31 67.9±6.0 
 0.63 0.22 41.8±16.2 2.9±5.0 6.250 2.16 39.0±8.0 
 0.31 0.11 25.3±12.6 1.4±2.4 3.125 1.08 21.4±8.5 
 0.00 0.00 0.0±0.0 0.0±0.0 0.000 0.00 0.0±0.0 
RO-14 / 2.6 10.00 3.85 79.8±4.7 1.6±2.7 100.0 38.46 52.0±1.0 
 5.00 1.92 62.1±4.4 1.1±1.9 50.00 19.23 31.8±5.1 
 2.50 0.96 41.4±2.2 0.6±1.1 25.00 9.62 13.3±8.9 
 1.25 0.48 26.4±5.5 0.0±0.0 12.50 4.81 6.2±5.4 
 0.63 0.24 18.0±2.9 0.4±0.6 6.250 2.40 3.9±5.2 
 0.31 0.12 6.0±5.5 0.4±0.6 3.125 1.20 0.3±0.5 
 0.00 0.00 0.0±0.0 0.0±0.0 0.000 0.00 0.0±0.0 
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TABLE 26. THE ANTICOAGULANT EFFECTS OF DIFFERENT VERSIONS OF SEMULOPARIN FOLLOWING 
SUPPLEMENTATION IN NORMAL HUMAN PLASMA.  
All results represent the mean ± standard deviation (n=4). AT, antithrombin; Xa, factor Xa, HCII, heparin cofactor II; IIa, thrombin; 
MW, mean molecular weight; % Inh, percent inhibition; sec, seconds. Statistically significant differences between treatment and 
control for each agent were determined by one-way ANOVA followed by Dunnett’s multiple comparison test. *p <0.05 compared to 
baseline values. 
  Normal Human Plasma 
Drug / MW (kDa) Concentration APTT TT (5U) Heptest Anti-Xa Anti-IIa 
 (µg/ml) (µM) (Sec) (Sec) (Sec) (% Inh) (% Inh) 
Semuloparin / 2.9 25.00 8.62 69.6±10.8* 14.9±0.2* 233.6±3.0* 87.9±2.1* 30.2±6.0* 
 12.50 4.31 55.3±6.9* 13.4±0.9* 203.2±2.2* 86.6±2.9* 16.8±3.3* 
 6.250 2.16 46.6±2.6 12.2±1.2 111.4±0.8* 79.1±5.5* 11.5±5.3* 
 3.125 1.08 41.3±3.7 11.7±1.4 92.5±0.6* 70.4±12.4* 1.4±2.5 
 1.563 0.54 36.4±5.7 11.3±1.3 64.8±1.9* 56.8±18.3* 0.0±0.0 
 0.000 0.00 31.1±2.6 11.0±0.2 17.4±2.5 0.0±0.0 0.0±0.0 
          
High-AT AF Semuloparin / 3.3 25.00 7.58 75.6±12.2* 17.5±0.3* 300.0±0.0* 92.6±4.3* 58.5±0.7* 
 12.50 3.79 52.5±8.8* 14.0±0.1* 300.0±0.0* 91.4±5.1* 45.3±3.8* 
 6.250 1.89 42.7±3.2 12.8±0.5* 206.4±3.9* 90.2±5.5* 28.0±1.3* 
 3.125 0.95 39.6±4.0 12.3±0.7* 167.1±1.0* 81.3±16.1* 9.8±8.9 
 1.563 0.47 37.1±3.3 11.9±0.9 143.2±2.6* 77.3±13.4* 4.0±3.5 
 0.000 0.00 31.1±2.6 11.0±0.2 17.4±2.5 0.0±0.0 0.0±0.0 
          
Non-AT AF Semuloparin / 2.6 25.00 9.62 53.2±4.9* 12.5±0.6* 162.0±3.5* 61.6±5.0* 0.1±0.1 
 12.50 4.81 43.2±5.7* 11.7±0.6 101.0±2.3* 58.8±3.2* 0.0±0.0 
 6.250 2.40 38.7±4.6 11.5±0.6 68.3±2.6* 54.3±1.6* 0.0±0.0 
 3.125 1.20 35.8±3.0 11.3±0.5 59.4±0.7* 19.0±16.5 0.0±0.0 
 1.563 0.60 34.2±1.1 11.1±0.5 51.0±2.2* 13.0±11.3 0.0±0.0 
 0.000 0.00 31.1±2.6 11.0±0.2 17.4±2.5 0.0±0.0 0.0±0.0 
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TABLE 27.  
 
POTENCY COMPARISON OF HIGH-AT AF SEMULOPARIN, SEMULOPARIN, 
AND NON-AT AF SEMULOPARIN WHEN SUPPLEMENTED IN NHP AND 
PURIFIED AT AS MEASURED BY THE AMIDOLYTIC ANTI-XA AND ANTI-IIA 
ASSAYS 
 
 
All results represent the mean IC50 value ± the standard deviation (n=3). If the percent 
inhibition did not reach 50% at the highest concentration, the IC50 value was presented as 
greater than the highest concentration tested and was considered to be a supramax 
concentration. Xa, factor Xa; IIa, thrombin; NHP, normal human plasma; AT, 
antithrombin. 
 NHP AT 
Drug  Anti-Xa Anti-IIa Anti-Xa Anti-IIa 
 IC50 (µg/ml) IC50 (µg/ml) IC50 (µg/ml) IC50 (µg/ml) 
     
Semuloparin 1.47±0.49 >25.00±0.00 1.62±0.11 >10.00±0.00 
     
High-AT AF Semuloparin  1.00±0.19 16.33±2.97 0.49±0.01 4.50±0.18 
     
Non-AT AF Semuloparin 5.78±0.22 >25.00±0.00 8.34±0.30 >10.00±0.00 
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TABLE 28 
 
POTENCY COMPARISON OF SEMULOPARIN, HAS, AND NAS ON THROMBIN 
GENEREATION FOLLOWING SUPPLEMENTATION IN NHP 
 
 
 
 
 
 
 
 
 
 
 
 
All results represent the mean ± standard error of the mean (n=3).  
Drug  Concentration 
 IC50 (µg/ml) 
  
Semuloparin 3.68 ± 0.138 
  
High-AT AF Semuloparin  0.703 ± 0.043 
  
Non-AT AF Semuloparin 5.00 ± 0.0 
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TABLE 29 
 
EFFECTS OF HEPARINS AND ITS DERIVATIVES ON AGONIST INDUCED 
PLATELET AGGREGATION 
 
 
 
All results represent the mean ± standard deviation (n=3).AA, arachidonic acid; ADP, 
adenosine diphosphate.
 Agonist 
Drug  Thrombin AA ADP Collagen 
 % Aggregation % Aggregation % Aggregation % Aggregation 
     
Saline 95.60±10.5 80.20±3.3 74.00±4.3 76.80±3.8 
     
UFH  7.00±4.9 78.40±7.6 79.40±6.2 77.60±3.6 
     
Enoxaparin 3.60±2.7 77.40±6.4 74.80±8.9 79.40±5.3 
     
Bemiparin 3.4±2.9 81.00±4.7 76±11.9 76.20±2.3 
     
Semuloparin 89±12.4 80.80±6.4 75±9.2 79.80±8.3 
     
RO-14  98.6±7.3 78.80±7.0 68±13.3 80.80±5.6 
     
 Agonist 
Drug  Thrombin AA ADP Collagen 
 Slope Slope Slope Slope 
     
Saline 85.60±9.9 52.20±12.6 39.60±5.0 52.20±8.6 
     
UFH  5.00±3.4 44.20±10.2 43.80±5.1 50.80±6.1 
     
Enoxaparin 3.40±0.5 53.80±12.7 41.20±5.4 52.80±4.9 
     
Bemiparin 14.4.±5.3 47.80±4.7 40.80±9.4 50.60±2.5 
     
Semuloparin 52.00±27.1 47.20±10.6 40.40±9.4 48.80±7.5 
     
RO-14  69.20±22.4 50.20±13.7 40.40±11.0 52.80±4.9 
     
[467] 
 
 
 
TABLE 30  
 
THE EFFECT OF HEPARIN AND ITS DERIVATIVES ON HIT POSITIVE 
ANTIBODY PLATELET AGGREGATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All results represent the mean ± standard deviation (n=3). HIT, heparin induced 
thrombocytopenia.
Drug % Aggregation Slope 
   
   
Saline 11.8±7.4 4.3±2.6 
   
UFH 84.5 ±5.3 20.3±3.9 
   
Enoxaparin 74.8±2.4 19.8±3.6 
   
Bemiparin 72.8±3.5 22.5±3.0 
   
Semuloparin 46.8±4.6 10.0±5.0 
   
RO-14 33.5±11.1 4.0±0.8 
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TABLE 31. NEUTRALIZATION PROFILE OF UFH AND ENOXAPARIN USING HEPARINASE AS DETERMINED BY 
VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
  UFH + Saline UFH + Heparinase 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
10.0 0.61 268.2±1.4 281.1±0.6 94.3±0.3 5.4±2.1 27.1±1.2 6.4±6.4 
5.00 0.30 182.6±9.2 115.8±2.5 85.9±0.8 2.3±0.5 13.8±1.3 5.5±3.7 
2.50 0.15 56.2±3.3 47.4±1.1 63.1±1.8 1.5±0.9 5.3±0.5 1.6±2.2 
1.25 0.08 14.2±3.1 26.3±1.9 34.2±3.0 1.2±0.7 2.4±0.6 0.7±1.2 
0.61 0.04 3.8±2.5 7.1±1.0 13.9±4.6 0.9±0.7 1.6±0.7 0.5±0.9 
0.00 0.00 0.0±0.0 0.0±0.0 0.00.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  Enoxaparin + Saline Enoxaparin + Heparinase 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
10.0 2.38 34.7±1.7 105.4±2.9 77.7±0.8 4.0±1.4 34.2±2.7 10.7±8.7 
5.00 1.19 17.1±2.5 56.8±0.7 63.6±0.6 2.8±0.9 27.7±0.9 5.0±3.9 
2.50 0.60 10.1±1.7 44.71.5 41.5±2.6 2.1±0.8 20.4±1.3 2.4±1.0 
1.25 0.30 5.2±2.6 30.1±0.7 32.1±2.7 1.8±0.7 15.9±0.4 1.7±1.6 
0.61 0.15 3.0±2.4 14.2±1.0 17.4±4.2 1.3±0.4 7.0±0.5 2.5±4.3 
0.00 0.00 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± SD (n=3). Molar values were calculated based on an average MW of 16.5 kDa for UFH and 4.2 kDa 
for enoxaparin. Statistically significant differences between treatment and control for each agent were determined by one-way 
ANOVA followed by Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa.
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TABLE 32. NEUTRALIZATION PROFILE OF BEMIPARIN AND SEMULOPARIN USING HEPARINASE AS DETERMINED 
BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
  Bemiparin + Saline Bemiparin + Heparinase 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
10.0 2.63 28.4±1.0 134.6±2.1 87.2±0.7 10.1±0.5 55.7±1.2 49.9±1.3 
5.00 1.32 16.0±0.5 75.2±1.5 72.9±2.0 6.4±0.4 48.7±1.1 29.1±0.5 
2.50 0.66 9.2±0.6 52.8±1.3 54.5±0.2 4.5±0.4 36.7±2.0 20.2±3.0 
1.25 0.33 6.2±0.3 37.7±3.2 35.4±1.5 3.6±0.7 26.2±0.4 11.7±2.3 
0.61 0.16 3.8±0.1 31.8±1.1 19.2±3.6 2.9±0.8 12.8±1.2 3.5±2.6 
0.00 0.00 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±1.2 0.0±0.0 
        
        
  Semuloparin + Saline Semuloparin + Heparinase 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
10.0 3.45 16.8±2.6 136.5±1.0 91.1±1.5 6.2±0.6 45.8±2.6 26.1±3.6 
5.00 1.72 11.4±1.6 89.4±0.7 80.0±2.3 4.2±0.6 37.0±5.7 18.4±1.3 
2.50 0.86 7.3±1.0 55.8±0.5 60.5±2.5 1.8±0.6 28.2±0.9 12.3±1.6 
1.25 0.43 5.3±0.9 41.3±0.5 41.5±5.0 1.2±1.0 16.2±0.6 8.2±2.0 
0.61 0.22 3.6±0.8 32.0±1.2 26.8±1.3 0.8±0.8 9.5±0.2 5.7±1.0 
0.00 0.00 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
All results represent the mean ± SD (n=3). Molar values were calculated based on an average MW of 3.8 kDa for bemiparin and 2.9 
kDa for semuloparin. Statistically significant differences between treatment and control for each agent were determined by one-way 
ANOVA followed by Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa.
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TABLE 33. NEUTRALIZATION PROFILE OF R0-14 USING HEPARINASE AS DETERMINED BY VARIOUS 
ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
 
  RO-14 + Saline RO-14 + Heparinase 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
10.0 3.85 13.0±2.4 83.8±1.0 69.2±1.1 5.8±0.2 41.8±0.9 23.4±5.7 
5.00 1.92 7.6±0.6 56.7±2.0 52.5±1.1 3.0±0.3 32.7±1.4 15.7±0.9 
2.50 0.96 4.5±0.4 46.9±1.5 38.6±1.1 2.0±0.6 30.0±0.7 11.2±2.4 
1.25 0.48 3.0±0.6 35.7±0.6 21.4±1.1 1.0±0.3 19.2±0.4 8.9±4.1 
0.61 0.24 1.7±0.7 28.2±1.9 15.4±1.9 0.2±0.1 9.7±0.7 5.8±5.4 
0.00 0.00 0.0±0.0 0.0±0.0 1.2±2.1 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
 
All results represent the mean ± SD (n=3). Molar values were calculated based on an average MW of 2.6 kDa. Statistically significant 
differences between treatment and control were determined by one-way ANOVA followed by Dunnett’s multiple comparison test. 
*p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
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TABLE 34 
 
% NEUTRALIZATION OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, 
AND RO-14 BY HEPARINASE 
 
All results represent the mean ± standard deviation (n=3). Xa, Factor Xa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug  APTT Heptest Anti-Xa 
 % Neutralization % Neutralization % Neutralization 
    
UFH  98.8±0.3 88.1±0.9 93.6±4.3 
    
Enoxaparin  83.6±2.9 51.2±1.4 92.2±6.2 
    
Bemiparin  59.7±1.5 35.2±1.3 60.0±0.6 
    
Semuloparin  62.8±8.8 58.6±6.3 77.0±1.6 
    
RO-14  60.7±1.4 42.3±2.9 70.0±1.7 
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TABLE 35. NEUTRALIZATION PROFILE OF UFH USING PROTAMINE SULFATE AND POLYBRENE AS DETERMINED 
BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
  UFH + Saline UFH + Protamine Sulfate 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 1.52 269.3±3.2 281.9±1.1 92.1±2.3 5.1±2.5 20.3±5.2 22.3±31.3 
12.50 0.76 269.3±3.2 281.9±1.1 90.5±4.1 3.5±2.5 9.0±5.7 6.4±9.5 
6.250 0.38 269.3±3.2 228.4±8.6 81.6±6.8 3.7±3.0 4.1±3.5 1.5±3.1 
3.125 0.19 86.8±7.8 128.7±19.0 62.7±10.9 4.2±3.4 1.9±1.5 2.0±2.5 
1.563 0.09 36.1±4.4 54.3±4.8 42.7±11.1 5.5±4.0 1.0±1.2 0.7±1.4 
0.000 0.00 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  UFH + Saline UFH + Polybrene 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 1.52 267.5±2.8 283.1±1.1 91.3±3.1 267.4±2.7 258.1±51.1 79.6±16.5 
12.50 0.76 267.5±2.8 283.1±1.1 91.3±4.9 134.8±153.9 85.1±85.0 48.0±49.1 
6.250 0.38 267.5±2.8 243.6±6.1 85.0±8.3 3.4±2.8 17.3±13.8 3.9±2.1 
3.125 0.19 110.0±36.9 119.1±42.4 67.6±16.4 2.1±1.2 4.8±3.0 4.0±4.4 
1.563 0.09 30.4±4.6 48.3±7.2 44.7±15.4 1.1±0.9 1.5±1.4 3.3±2.9 
0.000 0.00 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 16.5 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa.
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TABLE 36. NEUTRALIZATION PROFILE OF ENOXAPARIN USING PROTAMINE SULFATE AND POLYBRENE AS 
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
 
  Enoxaparin + Saline Enoxaparin + Protamine Sulfate 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 5.95 146.1±17.5 281.9±1.1 89.0±3.8 18.8±4.6 113.7±12.9 7.7±6.6 
12.50 2.98 53.1±13.8 222.8±31.0 83.2±4.2 13.0±3.6 98.0±16.3 6.2±5.5 
6.250 1.49 27.2±6.6 132.4±16.6 73.7±6.6 8.4±2.7 68.9±15.7 2.3±2.2 
3.125 0.74 13.5±1.7 71.2±9.7 55.7±9.2 6.4±1.6 53.6±9.5 2.1±1.6 
1.563 0.37 9.7±1.3 52.5±11.4 37.4±8.5 6.6±1.8 29.4±13.7 1.7±1.5 
0.781 0.19 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  Enoxaparin + Saline Enoxaparin + Polybrene 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 5.95 119.4±32.6 283.1±1.1 80.3±7.8 36.7±10.0 175.7±44.2 9.1±6.0 
12.50 2.98 68.8±21.4 236.9±14.2 78.5±6.1 19.9±8.1 97.8±5.1 3.7±5.5 
6.250 1.49 32.0±7.5 101.0±2.4 63.1±4.1 11.3±3.6 73.1±7.3 3.0±5.4 
3.125 0.74 16.8±4.4 71.5±9.0 46.0±2.5 7.1±2.1 50.4±8.9 2.5±4.7 
1.563 0.37 7.8±3.8 51.2±10.2 25.6±2.7 3.3±1.4 32.5±2.0 1.4±2.2 
0.781 0.19 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 4.2 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
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TABLE 37. NEUTRALIZATION PROFILE OF UFH USING PLATELET FACTOR 4 AND POLYMEDIX AS DETERMINED BY 
VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
 
  UFH + Saline UFH + Platelet Factor 4 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 1.52 271.4±0.9 280.7±1.2 94.5±2.5 271.3±0.8 280.7±1.2 85.0±5.6 
12.50 0.76 271.4±0.9 280.7±1.2 94.2±0.8 34.3±8.2 76.4±4.1 31.8±6.0 
6.250 0.38 271.4±0.9 180.4±2.5 89.0±2.6 6.7±6.7 17.6±3.7 2.5±1.5 
3.125 0.19 118.4±10.2 97.1±2.5 79.0±9.8 3.1±4.2 2.2±2.2 0.4±0.8 
1.563 0.09 33.4±2.8 51.6±1.6 46.1±3.9 2.3±4.0 0.8±0.7 0.0±0.0 
0.000 0.00 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  UFH + Saline UFH + Polymedix 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 1.52 265.8±4.2 282.9±2.9 92.5±2.3 265.8±4.2 269.2±2.9 70.9±8.7 
12.50 0.76 265.8±4.2 282.9±2.9 89.9±0.7 4.0±3.5 3.3±3 2.9±2.8 
6.250 0.38 265.8±4.2 227.9±9.7 87.3±2.1 3.3±2.8 0.1±0.2 1.6±2.7 
3.125 0.19 265.8±4.2 141.4±10.3 70.6±8.1 1.1±1.3 0.0±0.0 2.1±3.6 
1.563 0.09 75.9±37.9 71.4±2.9 46.8±8.1 0.0±0.0 0.0±0.0 0.6±1.0 
0.000 0.00 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 16.5 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
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TABLE 38. NEUTRALIZATION PROFILE OF ENOXAPARIN USING PLATELET FACTOR 4 AND POLYMEDIX AS 
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
 
  Enoxaparin + Saline Enoxaparin + Platelet Factor 4 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 5.95 124.8±8.4 280.7±1.2 89.2±4.7 31.9±1.0 175.8±6.4 89.2±4.7 
12.50 2.98 54.0±7.6 170.0±5.7 83.4±5.4 17.0±3.2 107.7±3.2 83.4±5.4 
6.250 1.49 27.0±7.4 94.2±3.4 74.0±1.6 9.9±5.3 77.6±2.9 74.0±1.6 
3.125 0.74 17.3±5.2 71.2±3.0 54.3±5.0 7.3±4.4 65.6±3.6 54.3±5.0 
1.563 0.37 10.2±2.8 51.5±1.7 33.1±1.1 2.7±2.4 45.8±4.7 33.1±1.1 
0.781 0.19 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  Enoxaparin + Saline Enoxaparin + Polymedix 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 5.95 153.2±12.9 282.9±2.9 86.4±3.4 86.4±3.4 124.7±1.3 63.5±10.0 
12.50 2.98 61.6±6.2 182.0±1.5 79.1±4.9 79.1±4.9 49.5±7.1 48.9±.5 
6.250 1.49 29.5±7.8 95.5±5.2 68.6±4.5 68.6±4.5 9.3±2.4 29.1±0.9 
3.125 0.74 17.2±5.7 74.0±2.4 51.4±3.6 51.4±3.6 5.2±2.1 15.0±2.8 
1.563 0.37 9.2±3.3 59.9±6.3 32.6±6.4 32.6±6.4 4.6±1.4 6.3±5.4 
0.781 0.19 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 4.2 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
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TABLE 39. NEUTRALIZATION PROFILE OF BEMIPARIN USING PROTAMINE SULFATE AND POLYBRENE AS 
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
 
  Bemiparin + Saline Bemiparin + Protamine Sulfate 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 6.58 121.1±7.3 194.5±37.3 91.0±0.6 52.0±12.2 116.5±16.5 91.7±0.6 
12.50 3.29 56.1±4.4 130.5±29.3 90.1±0.4 23.7±6.3 87.2±22.2 87.9±5.6 
6.250 1.64 32.7±1.8 74.3±3.6 87.1±3.1 16.2±1.3 60.7±3.0 83.2±0.5 
3.125 0.82 15.8±4.7 57.1±2.1 79.6±5.3 13.2±1.7 47.5±3.0 69.6±2.5 
1.563 0.41 9.7±2.9 42.1±4.2 64.7±4.9 11.5±2.4 33.9±10.9 54.1±2.4 
0.781 0.21 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  Bemiparin + Saline Bemiparin + Polybrene 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 6.58 92.7±15.6 281.2±3.3 92.0±0.6 46.6±8.1 244.5±24.6 91.8±0.7 
12.50 3.29 41.5±7.1 207.4±40.1 90.5±0.5 23.3±4.1 131.7±2.7 89.8±1.7 
6.250 1.64 23.6±3.2 123.0±13.1 83.6±1.7 14.8±2.3 89.4±3.2 79.3±1.9 
3.125 0.82 13.8±4.0 69.6±7.2 71.8±3.4 7.5±2.9 59.6±1.3 59.9±11.9 
1.563 0.41 9.9±3.2 57.1±10.5 54.9±2.3 5.9±2.3 48.1±2.8 42.0±6.7 
0.781 0.21 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 3.8 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
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TABLE 40. NEUTRALIZATION PROFILE OF BEMIPARIN USING PLATELET FACTOR 4 AND POLYMEDIX AS 
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
 
  Bemiparin + Saline Bemiparin + Platelet Factor 4 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 6.58 97.9±6.3 280.7±1.2 94.7±1.9 34.9±6.6 214.3±7.1 86.8±6.3 
12.50 3.29 40.9±3.7 156.0±3.3 92.0±1.9 17.9±0.9 125.5±5.0 80.2±2.3 
6.250 1.64 24.5±0.7 107.7±2.1 83.9±1.4 10.0±1.4 75.7±5.6 65.0±3.4 
3.125 0.82 17.6±0.5 69.5±1.6 67.5±9.0 7.5±2.4 64.8±1.2 40.9±4.1 
1.563 0.41 13.9±0.5 52.4±2.9 46.5±8.7 4.8±1.4 37.5±3.1 23.3±4.4 
0.781 0.21 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  Bemiparin + Saline Bemiparin + Polymedix 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 6.58 103.4±9.7 279.5±6.0 85.8±2.6 28.2±5.1 151.4±5.1 72.5±11.7 
12.50 3.29 46.3±10.7 182.9±23.7 83.9±2.9 10.2±5.9 63.9±1.0 62.3±7.2 
6.250 1.64 25.9±8.3 114.7±4.5 77.0±3.3 6.8±5.9 31.8±2.4 48.1±6.3 
3.125 0.82 14.1±3.9 69.5±3.3 54.1±8.7 2.4±2.2 18.1±2.1 26.9±2.0 
1.563 0.41 8.4±3.3 33.2±26.8 38.9±6.2 0.6±1.0 7.0±2.9 11.5±4.0 
0.781 0.21 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 3.8 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
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TABLE 41. NEUTRALIZATION PROFILE OF SEMULOPARIN USING PROTAMINE SULFATE AND POLYBRENE AS 
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
 
  Semuloparin + Saline Semuloparin + Protamine Sulfate 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 8.62 39.2±15.0 263.9±12.8 91.1±4.8 25.6±8.7 227.0±27.7 91.5±4.6 
12.50 4.31 23.3±4.7 219.3±8.3 89.4±5.9 17.2±3.8 207.6±35.7 87.2±5.9 
6.250 2.16 14.1±3.5 134.0±11.1 80.4±7.2 11.9±4.6 114.2±2.3 78.8±7.5 
3.125 1.08 10.6±3.8 110.7±22.1 66.6±13.1 10.4±3.9 89.8±8.6 66.3±9.5 
1.563 0.54 9.0±4.8 78.3±0.6 50.8±14.1 8.9±5.1 66.4±10.0 43.2±10.5 
0.781 0.27 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  Semuloparin + Saline Semuloparin + Polybrene 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 8.62 49.5±13.0 257.2±30.4 90.5±6.1 25.0±7.5 208.3±23.6 91.5±3.1 
12.50 4.31 23.4±4.7 172.5±15.2 85.3±5.4 16.4±3.5 161.9±22.3 86.5±4.6 
6.250 2.16 14.7±2.6 123.2±3.1 71.8±5.9 10.2±3.5 107.3±5.6 71.5±6.2 
3.125 1.08 9.7±1.5 81.6±19.0 55.0±8.5 7.1±1.3 80.7±18.1 61.2±5.1 
1.563 0.54 6.7±0.9 63.2±14.9 39.7±6.4 5.3±1.7 55.7±9.4 43.0±5.8 
0.781 0.27 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 2.9 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
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TABLE 42. NEUTRALIZATION PROFILE OF SEMULOPARIN USING PLATELET FACTOR 4 AND POLYMEDIX AS 
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
  Semuloparin + Saline Semuloparin + Platelet Factor 4 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 8.62 30.1±3.0 226.2±4.7 92.6±4.3 18.5±1.9 221.0±3.1 90.7±3.6 
12.50 4.31 18.5±1.4 147.4±1.7 86.8±5.3 10.9±1.1 149.9±3.6 87.1±3.4 
6.250 2.16 12.5±0.2 115.8±1.6 77.4±9.0 7.1±0.8 106.3±4.1 69.8±5.4 
3.125 1.08 8.7±0.3 69.1±1.9 60.4±12.0 4.0±0.9 78.7±6.1 58.2±3.1 
1.563 0.54 6.0±0.9 62.6±1.4 43.7±11.8 2.2±0.6 56.2±3.7 42.3±1.7 
0.781 0.27 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  Semuloparin + Saline Semuloparin + Polymedix 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 8.62 47.7±11.1 238.6±11.6 94.7±2.0 20.1±5.5 155.2±3.3 86.2±9.8 
12.50 4.31 28.1±7.7 149.9±2.9 88.0±5.5 14.6±4.6 79.5±3.1 79.7±9.8 
6.250 2.16 17.2±9.0 122.4±4.0 84.3±9.2 8.6±6.9 35.9±11.4 63.0±5.6 
3.125 1.08 12.5±7.3 88.1±0.3 68.1±12.9 4.1±3.5 24.5±2.9 48.8±9.1 
1.563 0.54 8.1±4.6 55.9±1.5 53.7±9.2 0.9±1.6 18.6±4.3 31.7±7.9 
0.781 0.27 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 2.9 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
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TABLE 43. NEUTRALIZATION PROFILE OF RO-14 USING PROTAMINE SULFATE AND POLYBRENE AS DETERMINED 
BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
 
  RO14 + Saline RO14 + Protamine Sulfate 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 9.62 17.3±1.0 123.7±6.0 88.0±1.5 21.1±3.1 110.2±9.7 83.2±4.0 
12.50 4.81 10.9±0.8 90.0±6.4 80.8±5.3 16.2±3.0 81.5±6.1 71.5±4.4 
6.250 2.40 6.9±0.6 72.8±3.3 65.5±4.9 13.4±2.9 64.2±2.8 60.2±4.6 
3.125 1.20 4.6±0.4 54.4±2.0 45.6±4.2 11.0±2.9 52.4±5.1 38.0±3.3 
1.563 0.60 3.0±0.3 42.3±6.6 29.5±3.4 9.3±2.7 36.8±13.3 27.6±1.4 
0.781 0.30 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  RO14 + Saline RO14 + Polybrene 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 9.62 21.0±1.9 146.2±3.0 88.5±2.3 16.9±2.4 142.3±7.2 87.3±1.6 
12.50 4.81 14.0±0.6 99.8±5.9 80.4±4.2 13.1±1.7 97.8±4.7 78.8±4.7 
6.250 2.40 9.0±0.7 73.7±1.6 65.5±3.0 8.9±1.7 70.5±2.5 59.9±0.6 
3.125 1.20 6.4±0.9 57.5±3.1 46.5±2.1 7.0±2.6 58.4±3.0 46.9±2.3 
1.563 0.60 4.8±0.7 44.4±1.8 32.1±3.1 5.4±2.6 42.7±1.9 36.5±4.3 
0.781 0.30 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 2.6 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
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TABLE 44. NEUTRALIZATION PROFILE OF RO-14 USING PLATELET FACTOR 4 AND POLYMEDIX AS DETERMINED 
BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS  
 
  RO14 + Saline RO14 + Platelet Factor 4 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 9.62 20.2±2.1 140.4±3.3 81.0±9.0 12.8±0.8 128.2±2.1 73.2±3.2 
12.50 4.81 13.2±1.3 101.0±2.1 68.5±11.5 8.0±0.5 92.6±8.4 58.3±6.5 
6.250 2.40 8.5±0.8 66.9±3.1 48.3±7.6 4.3±1.0 64.5±2.1 40.0±5.2 
3.125 1.20 6.9±0.2 51.7±4.5 32.6±4.0 2.8±1.0 50.2±2.2 26.1±2.9 
1.563 0.60 4.9±0.1 44.3±5.9 17.6±0.1 1.1±1.0 41.6±1.3 10.0±2.3 
0.781 0.30 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
        
        
  RO14 + Saline RO14 + Polymedix 
        
Concentration  APTT Heptest Anti-Xa APTT Heptest Anti-Xa 
(µg/ml) (µM) (Sec) (Sec) (% Inhibition) (Sec) (Sec) (% Inhibition) 
25.00 9.62 30.0±8.7 129.9±6.3 72.3±14.9 16.9±4.8 96.3±12.2 66.5±12.4 
12.50 4.81 18.3±8.8 83.1±2.4 65.6±5.6 11.2±6.1 50.6±2.5 55.7±14.3 
6.250 2.40 13.5±7.9 61.2±4.0 47.2±2.2 5.8±4.8 21.9±7.7 32.8±4.8 
3.125 1.20 10.2±6.3 47.6±2.2 32.4±3.8 3.0±2.8 15.6±3.1 22.3±10.5 
1.563 0.60 8.2±5.5 33.7±3.2 15.4±4.4 1.1±1.9 12.2±3.4 11.1±8.8 
0.781 0.30 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
All results represent the mean ± standard deviation (n=3-4). Molar values were calculated based on an average MW of 2.6 kDa. 
Statistically significant differences between treatment and control for each agent were determined by one-way ANOVA followed by 
Dunnett’s multiple comparison test. *p<0.05 compared to baseline values. Sec, seconds; Xa, Factor Xa. 
[482] 
 
 
 
[4
8
1
] 
TABLE 45 
 
% NEUTRALIZATION OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, 
AND RO-14 BY PLATELET FACTOR 4    
 
 
All results represent the mean ± standard deviation (n=3-4). Sec, seconds; Xa, Factor Xa. 
 
 
Drug  APTT Heptest Anti-Xa 
 % Neutralization % Neutralization % Neutralization 
    
UFH  97.5±2.5 90.3±1.9 97.1±1.8 
    
Enoxaparin  64.6±11.9 17.5±4.9 44.8±5.5 
    
Bemiparin  59.2±6.8 29.7±4.9 22.5±3.0 
    
Semuloparin  43.1±6.5 8.2±2.9 9.5±4.1 
    
RO-14  48.7±11.9 3.5±1.4 16.8±5.5 
    
[483] 
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TABLE 46 
 
% NEUTRALIZATION OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, 
AND RO-14 BY PMX 60056  
 
 
All results represent the mean ± standard deviation (n=3-4). Sec, seconds; Xa, Factor Xa. 
Drug  APTT Heptest Anti-Xa 
 % Neutralization % Neutralization % Neutralization 
    
UFH  98.8±1.1 99.9±0.1 98.1±3.1 
    
Enoxaparin  83.5±14.3 90.3±2.2 57.4±3.8 
    
Bemiparin  77.1±15.7 72.3±1.4 37.7±5.6 
    
Semuloparin  47.7±7.7 70.7±8.9 25.2±1.8 
    
RO-14  63.9±25.9 63.5±15.3 30.2±12.4 
    
[484] 
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TABLE 47 
 
% NEUTRALIZATION OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, 
AND RO-14 BY PROTAMINE SULFATE    
 
 
All results represent the mean ± standard deviation (n=3-4). Sec, seconds; Xa, Factor Xa. 
 
 
Drug  APTT Heptest Anti-Xa 
 % Neutralization % Neutralization % Neutralization 
    
UFH  98.7±1.1 98.3±1.4 98.3±3.4 
    
Enoxaparin  69.8±3.9 47.3±13.8 24.5±6.0 
    
Bemiparin  50.3±5.1 18.3±2.2 4.5±3.0 
    
Semuloparin  17.4±11.9 14.3±7.8 2.1±2.7 
    
RO-14  0.0±0.0 11.7±6.0 8.1±3.5 
    
[485] 
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TABLE 48 
 
% NEUTRALIZATION OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, 
AND RO-14 BY POLYBRENE   
 
 
All results represent the mean ± standard deviation (n=3-4). Sec, seconds; Xa, Factor Xa. 
Drug  APTT Heptest Anti-Xa 
 % Neutralization % Neutralization % Neutralization 
    
UFH  98.7±1.0 92.9±5.5 95.6±2.1 
    
Enoxaparin  64.5±11.4 27.7±5.6 16.9±5.3 
    
Bemiparin  37.4±2.7 26.7±7.8 5.1±1.9 
    
Semuloparin  32.1±17.0 12.8±5.0 0.6±0.7 
    
RO-14  8.1±10.2 4.3±3.9 8.4±5.0 
    
[486] 
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TABLE 49 
 
DIFFERENTIAL INHIBITION OF FIBRINOKINETICS BY UFH AND ITS 
DERIVATIVES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All results represent the mean ± standard deviation (n=3). MW, molecular weight.
Drug / MW (kDa) Concentration Fibrin Clot Formation 
 (µg/ml) (µM) % Inhibition 
    
UFH / 16.5 10.00 0.61 94.13±2.5 
 5.00 0.30 92.38±0.3 
 2.50 0.15 90.66±3.0 
 1.25 0.08 85.94±4.6 
 0.63 0.04 80.40±3.4 
 0.00 0.00 0.00±0.0 
    
Enoxaparin / 4.2 10.00 2.38 88.54±2.4 
 5.00 1.19 77.79±6.2 
 2.50 0.60 75.89±6.5 
 1.25 0.30 70.37±1.8 
 0.63 0.15 65.32±3.9 
 0.00 0.00 0.00±0.0 
    
Bemiparin / 3.8 10.00 2.63 74.84±9.1 
 5.00 1.32 67.40±2.5 
 2.50 0.66 64.56±3.8 
 1.25 0.33 57.65±1.6 
 0.63 0.16 51.19±16.2 
 0.00 0.00 0.00±0.0 
    
Semuloparin / 2.9 10.00 3.45 59.09±3.2 
 5.00 1.72 44.80±17.7 
 2.50 0.86 38.12±16.3 
 1.25 0.43 35.95±16.1 
 0.63 0.22 32.14±16.3 
 0.00 0.00 0.00±0.0 
    
RO-14 / 2.6 10.00 3.85 59.02±1.6 
 5.00 1.92 46.76±5.5 
 2.50 0.96 43.50±3.7 
 1.25 0.48 30.47±8.7 
 0.63 0.24 23.79±3.1 
 0.00 0.00 0.00±0.0 
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TABLE 50. THE EFFECTS OF UFH IN RATS AFTER IV AND SC ADMINISTRATION 
 
IV BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.17±0.60 3.00±0.25 26.38±0.88 22.73±1.95 55.48±3.22 25.28±1.08 0.00±0.00 0.00±0.00 
0.25 17.00±1.38 4.40±0.24 23.63±2.10 19.02±0.89 153.56±19.85 38.22±3.07 1.29±1.21 2.51±2.51 
0.5 19.40±1.57 4.80±0.20 32.75±1.10 34.94±3.91 169.26±37.35 164.26±57.56 25.42±3.03 41.98±2.23 
1.0 22.00±1.92 10.00±0.77 47.06±3.50 163.90±40.13 245.98±34.72 300.00±0.00 53.75±11.31 75.54±2.91 
         
         
SC BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.10±0.87 3.60±0.24 18.60±0.36 16.40±0.00 79.80±0.00 26.42±0.00 0.00±0.00 0.00±0.00 
0.25 6.40±0.60 3.60±0.40 21.4±0.52 17.18±0.24 74.44±4.92 24.3±1.45 2.24±1.35 5.93±1.56 
0.5 12.50±0.67 5.60±0.24 24.91±0.70 16.94±0.37 96.92±5.03 35.44±2.41 10.83±1.99 11.31±1.58 
1.0 19.00±2.68 6.60±0.24 26.86±0.73 21.26±1.15 251.58±20.91 216.04±31.62 36.63±1.84 36.34±1.83 
         
 
All results represent the mean ± standard deviation (n=5). IV, intravenous; SC, subcutaneous; JVC, jugular venous clamping; cps, 
clampings; WB, whole blood; PPP, platelet poor plasma; aPTT; activated partial thromboplastin time; TT, thrombin time; Xa, factor 
Xa; IIa, factor IIa; sec, seconds. Statistical analysis of the data was performed using a one-way ANOVA followed by Tukey’s multiple 
comparison test.  
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TABLE 51. THE EFFECTS OF ENOXAPARIN IN RATS AFTER IV AND SC ADMINISTRATION 
 
IV BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.17±0.60 3.00±0.25 26.38±0.88 22.73±1.95 55.48±3.22 25.28±1.08 0.00±0.00 0.00±0.00 
0.25 13.00±0.32 4.60±0.24 19.51±1.23 26.84±2.91 140.86±24.29 34.14±3.17 4.42±1.68 2.72±1.88 
0.5 17.00±1.38 4.80±0.37 26.09±3.11 26.24±1.20 225.90±36.93 37.64±2.61 27.47±2.05 20.77±2.58 
1.0 19.67±1.38 7.67±0.37 23.03±0.62 29.63±1.80 230.03±35.80 38.05±3.15 33.19±4.81 25.51±1.68 
         
         
SC BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.10±0.87 3.60±0.24 18.60±0.36 16.40±0.00 79.80±0.00 26.42±0.00 0.00±0.00 0.00±0.00 
0.25 6.50±0.63 5.00±0.00 22.64±0.73 17.90±0.06 95.6±3.91 23.16±0.62 22.72±1.77 10.49±1.07 
0.5 10.30±0.30 6.20±0.37 24.50±0.63 16.94±0.58 142.72±7.21 37.45±2.01 38.67±2.57 18.20±1.80 
1.0 16.80±1.71 7.20±0.37 24.56±1.02 16.70±0.54 174.16±11.74 27.73±2.20 53.66±2.44 26.97±1.27 
         
 
All results represent the mean ± standard deviation (n=5). IV, intravenous; SC, subcutaneous; JVC, jugular venous clamping; cps, 
clampings; WB, whole blood; PPP, platelet poor plasma; aPTT; activated partial thromboplastin time; TT, thrombin time; Xa, factor 
Xa; IIa, factor IIa; sec, seconds. Statistical analysis of the data was performed using a one-way ANOVA followed by Tukey’s multiple 
comparison test.  
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TABLE 52. THE EFFECTS OF BEMIPARIN IN RATS AFTER IV AND SC ADMINISTRATION 
 
IV BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.17±0.60 3.00±0.25 26.38±0.88 22.73±1.95 55.48±3.22 25.28±1.08 0.00±0.00 0.00±0.00 
0.25 15.60±0.63 5.00±0.32 22.34±1.31 20.82±0.53 152.46±14.58 33.10±1.90 11.53±2.69 7.91±3.42 
0.5 15.40±1.89 4.40±0.24 24.45±1.29 27.96±2.29 193.42±18.50 34.62±3.48 20.04±2.30 20.30±2.09 
1.0 15.20±1.29 9.60±0.68 24.80±1.43 28.30±0.51 234.60±18.33 41.38±2.49 49.72±1.12 22.93±2.53 
         
         
SC BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.10±0.87 3.60±0.24 18.60±0.36 16.40±0.00 79.80±0.00 26.42±0.00 0.00±0.00 0.00±0.00 
0.25 6.40±0.29 4.40±0.24 21.64±0.79 15.22±0.39 91.32±3.93 23.60±1.06 17.07±2.87 7.95±0.85 
0.5 13.20±1.20 6.40±0.40 23.91±0.85 15.22±0.28 142.22±13.96 30.88±1.19 16.87±2.31 11.93±1.10 
1.0 13.40±0.87 7.00±0.32 24.10±0.77 17.66±0.25 224.8±18.76 33.52±2.47 56.32±8.12 18.31±0.62 
         
 
All results represent the mean ± standard deviation (n=5). IV, intravenous; SC, subcutaneous; JVC, jugular venous clamping; cps, 
clampings; WB, whole blood; PPP, platelet poor plasma; aPTT; activated partial thromboplastin time; TT, thrombin time; Xa, factor 
Xa; IIa, factor IIa; sec, seconds. Statistical analysis of the data was performed using a one-way ANOVA followed by Tukey’s multiple 
comparison test.  
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TABLE 53. THE EFFECTS OF SEMULOPARIN IN RATS AFTER IV AND SC ADMINISTRATION 
 
IV BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.17±0.60 3.00±0.25 26.38±0.88 22.73±1.95 55.48±3.22 25.28±1.08 0.00±0.00 0.00±0.00 
0.25 9.00±0.63 4.20±0.20 20.28±1.08 24.62±0.73 223.28±19.71 25.06±0.47 25.83±3.37 7.50±2.21 
0.5 13.60±1.89 4.40±0.24 21.56±0.53 27.10±0.63 255.82±9.19 41.72±2.12 33.48±1.42 21.16±1.20 
1.0 13.10±1.29 8.00±0.32 28.46±2.17 28.88±0.32 282.64±6.44 42.42±3.29 63.81±1.60 21.40±0.86 
         
         
SC BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.10±0.87 3.60±0.24 18.60±0.36 16.40±0.00 79.80±0.00 26.42±0.00 0.00±0.00 0.00±0.00 
0.25 5.40±0.19 5.00±0.32 21.38±0.95 14.98±0.08 109.62±5.65 20.56±0.59 27.01±2.12 8.09±2.14 
0.5 9.40±1.36 6.60±0.24 25.14±0.91 15.58±0.22 162.66±7.46 28.7±0.90 41.00±2.01 7.37±0.91 
1.0 12.40±1.29 7.60±0.24 31.01±1.32 17.84±0.11 253.64±12.29 30.56±1.76 67.74±1.78 12.79±3.69 
         
 
All results represent the mean ± standard deviation (n=5). IV, intravenous; SC, subcutaneous; JVC, jugular venous clamping; cps, 
clampings; WB, whole blood; PPP, platelet poor plasma; aPTT; activated partial thromboplastin time; TT, thrombin time; Xa, factor 
Xa; IIa, factor IIa; sec, seconds. Statistical analysis of the data was performed using a one-way ANOVA followed by Tukey’s multiple 
comparison test.  
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TABLE 54. THE EFFECTS OF RO-14 IN RATS AFTER IV AND SC ADMINISTRATION 
 
IV BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.17±0.60 3.00±0.25 26.38±0.88 22.73±1.95 55.48±3.22 25.28±1.08 0.00±0.00 0.00±0.00 
0.25 6.70±0.30 3.80±0.20 18.87±0.50 24.10±1.95 123.20±7.08 26.74±0.66 10.95±0.86 0.00±0.00 
0.5 11.80±0.97 4.40±0.25 21.28±0.51 25.54±0.34 183.50±25.26 36.02±2.67 14.07±1.04 7.84±0.87 
1.0 14.00±2.24 5.20±0.59 26.52±1.50 26.38±0.13 188.56±17.45 38.04±1.71 31.42±2.89 20.78±1.27 
         
         
SC BT JVC aPTT (WB) aPTT (PPP) Heptest (PPP) TT (PPP) Anti-Xa (PPP) Anti-IIa (PPP) 
Conc. (mg/kg) Time (sec) # of cps Time (sec) Time (sec) Time (sec) Time (sec) % Inhibition % Inhibition 
         
0 7.10±0.87 3.60±0.24 18.60±0.36 16.40±0.00 79.80±0.00 26.42±0.00 0.00±0.00 0.00±0.00 
0.25 6.30±0.25 4.20±0.20 20.34±0.52 15.04±0.28 87.52±3.12 19.84±0.40 11.77±1.60 4.33±2.83 
0.5 12.00±1.10 4.80±0.20 18.34±0.52 15.54±0.35 112.00±9.99 30.9±1.05 19.19±3.94 4.51±1.30 
1.0 18.00±1.70 5.20±0.20 22.94±0.46 17.18±0.28 196.08±11.52 28.1±1.12 59.25±3.60 14.63±3.39 
         
 
All results represent the mean ± standard deviation (n=5). IV, intravenous; SC, subcutaneous; JVC, jugular venous clamping; cps, 
clampings; WB, whole blood; PPP, platelet poor plasma; aPTT; activated partial thromboplastin time; TT, thrombin time; Xa, factor 
Xa; IIa, factor IIa; sec, seconds. Statistical analysis of the data was performed using a one-way ANOVA followed by Tukey’s multiple 
comparison test.  
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TABLE 55. THE HEMORRHAGIC EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 IN A RAT-
TAIL BLEEDING MODEL AFTER IV ADMINISTRATION: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.25 p<0.001 vs saline control, semuloparin, and RO-14 
Enoxaparin 0.25 p<0.01 vs saline control and RO-14 
Bemiparin 0.25 p<0.001 vs saline control and RO-14; p<0.01 vs semuloparin 
Semuloparin 0.25 No statistical significance 
RO-14 0.25 No statistical significance 
   
UFH 0.5 p<0.001 vs saline control; p<0.05 vs RO-14 
Enoxaparin 0.5 p<0.05 vs saline control 
Bemiparin 0.5 p<0.05 vs saline control 
Semuloparin 0.5 No statistical significance 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.001 vs saline control; p<0.01 vs semuloparin; p<0.05 vs bemiparin and RO-14 
Enoxaparin 1.0 p<0.001 vs saline control; p<0.05 vs semuloparin 
Bemiparin 1.0 p<0.01 vs saline control 
Semuloparin 1.0 No statistical significance 
RO-14 1.0 p<0.05 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 56. THE HEMORRHAGIC EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 IN A RAT-
TAIL BLEEDING MODEL AFTER SC ADMINISTRATION: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.5 No statistical significance 
Enoxaparin 0.5 No statistical significance 
Bemiparin 0.5 No statistical significance 
Semuloparin 0.5 No statistical significance 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.01 vs saline control 
Enoxaparin 1.0 No statistical significance 
Bemiparin 1.0 p<0.01 vs saline control 
Semuloparin 1.0 No statistical significance 
RO-14 1.0 p<0.05 vs saline control 
   
UFH 2.5 p<0.001 vs saline control 
Enoxaparin 2.5 p<0.01 vs saline control 
Bemiparin 2.5 p<0.05 vs saline control 
Semuloparin 2.5 No statistical significance 
RO-14 2.5 p<0.001 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 57. THE ANTITHROMBOTIC EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 IN A 
RAT JUGULAR VEIN CLAMPING MODEL AFTER IV ADMINISTRATION: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.25 p<0.01 vs saline control 
Enoxaparin 0.25 p<0.01 vs saline control  
Bemiparin 0.25 p<0.001 vs saline control; p<0.05 vs RO-14 
Semuloparin 0.25 p<0.05 vs saline control 
RO-14 0.25 No statistical significance 
   
UFH 0.5 p<0.001 vs saline control 
Enoxaparin 0.5 p<0.001 vs saline control 
Bemiparin 0.5 p<0.01 vs saline control 
Semuloparin 0.5 p<0.01 vs saline control 
RO-14 0.5 p<0.01 vs saline control 
   
UFH 1.0 p<0.001 vs saline control and RO-14; p<0.05 vs enoxaparin 
Enoxaparin 1.0 p<0.001 vs saline control; p<0.05 vs RO-14 
Bemiparin 1.0 p<0.001 vs saline control and RO-14 
Semuloparin 1.0 p<0.001 vs saline control; p<0.01 vs RO-14 
RO-14 1.0 p<0.05 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 58. THE ANTITHROMBOTIC EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 IN A 
RAT JUGULAR VEIN CLAMPING MODEL AFTER SC ADMINISTRATION: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.5 No statistical significance 
Enoxaparin 0.5 p<0.05 vs saline control  
Bemiparin 0.5 No statistical significance 
Semuloparin 0.5 p<0.05 vs saline control and UFH 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.001 vs saline control 
Enoxaparin 1.0 p<0.001 vs saline control; p<0.05 vs RO-14 
Bemiparin 1.0 p<0.001 vs saline control; p<0.01 vs RO-14 
Semuloparin 1.0 p<0.001 vs saline control; p<0.01 vs RO-14 
RO-14 1.0 No statistical significance 
   
UFH 2.5 p<0.001 vs saline control; p<0.05 vs RO-14 
Enoxaparin 2.5 p<0.001 vs saline control and RO-14 
Bemiparin 2.5 p<0.001 vs saline control; p<0.01 vs RO-14 
Semuloparin 2.5 p<0.001 vs saline control and RO-14 
RO-14 2.5 p<0.01 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 59. THE WHOLE BLOOD ANTICOAGULANT EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, 
AND RO-14 AS MEASURED BY APTT AFTER IV ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.25 No statistical significance 
Enoxaparin 0.25 No statistical significance 
Bemiparin 0.25 No statistical significance 
Semuloparin 0.25 No statistical significance 
RO-14 0.25 No statistical significance 
   
UFH 0.5 p<0.001 vs saline control, enoxaparin, bemiparin, semuloparin, and RO-14 
Enoxaparin 0.5 No statistical significance 
Bemiparin 0.5 No statistical significance 
Semuloparin 0.5 No statistical significance 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.001 vs saline control, enoxaparin, bemiparin, semuloparin, and RO-14 
Enoxaparin 1.0 No statistical significance 
Bemiparin 1.0 No statistical significance 
Semuloparin 1.0 No statistical significance 
RO-14 1.0 No statistical significance 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 60. THE PLASMA ANTICOAGULANT EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 
AS MEASURED BY APTT AFTER IV ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.25 No statistical significance 
Enoxaparin 0.25 No statistical significance 
Bemiparin 0.25 No statistical significance 
Semuloparin 0.25 No statistical significance 
RO-14 0.25 No statistical significance 
   
UFH 0.5 p<0.01 vs saline control; p<0.05 vs RO-14 
Enoxaparin 0.5 No statistical significance 
Bemiparin 0.5 No statistical significance 
Semuloparin 0.5 No statistical significance 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.001 vs saline control, enoxaparin, bemiparin, semuloparin, and RO-14 
Enoxaparin 1.0 No statistical significance 
Bemiparin 1.0 No statistical significance 
Semuloparin 1.0 No statistical significance 
RO-14 1.0 No statistical significance 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 61. THE ANTICOAGULANT EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 AS 
MEASURED BY THE HEPTEST ASSAY AFTER IV ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.25 p<0.01 vs saline control 
Enoxaparin 0.25 p<0.01 vs saline control 
Bemiparin 0.25 p<0.01 vs saline control 
Semuloparin 0.25 p<0.001 vs saline control; p<0.01 RO-14; p<0.05 vs enoxaparin 
RO-14 0.25 No statistical significance 
   
UFH 0.5 p<0.05 vs saline control 
Enoxaparin 0.5 p<0.001 vs saline control 
Bemiparin 0.5 p<0.01 vs saline control 
Semuloparin 0.5 p<0.001 vs saline control 
RO-14 0.5 p<0.01 vs saline control 
   
UFH 1.0 p<0.001 vs saline control 
Enoxaparin 1.0 p<0.001 vs saline control 
Bemiparin 1.0 p<0.001 vs saline control 
Semuloparin 1.0 p<0.001 vs saline control 
RO-14 1.0 p<0.01 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 62. THE ANTICOAGULANT EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 AS 
MEASURED BY THE 5 U CA2+ TT ASSAY AFTER IV ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.25 p<0.01 vs saline control, semuloparin, and RO-14 
Enoxaparin 0.25 p<0.05 vs saline control 
Bemiparin 0.25 p<0.05 vs saline control and semuloparin 
Semuloparin 0.25 No statistical significance 
RO-14 0.25 No statistical significance 
   
UFH 0.5 p<0.01 vs saline control, enoxaparin, and RO-14; p<0.05 vs bemiparin and semuloparin 
Enoxaparin 0.5 No statistical significance 
Bemiparin 0.5 No statistical significance 
Semuloparin 0.5 No statistical significance 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.001 vs saline control, enoxaparin, bemiparin, semuloparin, and RO-14 
Enoxaparin 1.0 p<0.01 vs saline control 
Bemiparin 1.0 No statistical significance 
Semuloparin 1.0 p<0.001 vs saline control 
RO-14 1.0 p<0.05 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 63. THE INHIBITION OF FACTOR XA BY UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 AS 
MEASURED BY AMIDOLYTIC ANTI-XA ASSAY AFTER IV ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.25 No statistical significance 
Enoxaparin 0.25 No statistical significance 
Bemiparin 0.25 p<0.01 vs saline control; p<0.05 vs UFH 
Semuloparin 0.25 p<0.001 vs saline control, enoxaparin, bemiparin, semuloparin, and RO-14 
RO-14 0.25 p<0.05 vs saline control and UFH 
   
UFH 0.5 p<0.001 vs saline control; p<0.01 vs RO-14 
Enoxaparin 0.5 p<0.001 vs saline control and RO-14 
Bemiparin 0.5 p<0.001 vs saline control 
Semuloparin 0.5 p<0.001 vs saline control, bemiparin, and RO-14 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.001 vs saline control 
Enoxaparin 1.0 p<0.01 vs saline control 
Bemiparin 1.0 p<0.001 vs saline control 
Semuloparin 1.0 p<0.001 vs saline control; p<0.01 vs enoxaparin and RO-14 
RO-14 1.0 p<0.01 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 64. THE INHIBITION OF THROMBIN BY UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 AS 
MEASURED BY AMIDOLYTIC ANTI-IIA ASSAY AFTER IV ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.25 No statistical significance 
Enoxaparin 0.25 No statistical significance 
Bemiparin 0.25 No statistical significance 
Semuloparin 0.25 No statistical significance 
RO-14 0.25 No statistical significance 
   
UFH 0.5 p<0.001 vs saline control, enoxaparin, bemiparin, semuloparin, and RO-14 
Enoxaparin 0.5 p<0.001 vs saline control 
Bemiparin 0.5 p<0.001 vs saline control 
Semuloparin 0.5 p<0.001 vs saline control 
RO-14 0.5 p<0.001 vs saline control 
   
UFH 1.0 p<0.001 vs saline control, enoxaparin, bemiparin, semuloparin, and RO-14 
Enoxaparin 1.0 p<0.001 vs saline control 
Bemiparin 1.0 p<0.001 vs saline control 
Semuloparin 1.0 p<0.001 vs saline control 
RO-14 1.0 p<0.001 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 65. THE WHOLE BLOOD ANTICOAGULANT EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, 
AND RO-14 AS MEASURED BY APTT AFTER SC ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.5 p<0.01 vs saline control 
Enoxaparin 0.5 p<0.001 vs saline control; p<0.05 vs RO-14 
Bemiparin 0.5 p<0.001 vs saline control 
Semuloparin 0.5 p<0.01 vs saline control 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.001 vs saline control and RO-14 
Enoxaparin 1.0 p<0.001 vs saline control and RO-14 
Bemiparin 1.0 p<0.001 vs saline control and RO-14 
Semuloparin 1.0 p<0.001 vs saline control and RO-14 
RO-14 1.0 No statistical significance 
   
UFH 2.5 p<0.001 vs saline control and RO-14; p<0.05 vs bemiparin 
Enoxaparin 2.5 p<0.001 vs saline control  
Bemiparin 2.5 p<0.001 vs saline control  
Semuloparin 2.5 p<0.001 vs saline control, UFH, enoxaparin, bemiparin, and RO-14 
RO-14 2.5 p<0.001 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 66. THE PLASMA ANTICOAGULANT EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 
AS MEASURED BY APTT AFTER SC ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.5 No statistical significance 
Enoxaparin 0.5 No statistical significance 
Bemiparin 0.5 No statistical significance 
Semuloparin 0.5 No statistical significance 
RO-14 0.5 No statistical significance 
   
UFH 1.0 No statistical significance 
Enoxaparin 1.0 No statistical significance 
Bemiparin 1.0 No statistical significance 
Semuloparin 1.0 No statistical significance 
RO-14 1.0 No statistical significance 
   
UFH 2.5 p<0.001 vs saline control, enoxaparin, and RO-14; p<0.01 vs bemiparin and semuloparin 
Enoxaparin 2.5 No statistical significance 
Bemiparin 2.5 No statistical significance 
Semuloparin 2.5 No statistical significance 
RO-14 2.5 No statistical significance 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 67. THE ANTICOAGULANT EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 AS 
MEASURED BY THE HEPTEST ASSAY AFTER SC ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.5 No statistical significance 
Enoxaparin 0.5 No statistical significance 
Bemiparin 0.5 No statistical significance 
Semuloparin 0.5 p<0.01 vs saline control; p<0.001 vs UFH; p<0.05 vs RO-14 
RO-14 0.5 No statistical significance 
   
UFH 1.0 No statistical significance 
Enoxaparin 1.0 p<0.001 vs saline control; p<0.05 vs UFH 
Bemiparin 1.0 p<0.01 vs saline control; p<0.05 vs UFH 
Semuloparin 1.0 p<0.001 vs saline control and UFH 
RO-14 1.0 No statistical significance 
   
UFH 2.5 p<0.001 vs saline control; p<0.05 vs enoxaparin 
Enoxaparin 2.5 p<0.001 vs saline control 
Bemiparin 2.5 p<0.001 vs saline control 
Semuloparin 2.5 p<0.001 vs saline control; p<0.05 vs enoxaparin 
RO-14 2.5 p<0.01 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 68. THE ANTICOAGULANT EFFECT OF UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 AS 
MEASURED BY THE 5 U CA2+ TT ASSAY AFTER SC ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.5 No statistical significance 
Enoxaparin 0.5 No statistical significance 
Bemiparin 0.5 No statistical significance 
Semuloparin 0.5 No statistical significance 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.05 vs saline control 
Enoxaparin 1.0 p<0.01 vs saline control; p<0.05 vs semuloparin 
Bemiparin 1.0 No statistical significance 
Semuloparin 1.0 No statistical significance 
RO-14 1.0 No statistical significance 
   
UFH 2.5 p<0.001 vs saline control, enoxaparin, bemiparin, semuloparin, and RO-14 
Enoxaparin 2.5 No statistical significance 
Bemiparin 2.5 No statistical significance 
Semuloparin 2.5 No statistical significance 
RO-14 2.5 No statistical significance 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 69. THE INHIBITION OF FACTOR XA BY UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 AS 
MEASURED BY AMIDOLYTIC ANTI-XA ASSAY AFTER SC ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.5 No statistical significance 
Enoxaparin 0.5 p<0.001 vs saline control and UFH; p<0.01 vs RO-14 
Bemiparin 0.5 p<0.001 vs saline control and UFH 
Semuloparin 0.5 p<0.001 vs saline control, UFH, and RO-14; p<0.05 vs bemiparin 
RO-14 0.5 p<0.01 vs saline control; p<0.05 vs UFH 
   
UFH 1.0 p<0.05 vs saline control 
Enoxaparin 1.0 p<0.001 vs saline control, UFH, bemiparin, and RO-14 
Bemiparin 1.0 p<0.001 vs saline control 
Semuloparin 1.0 p<0.001 vs saline control, UFH, bemiparin, and RO-14 
RO-14 1.0 p<0.001 vs saline control 
   
UFH 2.5 p<0.001 vs saline control 
Enoxaparin 2.5 p<0.001 vs saline control 
Bemiparin 2.5 p<0.001 vs saline control; p<0.05 vs UFH 
Semuloparin 2.5 p<0.001 vs saline control and UFH 
RO-14 2.5 p<0.001 vs saline control; p<0.01 vs UFH 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 70. THE INHIBITION OF THROMBIN BY UFH, ENOXAPARIN, BEMIPARIN, SEMULOPARIN, AND RO-14 AS 
MEASURED BY AMIDOLYTIC ANTI-IIA ASSAY AFTER SC ADMINISTRATION IN RATS: EXACT P-VALUES 
 
Drug Dose (mg/ml) P values 
   
UFH 0.5 No statistical significance 
Enoxaparin 0.5 p<0.01 vs saline control 
Bemiparin 0.5 p<0.05 vs saline control 
Semuloparin 0.5 p<0.05 vs saline control 
RO-14 0.5 No statistical significance 
   
UFH 1.0 p<0.001 vs saline control; p<0.01 vs RO-14; p<0.05 vs enoxaparin 
Enoxaparin 1.0 p<0.001 vs saline control; p<0.001 vs semuloparin and RO-14 
Bemiparin 1.0 p<0.001 vs saline control; p<0.01 vs RO-14 
Semuloparin 1.0 p<0.01 vs saline control 
RO-14 1.0 No statistical significance 
   
UFH 2.5 p<0.001 vs saline control, bemiparin, semuloparin, and RO-14; p<0.05 vs enoxaparin 
Enoxaparin 2.5 p<0.001 vs saline control; p<0.01 vs semuloparin; p<0.05 vs RO-14 
Bemiparin 2.5 p<0.001 vs saline control 
Semuloparin 2.5 p<0.01 vs saline control 
RO-14 2.5 p<0.01 vs saline control 
   
 
All results represent the mean ± standard error of the mean (n=5). Statistical analysis of the data was performed using a one-way 
ANOVA followed by Tukey’s multiple comparison test.  
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TABLE 71. COMPARATIVE PHARMACODYNAMIC INVESTIGATION OF HEPARIN AND ITS DERIVATIVES IN 
PRIMATES AT A DOSE OF 0.25 MG/KG IV IN NON-HUMAN PRIMATES 
All results represent the mean ± standard error of the mean (n=6). APTT, activated partial thromboplastin time; TT, thrombin time; 
Xa, factor Xa; IIa, factor IIa; TFPI, tissue factor pathway inhibitor; Func, functional; TGA, thrombin generation assay; Inh, inhibition; 
Hrs, hours; Sec, seconds. Statistically significant differences between treatment and control for each agent were determined by one-
way ANOVA followed by Dunnett’s multiple comparison test. *p <0.05 compared to baseline values.
Drug Time APTT TT (5U) Heptest Anti-Xa Anti-IIa TFPI Antigen TFPI Func TGA 
0.25 mg/kg IV (Hrs) (Sec) (Sec) (Sec) (% Inh) (% Inh) (ng/ml) (U/ml) (% Inhibition) 
          
UFH 0 31.6±1.8  18.1±0.6 19.5±0.4 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
 1 53.2±7.4 207.9±58.2 53.4±10.1 58.9±5.9 60.5±5.8 71.9±2.6 0.61±0.43 82.2±6.2 
 4 43.1±5.7 116.1±58.2 54.0±15.8 6.3±0.9 3.7±0.6 14.7±1.5 0.61±0.19 41.1±4.6 
 6 34.0±1.8 20.2±0.7 24.5±2.2 4.3±1.1 1.8±0.4 5.7±1.5 0.35±0.09 31.1±7.6 
 28 33.8±1.4 19.0±0.6 20.7±0.6 2.3±1.0 0.2±0.2 2.5±1.1 0.14±0.11 15.2±6.4 
          
          
Enoxaparin 0 34.5±1.4 18.5±0.4 31.9±1.1 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
 1 59.3±3.9 29.7±0.9 82.7±4.5 58.2±5.0 17.8±3.6 46.1±3.8 0.43±0.14 81.5±6.4 
 4 46.5±2.0 22.3±0.6 54.3±1.7 20.0±3.6 3.0±1.1 14.8±3.1 0.45±0.08 43.2±4.1 
 6 39.9±2.2  20.9±0.7 49.4±1.2 15.5±3.2 1.1±0.9 6.8±2.0 0.23±0.10 23.2±5.1 
 28 37.2±1.9 19.5±0.4 33.9±1.5 7.1±2.1 0.2±0.2 3.5±1.2 0.09±0.06 10.2±4.9 
          
          
Semuloparin 0 39.1±3.0 17.7±0.4 33.8±1.3 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
 1 51.1±3.3 21.7±0.8 90.4±2.5 74.3±3.2 1.7±0.7 42.7±4.0 0.42±0.11 75.7±6.1 
 4 45.4±4.1 20.4±1.2 69.1±1.8 54.3±2.2  0.8±0.5 22.6±5.7 0.46±0.08 47.4±11.0 
 6 47.0±5.2 19.2±0.5 58.4±3.3 45.1±1.8 0.7±0.4 11.7±3.2 0.26±0.05 28.1±9.4 
 28 42.8±4.2 18.4±0.5 41.5±1.8 11.7±1.6 0.7±0.4 3.3±0.9 0.10±0.02 8.3±4.9 
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TABLE 72. COMPARATIVE PHARMACODYNAMIC INVESTIGATION OF HEPARIN AND ITS DERIVATIVES IN 
PRIMATES AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES 
All results represent the mean ± standard error of the mean (n=6). APTT, activated partial thromboplastin time; TT, thrombin time; 
Xa, factor Xa; IIa, factor IIa; TFPI, tissue factor pathway inhibitor; Func, functional; TGA, thrombin generation assay; Inh, inhibition; 
Hrs, hours; Sec, seconds. Statistically significant differences between treatment and control for each agent were determined by one-
way ANOVA followed by Dunnett’s multiple comparison test. *p <0.05 compared to baseline values. 
Drug Time APTT TT (5U) Heptest Anti-Xa Anti-IIa TFPI Antigen TFPI Func TGA 
0.5 mg/kg IV (Hrs) (Sec) (Sec) (Sec) (% Inh) (% Inh) (ng/ml) (U/ml) (% Inhibition) 
          
UFH 0 40.7±1.9 16.0±0.4 25.2±1.7 0.0±0.0 0.0±0.0 0.0±0.0 0.00±0.00 0.0±0.0 
 1 215.8±38.0 300.0±0.0 268.4±20.2 84.6±4.8 90.2±2.4 110.4±6.0 1.24±0.07 99.9±0.1 
 4 52.2±4.3 17.2±0.2 37.9±3.8 11.8±3.8 5.4±2.1 76.2±2.8 0.28±0.07 27.4±5.2 
 6 44.4±1.6 16.7±0.3  28.2±1.2 10.0±3.3 2.5±0.4 35.4±2.1 0.11±0.06 7.5±2.7 
 28 42.2±1.4 16.6±0.2 26.5±1.3 6.5±2.3 1.4±0.4 2.8±1.0 0.03±0.01 1.5±1.5 
          
          
Enoxaparin 0 32.3±1.4 11.2±0.2 36.8±2.3 0.0±0.0 0.0±0.0 0.0±0.0 0.00±0.00 0.0±0.0 
 1 45.8±4.7 14.6±1.2 116.9±9.6 77.7±3.1 49.2±3.1 61.3±3.4 0.71±0.03 99.1±0.5 
 4 40.3±2.8 13.9±0.9 77.8±3.4 50.1±4.5 8.6±4.2 35.5±8.2 0.18±0.05 72.6±11.0 
 6 34.4±1.6 11.7±0.4 61.1±0.8 37.6±4.7 2.8±1.0 23.5±7.5 0.05±0.02 41.3±12.2 
 28 32.1±1.3 10.9±0.4 44.2±3.6 7.2±2.9 1.3±0.5 3.3±1.9 0.00±0.02 16.6±9.5 
          
          
Semuloparin 0 33.8±0.8 17.3±1.1 20.7±0.5 0.0±0.0 0.0±0.0 0.0±0.0 0.00±0.00 0.0±0.0 
 1 58.2±3.0 20.5±0.5 115.4±3.6 86.5±2.0 5.9±1.6 52.7±3.5 0.90±0.05 97.5±1.4 
 4 43.4±2.3 19.4±0.5 91.3±2.2 70.8±2.0 1.7±1.1 30.3±4.9 0.39±0.10 93.2±3.0 
 6 39.5±1.6 18.3±0.8 84.4±2.9 59.8±3.1 0.0±0.0 24.8±4.9 0.14±0.03 74.8±10.2 
 28 37.0±0.8 17.9±0.8 43.1±2.3 19.0±4.8 1.1±0.7 5.7±1.4 0.10±0.02 37.2±10.7 
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TABLE 73. COMPARATIVE PHARMACODYNAMIC INVESTIGATION OF HEPARIN AND ITS DERIVATIVES IN 
PRIMATES AT A DOSE OF 1.0 MG/KG SC IN NON-HUMAN PRIMATES  
All results represent the mean ± standard error of the mean (n=6). APTT, activated partial thromboplastin time; TT, thrombin time; 
Xa, factor Xa; IIa, factor IIa; TFPI, tissue factor pathway inhibitor; Func, functional; TGA, thrombin generation assay; Inh, inhibition; 
Hrs, hours; Sec, seconds. Statistically significant differences between treatment and control for each agent were determined by one-
way ANOVA followed by Dunnett’s multiple comparison test. *p <0.05 compared to baseline values. 
Drug Time APTT TT (5U) Heptest Anti-Xa Anti-IIa TFPI Antigen TFPI Func TGA 
1.0 mg/kg SC (Hrs) (Sec) (Sec) (Sec) (% Inh) (% Inh) (ng/ml) (U/ml) (% Inhibition) 
          
UFH 0 36.9±2.1 20.0±1.2 19.9±0.4 0.0±0.0 0.0±0.0 0.0±0.0 0.00±0.00 0.0 ±0.0  
 1 51.6±5.4 34.1±6.0 40.1±5.4 16.0±4.5 2.1±1.7 26.2±9.2 0.34±0.07 43.9±12.4 
 4 66.3±10.1 174.6±56.7 83.9±3.4 41.2±7.5 42.8±4.6 41.2±10.3 0.56±0.09 91.0±5.5 
 6 51.8±3.1 300.0±0.0 66.5±4.7 29.9±6.7 31.1±3.4 37.2±8.2 0.43±0.10 83.6±11.0 
 28 42.3±2.7 19.4±1.2 21.2±0.4 2.1±0.8 0.0±0.0 0.8±0.8 0.0±0.00 7.3±4.6 
          
          
Enoxaparin 0 33.2±3.6  22.0±1.1 24.4±1.9 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
 1 41.9±5.9 29.8±2.2 62.9±1.9 38.8±6.4 7.6±2.9 25.9±9.1 0.25±0.05 66.1±11.9 
 4 43.9±5.8 65.4±8.5 109.2±3.7 36.0±2.3 24.3±4.2 42.3±10.3 0.30±0.07 95.4±2.8 
 6 39.4±4.5 42.9±5.4 94.7±3.9 28.6±3.2 21.7±3.3 36.1±7.0 0.13±0.03 59.5±25.3 
 28 33.3±4.5 20.1±1.0 31.1±2.2 9.5±3.5 1.6±0.9 1.7±1.7 0.00±0.00 5.1±3.6 
          
          
Semuloparin 0 36.1±5.1 20.8±0.3 23.2±1.1 0.0±0.0 0.0±0.0 0.0±0.0 0.00±0.00 0.0±0.0 
 1 55.2±5.1 24.1±0.2 104.9±5.5 29.7±1.8 1.5±0.7 25.6±8.7 0.42±0.10 48.6±17.9 
 4 62.6±6.0 22.5±0.2 141.5±2.5 67.1±2.1 8.9±1.8 41.9±4.2 0.52±0.10 93.2±2.5 
 6 56.8±5.5 20.3±0.3 129.6±1.4 54.5±2.8 6.9±1.9  38.0±12.7 0.32±0.07 74.0±20.5 
 28 50.3±4.8 18.6±0.6 57.6±2.3 31.9±3.5 1.8±0.5 1.3±1.3 0.02±0.02 6.0±4.8 
          
  
 
[5
1
1
] 
TABLE 74. COMPARATIVE PHARMACODYNAMIC INVESTIGATION OF HEPARIN AND ITS DERIVATIVES IN 
PRIMATES AT A DOSE OF 2.5 MG/KG SC IN NON HUMAN-PRIMATES 
 
All results represent the mean ± standard error of the mean (n=6). APTT, activated partial thromboplastin time; TT, thrombin time; 
Xa, factor Xa; IIa, factor IIa; TFPI, tissue factor pathway inhibitor; Func, functional; TGA, thrombin generation assay; Inh, inhibition; 
Hrs, hours; Sec, seconds. Statistically significant differences between treatment and control for each agent were determined by one-
way ANOVA followed by Dunnett’s multiple comparison test. *p <0.05 compared to baseline values 
 
          
Drug Time APTT TT (5U) Heptest Anti-Xa Anti-IIa TFPI Antigen TFPI Func TGA 
2.5 mg/kg SC (Hrs) (Sec) (Sec) (Sec) (% Inh) (% Inh) (ng/ml) (U/ml) (% Inhibition) 
          
Enoxaparin 0 39.6± 1.3 19.4±0.4 19.5±1.0 0.0±0.0 0.0±0.0 0.0±0.0 0.00±0.00 0.0±0.0 
 1 68.3±7.3 95.1±44.0 153.8±33.1 39.1±3.2 36.0±6.3 70.1±5.8 0.53±0.08 99.1±0.5 
 4 83.5±6.3 231.0±43.6 245.0±20.2 64.5±3.0 74.5±3.8 80.0±6.7 0.89±0.08 99.6±0.1 
 6 82.8±8.7 300.0±0.0 275.7±16.9 66.9±3.7 80.7±2.8 54.2±1.3 0.66±0.06 99.7±0.1 
 28 43.6±1.9 18.6±0.5 42.1±1.6 28.4±3.9 11.4±2.0 15.9±4.1 0.10±0.05 28.9±5.8 
 32 41.5±1.6 16.8±0.3 36.2±1.5 23.2±3.0 3.0±0.6 3.1±4.9 0.00±0.00 6.8±3.6 
          
          
Semuloparin 0 47.4±3.5 18.4±0.1 20.9±0.8 0.0±0.0 0.0±0.0 0.0±0.0 0.00±0.00 0.0±0.0 
 1 75.9±4.4 22.0±0.6 131.7±17.3 56.2±2.1 10.7±1.6 56.0±7.5 0.39±0.03 99.4±0.3 
 4 76.2±5.5 25.1±1.4 218.6±9.1 73.3±2.5 23.9±2.6 68.3±2.7 0.63±0.09 98.0±1.9 
 6 64.3±2.6 21.7±0.4 150.8±6.2 68.2±3.4 18.0±4.3 50.3±6.6 0.32±0.08 98.8±0.6 
 28 55.2±2.5 19.3±0.1 62.6±2.1 61.8±4.5 5.5±1.2 6.3±2.0 0.04±0.02 34.1±13.1 
 32 52.7±2.6 19.0±0.8 50.4±2.7 53.2±4.5 3.4±1.3 0.1±1.1 0.01±0.00 25.1±8.5 
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TABLE 75 
 
POTENCY COMPARISON OF HEPARIN AND ITS DERIVATIVES ON THE 
INHIBITION OF TAFI ACTIVAITON WHEN SUPPLEMENTED IN NORMAL 
MONKEY PLASMA  
 
 
 
 
 
 
 
 
 
 
 
 
All results represent the mean ± standard error of the mean (n=3). Statistically significant 
differences between treatment and control for each agent were determined by one-way 
ANOVA followed by Tukey’s multiple comparison test. *p <0.05 compared to baseline 
values. 
 
Drug  Concentration 
 IC50 (µg/ml) 
  
UFH  3.0 ± 0.06 
  
Enoxaparin  5.3 ± 0.03 
  
Semuloparin  5.8 ± 0.03 
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TABLE 76. THE PLASMA CONCENTRATIONS FOR HEPARIN AND ITS DERIVATIVES AS DETERMINED BY VARIOUS 
ANTICOAGULANT AND ANTIPROTEASE ASSAYS AFTER IV ADMINISTRATION IN NON-HUMAN PRIMATES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All results represent the mean ± standard error of the mean (n=5-6). Xa, factor Xa; TGA, thrombin generation assay; Hrs, hours. 
Statistically significant differences between treatment and control for each agent were determined by two-way ANOVA followed by 
Bonferroni’s multiple comparison test. *p <0.05 compared to baseline value 
.
  0.25 mg/kg 0.5 mg/kg 
Drug Time Heptest Anti-Xa TGA  Heptest Anti-Xa TGA  
 (Hrs) (μg/ml) (μg/ml) (μg/ml) (μg/ml) (μg/ml) (μg/ml) 
        
UFH 0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
 1 0.67 ± 0.20 1.99 ± 0.53 0.72 ± 0.26 7.87 ± 1.12 7.07 ± 0.95 1.51 ± 0.01 
 4 0.70 ± 0.33 0.09 ± 0.01 0.09 ± 0.02 0.25 ± 0.07 0.28 ± 0.03 0.05 ± 0.01 
 6 0.09 ± 0.04 0.06 ± 0.02  0.07 ± 0.03 0.06 ± 0.01 0.23 ± 0.02 0.01 ± 0.00 
 28 0.02 ± 0.01 0.03 ± 0.01  0.03 ± 0.01 0.03 ± 0.01  0.14 ± 0.02 0.00 ± 0.00 
        
Enoxaparin 0 0.00 ± 0.00  0.00 ± 0.00  0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
 1 2.54 ± 0.24 4.47 ± 1.10  4.22 ± 0.91 4.48 ± 0.70 8.61 ± 1.07 7.50 ± 0.19 
 4 0.39 ± 0.02 0.85 ± 0.20  1.02 ± 0.14 1.76 ± 0.25 3.18 ± 0.55 3.42 ± 0.98 
 6 0.31 ± 0.01 0.62 ± 0.14  0.45 ± 0.13 0.60 ± 0.09 1.99 ± 0.37 1.16 ± 0.42 
 28 0.04 ± 0.01 0.26 ± 0.08  0.18 ± 0.10 0.29 ± 0.09 0.27 ± 0.12 0.37 ± 0.26 
        
Semuloparin 0 0.00 ± 0.00 0.00 ± 0.00  0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
 1 1.63 ± 0.12 5.11 ± 0.76  2.82 ± 0.71 2.78 ± 0.20 9.06 ± 0.95 9.22 ± 0.68 
 4 0.60 ± 0.08 2.22 ± 0.17  1.03 ± 0.34 1.65 ± 0.10 4.10 ± 0.36 8.21 ± 1.51 
 6 0.26 ± 0.05 1.57 ± 0.11  0.34 ± 0.15 1.35 ± 0.13 2.88 ± 0.36 4.35 ± 1.41 
 28 0.07 ± 0.02 0.27 ± 0.04  0.08 ± 0.05 0.17 ± 0.02 0.50 ± 0.14 0.68 ± 0.29 
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TABLE 77. THE PLASMA CONCENTRATIONS FOR HEPARIN AND ITS DERIVATIVES AS DETERMINED BY VARIOUS 
ANTICOAGULANT AND ANTIPROTEASE ASSAYS AFTER SC ADMINISTRATION IN NON-HUMAN PRIMATES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All results represent the mean ± standard error of the mean (n=4-6). Xa, factor Xa; TGA, thrombin generation assay; Hrs, hours. 
Statistically significant differences between treatment and control for each agent were determined by two-way ANOVA followed by 
Bonferroni’s multiple comparison test. *p <0.05 compared to baseline value. 
  1.0 mg/kg 2.5 mg/kg 
Drug Time Heptest Anti-Xa TGA  Heptest Anti-Xa TGA  
 (Hrs) (μg/ml) (μg/ml) (μg/ml) (μg/ml) (μg/ml) (μg/ml) 
        
UFH 0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 - - - 
 1 0.39 ± 0.11 0.27 ± 0.09 0.15 ± 0.07 - - - 
 4 1.29 ± 0.07 1.04 ± 0.32 1.03 ± 0.27 - - - 
 6 0.92 ± 0.10 0.62 ± 0.20 0.93 ± 0.29 - - - 
 28 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 - - - 
 32 - - - - - - 
        
Enoxaparin 0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00  0.00 ± 0.00 
 1 0.81 ± 0.11 2.21 ± 0.58 3.39 ± 0.79 7.82 ± 2.63 20.43 ± 2.58  7.48 ± 0.17 
 4 3.99 ± 0.26 13.12 ± 1.87 6.94 ± 0.35 15.05 ± 1.60 51.50 ± 5.78 7.70 ± 0.04 
 6 2.98 ± 0.28 3.71 ± 1.47 4.15 ± 0.56 17.49 ± 1.34 57.23 ±7.97 7.72 ± 0.06 
 28 0.10 ± 0.03 0.37 ± 0.15 0.09 ± 0.06 0.33 ± 0.03 1.32 ± 0.24 0.59 ± 0.15 
 32 - - - 0.23 ± 0.03 1.0 ± 0.16 0.11 ± 0.06 
        
Semuloparin 0 0.00 ± 0.00 0.00 ± 0.0 0.00 ± 0.00 0.00 ± 0.00 0.00 ±  0.00 0.00 ± 0.00 
 1 2.26 ± 0.24 0.83 ±0.07 1.68 ± 1.09 4.88 ± 1.29 23.85 ± 1.81 9.81 ± 0.10 
 4 5.03 ± 0.24 36.09 ± 2.70 7.21 ± 1.19 12.50 ± 0.86 47.14 ± 4.64 9.99 ± 0.00 
 6 3.88 ± 0.14 22.73 ± 2.54 6.16 ± 2.06 6.09 ± 0.58 39.18 ± 5.21 9.86 ± 0.10 
 28 0.32 ± 0.03 0.95 ± 0.14  0.08 ± 0.004 0.42 ± 0.06 3.17 ± 0.58 0.63 ± 0.30 
 32 - - - 0.24 ± 0.03 2.20 ± 0.37 0.24 ± 0.10 
  
 
 
[5
1
5
] 
TABLE 78A. ESTIMATION OF PHARMACOKINETIC PARAMETERS CALCULATED FROM PLASMA CONCENTRATION 
TIME CURVES AT A DOSE OF 0.25 MG/KG IV IN NON-HUMAN PRIMATES 
 
Hrs, Hours; AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa, Factor Xa; TGA, thrombin generation assay. 
 
 
 
 
 
 
 
Test Drug  Half-life; hrs AUC0-∞; (µg*hr)/ml Clsys; ml/ (kg*hr) Vd; ml/kg 
Heptest  
IV 250 µg/kg 
UFH 5.91 ± 0.31 5.56 ± 0.90 50.08 ± 10.70 414.78 ± 65.66 
Enoxaparin 6.88 ± 0.69 10.50 ± 0.60 24.15 ± 1.23 236.50 ± 21.78 
Semuloparin 8.98 ± 1.20 9.00 ± 0.99 29.27 ± 3.49 359.13 ± 36.57 
      
Anti-Xa 
IV 250 µg/kg 
UFH 5.95 ± 0.57 5.59 ± 1.18 55.27 ± 10.60 480.83 ± 103.66 
Enoxaparin 8.74 ± 0.90 22.04 ± 2.46 11.71 ± 1.08 156.20 ± 12.44 
Semuloparin 7.39 ± 0.75 40.86 ± 1.45 6.16 ± 0.22 66.59 ± 8.93 
      
TGA 
IV 250  µg/kg 
UFH 4.97± 0.53 3.05± 0.99 127.22 ± 31.60 655.57 ± 134.30 
Enoxaparin 2.64 ± 0.62 19.34 ± 2.67 14.49 ±2.34 50.86 ± 10.40 
Semuloparin 1.77 ± 0.51 13.36 ± 1.29 19.37 ± 1.73 46.16 ± 10.87 
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TABLE 78B. 
  
ESTIMATION OF PHARMACOKINETIC PARAMETERS CALCULATED FROM 
PLASMA CONCENTRATION TIME CURVES AT A DOSE OF 0.25 MG/KG IV IN 
NON-HUMAN PRIMATES 
 
 
Hrs, Hours; AUC, area under the curve; U, Units; TFPI, tissue factor pathway inhibitor. 
 
 
 
Test Drug  Half-life; hrs AUC0-∞; (ng*hr)/ml 
TFPI Antigen 
IV 250 µg/kg 
UFH 7.16 ± 1.18 310.92 ± 46.47 
Enoxaparin 9.40 ± 1.54  308.88 ± 59.34 
Semuloparin 8.46 ± 0.68 362.51 ± 74.69 
    
Test Drug Half-life; hrs AUC0-∞; (U*hr)/ml 
TFPI Functional 
IV 250 µg/kg 
UFH 13.74 ± 8.15 13.77 ± 6.54 
Enoxaparin 11.92 ± 4.57 9.02 ± 3.67 
Semuloparin 16.92 ± 3.49 8.67 ± 1.20 
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TABLE 79A. ESTIMATION OF PHARMACOKINETIC PARAMETERS CALCULATED FROM PLASMA CONCENTRATION 
TIME CURVES AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES 
 
 
Hrs, Hours; AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa, Factor Xa; TGA, thrombin generation assay. 
 
 
 
 
 
 
Test Drug  Half-life; hrs AUC0-∞; (µg*hr)/ml Clsys; ml/ (kg*hr) Vd; ml/kg 
Heptest  
IV 500 µg/kg 
UFH 5.68 ± 0.28 17.06 ± 2.82 33.54 ± 6.42 278.30 ± 58.76 
Enoxaparin 8.22 ± 0.87 27.64 ± 5.16 22.14 ± 4.61 239.82 ± 32.62 
Semuloparin 6.96 ± 0.37 29.45 ± 2.23 17.46 ± 1.29 174.71 ± 14.88 
      
Anti-Xa 
IV 500 µg/kg 
UFH 7.97 ± 0.56 20.85 ± 1.78  24.53 ± 2.13  280.18 ± 22.94  
Enoxaparin 8.40 ± 0.67 54.21 ± 6.67 10.05 ± 1.37  124.34 ± 21.32  
Semuloparin 8.42 ± 0.39  74.41 ± 6.78  7.06 ± 0.75  87.35 ± 12.81 
      
TGA 
IV 500  µg/kg 
UFH 0.69 ± 0.05 3.30 ± 0.07 151.51 ± 3.14 150.92 ± 9.05 
Enoxaparin 3.04 ± 1.14 43.16 ± 9.36 14.80 ± 3.99 50.48 ± 11.09 
Semuloparin 5.35 ± 1.67 107.03 ±26.49 6.66 ± 1.80 32.87 ± 5.85 
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TABLE 79B. ESTIMATION OF PHARMACOKINETIC PARAMETERS 
CALCULATED FROM PLASMA CONCENTRATION TIME CURVES AT A DOSE 
OF 0.5 MG/KG IV IN NON HUMAN-PRIMATES 
 
 
Hrs, Hours; AUC, area under the curve; U, Units; TFPI, tissue factor pathway inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test Drug  Half-life; hrs AUC0-∞; (ng*hr)/ml 
TFPI Antigen 
IV 500 µg/kg 
UFH 4.98 ± 0.57 891.15 ± 46.77 
Enoxaparin 6.18 ± 2.64 659.82 ± 134.81 
Semuloparin 9.01 ± 0.94 624.07 ± 105.61 
    
Test Drug Half-life; hrs AUC0-∞; (U*hr)/ml 
TFPI Functional 
IV 500 µg/kg 
UFH 6.46 ± 0.96 5.20 ± 0.93 
Enoxaparin 6.19 ± 2.42 2.75 ± 0.65 
Semuloparin 13.43 ± 2.90 8.00 ± 1.35 
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TABLE 80A. ESTIMATION OF PHARMACOKINETIC PARAMETERS CALCULATED FROM PLASMA CONCENTRATION 
TIME CURVES AT A DOSE OF 1.0 MG/KG SC IN NON-HUMAN PRIMATES 
 
 
Hrs, Hours; AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa, Factor Xa; TGA, thrombin generation assay. 
 
 
 
 
 
 
 
 
 
 
Test Drug  Half-life; hrs AUC0-∞; (µg*hr)/ml Clsys; ml/ (kg*hr) Vd; ml/kg 
Heptest  
SC 1.0 mg/kg 
UFH 3.60 ± 0.33 16.44 ± 1.28 62.15 ± 4.22 320.04 ± 28.90 
Enoxaparin 5.11 ± 0.19 49.14 ± 4.46 21.13 ± 1.73 156.41 ± 15.31 
Semuloparin 6.08 ± 0.22 70.11 ± 1.51 14.30 ± 0.32 125.08 ± 2.65 
      
Anti-Xa 
SC 1.0 mg/kg 
UFH 4.57 ± 0.75 10.14 ± 3.69 236.51 ± 91.33 1676.02 ± 761.34 
Enoxaparin 3.57 ± 0.13 206.09 ± 27.77 5.25 ± 0.74 35.60 ± 7.66 
Semuloparin 4.65 ± 0.22 396.58 ± 38.17 2.63 ± 0.23 17.74 ± 2.10 
      
TGA 
SC 1.0 mg/kg 
UFH 3.48 ± 3.38 20.94 ± 1.18 48.07 ± 2.77 220.53 ± 20.77 
Enoxaparin 5.96 ± 0.47 75.44 ± 7.43 13.66 ± 1.37 115.34 ± 8.56 
Semuloparin 3.48 ± 0.56 121.93 ± 8.91 8.29 ± 0.58 44.54 ± 9.83 
[520] 
 
 
[5
1
9
] 
TABLE 80B. 
 
ESTIMATION OF PHARMACOKINETIC PARAMETERS CALCULATED FROM 
PLASMA CONCENTRATION TIME CURVES AT A DOSE OF 1.0 MG/KG SC IN 
NON HUMAN-PRIMATES 
 
 
Hrs, Hours; AUC, area under the curve; U, Units; TFPI, tissue factor pathway inhibitor. 
 
 
 
 
 
 
 
 
 
 
Test Drug  Half-life; hrs AUC0-∞; (ng*hr)/ml 
TFPI Antigen 
SC 1.0 mg/kg 
UFH 5.17 ± 0.83 329.59 ± 85.25 
Enoxaparin 4.61 ± 0.23 206.08 ± 51.46 
Semuloparin 5.25 ± 0.59 195.03 ± 41.21 
    
Test Drug  Half-life; hrs AUC0-∞; (U*hr)/ml 
TFPI Functional 
SC 1.0 mg/kg 
UFH 5.67 ± 1.39 2.51 ± 0.38 
Enoxaparin 2.54 ± 0.90 1.38 ± 0.24 
Semuloparin 4.65 ± 1.25 4.96 ± 2.05 
    
  
 
[5
2
1
] 
TABLE 81A. ESTIMATION OF PHARMACOKINETIC PARAMETERS CALCULATED FROM PLASMA CONCENTRATION 
TIME CURVES AT A DOSE OF 2.5 MG/KG SC IN NON-HUMAN PRIMATES 
 
 
Hrs, Hours; AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa, Factor Xa; TGA, thrombin generation assay. 
 
 
 
 
 
 
 
 
 
 
 
Test Drug  Half-life; hrs AUC0-∞; (µg*hr)/ml Clsys; ml/ (kg*hr) Vd; ml/kg 
Heptest  
SC 2.5 mg/kg 
Enoxaparin 4.32 ± 0.04 269.27 ± 22.94 9.71 ± 1.01 60.36 ± 5.81 
Semuloparin 5.18 ± 0.11 121.79 ± 6.01 20.78 ± 1.04 154.64 ± 5.97 
      
Anti-Xa 
SC 2.5 mg/kg 
Enoxaparin 4.37 ± 0.11 881.85 ± 102.19 3.02 ± 0.32 18.90 ± 1.81 
Semuloparin 6.21 ± 0.23 702.08 ± 80.15 3.80 ± 0.42 33.81 ± 3.59 
      
TGA 
SC 2.5 mg/kg 
Enoxaparin 5.72 ± 0.30 135.24 ± 2.24 18.51 ± 0.31 152.13 ± 6.02 
Semuloparin 5.29 ± 0.80 173.86 ± 4.54 14.42 ± 0.37 108.47 ± 14.47 
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TABLE 81B.  
 
ESTIMATION OF PHARMACOKINETIC PARAMETERS CALCULATED FROM 
PLASMA CONCENTRATION TIME CURVES AT A DOSE OF 2.5 MG/KG SC IN 
NON-HUMAN PRIMATES 
Hrs, Hours; AUC, area under the curve; U, Units; TFPI, tissue factor pathway inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test Drug Half-life; hrs AUC0-∞; (ng*hr)/ml 
TFPI Antigen 
SC 2.5 mg/kg 
Enoxaparin 8.80 ± 1.83 1303.17 ± 121.14 
Semuloparin 5.92 ± 0.55 977.86 ± 107.44 
    
Test Drug  Half-life; hrs AUC0-∞; (U*hr)/ml 
TFPI Functional 
SC 2.5 mg/kg 
Enoxaparin 8.80 ± 1.44 9.66 ± 2.65 
Semuloparin 5.40 ± 1.39 6.10 ± 1.57 
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TABLE 82. HEPARIN AND ITS DERIVATIVES EFFECTS ON TUMOR GROWTH IN A MURINE LEWIS LUNG 
CARCINOMA TUMOR MODEL AT A CONCENTRATION OF 1.0 MG/KG SC 
 
Treatment 1.0 mg/kg Tumor vol. (mm³) % Inhibition Tumor WT (g) Spleen WT (g) Spleen Length (mm) 
 
Saline/saline (N=11) 3317.2 ± 545.6 0.0 ± 0.0 4.17 ± 0.5 0.157 ± 0.02^ 15.8 ± 0.8* 
Saline/taxol (N=10) 1302.4 ± 418.8** 64.4 ± 10.1*** 2.0 ± 0.6* 0.172 ± 0.02^ 16.5 ± 1.2 
NAA-UFH (N=5) 912.1 ± 729.2** 55.0 ± 22.0*** 1.3 ± 0.9** 0.368 ± 0.03* 16.1 ± 1.4 
Enoxaparin/saline (N=8) 838.0 ± 404.9*** 75.4 ± 11.6*** 1.3 ± 0.5*** 0.152 ± 0.03 16.4 ± 1.4 
Enoxaparin/taxol (N=9) 764.0 ± 197.0*** 77.0 ± 6.0*** 1.3 ± 0.3*** 0.192 ± 0.03 17.5 ± 0.9 
Bemiparin/saline (N=7) 1297.2 ± 543.8** 64.0 ± 13.0*** 2.1 ± 0.9* 0.132 ± 0.02 15.2 ± 0.8 
Bemiparin/taxol (N=8) 862.6 ± 284.4*** 74.0 ± 8.6*** 1.4 ± 0.4** 0.173 ± 0.04 17.6 ± 0.9 
Semuloparin/saline(N=9) 562.3 ± 241.2*** 83.1 ± 7.3*** 1.0 ± 0.4*** 0.110 ± 0.01 14.4 ± 0.5 
Semuloparin/taxol (N=13) 1203.2 ± 402.0*** 65.3 ± 11.0*** 1.8 ± 0.5** 0.214 ± 0.02 17.3 ± 0.7 
NAA-Semuloparin (N=9) 651.2 ± 241.0*** 71.8 ± 7.3*** 0.9 ± 0.2*** 0.369 ± 0.01* 16.0 ± 1.2 
 
All data points are presented as mean ± SEM. Statistical analysis of the data (tumor volume, % inhibition, and tumor weight) was 
performed using a Kruskal-Wallis test followed by Kruskal-Wallis multiple comparison test (versus saline/saline or saline/taxol) or a 
one-way ANOVA (spleen weight and length) followed by a Dunnett multiple comparison test (versus saline/saline or control no tumor 
(CT)). *p < 0.05, ** p < 0.01, and ***p < 0.001 vs. saline control. ^p < 0.05 vs. control no tumor (12.6 ± 0.52 mm). SEM, standard 
error of the mean; vol, volume; WT, weight; NAA, non-antithrombin affinity; UFH, unfractionated heparin. 
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TABLE  83. HEPARIN AND ITS DERIVATIVES EFFECTS ON TUMOR GROWTH IN A MURINE LEWIS LUNG 
CARCINOMA TUMOR MODEL AT A CONCENTRATION OF 0.5 MG/KG SC 
 
Treatment 0.5 mg/kg 
 
Tumor vol. (mm³) % Inhibition Tumor WT (g) Spleen WT (g) Spleen Length (mm) 
 
Saline/saline (N=9) 2060.1 ± 276.0 0.0 ± 0.0 3.0 ± 0.4 0.195 ± 0.02^ 16.2 ± 1.0* 
Saline/taxol (N=8) 1128.5 ± 344.6* 50.1 ± 12.0*** 1.8 ± 0.4 0.171 ± 0.03 15.4 ± 0.9 
UFH/taxol (N=6)  428.9 ± 120.4*** 79.2 ± 10.1*** 0.8 ± 0.2*** 0.126 ± 0.02 14.8 ± 1.1 
Enoxaparin/saline (N=10) 557.6 ± 210.5*** 73.3 ± 11.1*** 1.2 ± 0.4*** 0.182 ± 0.05 16.5 ± 1.3 
Enoxaparin/taxol ( N=10) 559.5 ± 165.5*** 72.8 ± 8.5*** 1.2 ± 0.3*** 0.138 ± 0.01 15.1 ± 0.6 
Bemiparin/saline (N=10) 447.3 ± 161.5*** 78.3 ± 8.8*** 1.1 ± 0.4*** 0.109 ± 0.02 14.3 ± 0.6 
Bemiparin/taxol (N=7) 360.0 ± 128.6*** 77.6 ± 6.0*** 0.75 ± 0.2*** 0.103 ± 0.00 13.7 ± 0.5 
Semuloparin/saline (N=8) 202.7 ± 68.1^*** 90.2 ± 3.1^*** 0.5 ± 0.1*** 0.162 ± 0.03 15.6 ± 1.1 
Semuloparin/taxol (N=8) 437.4 ± 99.5*** 78.8 ± 4.0*** 1.0 ± 0.2*** 0.130 ± 0.01 15.0 ± 0.8 
NAA-Semuloparin (N=10) 817.5 ± 284.3*** 60.3 ± 86.2*** 1.2 ± 0.4 0.385 ± 0.04* 15.6 ± 0.9 
 
All data points are presented as mean ± SEM. Statistical analysis of the data (tumor volume, % inhibition, and tumor weight) was 
performed using a Kruskal-Wallis test followed by Kruskal-Wallis multiple comparison test (versus saline/saline or saline/taxol) or a 
one-way ANOVA (spleen weight and length) followed by a Dunnett multiple comparison test (versus saline/saline or control no tumor 
(CT)). *p < 0.05, ** p < 0.01, and ***p < 0.001 vs. saline control or ^p < 0.05 vs. saline/taxol. * p < 0.05 vs. control no tumor (12.6 ± 
0.52 mm). . SEM, standard error of the mean; vol, volume; WT, weight; NAA, non-antithrombin affinity; UFH, unfractionated 
heparin. 
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TABLE  84. HEPARIN AND ITS DERIVATIVES EFFECTS ON TUMOR GROWTH IN A MURINE LEWIS LUNG 
CARCINOMA TUMOR MODEL AT A CONCENTRATION OF 0.25 MG/KG 
 
Treatment 0.25 mg/kg 
 
Tumor vol. (mm³) % Inhibition Tumor WT (g) Spleen WT (g) Spleen Length(mm) 
 
Saline/saline (N=11) 3405.7 ± 369.1 0.0 ± 0.0 4.7 ± 0.8 0.255 ± 0.04^ 16.3 ± 1.3 
Saline/taxol (N=5) 1260.1 ± 691.1* 66.5 ± 16.9*** 1.7 ± 0.7* 0.121 ± 0.00 15.3 ± 0.7 
UFH/saline (N=9) 2617.2 ± 600.8 34.9 ± 11.6 2.7 ± 0.5 0.217 ± 0.04 17.2 ± 1.0 
UFH/taxol (N=7) 2486.7 ± 655.0 36.2 ± 13.5 3.0 ± 0.9 0.275 ± 0.07 18.8 ± 1.6 
Enoxaparin/saline (N=7) 1980.6 ± 519.8 45.2 ± 13.1* 2.7 ± 0.9 0.228 ± 0.05 15.0 ± 2.0 
Enoxaparin/taxol (N=6) 1673.3 ± 662.0* 52.6 ± 18.4** 1.7 ± 0.6* 0.417 ± 0.06 14.5 ± 2.1 
Bemiparin/saline (N=8) 1264.3 ± 254.7** 62.9 ± 7.5*** 1.4 ± 0.3** 0.218 ± 0.05 16.2 ± 0.9 
Bemiparin/taxol (N=8) 1518.5 ± 314.2* 55.4 ± 9.2** 1.9 ± 0.5* 0.310 ± 0.06 17.3 ± 0.7 
Semuloparin/saline (N=11) 1257.7 ± 391.8** 65.1 ± 10.1*** 1.6 ± 0.6** 0.187 ± 0.05 16.8 ± 1.2 
Semuloparin/taxol (N=5) 1800.0 ± 646.8 51.5 ± 15.2* 2.2 ± 0.8 0.268 ± 0.07 15.4 ± 0.5 
NAA-Semuloparin (N=9) 2276.5 ± 412.4 36.74 ± 6.0 2.4 ± 0.3 0.482 ± 0.07* 18.4 ± 1.5 
 
All data points are presented as mean ± SEM. Statistical analysis of the data (tumor volume, % inhibition, and tumor weight) was 
performed using a Kruskal-Wallis test followed by Kruskal-Wallis multiple comparison test (versus saline/saline or saline/taxol) or a 
one-way ANOVA (spleen weight and length) followed by a Dunnett multiple comparison test (versus saline/saline or control no tumor 
(CT)). *p < 0.05, ** p < 0.01, and ***p < 0.001 vs. saline control. SEM, standard error of the mean; vol, volume; WT, weight; NAA, 
non-antithrombin affinity; UFH, unfractionated heparins.  
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